Conditions: Epilepsy
Keywords: Epilepsy pediatric intravenous children Lacosamide VIMPAT® seizure
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 103
Healthy volunteers: no

Brief summary:
EP0060 is a multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) Lacosamide (LCM) in pediatric subjects \>= 1 month to \< 17 years of age with epilepsy.

Detailed description:

Arms:
arm 1: Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are \>=8 to \<17 years. For Cohort 2 every attempt will be made to enroll 20 subjects \>= 4 to \< 8 years of age, 12 subjects \>= 2 to \< 4 years of age and 12 subjects \>= 1 month to \< 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).

Interventions: intervention 1: Lacosamide
Intervention descriptions: intervention 1: Pharmaceutical form: solution for infusion

Concentration: 10 mg/ml

Route of Administration: intravenous

Protocol document:
Prot_001.pdf: 
UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 1 of 240
PROTOCOL EP0060 AMENDMENT 3
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE 
THE SAFETY AND TOLERABILITY OF INTRAVENOUS 
LACOSAMIDE IN CHILDREN (≥1 MONTH TO <17 YEARS OF 
AGE) WITH EPILEPSY
PHASE 2/3
EudraCT Number: 2014-003294-42
IND Number: 068407
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC 27617
UNITED STATES
Protocol/Amendment number
Date
Type of 
amendment
Final Protocol
16 Dec 2014
Not applicable
Protocol Amendment 1
21 Jul 2015
Substantial
Protocol Amendment 2
30 Nov 2016
Substantial
Protocol Amendment 3
30 Apr 2018
Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED
ED S
ED 
umbe
umbe
DA
COPY
rate 
rate
NC 27
NC 27
This document cannot 
ca
be used to 
o support 
ent 2
nt 2
t
ndmen
dme
pp
s
any 
a
marketing 
er
ke
m
authorization
7617
617
TATE
TATE
au
application 
Drive
rive
7
and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 2 of 240
STUDY CONTACT INFORMATION
Sponsor
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC 27617
UNITED STATES
Principal/Coordinating Investigator
Name:
TBD
Affiliation:
Address:
Phone:
Fax:
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES, GmbH.
Alfred-Nobel-Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Mobile:
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Not Applicable
 
REDACTED 
S, G
S, G
aβe 10
aβe 10
m am
m am
R
COPY 
Y
Gm
Gm
CO
This document cannot 
n
an
an
an
be used to suppo
up
su port 
r
or
uppo
any y mark
rketing 
ing
rketi
ma
authorization 
mbH.
bH.
0
m Rhei
Rhei
n application 
on
pl
and 
nd any 
any extensions 
ns
ns
ex
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 3 of 240
Clinical Trial Biostatistician
Name:
Address:
UCB BIOSCIENCES, GmbH.
Alfred-Nobel-Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Fax:
Not Applicable
Clinical Monitoring Contract Research Organization
Name:
PRA Health Sciences
Address:
4130 Park Lake Avenue, Suite 400
Raleigh, NC 27612
UNITED STATES
Phone:
+1-919-786-8200
Fax:
+1-919-786-8201
REDACTED COPY 
PY
C
This document cannot be used to support any marketing authorization 
tio
application 
ca
app
and any 
ny extensions 
io
xt
or r
or variations 
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 4 of 240
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949 or +1 866 890 3175
Email
Global: DS_ICT@ucb.com (for interventional clinical studies)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or 
o variations 
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 5 of 240
TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................9 
1 
SUMMARY.....................................................................................................................11 
2 
INTRODUCTION ...........................................................................................................15 
3 
STUDY OBJECTIVE(S).................................................................................................16 
4 
STUDY VARIABLES.....................................................................................................16 
4.1 
Primary safety variables...............................................................................................16 
4.2 
Other safety variables ..................................................................................................16 
4.3 
Other pharmacokinetic variables .................................................................................17 
5 
STUDY DESIGN.............................................................................................................17 
5.1 
Study description .........................................................................................................17 
5.1.1 
Study duration per subject ...................................................................................21 
5.1.2 
Planned number of subjects and site(s) ...............................................................21 
5.1.3 
Anticipated regions and countries .......................................................................21 
5.2 
Schedule of study assessments.....................................................................................22 
5.3 
Rationale for study design and selection of dose.........................................................28 
6 
SELECTION AND WITHDRAWAL OF SUBJECTS...................................................30 
6.1 
Inclusion criteria ..........................................................................................................30 
6.2 
Exclusion criteria .........................................................................................................31 
6.3 
Withdrawal criteria ......................................................................................................33 
6.3.1 
Potential drug-induced liver injury IMP discontinuation criteria........................34 
7 
STUDY TREATMENT(S) ..............................................................................................35 
7.1 
Description of investigational medicinal product(s)....................................................35 
7.1.1 
Lacosamide solution for infusion ........................................................................35 
7.1.2 
Lacosamide oral solution for RxL and IIL subjects transitioning to SP848........35 
7.2 
Treatment(s) to be administered ..................................................................................35 
7.2.1 
Treatment Period .................................................................................................35 
7.2.2 
Transition oral lacosamide...................................................................................37 
7.3 
Packaging.....................................................................................................................37 
7.4 
Labeling .......................................................................................................................37 
7.5 
Handling and storage requirements .............................................................................37 
7.6 
Drug accountability......................................................................................................38 
7.7 
Procedures for monitoring drug accountability ...........................................................38 
7.8 
Concomitant medication(s)/treatment(s) .....................................................................38 
7.8.1 
Permitted and prohibited concomitant treatments (medications and therapies)..38 
7.9 
Blinding........................................................................................................................39 
7.10 
Randomization and numbering of subjects..................................................................39 
8 
STUDY PROCEDURES BY VISIT ...............................................................................39 
REDACTED 
....
....
.........
......
....
liver i
liver i
COPY 
se
se.
BJEC
BJE
This document 
7.7
7.7
7
cannot 
Han
Han
D
be
belin
belin
used 
nsiti
sit
ging
ging
to 
en
tion
tion
support
ral s
al s
be adm
be ad
nt Per
t Per
any
n fo
n f
solu
sol
marketing
injur
nju
.......
...
nal me
nal m
for
for
authorization 
CT
......
....
......
....
..........
ury
ury
application 
.....
...
.......
....
........
....
TS.
and 
..........
any 
......
.....
extensions 
......
....
.........
.....
....
or 
..... .
variations 
.16
16
1
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 6 of 240
8.1 
Screening/Baseline Period ...........................................................................................39 
8.1.1 
Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline....................39 
8.2 
Treatment Period..........................................................................................................41 
8.2.1 
Visit 2 (Day 1) .....................................................................................................41 
8.2.2 
Visit 3 (Day 2 to Day 5) ......................................................................................43 
8.3 
Unscheduled Visit........................................................................................................43 
8.4 
End-of-Study Period ....................................................................................................43 
8.4.1 
Final Visit (Day 1 to 6)/Termination Visit ..........................................................43 
8.4.2 
Telephone Contact 1 (Day 2 to Day 9)................................................................44 
8.4.3 
Transition Visit (Day 1 to Day 13)......................................................................45 
8.4.4 
Telephone Contact 2 (Day 29 to Day 37)............................................................45 
9 
ASSESSMENT OF PHARMACOKINETICS................................................................45 
10 ASSESSMENT OF SAFETY..........................................................................................46 
10.1 
Adverse events.............................................................................................................46 
10.1.1 
Definition of adverse event..................................................................................46 
10.1.2 
Procedures for reporting and recording adverse events.......................................47 
10.1.3 
Description of adverse events..............................................................................47 
10.1.4 
Follow up of adverse events ................................................................................47 
10.1.5 
Rule for repetition of an adverse event................................................................47 
10.1.6 
Pregnancy ............................................................................................................47 
10.1.7 
Suspected transmission of an infectious agent via a medicinal product..............48 
10.1.8 
Overdose of investigational medicinal product ...................................................48 
10.1.9 
Safety signal detection.........................................................................................48 
10.2 
Serious adverse events .................................................................................................49 
10.2.1 
Definition of serious adverse event .....................................................................49 
10.2.2 
Procedures for reporting serious adverse events .................................................49 
10.2.3 
Follow up of serious adverse events....................................................................50 
10.3 
Adverse events of special interest................................................................................50 
10.4 
Immediate reporting of adverse events........................................................................51 
10.5 
Anticipated serious adverse events ..............................................................................51 
10.6 
Laboratory measurements............................................................................................52 
10.6.1 
Pregnancy testing.................................................................................................53 
10.6.2 
Liver function tests and evaluation of PDILI ......................................................53 
10.6.2.1 
Consultation with Medical Monitor and local hepatologist ......................57 
10.6.2.2 
Immediate action: determination of IMP discontinuation.........................57 
10.6.2.3 
Testing: identification/exclusion of alternative etiology...........................57 
10.6.2.4 
Follow-up evaluation.................................................................................59 
10.7 
Other safety measurements..........................................................................................60 
REDACTED 
e even
e even
.....
.....
of an i
of an i
ona
on
COPY 
......
....
....
...
This document
10
10
cannot
Labo
Labo
0.6.1
.6.1
0
be
ticip
ticip
used 
ve
ve
diate re
iate r
pat
to
ents
ents
support 
r
for rep
or re
p of se
p of se
any 
.
ous a
ous a
marketing 
inf
al med
l med
.......
....
....
authorization 
......
......
ntnt.....
......
.....
nfect
fect
application 
..
.......
.....
events
event
......
.....
and 
.......
.....
any 
.....
....
..
extensions 
......
....
......
...
......
....
or 
......
variations 
43
43
43
4
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 7 of 240
10.7.1 
Vital signs, body weight, and height ...................................................................60 
10.7.2 
12-lead ECG ........................................................................................................60 
10.7.3 
Overall ECG interpretation..................................................................................60 
10.7.4 
Physical examination...........................................................................................60 
10.7.4.1 
Complete physical examination ................................................................60 
10.7.4.2 
Brief physical examination........................................................................60 
10.7.5 
Assessment of suicidality ....................................................................................60 
10.7.6 
Neurological examination....................................................................................61 
10.7.6.1 
Complete neurological examination..........................................................61 
10.7.6.2 
Brief neurological examination.................................................................61 
11 STUDY MANAGEMENT AND ADMINISTRATION.................................................61 
11.1 
Adherence to protocol..................................................................................................61 
11.2 
Monitoring ...................................................................................................................61 
11.2.1 
Definition of source data .....................................................................................62 
11.2.2 
Source data verification .......................................................................................62 
11.3 
Data handling...............................................................................................................62 
11.3.1 
Case Report form completion..............................................................................62 
11.3.2 
Database entry and reconciliation........................................................................63 
11.3.3 
Subject Screening and Enrollment log/Subject Identification Code list..............63 
11.4 
Termination of the study..............................................................................................63 
11.5 
Archiving and data retention........................................................................................63 
11.6 
Audit and inspection ....................................................................................................64 
11.7 
Good Clinical Practice .................................................................................................64 
12 STATISTICS ...................................................................................................................64 
12.1 
Definition of analysis sets............................................................................................64 
12.2 
General statistical considerations.................................................................................64 
12.3 
Planned pharmacokinetic analyses ..............................................................................65 
12.4 
Planned safety analyses................................................................................................65 
12.5 
Handling of protocol deviations...................................................................................65 
12.6 
Handling of dropouts or missing data..........................................................................65 
12.7 
Planned interim analysis and data monitoring.............................................................65 
12.7.1 
Definition of stopping rules.................................................................................65 
12.7.2 
Data Monitoring Committee................................................................................66 
12.8 
Determination of sample size.......................................................................................67 
13 ETHICS AND REGULATORY REQUIREMENTS......................................................67 
13.1 
Informed consent .........................................................................................................67 
13.2 
Subject identification cards..........................................................................................67 
13.3 
Institutional Review Boards and Independent Ethics Committees..............................68 
REDACTED 
ent log
ent lo
......
.....
......
......
COPY 
......
....
....
...
This document
12
12
12
12
cannot
Plan
Plan
2.7.1
.7.1
2
be
ndlin
ndlin
used 
afe
af
ng of 
ng of 
ng
to
fety 
ety 
support 
s 
l consi
con
macoki
macoki
any 
.
sets
sets
marketing 
..
.......
.....
.......
....
....
authorization 
......
......
og/Sub
g/Sub
......
.....
....
application 
..
.......
.....
........
...
......
.....
and 
.......
.....
any 
.....
....
..
extensions 
......
....
......
...
.........
or 
......
variations 
60
60
61
6
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 8 of 240
13.4 
Subject privacy.............................................................................................................68 
13.5 
Protocol amendments...................................................................................................69 
14 FINANCE, INSURANCE, AND PUBLICATION.........................................................69 
15 REFERENCES ................................................................................................................69 
16 APPENDICES .................................................................................................................71 
16.1 
Protocol Amendment 1 ................................................................................................71 
16.2 
Protocol Amendment 2 ..............................................................................................116 
16.3 
Protocol Amendment 3 ..............................................................................................201 
17 DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................239 
18 SPONSOR DECLARATION ........................................................................................240 
LIST OF TABLES
Table 5‒1: 
Schedule of study assessments.........................................................................23 
Table 5‒2: 
Timing of infusion, blood sampling, and measurement of vital signs and 
ECG on Treatment Days (Infusion Day 1 to Day 5) .......................................28 
Table 10‒1: 
Anticipated SAEs for the pediatric epilepsy population..................................51 
Table 10‒2: 
Laboratory tests................................................................................................53 
Table 10‒3: 
Required investigations and follow up for PDILI............................................55 
Table 10‒4: 
PDILI laboratory measurements......................................................................58 
Table 10‒5: 
PDILI information to be collected ...................................................................59 
REDACTED 
..
follow
follow
uremen
ureme
o be c
o be c
COPY
pileps
pilep
.....
This document cannot be used to support any marketing
collec
collec
authorization 
......
.....
w up 
w up 
ents
nts.
application 
ement 
ment
Day 5)
Day 5)
y popu
y pop
and 
......
....
any extensions 
........
......
...
or 
..2
variations 
16
201
20
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 9 of 240
LIST OF ABBREVIATIONS
AE
adverse event
AED
antiepileptic drug
ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AV
atrioventricular
bid
twice daily
BP
blood pressure
CDMS
clinical data management system
CHMP
Committee for Medicinal Products for Human Use
CPM
Clinical Project Manager
CPMP
Committee for Proprietary Medicinal Products
CRF
Case Report form
C-SSRS
Columbia-Suicide Severity Rating Scale
CV
coefficient of variation
DMC
Data Monitoring Committee
ECG
electrocardiogram
EDC
electronic data capture
EMA/EMEA
European Medicines Agency
EMU
epilepsy monitoring unit
EudraCT
European Union Drug Regulating Authorities Clinical Trials
FDA
Food and Drug Administration
GCP
Good Clinical Practice
ICH
International Council for Harmonisation
IEC
Independent Ethics Committee
IIL
initiating intravenous lacosamide
IMP
investigational medicinal product
IND
Investigational New Drug
IRB
Institutional Review Board
iv
intravenous
LCM
lacosamide
REDACTED 
erit
erit
ion
ion
ng Com
ng Com
ogram
ogram
COPY 
ty R
ty R
This document 
IMP
IMP
cannot be used to support 
eps
ps
Europ
Europ
Fo
F
any 
n M
n M
sy m
sy m
marketing 
m
ata cap
ta cap
Med
Me
authorization 
Rating
ating
mmitt
mmit
application 
l Produ
Prod
and
n Use
Use
any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 10 of 240
LFT
liver function test
MAOI
monoamine oxidase inhibitor
OLL
open-label lacosamide
PDILI
potential drug-induced liver injury
PK
pharmacokinetic(s)
PK-PPS
Pharmacokinetic-Per Protocol Set
PS
Patient Safety
QTc
corrected QT interval
RxL
prescribed lacosamide (eg, VIMPAT)
SAE
serious adverse event
SD
standard deviation
SOP
Standard Operating Procedure
SS
Safety Set
ULN
upper limit of normal
VNS
vagus nerve stimulation
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 11 of 240
1
SUMMARY
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥1 month to <17 
years of age with epilepsy. 
EP0060 will include approximately 100 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other 
pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2.
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
REDACTED
LCM 
LCM
eated 
eated 
ons w
ons w
t feasib
t feasib
M
COPY
and R
and R
s curr
 cur
This document cannot
s

be
adm
adm
sur
su
used
cal n
al n
proced
oced
min
min
to 
nee
ne
support
oses 
oses 
LCM 
LCM 
any
CM
CM
n EM
n EM
marketing
ible 
le 
is 10.
is 10.
n: Subje
Sub
M a
M a
authorization
rently
rently
admin
admin
at an 
at an 
where i
here 
e (ie
(i
application 
RxL sub
xL su
and
apy is
py i
any 
d will
d wil
s n
extensions 
, o
CM fro
M fro
or
or ot
r o
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 12 of 240
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia. Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥1 month to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including approximately 44 subjects who are ≥1 month to <8 years. Within Cohort 1, at 
least 20 subjects will be ≥12 to <17 years of age and at least 20 subjects will be ≥8 to <12 years 
of age. Within Cohort 2, every attempt will be made to enroll 20 subjects ≥4 to <8 years of age, 
12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
A Data Monitoring Committee (DMC) will review the safety and tolerability data for each 
cohort to make the following recommendations: the progression of the current cohort, including 
iv infusion durations to be evaluated, and progression to initiate enrollment in the next cohort 
(Cohort 2). 
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
REDACTED
up to 
up to
p to 2 
p to 2
(1 day
(1 da
C
COPY 
day
da
1
This documen
prov
rov
elec
elec
cannot 
all su
all su
vid
vid
be 
◦
used
L and 
and 
E
to
ys a
ys a
support
n SP8
SP8
ion Vi
on V
afte
aft
any 
cts wh
cts w
84
84
marketing 
y), 
y),
Contact
Contac
cts as f
ts as
authorization 
10 do
0 do
 conse
cons
application 
,
and any 
inin
extensions 
ta for 
a for 
t coho
coho
n th
n th
or
of 
of 
variations 
1, at 
1, at 
years
ears
f ag
f a
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 13 of 240
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses [over 
approximately 24 hours]) for elective administration. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg bid (subjects weighing <50kg) or 50mg bid (subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion 
and available time to complete all assessments. The Final Visit can be conducted on the same 
day as the last dose of iv LCM if time permits to complete all assessments. Otherwise, the Final 
Visit should be conducted the day following the last dose of iv LCM. The safety follow-up
Telephone Contact 1 should occur 1 to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
REDACTED 
and ch
nd ch
concu
concu
bjects 
bjects
nsitio
nsitio
COPY 
ple
pl
st dos
st dos
ter th
er th
This document cannot
App
App
be
term
erm
used 
cts 
ts
her res
er res
m
to
s in 
s in
support
tions 
ons
y 16 da
y 16 d
any 
a
marketing
on Vi
on V
not con
ot co
hould o
ould
authorization
se
he Fin
he Fin
hoose 
oose 
urrent
urrent
to all
o all
application
ming 
ming
it can b
t can 
allll ass
as
 of iv
of iv
and any 
cokin
cokin
extensions
≥50k
≥50k
50kg)
0kg)
7 days
7 days
or
LC
LC
kg
k
variations 
nd d 
CM
CM
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 14 of 240
Subjects should continue antiepileptic drug (AED) treatment at the discretion of the treating 
physician. For RxL subjects who will discontinue use of LCM, the subject should complete the 
EP0060 Final Visit and taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes,
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to receive 
iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of 
30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped. 
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
REDACTED 
ed.
ed.
ects ≥
ects ≥
Coh
Co
COPY
e enro
enr
mi
minut
nu
This document
d
x
cannot
minu
minu
OR a
OR 
be
gator
gato
used
efit
fit f
ed
not d
not d
to
on o
on o
f
support 
ws: 
ws: 
mately 
mately
of 1
f
any 
sub
su
hort 1 
ort 1
marketing
≥1 m
1 m
ohort 2,
hort 2
inutes 
nutes
ubjec
bje
authorization 
tes,
es,
mo
mo
application
ts sho
ts sho
lled in 
led in
and 
he
the o
the o
any
subj
subj
ny
inve
inv
extensions
and
omme
mme
1 wit
1 wit
j
or 
d d 
variations 
er 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 15 of 240
2
INTRODUCTION
Epilepsy is the second most prevalent neurological disorder in the world. It is estimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most 
patients with epilepsy require appropriate pharmacological therapy (Perucca, 1996). The Institute 
of Medicine of the National Academies recently provided a review of the burdens of epilepsy, 
global incidence and prevalence of epilepsy, classification systems for seizure types and 
syndromes, gaps in information about epilepsy, and general recommendations (Institute of 
Medicine, 2012). In the past 2 decades, several new options for the medical treatment of epilepsy 
have been introduced, including novel AEDs and vagus nerve stimulation (VNS).
The classification of seizures and epilepsy syndromes in children was described in 1989 by the 
Commission on Classification and Terminology of the International League Against Epilepsy 
(1989; Aicardi, 1994). Seizures are categorized based on whether the onset is focal or 
generalized and whether the disorder is idiopathic, symptomatic, or cryptogenic. Specific 
syndromes are further classified according to a number of criteria, including seizure type, cause, 
anatomy, precipitating factors, age at onset, and sometimes prognosis.
The newer AEDs differ from older agents in several important ways, including mechanism of
action, spectrum of activity, and PK characteristics (Herman and Pedley, 1998). However, more 
than 30% of patients have inadequate seizure control on currently available AEDs or experience 
significant adverse drug effects (CHMP/EWP/566/98, 2010).
Among the newer AEDs, only 6 (gabapentin, lamotrigine, oxcarbazepine, topiramate, 
levetiracetam, and perampanel) have successfully demonstrated efficacy as adjunctive therapy in 
children with difficult-to-treat partial-onset seizures (Rheims and Ryvlin, 2013; Glauser et al, 
2006; Appleton et al, 1999; Duchowny et al, 1999; Elterman et al, 1999). Despite the availability 
of new AEDs, more than 25% of pediatric patients have inadequate seizure control on currently 
available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007). Therefore, a need remains for AEDs with improved effectiveness and tolerability 
(Shorvon, 2009).
Intravenous formulations are particularly helpful as short-term replacement of oral formulations 
for patients unable to take oral products (eg, preoperative and postoperative patients, patients 
with acute gastrointestinal disorders). Such formulations allow patients to be maintained on the 
same AED on their stable dose when they are unable to take the drug orally. Intravenous 
formulations may also be helpful in the initiation of treatment in certain situations when the 
patient is unable to take oral medications.
In the US, oral tablets and oral solution (syrup) of LCM are indicated for the treatment of partial-
onset seizures in patients 4 years of age and older. As the safety of LCM injection for iv use has 
not been established in pediatric patients, LCM injection for iv use at infusion durations of 15 to 
60 minutes is indicated for the treatment of partial-onset seizures only in patients 17 years of age 
and older as an alternative when oral administration is temporarily not feasible. 
Additionally, LCM has been approved in the EU (oral tablets, oral solution [syrup], and solution 
for iv infusion), as monotherapy and adjunctive therapy in the treatment of partial-onset seizures 
with or without secondary generalization in patients 4 years of age and older. The iv formulation 
REDACTED 
56
in, lam
in, lam
ccessfu
cess
onset
onset
wny e
wny e
COPY
Herm
Her
rol on
rol on
66/98
6/98
This document
s
not b
not b
60
60
cannot 
un
u
e US, 
US, 
et se
t se
be 
s m
unabl
unab
sed
their s
heir s
may 
may
to
testi
test
support 
ns are p
s are
take o
take 
in
any
ns fo
ns f
marketing
t s
et al, 
et al, 
diatric p
iatric 
gnifican
nifica
for
for
authorization 
n c
8, 201
, 201
motrig
motrig
fully d
ully d
seizu
eizu
application
osis.
osis
nt ways
nt way
an and 
n and
curren
urren
and
ptp
ncludi
cludi
s
any
is 
is
togen
ogen
extensions 
in 19
n 19
Agains
gains
s fo
fo
o
f epi
ep
variations 
ile
il
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 16 of 240
at infusion durations of 15 to 60 minutes is approved as an alternative for patients when oral 
administration is temporarily not feasible.
Recently, a retrospective evaluation was conducted to examine the use of iv LCM in 47 infants 
and children from 4 months to <12 years of age (Arkilo et al, 2016). The median age across the 
47 children was 6.5 years, and 18 children were <3 years of age. Intravenous LCM was 
administered as adjunctive treatment along with ≥2 other AED. Lacosamide dose levels ranged 
from 1 to 11mg/kg, and the infusion was given over 30 minutes. Fifteen of the children were 
administered iv LCM either as replacement treatment for oral maintenance dose (n=10) or to 
initiate maintenance dose (n=5). For the remaining children, iv LCM was used to treat acute 
exacerbation of seizure frequency (n=18), status epilepticus (n=11) or epilepsia partialis continua 
(n=3). Children were observed for at least 48 hours after infusion. The 11 children with status 
epilepticus were not able to respond to inquiries about adverse effects. Of the remaining 
36 subjects, 5 experienced adverse effect of sedation which resolved in all 5 within 24 hours. No 
other observable adverse effects were noted. No cardiac events were noted during the infusions 
for the 80% of children who had ECG evaluation during the infusion. This study shows an initial 
positive benefit-risk profile for the use of iv LCM in infants and children from 4 months to 
<12 years of age. 
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment 
initiation in pediatric subjects ≥1 month to <17 years with epilepsy.
3
STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy. An additional objective is 
to evaluate the PK of iv LCM in pediatric subjects with epilepsy. 
4
STUDY VARIABLES
4.1
Primary safety variables
Safety and tolerability will be assessed using the following primary variables:
x Adverse events (AEs) reported spontaneously by the subject and/or caregiver (including 
parent/legal guardian) or observed by the investigator
x Subject withdrawals due to AEs
4.2
Other safety variables
Other safety variables include the following:
x Changes in 12-lead electrocardiograms (ECGs)
x Changes in vital sign measurements (blood pressure [BP] and pulse rate)
x Changes in physical examinations
x Changes in neurological examinations
REDACTED 
S)
S)
evalu
evalu
onth
onth t
diatri
diatri
COPY
LCM 
LCM
ears w
ears w
This document cannot
safety
afety
x
C
be used
withd
with
O
to
gua
gu
support 
l be a
be a
s (AEs
(AE
uard
uard
any
ty v
ty 
ass
as
marketing
to
ric sub
ic sub
BLES
BLES
va
va
authorization
with 
with
uate th
ate th
o <17
<17
application 
PK data
K dat
or for a
or for 
h ep
ep
and
Thihi
ldren
dren
any
d dur
d du
is st
is s
extensions
alis c
lis 
n with 
with
emain
emain
withi
with
or
cute
cut
co
variations 
to
tet
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 17 of 240
4.3
Other pharmacokinetic variables
Other PK variables will include plasma concentration of LCM and its main metabolite,
SPM 12809.
5
STUDY DESIGN
5.1
Study description
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥1 month to <17 years of age with epilepsy. EP0060 will 
include approximately 100 subjects. The following subjects will be eligible for enrollment in 
EP0060:
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants 
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescribed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM 
is 10.
 Elective administration: subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
REDACTED 
bjects
bjects
eg, LC
eg, L
are tre
re tre
nistr
nistr
COPY 
LL an
LL an
This document cannot
a
be
Cli
a pr
a pr
used
ve iv
e iv
inica
nic
to 
iv L
iv L
support
eg, L
g, 
on at an
n at a
f iv do
iv do
any
ation:
ation
LC
LC
marketing
ea
ration 
ration
In thes
In the
authorization
nd Rx
nd Rx
s curre
curre
CM ad
CM a
ted a
ted a
application
ve iv L
ve iv 
is not p
is not
and any 
merc
merc
extensions 
men
apy as
apy as
study
tudy
or
nt i
nt
variations 
of iv
f iv
will
will
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 18 of 240
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia. Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40 subjects who are ≥8 to <17 years and Cohort 2 including approximately 44 subjects who are 
≥1 month to <8 years. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age and 
at least 20 subjects will be ≥8 to <12 years of age. Within Cohort 2, every attempt will be made 
to enroll 20 subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 
month to <2 years of age. 
A DMC will review the safety and tolerability data for each cohort to make the following 
recommendations: the progression of the current cohort, including iv infusion durations to be 
evaluated, and progression to initiate enrollment in the next cohort (Cohort 2). Details regarding 
the DMC are provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
REDACTED
see ab
see a
n (see a
n (see a
urs
urs
COPY 
day
da
b
This document 
For
For
cannot be 
RxL
RxL
used
rans
ans
days
day
to 
ea
sit
sit
support 
co
co
L subje
subje
ars in 
rs in
any 
on
on
ontac
onta
marketing 
(1 day
(1 da
ne C
ne C
authorization 
bove in
ove in
above
bove
application 
,
and any 
2)
2)
extensions 
follow
ollow
durat
durat
). D
). D
or
ject
jec
variations 
nd 
nd 
made
made
cts
cts
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 19 of 240
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily 
dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg bid (subjects weighing <50kg) or 50mg bid (subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase. 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead 
ECG, clinical hematology and chemistry, and Columbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion
and available time to complete all assessments. The Final Visit can be conducted on the same 
day as the last dose of iv LCM if time permits to complete all assessments. Otherwise, the Final 
Visit should be conducted the day following the last dose of iv LCM. The safety follow-up
Telephone Contact 1 should occur 1 to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
REDACTED
ts 
ts to c
to c
ng the
ng the
3 day
3 day
igibl
igibl
COPY 
pend o
pend 
The F
he F
This document cannot be 
Sub
Sub
used 
udy
udy
xima
xima
to
dy du
y d
support 
who o 
ontact 2
ntact 
any
Tra
Tr
o wil
w
marketing
le and
le an
her con
her co
 subjec
subje
rans
ran
authorization
o
Final V
Final 
comple
omple
e last 
e last 
ys afte
s afte
application
xam
am
de Seve
e Sev
n the 
n the
V
and
analy
analy
ms,
ms
any 
s
extensions
e iv 
iv 
ng ≥50
g ≥5
g <50k
g <50k
st 7 d
t 7 d
or 
an
an
L
variations 
ily 
ily 
o
nd
nd
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 20 of 240
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL
subjects who directly enrolled and will discontinue use of LCM, the subject should complete the 
EP0060 Final Visit and taper at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to receive 
iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of 
30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped. 
REDACTED 
s.s.
ects w
ects w
ger tha
ger th
COPY 
n th
n th
inute 
inute 
n. Th
n. Th
This document 
w
i
cannot
usion
sion
directl
irectl
an
wh
wh
be
R ap
R ap
d
used 
atata
ons as
ns as
to
th
a fro
a fr
support 
bjec
jec
r than 6
than
he fir
he fir
any
4 sub
4 su
cts i
cts
marketing 
initiat
nitia
bje
bj
authorization
hese s
hese s
will be
will be
an 60 
n 60 
application
ed 
ed in 
in 
utes
utes on
o
opinion
pinio
nfusio
nfusi
and 
C
any 
th
make
mak
extensions
hort 
ort
tes wh
es wh
he sa
e sa
or
rs o
rs o
t 1
variations 
of a
of a
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 21 of 240
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
5.1.1
Study duration per subject
For clinical need administration, the planned maximum iv LCM exposure will be up to 10 doses 
(or up to 5 days). For elective administration, the planned maximum iv LCM exposure will be up 
to 2 consecutive doses (over approximately 24 hours). 
For OLL subjects, the planned maximum total study duration assuming clinical need 
administration will be approximately 16 days (up to 7 days for screening, up to 5 days of 
treatment, 1 day for discharge/Final Visit, and a safety follow-up Telephone Contact 1 at 1 to 3 
days after the Final Visit). 
For RxL and IIL subjects who will continue LCM treatment in SP848, the planned maximum 
total study duration assuming clinical need administration will be approximately 23 days to 
allow arrangement for assessments to transition to SP848 (up to 7 days for screening, up to 
5 days of treatment, 1 day for discharge/Final Visit, safety follow-up Telephone Contact 1 at 1 to 
3 days after the Final Visit, and the Transition Visit at 1 to 7 days after the last dose). The Final 
Visit and the Transition Visit may occur on the same day or separate days, depending on 
availability and scheduling.
For RxL and IIL subjects who will not continue LCM treatment in SP848, the planned maximum 
total study duration (assumes clinical need administration) will be approximately 45 days to 
allow for further safety follow-up (up to 7 days for screening, up to 5 days of treatment, 1 day for
discharge/Final Visit, safety follow-up Telephone Contact 1 at 1 to 2 days after the Final Visit, 
and safety follow-up Telephone Contact 2 at 30 days [±2 days] after the last dose).
For those subjects electively receiving iv LCM, the above maximum total study durations are 
reduced by 4 days. 
The end of the study is defined as the date of the last contact of the last subject in the study.
5.1.2
Planned number of subjects and site(s)
Approximately 100 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12 to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: every attempt will be made to enroll 20 subjects ≥4 to <8 years of age, 12 
subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
The remaining subjects may be enrolled in either of the 2 cohorts.
5.1.3
Anticipated regions and countries
The study will be conducted at selected sites from North America, Europe, and Asia. Additional 
sites or regions may be added as deemed necessary.
REDACTED
nue L
nue L
d admi
admi
o 7
o 7 da
da
up Tel
up Te
ntac
ntac
COPY
e day
e day
C
This document 
Th
Th
cannot 
≥12
12
x
C
be 
hort
ort
toto
used
cohor
ohor
1
to
sub
su
support 
ned
ne
d num
d num
ubjec
bje
any 
d as 
d a
marketing 
lep
ep
ct 2 at 3
2 at 
ving iv 
ing iv
authorization 
CM tre
CM tr
inistra
nistra
ays for
ys for
pho
pho
application 
day
w-up T
up 
days a
days 
or sepa
r sep
and
proxi
roxi
ays f
ys 
any
e plan
e pla
ima
extensions 
days o
ays o
ontact 
ntact
or variations 
s s 
be up
e up 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 22 of 240
5.2
Schedule of study assessments
The schedule of study assessments is provided in Table 5‒1, and timing of infusion, blood 
sampling, and measurement of vital signs and ECG on treatment days is provided in
Table 5‒2.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 23 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
Written informed consent
X
Inclusion/exclusion criteria
X
Xi
Demographics
X
Medical procedures
X
X
X
X
X
X
X
X
Procedure historyj
X
Medical history/updatej
X
X
Diagnosis of epilepsyj
X
Seizure historyk
X
Childbearing potentialj
X
LCM dosing historyl
X
X
LCM dosing information since 
Treatment Period
X
X
X
Prior and concomitant medicationsm
X
X
X
X
X
X
X
X
X
Concomitant AEDs/VNS settings/ 
ketogenic diet 
X
X
X
X
X
X
Xn
Xn
Urine pregnancy testing (as 
applicable)
X
X
X
Withdrawal criteria
X
X
X
X
X
X
AE reporting
X
X
X
X
X
X
X
X
X
REDACTED 
D
TE
AC
DA
R
COPY 
Y
OPY
C
This document t cannot 
n
c
be 
be used 
ed
us
to 
X
support 
X
ort
up
su
any 
a
marketing 
ng
n
rk
m
authorization 
on
tio
riz
ut
application 
on
X
lic
ap
and 
nd
nd
nd
nd
and any 
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 24 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
Physical examination (complete)
X
X
Physical examination (brief)
X
Xo
Xo
X
Neurological examination 
(complete)
X
X
Neurological examination (brief)
X
Xo
Xo
X
Clinical chemistry and 
hematologyp,q
X
Xr
X
12-lead ECG
X
X
Xs
Xs
X
Vital signs
X
X
Xt
Xt
X
X
Body weight and height
X
PK blood sampling
Xu
Xv
Intravenous LCM infusionw
X
X
C-SSRSx
X
Xy
Xo
Xo
Xd
X
Additional items for RxL and IIL subjects continuing into SP848
Dispense transitional supply of 
oral LCM solutiong
Xz
Collect transitional supply of 
oral LCM solution
X
Visit 1 SP848 assessments 
(documented in SP848) 
X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C-SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogram; IIL=initiating iv 
CT
AC
Xt
DA
R
COPY 
Y
CO
This document
ED=an
D=an
t
P84
8
t cannot 
ments
ents
48)
48)
ot
c
be 
f 
used 
us
us
us
us
us
to 
o support 
Xy
t
ontinu
ontinu
pp
s
any y
a
marketing 
n
ting
n
Xu
rk
m
authorization 
n
on
Xs
or
au
application 
on
p
and 
nd
nd
nd
nd
and any 
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 25 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
LCM; iv=intravenous; LCM=lacosamide; OLL=open-label LCM; PK=pharmacokinetics; RxL=prescribed commercial LCM; TC=Telephone Contact; V=Visit; 
VNS=vagus nerve stimulation
a
The Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion, if necessary. In this case, it is required that all Screening 
procedures are performed and the results of examinations (ie, ECG, laboratory measurements) are available to allow verification of subject eligibility.
b
Visit 1b only applies when Screening and Baseline occur on separate days. 
c
If iv LCM treatment is continued after Day 1, assessments for Visit 3 (excluding PK blood sampling [see footnote v]) must be completed for each infusion 
of iv LCM treatment in EP0060, unless otherwise noted (see footnote o).  
d
If an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. If the 
Unscheduled Visit is due to an AE, the C-SSRS assessment should be completed and collection of a blood sample for LCM PK analysis is at the discretion 
of the investigator.
e
A Final Visit must be completed for all subjects who complete or withdraw prematurely from EP0060. The Final Visit may occur on the same day as the last 
dose of iv LCM, time permitting. Otherwise, the Final Visit should occur on the following day. For subjects who will discontinue use of LCM, the subject 
should complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen for OLL subjects or taper at the discretion of the 
treating physician for RxL subjects.
f
The Telephone Contact 1 Visit assessment should be performed 1 to 3 days after the Final Visit. During the contact, the site should inquire as to whether the 
subject noted any change at the site of the infusion.
g
The Transition Visit will only be conducted for RxL and IIL subjects who will continue LCM treatment in SP848. This visit can occur at the same time as 
the Final Visit or on another day up to and including 7 days after the Final Visit and should occur at the same time as Visit 1 for SP848. 
h
The Telephone Contact 2 Visit will only be conducted for RxL and IIL subjects who will not continue LCM treatment in SP848.
i
Verification that the subject continues to meet inclusion/exclusion criteria if Screening and Baseline occur on separate days.
j
Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be collected for RxL and IIL subjects at Screening. For OLL 
subjects, a medical history update will be captured in the previous long-term open-label study and not in EP0060. 
k
Subject or caregiver (including parent/legal guardian) will be asked how many seizures the subject has had over the past 4 weeks as a historical baseline for 
RxL and IIL subjects.
l
For OLL and RxL subjects, LCM dosing history will include date, time, and dosage information during the last 3 days.
m
Prior medications will only be collected for direct-enroll subjects. 
n
At Telephone Contact follow-up calls, only concomitant AED and ketogenic diet information will be gathered (ie, settings for VNS will not be gathered).
o
During the Treatment Period, brief physical examination, brief neurological examination, and C-SSRS should be performed once per day and after an 
infusion.
p
Screening laboratory assessments may be conducted up to and including the day of the infusion provided they are reviewed and meet inclusion/exclusion 
criteria prior to the infusion. For all subjects, local laboratory results obtained for routine diagnostic and medical care can be used whenever possible if 
mple
mple
ithdraw
thdra
uld occ
uld occ
e long
 long
COPY 
PK b
PK
Additi
Addit
ete
ete
This document 
ry as
y as
he infu
he infu
cannot 
w-up
up
riod, br
iod, b
asse
sse
be
colle
colle
up c
up c
used 
g
dosing
dosing
ct
to
gal g
gal g
support 
ted
ed
nclusion
clusio
of epile
of epi
aptured
pture
any
days 
days
d for 
d for
marketing 
term
erm
d 1 to 3
d 1 to 
IL sub
L su
authorization
ional 
onal
d and c
and 
w prem
w prem
ur on t
r on t
m, o
m,
application 
ecess
ces
are ava
are av
od samp
d sam
as
and 
d co
c
ssar
sar
any 
omm
omm
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 26 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
collected no more than 24 hours prior to Screening/Baseline Visit in order to minimize blood loss associated with the study. Use of the central or local 
laboratory is at the discretion of the investigator for all visits except the Final Visit. The central laboratory must be used for laboratory samples collected at 
the Final Visit.
q
Bicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for bicarbonate in subjects weighing less than 8kg in cases of suspected 
metabolic disturbances such as metabolic acidosis.
r
If Screening and Baseline Visits are not performed on the same day, repetition of laboratory assessments at Baseline is at the discretion of the investigator.
s
A 12-lead ECG will be performed approximately 20 minutes prior to each infusion and at approximately 15, 30, 60 minutes, and 2 hours from the start of 
each iv administration. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should be at rest (sitting or supine) at 
least 3 minutes prior to each ECG recording and should be motionless during the recording, when feasible.
t
Vital signs will be performed approximately 10 minutes prior to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diastolic) and pulse rate will be measured at study visits after at least 3 minutes at rest, when feasible.
u
Plasma samples will be obtained from a different region of the body from the region in which the solution for infusion was administered for the first iv LCM 
infusion (Day 1): predose for OLL and RxL subjects (within 1 hour prior to iv LCM infusion) and postdose for all subjects (within 1 to 4 hours after end of 
iv LCM infusion). If the postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK sample will be drawn after 
ECG and vital signs have been taken. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the event of a 
relevant treatment-emergent AE.
v
If the subject has more than 1 iv LCM infusion, it is optional to also collect plasma samples for the final iv LCM infusion (Day 2 to 5/Early Termination): 
predose for all subjects (within 1 hour prior to iv LCM infusion) and postdose for all subjects (within 1 to 4 hours after end of iv LCM infusion). If the 
postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK sample will be drawn after ECG and vital signs 
have been taken. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the event of a relevant 
treatment-emergent AE.
w
During the Treatment Period subjects will receive at least 1 dose of iv LCM. If more than 1 infusion is needed, infusions will occur bid at approximately 
12-hour intervals up to either 2 doses (elective administration) or 10 doses (clinical need administration). 
x
All subjects ≥6 years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent visits. If the subject is <6 years of age, assessment for signs of 
depression will be conducted as described in Section 10.7.5 of the protocol.
y
The C-SSRS assessment does not need to be completed twice if Screening/Baseline assessments are done on the same day. If Screening/Baseline and Visit 2 
occur on the same day, 2 assessments should be completed with 1 predose and 1 after infusion.
z
For RxL and IIL subjects who are eligible and wish to enroll in SP848, a short-term oral LCM solution will be dispensed to allow continuity of LCM 
treatment while visits and assessments are scheduled for starting SP848. Subjects (or their caregivers) will administer the oral LCM solution twice a day,
REDACTED
ring 
ring
nfusio
nfusio
pulse r
pulse 
ody fro
ody fro
1 hour p
 hour 
milar 
milar 
COPY 
labo
lab
sion an
sion an
t and q
and q
thth
This document 
bjec
jec
visits a
isits a
cannot 
d as 
as 
does n
oes n
, 2 asse
2 asse
cts
cts
be
age a
age a
s de
s de
used
mplete 
plete
mes 6
mes 6
an
to
ectiv
ectiv
support 
CG
CG
PK anal
K ana
eceive
ceive
any
infus
infu
G and
G an
marketing 
prio
ri
time fo
time fo
es f
s for PK
or P
f
nal to a
al to
i
authorization
quality
uality
e recor
reco
n and a
n and a
rate wi
rate wi
om the 
m the 
ior to
or to
application 
onate i
onate 
tory ass
ry as
d at app
at ap
y E
and
ciat
ia
oratory
ratory
any
ted w
ted 
ny 
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 27 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
starting approximately 12 hours after the final iv LCM infusion, according to the investigator’s instructions until the subject returns for the Transition Visit.
COPY 
This document cannot be used to support any marketing authorization application and 
ion
on
any 
ns un
ns u
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 28 of 240
Table 5‒2:
Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points in relation 
to iv LCM infusion  
Vital signsa
12-lead ECGb
PK blood samplingc
-59min to -3min
Xd
-20min (±10 min)
X
-10min (±5 min)
X
T0 (start of infusion)
+5min (±2 min)
X
+10min (±2 min)
X
+15min (±5 min)
X
+20min (±5 min)
X
+30min (±5 min)
X
+45min (±5 min)
X
+60min (±10 min)
X
X
+1h to +4he
X
+2h (±15 min)
X
X
AE=adverse event; BP=blood pressure; ECG=electrocardiogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
a Noninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before and after the start of each iv LCM infusion.
b A 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should 
be at rest (sitting or supine) at least 3 minutes prior to each ECG recording and should be motionless during the 
recording, when feasible.
c If the postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK 
sample will be drawn after ECG and vital signs have been taken. Plasma samples will be obtained a different 
region of the body from the region in which the solution for infusion was administered for the first iv LCM 
infusion (Day 1). If the subject has more than 1 iv LCM infusion, it is optional to also collect plasma samples for 
the final iv LCM infusion (Day 2 to 5/Early Termination), predose and postdose, at the time points indicated in the 
table. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE. Depending on the target duration defined for the cohort and subject 
tolerability, end of infusion can be at 15, 30, or 60 minutes, or whenever the infusion is stopped (if prematurely 
terminated).
d For the first LCM infusion, the predose PK sample is required for OLL and RxL subjects and not required for IIL 
subjects. For optional PK sample collection of a subsequent LCM infusion, the predose sample should be collected 
from all subjects.
e Time points are in reference to T0 (start of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.
5.3
Rationale for study design and selection of dose
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥1 month to <17 years. The results of EP0060 will provide 
REDACT
ectroca
ctroc
me
me
nd pul
nd pul
po
p
CTED 
X
D
CT
COPY 
OP
This document
from
from
e Ti
Ti
cannot 
y
ated).
ed).
the firs
he fir
bjects
jects
be
ev
, end 
, end
used 
nfus
fus
al blood
bloo
vant 
ant 
to 
he su
he su
sion
sion
support 
aken a
ken 
ECG an
ECG a
the regi
he reg
ubje
ubj
any
mi
m
at
marketing 
lse rat
e ra
oints be
ints be
ndicated
dicat
o assure 
assur
minut
minu
author
ardiogr
rdiogr
tet
orization 
ati
or
application 
X
tio
lic
p
a
and 
an
any 
ny
an extensions 
ns
ns
ex
or r variations 
on
on
on
on
ria
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 29 of 240
safety and PK data regarding the use of the iv LCM formulation in pediatric subjects 
(≥1 month to <17 years of age). The EP0060 design is based on components of the study design 
for SP757, which evaluated iv LCM replacement in adults with partial-onset seizures, as well as 
based on design elements of other pediatric iv AED studies. In an effort to maximize the patient 
pool used in the evaluation of the safety of iv LCM in pediatric subjects, EP0060 has opened 
enrollment to include OLL and RxL subjects who are on a stable dose of oral LCM and elect to 
receive iv LCM as well as IIL subjects who are not currently taking LCM and initiate adjunctive 
LCM treatment using iv LCM. The expansion of the subject population occurred prior to the start 
of study enrollment. EP0060 also includes the option for RxL and IIL subjects to continue oral 
LCM treatment after completion of iv LCM, if determined clinically appropriate, in SP848. If 
required, a short-term supply of oral LCM solution will be provided for RxL and IIL subjects 
transitioning to start SP848 to ensure continuity of LCM treatment while allowing flexibility to 
schedule a clinical visit to initiate SP848. For RxL and IIL subjects who do not continue into 
SP848 (either by choice or not clinically appropriate), an additional telephone contact 
approximately 30 days after last dose of iv LCM IMP is added in order to collect final safety 
data. 
The iv LCM formulation at infusion durations of 15 to 60 minutes is approved at doses of 200 to 
400mg/day as adjunctive therapy in the treatment of partial-onset seizures in subjects ≥17 years 
of age with epilepsy when oral administration is temporarily not feasible, which can also include 
initiation of LCM treatment. Additionally in the EU, the iv formulation at infusion durations of 
15 to 60 minutes is also approved in pediatric subjects down to 4 years of age at maximum 
weight-based doses depending on weight band and whether LCM is administered as 
monotherapy or adjunctive therapy. An infusion duration of at least 30 minutes for 
administration >200mg per infusion (ie, >400mg/day) is preferred.
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day 
(subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatric subjects (Cohort 1) and will include at least 
20 subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 will 
enroll approximately 44 subjects (with every attempt to enroll 20 subjects ≥4 to <8 years of age, 
12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age) and will follow 
sequentially based on DMC recommendation. After completion of the first 20 subjects (Cohort 
1) and after completion of 20 subjects (Cohort 2) have received iv LCM over infusion durations 
of 30 to 60 minutes, the DMC will review the available safety and tolerability data. Based on 
their review, the DMC will recommend the target infusion duration for the remaining subjects in
the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 minutes [only for subjects 
REDACTED
ub
nd and
nd an
nfusion
fusion
e, >40
e, >40
e for
e for
COPY
pora
por
U, the
U, the
bject
bject
This document
20 su
su
enr
enr
can
00
nnot
reas
eas
60 w
60 w
ub
be
at in
at in
se
se
used
des 
des 
kg), w
kg), w
i
to
ay o
ay o
thth
support
ng
00mg/
0mg/
/kg/day
kg/da
or 6
or 6
any
owe
ow
es of
es of
marketing
or pedi
r ped
tudies 
udies
0mg/da
mg/d
eve
ev
authorization 
e i
ts dow
s dow
d whe
d whe
n dura
n dur
00mg/
0mg/
application
es is a
es is 
nset se
nset s
ly not 
y not
iv for
v for
and any
one 
ne
o coll
o coll
extensions 
P84
L subj
L sub
ng flex
g flex
ot con
t con
e co
e co
or
48.
48
variations 
ve
e start
start
oral
oral
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 30 of 240
who would directly benefit from an increased infusion rate, in the opinion of the investigator;
otherwise 30 to 60 minutes]), if the study/cohort should be stopped, and if the next cohort can be 
initiated (Section 12.7.2).
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥1 month to <17 years of age over a range of 
infusion durations. 
Taken together, the iv LCM dosing scheme and planned target infusion durations being 
evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for 
administration of a range of pediatric doses, and include infusion durations that are the same as 
those approved for adults and adolescents. 
6
SELECTION AND WITHDRAWAL OF SUBJECTS
6.1
Inclusion criteria
To be eligible to participate in EP0060, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject or by the parent(s) or legal 
representative. The Informed Consent form or a specific Assent form, where required, will be 
signed and dated by minors.
2. Subject is male or female from ≥1 month to <17 years of age.
3. Subject has a diagnosis of epilepsy with partial-onset seizures or primary generalized 
tonic-clonic seizures.
4. Subject meets 1 of the following criteria:
 OLL subject: Subject is currently receiving oral LCM as adjunctive or monotherapy as 
participants in an open-label long-term study (SP848, EP0034, or other pediatric study); 
OR,
 RxL subject: Subject is currently receiving prescribed oral LCM from commercial supply 
(eg, VIMPAT) as adjunctive or monotherapy; OR, 
 IIL subject: Subject is not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
5. Subject is an OLL or RxL subject and meets both of the following criteria: 
 Subject has been administered LCM for the treatment of epilepsy for at least 2 weeks 
prior to Screening; AND, 
 Subject has been administered (OLL) or prescribed (RxL) oral LCM at a dose of 
2mg/kg/day to 12mg/kg/day (for subjects <50kg) or 100mg/day to 600mg/day (for 
subjects ≥50kg). Open-label study drug LCM (OLL) or prescribed oral LCM dose (RxL) 
must be stable for at least 3 days prior to first LCM infusion.
-OR-
REDACTED 
partia
partia
criter
criter
COPY 
<17 y
<17 y
This document cannot 
Subj
Subj
p
be
t is a
t is a
used 
e trtr
ts.
to
Su
reat
rea
support 
ct isi
s adjun
adju
ubject
ubjec
any 
s cur
s cu
marketing 
ria:a:
ntly rec
ntly re
el long
l long
authorization
years 
years 
al-ons
ons
:
application 
mmit
mi
or by th
r by t
Assen
Assen
and 
ust b
st b
ittee
tte
any 
be m
be
extensions 
e s
S
or
am
am
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 31 of 240
Subject is an ILL subject and is on a stable dosage regimen of at least 1 AED. The daily 
dosage regimen of concomitant AED therapy must be kept constant for a period of at least 2 
weeks prior to Screening.
6. Subject is an acceptable candidate for venipuncture and iv infusion.
7. Subject is, in the opinion of the investigator, able to comply with all study requirements. 
Subject (or parent[s] or legal representative) is willing to comply with all study requirements.
8. Subject weighs ≥4kg.
6.2
Exclusion criteria
Subjects are not permitted to enroll in EP0060 if any of the following criteria are met:
1. Subject has previously received iv LCM in this study. 
2. Subject has any medical, neurological, or psychiatric condition that, in the opinion of the 
investigator, could jeopardize the subject’s health or compromise the subject’s ability to 
participate in EP0060.
3. Subject has clinically significant hypotension or bradycardia in the opinion of the 
investigator.
4. Subject ≥6 years of age has a lifetime history of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as 
indicated by positive responses (“Yes”) to either Question 4 or Question 5 of the C-SSRS at 
Screening.
5. Subject is taking monoamine oxidase A inhibitors (MAOI-A). 
For OLL subjects, enrollment in EP0060 is not permitted if any of the following additional 
criteria are met:
6. Subject has any ongoing AE in their long-term, open-label study that, in the opinion of the 
investigator, could jeopardize or would compromise the subject’s ability to participate 
EP0060 or the subject meets any of the criteria for required withdrawal from the long-term
open-label study.
For RxL and IIL subjects, enrollment in EP0060 is not permitted if any of the following 
additional criteria are met:
7. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.
8. Subject has a known hypersensitivity to any component of the investigational medicinal 
product (IMP).
9. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of participation in EP0060. 
a) Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30μg ethinylestradiol per intake (or 50μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, 
REDACTED
eith
eith
ase A i
ase A 
EP00
EP00
COPY
f suici
suic
as suic
as sui
her
h
This document 
9.9. S
cannot 
p
ubject 
bject
prod
prod
be
tion,
tion,
used 
ia a 
as a m
s a m
to 
ub
a ar
ar
support
meet
mee
bject
bject
any
ize o
ize o
ets a
ets
marketing
060 is
060 is
n their
n the
authorization
cida
cida
er Que
r Que
inhibi
nhibi
application
a in the
in th
de atte
de att
al id
l
and 
he
any
the 
the
subje
subj
extensions 
met:
met:
e o
e o
or variations 
ts.
ts.
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 32 of 240
oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also an acceptable method of contraception. 
b) The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.
10. Subject has creatinine clearance less than 30mL/min.
11. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart block at rest or a QT prolongation greater than 450ms).
12. Subject has hemodynamically significant heart disease (eg, heart failure).
13. Subject has an arrhythmic heart condition requiring medical therapy.
14. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.
15. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressive or 
neurodegenerative disease (malignant brain tumor or Rasmussen syndrome).
16. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
17. Lacosamide is intended for treatment of generalized convulsive status epilepticus. 
18. Subject has exclusively typical absence (Type IIA1) or atypical absence (Type IIA2) seizures 
(no other generalized seizure types are reported).
19. Subject has diagnosis of Dravet’s syndrome.
20. Subject has >2 upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
For enrolled subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a 
Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the Case Report form (CRF).
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re-screening.
20a. Subject is currently participating in another study of an IMP.
For IIL subjects, enrollment in EP0060 is not permitted if the following additional criterion 
is met:
REDACTED
ener
ener
ce (Typ
e (Typ
are re
are re
s syn
s syn
COPY 
o
pathy,
pathy,
ral
ral
This document 
d
cannot
eat th
at th
releva
eleva
disc
disc
be
ect h
ect h
h
used 
gnos
no
d and r
and 
to
je
osis 
osis
support
bilir
bili
diagnos
iagno
ects w
cts w
any
xULN
xUL
irub
irub
marketing
ndrom
ndrom
rmal (U
mal 
rtate a
rtate 
N
authorization 
, s
lized c
zed c
ype IIA
ype IIA
eporte
porte
application
s sys
sy
y other 
othe
asmuss
smus
such 
uch 
and
rious
ous
yste
yste
any 
s bl
s b
extensions
inv
inv
n 450m
450m
or 
ves
ves
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 33 of 240
21. Subject has been treated with LCM within the last 3 months prior to Screening.
6.3
Withdrawal criteria
Subjects are free to withdraw from EP0060 at any time, without prejudice to their continued 
care. The following criteria for subject withdrawal from EP0060 are outlined below. Additional 
discontinuation criteria for potential drug-induced liver injury are presented in Section 6.3.1.
Subjects must be withdrawn from EP0060 if any of the following events occur:
1. Subject experiences intolerable AEs and AEs associated with iv administration that, in the 
opinion of the investigator, preclude further participation in EP0060.
2. The subject requires more than 10 iv LCM doses.
3. The sponsor or a regulatory agency requests withdrawal of the subject.
4. Subject has corrected QT interval (QTc) ≥500ms that is confirmed by a cardiologist over 
read on any ECG.
5. Subject becomes pregnant during the study, as evidenced by a positive urine pregnancy test.
6. Subject develops a second- or third-degree atrioventricular (AV) block or another clinically 
relevant change in medical condition (or ECG) as determined by the investigator, or if the 
investigator feels it is in the interest of the subject to withdraw.
7. For subjects ≥6 years of age, subject has actual suicidal ideation since last visit as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Children’s Since 
Last Visit” version of C-SSRS. The subject should be referred immediately to a Mental 
Healthcare Professional and must be withdrawn from EP0060.
8. Subject is unwilling or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in EP0060.
9. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.
Participation in EP0060 may be withdrawn for any of the following reasons:
10. Subject experiences generalized convulsive status epilepticus.
11. Subject has any clinically relevant change in medical or psychiatric condition (if, in the 
opinion of the investigator, the change in condition warrants discontinuation from EP0060).
12. Subject requires a medication that is not permitted by the protocol (see Section 7.8.1).
13. Subject and/or delegated caregiver is noncompliant with EP0060 procedures or medication, 
in the opinion of the investigator.
14. Subject who initiated adjunctive LCM treatment in EP0060 and requires a change in LCM 
dose during the Treatment Period.
15. Subject electively administering LCM requires more than 2 iv doses. If, in the opinion of the 
investigator, there is a clinical need to administer more than 2 iv doses, the subject may 
remain in the study. The investigator should document the clinical need in the medical 
record/source documents. 
REDACTED
tu
Questi
Quest
ubject 
bject 
e with
e with
 con
 con
COPY
ct to 
ct to
ual su
al su
This document
14.
14. S
cannot 
ubject 
bject 
in the
in the
be
t req
t req
used 
ny y
the in
he in
to
y clin
cli
support
may
ay b
es gen
es gen
any marketing
ntinue
ntinue
n EP
EP00
0
drawa
draw
authorization
uicida
uicida
ion 4 o
on 4 
t shou
shou
hdraw
draw
application 
po
(AV) b
(AV)
mined b
mined 
withdr
withd
and 
ositiv
sitiv
any
a ca
a ca
extensions 
ard
ard
or variations 
the
the
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 34 of 240
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance. Investigators should also attempt to obtain information on subjects in the 
case of withdrawal. Withdrawal assessments, which are the same as those for Final Visit, will be 
recorded in EP0060. For subjects considered as lost to follow up, the investigator should make 
efforts (at least 1 phone call and 1 written message to the subject/subject’s parent or legal 
guardian), and document his/her efforts (date and summary of the phone call and copy of the 
written message in the source documents), to complete the final evaluation. All results of these 
evaluations and observations, together with a narrative description of the reason(s) for removing 
the subject, must be recorded in the source documents. The Case Report form (CRF) must 
document the primary reason for withdrawal.
For subjects returning to a long-term, open-label study, withdrawal assessments from the 
long-term open-label study should be evaluated separately from the EP0060 withdrawal 
assessments. The Medical Monitor may provide guidance on whether the subject should return to 
continued treatment within the long-term open-label study (OLL subject), be allowed to enroll in 
SP848 (RxL and IIL subjects), or withdraw completely. For the particular withdrawal criterion of 
requiring more than 10 iv doses or if the route of LCM administration (iv) is the sole reason for 
withdrawal of consent, subjects may be allowed to return to their long-term open-label study 
(OLL subjects) or enroll in SP848 (RxL and IIL subjects) after discussion with and agreement 
from the Medical Monitor. If an OLL subject is advised to withdraw from the long-term 
open-label study (EP0034 or SP848), the subject will be required to return to the long-term 
open-label study to complete the required withdrawal and safety follow-up assessments.
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be immediately and permanently discontinued. In addition, all concomitant medications 
and herbal supplements that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and 
right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever 
(without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below requires discussion with Medical Monitor to decide whether subject 
is allowed to continue on IMP. 
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 10.6.2. If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
REDACTED 
dra
liver 
liver 
ver inj
ver inj
tly dis
tly dis
me
m
COPY
sed t
ed
will be
will be
awal
awal
This document 
alal
cannot
with
with
PDIL
PDIL
llow
low
be
ht up
up
tho
tho
used 
with
wit
tis or h
s or h
ppe
pp
to 
th A
th A
support
5xUL
5xU
ST ≥3x
ST ≥3x
any
the f
he 
LN
marketing
scon
on
edically
dically
mmedi
mme
f
authorization 
e r
al and 
l and 
injur
njur
njury (
ury (
ntin
nti
application
r long
r long
er discu
er disc
withdr
withd
requi
equi
and
ular
lar
on (iv
n (iv
any
be a
be 
r wi
r w
extensions 
rom th
m th
ithdraw
thdraw
bject 
ject 
or variations 
ving 
ving 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 35 of 240
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The CRF must document the primary 
reason for IMP discontinuation.
7
STUDY TREATMENT(S)
7.1
Description of investigational medicinal product(s)
7.1.1
Lacosamide solution for infusion
Investigational medicinal product for infusion will be provided as LCM solution for infusion in 
glass iv vials (10mg/mL in a 20mL vial; each vial contains LCM 200mg). Both the iv vials and 
the carton containing the vials will be labeled for the study.
Further details regarding dilution and storage of LCM solution for infusion are provided in the 
IMP Handling Manual.
7.1.2
Lacosamide oral solution for RxL and IIL subjects transitioning to 
SP848
Lacosamide syrup/oral solution will be provided in a polyethylene terephthalate bottle 
(10mg/mL in 200mL bottle). The bottle will be labeled for the study. Study medication will be 
measured and administered via a dosing syringe.
Lacosamide oral solution will only be distributed to those RxL and IIL subjects who are eligible 
and choose to participate in SP848. This supply, if required, will be dispensed at Visit 2 in the 
event that additional time is needed to coordinate scheduling of Visit 1 of SP848, and any 
remaining oral LCM solution will be returned to the site at the Transition Visit.
7.2
Treatment(s) to be administered
7.2.1
Treatment Period 
During the Treatment Period, subjects will receive at least 1 dose of iv LCM at the dose levels 
noted below. The first iv LCM dose will be given on Day 1. If more than 1 infusion is given, iv 
LCM will be administered bid at approximately 12-hour intervals, once in the morning and once 
in the evening, for up to 10 doses (or up to 5 days) for clinical need administration or up to 2 
consecutive doses (over approximately 24 hours) for elective administration. 
Specific dosing regimens for subjects who will receive iv LCM replacement therapy for oral 
treatment (OLL and RxL subjects) or for subjects who will initiate adjunctive LCM treatment 
(IIL subjects) are as follows:
x Replacement for oral treatment: For OLL and RxL subjects, the iv LCM daily dose 
will be equivalent (mg-for-mg) to the subject’s current oral LCM dose or prescribed oral 
LCM (ie, VIMPAT) dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 
600mg/day. The first infusion must be equivalent to the subject’s stable oral LCM dose.
x Adjunctive LCM treatment initiation: For IIL subjects, the iv LCM daily dose will be 
2mg/kg/day for subjects <50kg or 100mg/day for subjects ≥50kg. As LCM is given bid, 
nge.
nge.
stribut
tribut
his sup
his sup
to co
to co
COPY 
n a pol
n a po
abele
abele
This document cannot 
do
do
ment (O
ent (O
L subj
subj
be 
osing
osing
used
for up
or u
oses (
oses 
to
niste
niste
up
support 
riod, s
iod, s
iv LC
LC
tered
er
any 
eriod
eriod
marketing
oordin
oordi
returne
return
o be a
o be 
authorization
y
ed for
d for
ted to 
ted to
pply, 
ply, 
application 
 subje
sub
yethyl
ethy
t
and 
usio
sio
any 
on ar
on
extensions 
for in
for in
th the 
h the
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 36 of 240
the actual dose for the first infusion will be LCM 1mg/kg (subjects weighing <50kg) or
50mg (subjects weighing ≥50kg). For these subjects, the LCM dose should remain 
unchanged for the duration of the iv Treatment Period (see Section 6.3).
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to administration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv 
LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline 
(NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total volume of 
fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.
For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 20 subjects 
≥1 month to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but 
no longer than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in each cohort will be based on DMC 
recommendation: 
x EITHER target infusion duration of 15 minutes but no longer than 30 minutes only in 
subjects who would directly benefit from an increased infusion rate, in the opinion of the 
investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion, in the 
opinion of the investigator, cannot receive the faster infusion. These subjects should receive 
an infusion of 30 minutes but no longer than 60 minutes.
x OR all remaining subjects will have a target infusion duration of 30 minutes but no longer 
than 60 minutes 
Further details on the timing of DMC recommendations regarding infusion duration are provided 
in Section 12.7.2.
For OLL and RxL subjects, the iv LCM dose can be modified after the first infusion when 
necessary for the safety of the subject or when the investigator deems it appropriate; however, 
modification should not occur until after the Day 1 PK samples have been taken. Modification of 
iv LCM dose is not permitted for IIL subjects.
A subject cannot receive iv LCM for more than 10 doses (up to 5 days) within the Treatment 
Period of EP0060 (or more than 2 consecutive doses [over approximately 24 hours] for elective 
administration. If a subject requires iv LCM treatment for more than 5 days, the subject may 
continue on iv VIMPAT, but he/she will need to discontinue EP0060. Upon 
completion/discontinuation of EP0060, OLL subjects are eligible to resume participation in their 
respective open-label study, according to the protocol requirements. If a subject is withdrawn 
from EP0060 due to requirement of more than 10 iv LCM doses, the subject may be allowed to 
return to their long term open-label study (OLL subjects) or enroll in SP848 (RxL and IIL
REDACTED 
15 min
5 min
fit
fit from
fro
ED
not di
not di
COPY 
cts in 
ts in
This document
Perio
Perio
adm
adm
cannot
M dos
dos
ubjec
ubjec
d
be
on sh
on sh
used
xL su
L su
the sa
the s
h
to 
ub
support 
ming o
ming 
any
will h
will 
marketing
irectl
irectl
t receiv
t rece
no long
o lon
ha
h
authorization
n each
each
nutes b
nutes 
m an i
m an i
l
application 
hort 1 
hort 1
d over a
over 
h
and 
s afte
s afte
any 
ody w
dy w
extensions 
g bod
bod
or 
me 
me
variations 
iviv
saline
aline
e o
e o
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 37 of 240
subjects) after discussion with and agreement from the Medical Monitor. If an OLL subject 
meets any other “must withdrawal” criteria for the respective open-label study, the subject will 
return to the open-label study to complete the appropriate withdrawal assessments and safety 
follow-up.
For RxL and IIL subjects, AED treatment will continue at the discretion of the treating 
physician, upon completion/discontinuation of EP0060. If determined clinically appropriate, 
these subjects will be given the option to continue oral LCM treatment for up to 2 years in 
SP848. If LCM treatment is not continued in SP848 (either by choice or not clinically 
appropriate), RxL and IIL subjects will be followed for approximately 30 days after the Final 
Visit in order to collect safety data. All concomitant medications taken during this 30-day period, 
including prescribed AEDs, will be collected at TC2.
If subjects need to discontinue LCM, OLL subjects should be tapered off LCM as specified in 
their long-term, open-label study or at the discretion of the treating physician for RxL subjects. 
For OLL subjects, this taper should occur as a part of the long-term, open-label study and not as 
a part of EP0060.
7.2.2
Transition oral lacosamide
Oral LCM solution will only be distributed to those RxL and IIL subjects who are eligible and 
choose to participate in SP848.
For OLL and RxL subjects, the oral LCM daily dose will be equivalent (mg-for-mg) to the 
subject’s current oral LCM dose or prescribed oral LCM (ie, VIMPAT) dose (always in bid 
regimen) of 2 to 12mg/kg/day.
For IIL subjects, the oral LCM solution daily dose (always in bid) will be 2mg/kg/day for 
subjects <50kg or 100mg/day for subjects ≥50kg if the subject has been taking LCM for less than 
7 days. If the subject has reached 7 days of LCM exposure, an increase in dose titration can be 
initiated.
7.3
Packaging
Lacosamide is manufactured, packaged, and labeled according to Good Manufacturing Practice 
guidelines and applicable laws or regulations. Lacosamide will be suitably packaged in such a 
way as to protect LCM from deterioration during transport and storage. 
7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing 
Practice and will include any locally required statements. If necessary, labels will be translated 
into the local language.
7.5
Handling and storage requirements
The investigator (or designee) is responsible for the safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access 
according to the storage conditions mentioned on the label.
REDACTED
d ora
d ora
n dail
n dail
bject
bject
COPY 
dose w
ose 
l
This document 
7.5
7.5
cannot 
sata
ce and
e and
o the l
the l
be 
g s
g s
ation
ation
used
Labe
abe
supp
supp
to 
CM
el
e
support
red, p
ed, p
ble law
le law
M from
M fro
any 
pac
marketing
ts ≥50
ts ≥5
ays
ays of L
of
authorization
will b
will b
LCM
LCM
y dos
y dos
0
application 
d IIL su
IIL s
be
and any 
an 
an
n-labe
lab
extensions
-day
da
M as s
M as s
n for
fo
or
Fin
Fin
y
variations 
nal
nal
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 38 of 240
Appropriate storage conditions must be ensured by controlling the temperature and by 
completion of a temperature log in accordance with local requirements on a regular basis, 
showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.
In the case of dispensing oral LCM solution, the investigator (or designee) will instruct the 
subject’s parent or guardian to store the IMP following the instructions on the label.
7.6
Drug accountability
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of LCM until returned or destroyed by a UCB representative.
The investigator may assign some of the investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The investigator must ensure that LCM is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired LCM must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
7.7
Procedures for monitoring drug accountability
Drug accountability must be recorded on the Drug Accountability form by site staff and 
reviewed by the UCB representative during periodic monitoring visits. 
7.8
Concomitant medication(s)/treatment(s)
7.8.1
Permitted and prohibited concomitant treatments (medications and 
therapies)
Stable use of amphetamines and sedative antihistamines is permitted during the study. 
Use of the following concomitant treatments (medications and therapies) is prohibited during 
EP0060:
x MAOI-A inhibitors
x Cannabidiols not approved or indicated for epilepsy by local health authority
Therapy which becomes necessary in the investigator’s opinion during the course of the study 
must not be refused to a subject even if described above as therapy that is expressly not 
permitted. In such cases, the subject’s participation in EP0060 may be discontinued.
REDACTED
ed on
ed on
he clin
he cli
maged
maged
cal law
cal law
COPY
r’s du
r’s d
l
This document 
EP00
P00
canno
use o
e o
of the
of th
06
06
be 
of
of
used
Perm
Perm
the
the
to 
nco
co
support
be re
e re
epresen
prese
om
om
any
for 
for 
eco
marketing
aws, r
ws, r
product
roduc
protoc
roto
m
authorization 
y in a
y in a
nical p
nical p
, and/
and/
re
application
d, unu
d, un
esentat
senta
ties for
ies fo
and any 
he
h
ghout 
ghout
extensions
rmati
mati
study
study
d, disp
disp
e ap
e ap
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 39 of 240
7.9
Blinding
This is an open-label study. 
7.10
Randomization and numbering of subjects
Subjects will not be randomized in EP0060. For an OLL subject, the unique identification 
number assigned to them in that study will be used to identify them and maintain subject 
confidentiality throughout EP0060. A unique identification number in EP0060 will be assigned 
for RxL and IIL subjects.
8
STUDY PROCEDURES BY VISIT 
Detailed tabular schedules of study procedures are provided in Section 5.2.
8.1
Screening/Baseline Period
8.1.1
Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline
Prior to the conduct of any study-related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments may be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 2). 
The Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion 
(Day 1), if necessary, provided all test results (ie, 12-lead ECG and laboratory results) are 
available and reviewed to assess inclusion and exclusion criteria prior to enrollment/treatment in 
the study. For all subjects, laboratory results obtained for routine diagnostic and medical care can 
be used whenever possible if collected no more than 24 hours prior to Screening/Baseline Visit 
in order to minimize blood loss associated with the study. At the Screening/Baseline Visit, the 
use of a central or local laboratory is at the discretion of the investigator.
If Screening/Baseline do not occur on the same day as the first infusion, oral LCM will be 
administered for OLL and RxL subjects during the Screening/Baseline Period from their 
open-label study or prescribed LCM supply in accordance with each subject’s current stable 
LCM dosage regimen of 2 to 12mg/kg/day or 100 to 600mg/day. For IIL subjects, no LCM will 
be administered during the Screening Period.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. Demographic data will be collected at Visit 1a. The following 
pretreatment assessments will be carried out at Visit 1a:
x Height and weight 
x Medical procedures
x Procedure history
x Diagnosis of epilepsy
REDACTED
bject
bjec
nts m
nts m
can o
can o
st r
st
COPY
en po
en p
orm w
orm w
cts
cts
This document
riter
iter
pret
pret
cannot
niste
niste
h subj
subj
eria
eria
be
ge re
e r
tere
ter
used 
OL
OL
dy or 
dy or 
reg
reg
to 
ne 
LL
LL
support
loss
oss
laborat
abora
do n
do n
any
ollec
ollec
ss as
s a
marketing
occu
ccu
results
results
clusion 
lusion
ory re
ory r
t
authorization
will a
ll 
will b
will b
may be
ay be
cur
ur
application 
su
su
t/legal 
legal
an will 
n wil
ssible, 
sible
also
als
and
anati
anati
ubje
ubje
any
nd/o
nd/
ion
i
extensions or variations 
ed 
ed 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 40 of 240
x Childbearing potential
x Complete medical history for RxL and IIL subjects (a medical history update will be 
captured in the previous long-term open-label study for OLL subjects) 
x For OLL and RxL subjects, LCM dosing history (including formulation, date, and time of 
use, and dose and unit during the last 3 days)
x Prior and concomitant medication(s) assessment (prior medications will only be collected 
for direct-enroll subjects)
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose),  
VNS settings, and/or use of ketogenic diet
x Urine pregnancy testing for subjects of childbearing potential 
x Withdrawal criteria
x Complete neurological examination
x Complete physical examination
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse rate) assessment (measured on subjects who have rested [sitting 
or supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x AE reporting (AEs occurring since signature of Informed Consent form). Ongoing AEs 
from the long-term open-label studies will be followed, as well as recording of new AEs 
during EP0060.
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of
depression will be evaluated as described in Section 10.7.5.
x Seizure history for RxL and IIL subjects
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will continue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open-label study or prescribed oral LCM supply, 
respectively.
The following assessments will be carried out at Visit 1b if Screening and Baseline occur on 
separate days:
x Verification that the subject continues to meet the inclusion criteria
x For OLL and RxL subjects, the LCM dosing history will be collected (including 
formulation, date, and time of use, and dose and unit during the last 3 days)
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose), 
VNS settings, and/or ketogenic diet
REDACTED
who h
who 
n feasi
feasi
since s
since 
el stu
el stu
COPY
measu
meas
asible)
asible
This document cannot
owin
wi
ate da
te da
x
be 
ing
ing
used
n and 
and 
to
OLL
OLL
support
r RxL
RxL
and th
and th
L a
L
any
uated
uate
marketing
udies 
udies
years o
ears 
d
authorization 
)
have r
have r
ible)
ible)
ignat
gnat
application 
ured on
red o
and any extensions 
las
or
st d
st d
variations 
cted 
cted 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 41 of 240
x AE reporting (AEs occurring since signature of Informed Consent form)
x Blood sample for clinical chemistry and hematology (Repetition of laboratory 
assessments is at the discretion of the investigator if Visit 1b is on a separate day from 
Visit 1a.)
x Withdrawal criteria
x Vital signs (BP and pulse rate) assessment (measured on subjects who have rested [sitting 
or supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5.
x Medical procedures
x Medical history update for OLL subjects, or complete medical history for RxL and IIL 
subjects 
x Urine pregnancy testing for subjects of childbearing potential
x Brief physical examination
x Brief neurological examination
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will continue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open-label study or prescribed oral LCM supply, 
respectively.
8.2
Treatment Period
8.2.1
Visit 2 (Day 1)
Intravenous LCM infusion treatment will begin at this visit. Subjects will receive at least 1 dose 
of iv LCM. If more than 1 infusion is given, iv LCM will be administered bid at approximately 
12-hour intervals, once in the morning and once in the evening, for up to 10 doses (or up to 5 
days) for clinical need administration or up to 2 consecutive doses (over approximately 24 hours) 
for elective administration. 
Screening laboratory assessments may be conducted up to and including the day of the infusion 
provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion. 
Section 8.1.1 details under what conditions laboratory results within 24 hours of signing the 
Informed Consent form can be used. 
The following assessments will be carried out:
x Intravenous LCM infusion
x Medical procedures
x Prior and concomitant medication(s) assessment
REDACTED 
n do n
n do n
cts wil
cts wil
ct’s op
ct’s op
COPY 
This document 
nfo
fo
Th
Th
cannot
ed the
d the
ion
on 8.8
orm
rm
be
labo
labo
used 
ne
ne
minis
minis
to
nc
eed 
eed
support
n trea
trea
n 1 inf
n 1 in
ce in t
e in 
any 
)
tm
marketing 
pen
en
od
authorization 
not oc
ot oc
ll con
l con
-lala
application 
potenti
poten
and 
al his
al his
any extensions 
st 3
symp
symp
or
3 m
3 m
variations 
ting
ting 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 42 of 240
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
x Withdrawal criteria
x AE reporting
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 
15, 30, 60 minutes, and 2 hours from the start of iv LCM infusion) (conducted on 
subjects who have rested [sitting or supine] for at least 3 minutes prior to each ECG 
recording, when feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and 
at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM 
infusion) (measured on subjects who have rested [sitting or supine] for at least 3 minutes, 
when feasible)
x Blood sample for LCM PK (Blood draws will be performed from a region of the body 
that is different from the region where the iv LCM infusion will be administered at the 
time points described in Section 9. An indwelling peripheral cannula used for the iv LCM 
infusion may not be used for PK blood sampling.) 
x C-SSRS (for subjects ≥6 years of age) after infusion. For subjects <6 years, signs and 
symptoms of depression will be evaluated as described in Section 10.7.5.
x Brief physical examination
x Brief neurological examination
x For RxL and IIL subjects who are eligible and choose to participate in the long-term 
open-label oral LCM study SP848 after completion of EP0060, a short-term oral LCM 
solution will be dispensed at Visit 2. This supply is to allow continuity of LCM treatment 
after the last iv LCM infusion and the scheduled Transition Visit. Oral LCM solution 
administration should begin approximately 12 hours after the final iv LCM infusion.
If a second iv LCM infusion is given, it will be administered at approximately 12 hours after the 
start of the first infusion, and the following assessments will be carried out:
x Intravenous LCM infusion
x AE reporting
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 
15, 30, 60 minutes, and 2 hours from the start of iv LCM infusion) (conducted on 
subjects who have rested [sitting or supine] for at least 3 minutes prior to each ECG 
recording, when feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and 
at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM 
infusion) (measured on subjects who have rested [sitting or supine] for at least 3 minutes, 
when feasible)
x Withdrawal criteria
REDACTED 
ho
ho are 
are 
P8
P
COPY
infusi
nfus
d as de
d as d
This document cannot
15, 3
15, 3
su
su
be
lead
lead
used 
portin
ortin
to
 LC
LC
support
ion is 
on is
on, and
n, an
CM
CM
any
begin
begin
marketing
e elig
elig
848 aft
48 aft
t Visit 
Visit
sion a
ion 
authorization
escr
escr
gib
gib
application
eral ca
eral c
on. Fo
on. Fo
ribe
ib
and
om 
m 
will b
will b
any 
a re
a r
extensions 
M infus
M infus
iv LC
v LC
r at le
at le
or variations 
G 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 43 of 240
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
If the subject has more than 1 iv LCM infusion, it is optional to also collect blood samples for 
LCM PK before and after the final iv LCM infusion at the time points described in Section 9. In 
addition, during the course of the study, additional blood samples for PK analysis can be taken at 
the discretion of the investigator, especially in the event of a relevant treatment-emergent AE.
8.2.2
Visit 3 (Day 2 to Day 5)
If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. If the subject has more than 1 iv LCM infusion, it is 
optional to also collect blood samples for LCM PK before and after the final iv LCM infusion at 
the time points described in Section 9. In addition, during the course of the study, additional 
blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE. 
8.3
Unscheduled Visit
The following assessments will be carried out during the Unscheduled Visit:
x Medical procedures
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x AE reporting
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x Withdrawal criteria
x C-SSRS (for subjects ≥6 years of age). The C-SSRS assessment should be completed if 
the Unscheduled Visit is due to an AE. For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5.
x Brief physical examination
x Brief neurological examination
Additional assessments can be performed at the investigator’s discretion, including collection of 
a blood sample for LCM PK if the reason for the Unscheduled Visit is an AE.
8.4
End-of-Study Period
8.4.1
Final Visit (Day 1 to 6)/Termination Visit
The Final Visit may occur on the same day as the last infusion, time permitting. Otherwise, the 
Final Visit should occur on the following day.
REDACTED 
ent
ent
nt (ide
nt (ide
ketoge
ketoge
COPY
g the
g the
This document
a blo
a blo
8
cannot
Brie
Brie
dition
ition
be
ef ph
f p
f
used
on w
n w
phy
hy
to
dule
dule
i
support 
a
ubject
ubject
ed V
ed
any 
le)e)
marketing 
enic
nic
ed on 
ed on
authorization 
entific
ntific
ic d
c d
application 
Unsche
Unsch
and
vesti
vesti
any 
l i
l 
he stu
he stu
ga
extensions
pleted 
eted
same
same
LCM 
CM 
iv L
iv L
or variations 
at 
at 
E.
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 44 of 240
The following assessments will be carried out after the last dose of iv LCM for subjects who 
complete the study, discontinue the study, or withdraw from the study prematurely:
x Medical procedures
x Concomitant medication(s) assessment
x Urine pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x AE reporting
x Complete physical examination
x Complete neurological examination
x Blood sample for clinical chemistry and hematology which must be analyzed at the 
central laboratory
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] for at least 3 
minutes prior to each ECG recording, when feasible)
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x Withdrawal criteria
x Oral LCM administration, if applicable:
 For OLL subjects, oral LCM administration will continue in accordance with each 
subject’s LCM dosage regimen using the subject’s open-label study LCM supply
 For RxL subjects who are not eligible or do not wish to continue LCM treatment in 
SP848, oral LCM administration may continue from the subject’s prescribed LCM 
supply at the physician’s recommended dosage regimen.
 For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM 
administration, from the short-term oral LCM solution that was dispensed at Visit 2,
should begin approximately 12 hours after the final iv LCM infusion regardless of 
when the Final Visit occurs. Additional assessments will be conducted at the 
Transition Visit, as outlined in Section 8.4.3.
x C-SSRS (for subjects ≥6 years of age) For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5.
8.4.2
Telephone Contact 1 (Day 2 to Day 9)
One to 3 days after the Final Visit, a safety follow-up/telephone assessment will be conducted 
during the End-of-Study Period. The following assessments will be collected:
x Medical procedures
x Concomitant medication(s) assessment
x AE reporting
REDACTED 
icable
icable
CM ad
CM a
gim
gi
COPY
o hav
o hav
This document 
.4.
4
On
On
cannot
C-SS
SS
dep
dep
.2
be 
r
SSR
SSR
used
n the
the
ansit
ansit
to
begi
begi
F
support 
IIL sub
IIL su
tion
ion, f
in a
any 
min
mi
cian’
cian
marketing 
adm
men us
men us
are not
re no
inist
inis
authorization 
e:
mini
mini
application
tting o
ting 
e rested
reste
and any 
be an
be an
extensions or variations 
se), 
e),
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 45 of 240
x Information regarding LCM dosing since Final Visit
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
During the contact, the site should inquire as to whether the subject noted any change at the 
site of the infusion.
8.4.3
Transition Visit (Day 1 to Day 13)
For RxL and IIL subjects who are eligible and wish to enroll in SP848, the Final Visit and 
Transition Visit may occur on the same day or may occur up to 7 days after the Final Visit. The 
Transition Visit for EP0060 should occur on the same day as Visit 1 in SP848.
The following assessments will be conducted at the Transition Visit if the visit is not conducted 
on the same day as the Final Visit:
x Collection of the short-term oral LCM solution, if dispensed at Visit 2 
x Information regarding LCM dosing since Final Visit
x Concomitant medication(s) assessment
x AE reporting
Additional assessments for enrollment in SP848 (Visit 1) are detailed within the SP848 protocol.
8.4.4
Telephone Contact 2 (Day 29 to Day 37)
Thirty days (±2 days) after the Final Visit, a safety follow-up/telephone assessment will be 
conducted during the End-of-Study Period (29 to 37 days after Visit 2/Day 1). This assessment 
will only occur for those subjects who directly enrolled in EP0060 and will not be continuing 
LCM therapy in SP848. 
The following assessments will be collected:
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or use of ketogenic diet
x AE reporting
x Information regarding LCM dosing since Telephone Contact 1
x Medical procedures
During the contact, the site should inquire as to whether the subject noted any change at the 
site of the infusion.
9
ASSESSMENT OF PHARMACOKINETICS
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of IMP and the time of blood sampling must be 
recorded.
During the Treatment Period, plasma samples will be taken for LCM and SPM 12809
determination after ECG and vital signs have been taken. Plasma samples will be obtained from 
REDACTED
safety
safet
d (29 t
(29 t
direct
direc
COPY
sit 1)
sit 1
9 to D
to D
This document 
9
Bl
Bl
cannot
ng t
ng t
te of t
e of t
be 
ic
the
th
used
ion r
n 
al pr
al p
to 
n reg
reg
support
) a
)
genic 
genic
any 
asses
asses
d
marketing 
ollected
llecte
) asse
) ass
authorization
Day 
ay 
y follo
y follo
to 37 
to 37 
tly enr
ly en
application 
are det
re de
37
3
and any extensions 
not con
ot co
2
or variations 
t. The
. The
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 46 of 240
a different region of the body from the region in which the solution for infusion was 
administered, at the following time points:
First iv LCM infusion (Day 1) – required samples:
x Predose (within 1 hour prior to iv LCM dose) for OLL and RxL subjects
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
Final iv LCM infusion (Day 2 to 5/Early Termination) – optional samples:
x Predose (within 1 hour prior to iv LCM dose)
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
Additional blood samples for PK analysis can be taken at the discretion of the investigator, 
especially in the event of a relevant treatment-emergent AE.
The study-related blood loss (including any losses in the maneuver), per study subject, will not 
exceed 3% of the total blood volume during a period of 4 weeks and will not exceed 1% at any 
single time. The total volume of blood is estimated at 80 to 90mL/kg body weight; 3% is 2.4mL 
of blood per kg of body weight. With today’s microanalytical techniques, plasma samples for 
drug level determinations can be small, with less than 1mL needed.
Details of plasma sample collection and processing, sample labeling, and shipment will be 
provided in the laboratory manual.
10
ASSESSMENT OF SAFETY
10.1
Adverse events
10.1.1
Definition of adverse event
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, 
whether or not related to the IMP.
In order to ensure complete safety data collection, all AEs occurring during EP0060 (ie, after the 
signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by the protocol (excluding hospitalization procedures for other conditions other than 
those related to epilepsy), must be reported in the CRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the
investigator from the subject’s history or the Screening/Baseline assessments.
REDACTED
AFET
AFET
rse e
rse e
COPY
, samp
, sam
This document 
ign
gn
recor
recor
inin
cannot 
oce
ce
s that
that
ns o
ns o
be 
d to
edur
edur
used
orm
or
e proto
proto
to ep
o ep
to
rmed
me
support 
g), 
), 
the IM
he IM
mplete
mplet
d
any
efore
for
sym
sym
marketing 
even
ven
urrence
urrenc
oduct t
duct
e b
e
authorization 
TY
nt
application 
kg
echniqu
chniq
eeded.
eeded
ple lab
le lab
and
will 
will 
g bod
bod
any
study
study
no
no
extensions 
nvesti
vesti
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 47 of 240
10.1.2
Procedures for reporting and recording adverse events
The subject (or parent[s] or legal representative) will be given the opportunity to report AEs to 
the investigator spontaneously. A general prompt will also be given by the investigator at each 
study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
10.1.3
Description of adverse events
When recording an AE, the investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The CRF and 
source documents should be consistent. Any discrepancies between the subject’s own words (or 
the words of parent[s] or legal representative) on his/her own records (eg, diary card) and the 
corresponding medical terminology should be clarified in the source documentation.
Details for completion of the Adverse Event CRF (including judgment of relationship to IMP)
are described in the CRF Completion Guidelines.
10.1.4
Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the investigator determines 
that it is no longer clinically significant, or the subject is lost to follow up.
If an AE is ongoing at the end of EP0060 for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
investigator must provide a justification. The follow up will usually be continued for 30 days 
after the subject has discontinued IMP. Any ongoing AEs at the end of EP0060 for the subjects 
enrolled in the open-label studies will not need to be re-recorded in the long-term, open-label 
study.
10.1.5
Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:
x The outcome date of the first AE that is not related to the natural course of the disease 
being the same as the start date of the repeated AE, and the outcome of “worsening”
x The AE verbatim term being the same for the first and repeated AE, so that the repeated 
AE can be easily identified as the worsening of the first one
10.1.6
Pregnancy
If an investigator is notified that a subject has become pregnant after the first dose of iv LCM 
infusion, the investigator must immediately notify UCB’s Patient Safety (PS) department by 
providing the completed Pregnancy Report and Outcome form (for contact details see Serious 
Adverse Event reporting information at the beginning of this protocol). The subject should be 
withdrawn from the study as soon as pregnancy is known (by positive pregnancy test), and the 
following should be completed:
x The subject may need to discontinue iv LCM. The decision to stop the intake of iv LCM 
will be at the discretion of the investigator. 
or
ost to 
ost to
The fo
he fo
. Any 
. Any
ll not
ll not
COPY 
bject, f
ject, f
r unti
unti
This document
rov
ov
Adv
Adv
w
cannot
vesti
vesti
sion, t
ion, t
vidi
vidi
be used
be ea
e ea
P
to
bati
bat
support
of the
of th
as the 
as th
im
any
an A
an A
marketing
nee
nee
on of a
n of
E
authorization
fo
til the 
il the
fol
follow
low
ollow 
ollow 
ongo
ongo
ed
ed
application 
quelae
quelae
t to fol
to fo
ollow
llow
and any
elat
ela
extensions
wn wo
n wo
ard) a
ard) a
tation
ation
atio
atio
or
CRF
CR
variations 
g
F
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 48 of 240
x A Safety Follow-Up Visit should be scheduled 1 to 3 days after the subject has 
discontinued her iv LCM infusion.
The investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions related to the data collection for 
the pregnancy, eventual birth, and follow up.
A pregnancy becomes a serious adverse event (SAE) in the following circumstances: 
miscarriage, abortion (elective or spontaneous), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal 
demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally 
reported using the Investigator SAE Report form.
10.1.7
Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
10.1.8
Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the CRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
10.1.9
Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital
REDACTED
f an
f an
ected 
ected 
SAE; s
SAE; 
owe
owe
COPY 
bab
b
n i
n i
This document 
afet
fe
autho
autho
T
cannot 
cted d
ted d
ety c
ty c
be used
ted 
ed 
AE (e
AE (e
to
her S
her 
cl
support 
d that 
d tha
Any SA
Any S
SA
SA
any 
inve
inve
marketing 
suc
uc
ed as a
ed as a
ng tran
ng tra
nfectio
nfect
authorization 
infect
nfect
transm
rans
ch c
ch c
application
nancy
nanc
ctly us
ctly u
y. Thos
Tho
and 
g circ
g circ
any 
e d
e d
extensions
In
an 30 
an 30 
mentati
entati
led at 
ed at 
data
dat
or
n ce
n ce
variations 
ade to
de to
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 49 of 240
signs, laboratory, or ECG results) for which data will be periodically reviewed during the course 
of the study.
10.2
Serious adverse events
10.2.1
Definition of serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet at least 1 of the following criteria:
x Death
x Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred 
in a more severe form.)
x Significant or persistent disability/incapacity
x Congenital anomaly/birth defect (including that occurring in a fetus)
x Important medical event that, based upon appropriate medical judgment, may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent 1 of the 
other outcomes listed in the definition of serious
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 10.3], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)
x Initial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization 
criteria. However, emergency room visits that do not result in admission to the hospital 
would not qualify for this criteria and, instead, should be evaluated for 1 of the other 
criteria in the definition of serious [eg, life-threatening or important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or 
manifested in an unusual or uncharacteristic manner] do not qualify for reporting. For 
example, if a subject has a condition recorded on his/her medical history and later has a 
preplanned surgery for this condition, it is not appropriate to record the surgery or 
hospitalization as an SAE, since there is no AE upon which to assess the serious criteria. 
Please note that, if the pre-existing condition has worsened or manifested in an unusual or 
uncharacteristic manner, this would then qualify as an AE and, if necessary, the 
seriousness of the event would need to be determined.)
10.2.2
Procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The investigator must forward to UCB (or its representative) 
REDACTED 
equ
equ
not re
not re
or dru
or dr
on or p
on or p
t
COPY 
us
us
ut are n
ut are
uirin
uiri
This document cannot
prep
prep
ho
ho
be
ampl
ampl
l
used
or el
r el
ested 
sted 
to
tion
tion
lec
ec
support
for th
or th
efinitio
finitio
ns fo
ns
any 
w
ergenc
rgen
his
hi
marketing 
pro
ro
tal, eve
al, ev
ent hos
nt ho
would
woul
authorization 
not
no
ng int
g int
esult i
sult i
ug abu
ug ab
olon
olon
application
dical 
ical
cal inte
al int
ot lim
t lim
and
a fetu
fetu
l j
any 
us)
extensions 
h had 
had 
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 50 of 240
a duly completed “Investigator SAE Report Form for Development Drug” (SAE report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.
An Investigator SAE report form will be provided to the investigator. The Investigator SAE 
Report form must be completed in English. 
It is important that the investigator, when completing the SAE report form, includes the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE report form.
The investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the investigator of any SAE within this period. Serious AEs that the 
investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the Investigator’s 
Brochure.
10.2.3
Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events are provided in Section 10.6.2.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety database without limitation of time.
10.3
Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.
The following are AEs of special interest:
x The following arrhythmias: atrial fibrillation/flutter, ventricular tachycardia or 
fibrillation, AV block (second-degree Type I and II and third-degree), and marked 
bradycardia (<45beats/min)
x Syncope or loss of consciousness (other than seizure related)
IM
IM
tudy.
tudy.
UCB w
UCB w
e expe
e expe
COPY
nd to
nd t
ithin t
ithin 
MP m
MP
This document
admi
dmi
Th
T
cannot 
E of sp
of sp
edited
edite
ini
be used
AE
A
e with
with
A
to
Es o
Es o
support 
ger 
er
pplies t
plies
f PDIL
f PDIL
b
any
til it
til i
clin
cli
marketing 
ecte
cte
ous a
ous a
t h
t
authorization
this 
his
must b
must 
will pe
ill pe
tedn
edn
application 
o UCB
UCB
way ass
ay as
also in
also i
s pe
s pe
and 
e do
do
any
comp
com
ocum
ocu
extensions
he
in an
in an
vestig
vestig
mp
or
e IM
e IM
variations 
insigh
nsig
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 51 of 240
x Serious suspected multiorgan hypersensitivity reactions
Serious suspected multiorgan hypersensitivity cases may be identified and reported to the 
sponsor by the investigator using the following algorithm as agreed with the US Food and Drug 
Administration; an AE or laboratory value (as defined in the following text) suggestive of 
internal organ involvement (including, but not limited, to hepatitis, nephritis, pneumonitis, 
carditis, colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system involvement) 
combined with at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia.
Treatment-emergent abnormal laboratory value criteria suggestive of internal organ involvement 
or eosinophilia:
 Eosinophils % ≥10%
 Eosinophils absolute ≥0.5G/L
 Neutrophils absolute <1.5G/L
 Platelets ≤100G/L
 ALT ≥2×ULN
 AST ≥2×ULN
x Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality, must ALWAYS be reported to UCB as an AE of special 
interest (ie, without waiting for any additional etiologic investigations to have been 
concluded). Follow-up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.
10.4
Immediate reporting of adverse events
The following AEs must be reported immediately by the investigator to UCB:
x SAE: AE that the investigator classifies as serious by the above definitions regardless of 
causality
x Suspected transmission of an infectious agent via a medicinal product
x AE of special interest (see Section 10.3)
10.5
Anticipated serious adverse events
The following list of anticipated SAEs is anticipated to occur in the epilepsy population at some 
frequency that is independent of drug exposure. 
This list does not change the investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 10.2.2.
Table 10‒1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC
MedDRA PT
Congenital, familial and genetic disorders
Teratogenicity
REDACTED
AYS
AYS
y addi
addi
tion sh
tion sh
on and
on and
COPY 
LT or 
LT or
, with
with
b
This document 
his
his
SAE
SAE
cannot 
owi
wi
ency t
ncy t
s lis
s lis
be 
wing
wing
used 
ecia
cia
An
An
to
al in
al i
support 
nsmissi
smiss
any 
stigat
stiga
marketing
d mo
mo
ing of
ng o
ted im
ed im
authorization
h no a
h no 
be rep
be rep
itiona
tiona
hould
ould
mon
on
application 
AST w
AST 
l
and any extensions or variations 
t)
veme
eme
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 52 of 240
Table 10‒1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC
MedDRA PT
General disorders and administrative site 
conditions
Sudden unexplained death in epilepsy
Nervous system disorders
Convulsiona
Incontinence
Status epilepticus
Pregnancy, puerperium and perinatal disorders
Abortion spontaneous
Psychiatric disorders
Psychotic behavior
Abnormal behavior
Anxiety
Sleep disorder
Reproductive system and breast disorders
Menstrual disorder
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; 
SOC=system organ class
a Convulsion if consistent with the seizure type known for the subject. 
10.6
Laboratory measurements
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study assessments (Section 5.2). To minimize risk from 
blood loss associated with this study, local laboratory results obtained for routine diagnostic and 
medical care can be used whenever possible if collected no more than 24 hours prior to 
Screening/Baseline Visit. Use of the central or local laboratory is at the discretion of the 
investigator for all visits except the Final Visit. The central laboratory must be used for 
laboratory samples collected at the Final Visit. Samples will be prepared and evaluated by a 
central laboratory as described in the laboratory manual.
All laboratory values that are outside the normal reference range must be assessed by the 
investigator for clinical relevance. The following parameters will be measured:
nts
nts
matolo
matolo
tudy a
tudy a
y, loc
y, loc
COPY 
fefe
he subj
he sub
This document cannot be used to
nica
nica
support
ribed 
bed
that ar
hat ar
al re
al r
any 
the
th
at the 
t the
i
marketing
cal lab
cal lab
ossible
ossibl
he cent
e cen
he Fin
e F
authorization
ject.
ect.
ogy an
ogy an
ssessm
sessm
b
applica
term;
erm; S
cation 
derer
n
ca
and 
d
a
any y extensions 
io
te
or 
o variations 
tititi
ati
va
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 53 of 240
Table 10‒2: Laboratory tests
Hematology
Clinical chemistry
Hematocrit
Hemoglobin
Platelet count
Red blood cell count
White blood cell (WBC) count
WBC differential count
Calcium
Phosphorus
Serum electrolytes (sodium, potassium, chloride, bicarbonatea)
Creatinine
Blood urea nitrogen
AST
ALT
Total bilirubin
Alkaline phosphatase
Gamma-glutamyltransferase
Glucose
Albumin
Total protein
Cholesterol
Triglycerides
Uric acid
ALT=alanine aminotransferase; AST=aspartate aminotransferase; WBC=white blood cell
a Bicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for bicarbonate in subjects 
weighing less than 8kg in cases of suspected metabolic disturbances such as metabolic acidosis. 
10.6.1
Pregnancy testing
Females of childbearing potential will have pregnancy testing performed according to the tabular 
schedule of study procedures (Section 5.2).
10.6.2
Liver function tests and evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 10.6.2.2 with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 10.3), and, if applicable, also reported as an 
SAE (see Section 10.2.1). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 10‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 10.6.2.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 10.6.2.4).
TE
minotra
inotr
eighin
eighin
ed met
ed met
COPY 
This document 
Tabl
abl
con
con
h
cannot
ee Se
Se
luatio
uatio
lele
be
 an
 an A
ec
ec
used
d as 
as 
rence.
ence.
A
to 
ired
re
an
an
support
tion
ion
ntinuati
tinua
ed fo
d f
any
ect
ec
n te
n
marketing 
tabo
abo
will ha
will h
tion
tio
authorization 
riz
ansfera
ansfera
g less t
less t
olic
olic
application and any extensions or variations 
n
on thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 54 of 240
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be
recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI. 
REDACTED 
nve
nve
COPY 
g in
estig
esti
This document cannot be used to support any marketing authorization 
gate P
gate P
application 
, IM
uced liv
ced li
and 
IMP
MP
any
to a s
o a 
extensions 
hat are
at are
r shou
shou
d cons
cons
s
or variations 
the
he
to be
to b
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 55 of 240
Table 10‒3: Required investigations and follow up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptoms
a of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULN
b
NA
Hepatology consult.
c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 10.6.2.3);
recommended to 
occur at the site 
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.
d
≥5xULN
NA
NA
≥3xULN
NA
Yes
≥3xULN 
(and ≥2x 
Baseline) 
and
<5xULN
<2xULN
No
Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 10.6.2.2).
Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).
≥5xULN 
(and ≥2x 
Baseline) 
<2xULN
No
Discussion with 
Medical Monitor 
required.
Immediate, 
permanent IMP 
discontinuation.
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see 
Section 10.6.2.3).
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d
REDACTED 
T
r 
e
llo
ll
T
CTE
F
TE
CT
COPY 
This document t cannot 
c
be used to 
o support 
dical
ica
require
equir
s
any 
sion w
sion w
al M
l M
y marketing 
ows 
ws 
nuation
uatio
g
m
authoriz
Furthe
Furthe
– im
im
d
authorization 
riz
a
application 
a
tes
te
io
and
hemis
emi
and 
nd
any 
l: M
l: 
repeat
repea
t
extensions 
Ev
Ev
o
Mu
Mu
xt
o
Follo
oll
o variations 
on
ow
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 56 of 240
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
c Details provided in Section 10.6.2.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabilization is at the discretion 
of the investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any
nee
ne
extensions
he Me
e Me
n for a
for a
ermina
rmina
ed
ed
or variations 
on
ealthca
althca
normal
ormal
ms in
ms in
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 57 of 240
10.6.2.1
Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 10.6.2.3) and SAE report (if applicable).
10.6.2.2
Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 10‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
10.6.2.3
Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 10‒4 (laboratory measurements) and Table 10‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
REDACTED
on req
on req
may h
may h
 and 
 and T
mation
mation
t
COPY
otox
otox
sion o
sion o
This document cannot be used to support
e s
also be
lso be
remen
emen
any 
tored
tored
marketing
n col
col
story of
ory of
ese add
se ad
authorization
of a
of a
quired 
uired 
have b
have b
Table
able
olle
lle
application
l s
or sho
or sho
nd cons
nd con
c to a su
to a 
alte
lt
and 
1
supp
upp
any
iate
iat
0‒3 f
extensions 
f hepa
f hepa
e i
e i
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 58 of 240
Table 10‒4: PDILI laboratory measurements
Virology-
related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology
Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
WBC differential count
Urinalysis
Toxicology screen
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
ALT
AST
ALP
GGT
Albumin
Additional
Prothrombin time/INR
a
Serum pregnancy test
PK sample
ED
AC
unt
unt
RE
COPY 
Y
CO
This document 
m
um
cannot be use
A
used
elev
ev
se
u
to
rum
um
vat
support 
rubin
rubi
n
m CP
m C
up
any 
n
an marketing 
t
g
ket
ma
authorization 
n
za
tho
a
application
(quali
(qual
tio
pl
and
tative
ativ
iti
an
any 
e)
an extensions 
obtain
btain
on
ex
or 
or variations 
on
on
on
on
ria
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 59 of 240
Table 10‒4: PDILI laboratory measurements
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase; GGT=gamma-glutamyltransferase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RBC=red 
blood cell; RNA=ribonucleic acid; ULN=upper limit of normal; WBC=white blood cell
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
Table 10‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
x 
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
x 
Adverse reactions to drugs
x 
Allergies
x 
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)
x 
Recent travel 
x 
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
10.6.2.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 10‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilization is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
REDACTED 
e disor
e diso
COPY 
no
n
This document 
A
cannot
postmo
ostm
ot 
f an
an
ot
ca
ALT
ALT
be 
ny s
ny s
e used 
dru
dru
r imag
imag
ed to 
ug u
ug u
o supp
icant h
cant h
pport 
t pa
p
pp
s
any
linic
linic
ain o
ain 
marketing 
lving th
ving t
anation
anatio
al
m
authorization 
rders (
rders 
application 
coholic
cohol
n and
phen,
hen
any 
he
h
an extensions 
ex
or variations 
rnative
ative
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 60 of 240
10.7
Other safety measurements
10.7.1
Vital signs, body weight, and height
Noninvasive measurements of BP (systolic and diastolic) and pulse rate will be performed after 
at least 3 minutes at rest, when feasible, according to the tabular schedule of study assessments 
(Section 5.2). Body weight will be determined without shoes and wearing light clothing, and 
height will be measured without shoes; body weight and height will be assessed according to the 
tabular schedule of study procedures (Section 5.2).
10.7.2
12-lead ECG
Standard 12-lead ECGs will be performed according to the tabular schedule of study procedures 
(Section 5.2).
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 3 minutes prior to each recording and should be motionless during the 
recording, when feasible.
10.7.3
Overall ECG interpretation
An immediate initial review of the ECGs will be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically significant, then the ECG 
should be repeated in 1 hour, unless circumstances require a more rapid assessment. If the 
clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, the subject must be withdrawn from EP0060 (see Section 6.3). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the 
complete clinical picture and whether this finding influences the subject’s participation in 
EP0060. Additionally, the ECGs will be sent to a central reader for review.
10.7.4
Physical examination
10.7.4.1
Complete physical examination
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. Clinically significant physical examination findings 
are to be reported as AEs.
10.7.4.2
Brief physical examination
The brief physical examination will include a review of the following body systems: 
cardiovascular, pulmonary, abdominal (hepato-gastrointestinal), and dermatologic.
10.7.5
Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5‒1). If the Screening 
and Baseline visit is on the same day, the C-SSRS does not need to be completed twice. The 
C-SSRS should be performed once per day during the Treatment Period. If Screening/Baseline 
REDACTED
d by 
d by
withdra
withdra
ologist
ologis
CG ab
CG ab
CG
CG
COPY
rere
ator to
ator to
es req
es req
th
This document
10.7
0.7
S
cannot
ief ph
ef ph
diovas
iovas
be used
ted as
d as
B
to
eview
vie
support
e phy
e phy
al exam
l exa
w
any
mina
min
marketing 
bno
no
findin
findin
er this f
r this
will be
will b
authorization
quire
quire
he rep
he rep
awn fr
wn f
t at th
at th
norm
orm
application 
cally by
ally b
ng iden
g ide
be clin
be cl
a
and any
nless
les
extensions
y proc
pro
dings.
dings.
s d
s d
or variations 
he
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 61 of 240
and Visit 2 occur on the same day, 2 assessments should be completed with 1 predose and 1 after 
infusion.
All subjects who are ≥6 years of age will complete the “Baseline/Screening” version of the 
C-SSRS at Visit 1 and will complete the “Since Last Visit” version at subsequent visits. If a 
subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS 
should be used at the first visit at which the subject is 6 years of age and the “Since Last Visit” 
version used at subsequent visits.
The C-SSRS is not validated for subjects <6 years of age and will not be used for this population. 
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The investigator should be aware of common warning signs that might be a signal for 
risk of depression. For common signs and symptoms of depression in children younger than 
6 years old, reference should be made to the current version of the Diagnostic and Statistical 
Manual of Mental Disorders. Parents and caregivers should also be advised accordingly and 
effort should be made at clinic visits to specifically assess potential depression.
10.7.6
Neurological examination
10.7.6.1
Complete neurological examination
The complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and 
sensation. Clinically significant neurological examination findings are to be reported as AEs.
10.7.6.2
Brief neurological examination
The brief neurological examination will include selected assessment of mental status, cranial 
nerves, and coordination/cerebellar function.
11
STUDY MANAGEMENT AND ADMINISTRATION 
11.1
Adherence to protocol
The investigator should not deviate from the protocol. However, the investigator should take any 
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the IEC/IRB or sponsor.
After implementation of such measure, the investigator must notify the CPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
11.2
Monitoring
UCB (or designee) will monitor the study according to UCB (or designee) approved Standard 
Operating Procedures (SOPs), ICH-GCP guidelines, and applicable regulatory requirements, to 
ensure that study initiation, conduct, and closure are adequate.
The investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The investigator(s)/institution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
REDACTED
exam
exam
mina
mina
will inc
will in
func
func
COPY
ele
el
h), cra
h), cr
one), c
ne), 
i
This document 
CB
C
Oper
Oper
en
en
cannot 
B (o
B (o
be
hour
hour
used 
mm
mm
entati
entati
o
med
med
support
ot dev
t dev
eviatio
viatio
ny im
ny im
i
any
o pr
o p
viai
marketing 
cl
ction.
ction.
GEME
GEM
ro
r
authorization
coord
coord
minatio
natio
ation
ation
lude
ude
application 
ed asse
d asse
nial ne
nial n
din
d
and any 
ac
a
ession
ession
extensions
s
be a s
e a s
ounge
unge
and S
and S
acco
cco
or
igns
ign
variations 
ulatio
ulatio
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 62 of 240
The investigator will allow UCB (or designee) to periodically review all CRFs and 
corresponding source documents (eg, hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of CRFs, ensure that all protocol 
requirements, applicable authorities regulations, and investigator’s obligations are being fulfilled, 
and resolve any inconsistencies in the study records.
11.2.1
Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Printouts of electronic CRF screens are not considered 
acceptable source documents.
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, or quality of life 
questionnaires, for example. Source documents should be kept in a secure, limited access area.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the investigator and become a permanent part of the subject’s source documents. The 
investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
11.2.2
Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the CRF should be supported by source 
documents, unless otherwise specified in Section 11.2.1.
11.3
Data handling
11.3.1
Case Report form completion
The study is performed using electronic data capture (EDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the electronic CRFs and in all 
required reports.
Any change or correction to the CRF after saving must be accompanied by a reason for the 
change.
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will need to be reapproved by the investigator.
The investigator should maintain a list of personnel authorized to enter data into the electronic 
CRF.
Detailed instructions will be provided in the CRF Completion Guidelines.
REDACTED 
ling
ling
to en
to en
ion
ion
uracy
uracy
h
COPY
ted, t
ted, 
of the
of the
ng th
g t
This document
Corr
Corr
pa
pa
cannot
hange
hange
nge.
nge.
be
port
port
used
form
orm
ing o
ing o
to 
e
me
me
support 
andlin
ndlin
Repo
Rep
any 
ll l 
specif
peci
marketing
y and
y and
h regard
h rega
s, recor
reco
data
dat
authorization
e sub
sub
he mo
he mo
sure a
ure a
d
application
n a sec
n a se
ectroni
ectron
hese co
ese co
ubjec
bje
and 
ratat
scales
cales
any
d. Th
d. T
tory 
ory
extensions
rin
tachm
achm
consid
consi
he
h
or
ntin
tin
variations 
eing
ing
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 63 of 240
11.3.2
Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. As the study is performed using EDC, the data are entered into the electronic CRFs 
once and are subsequently verified.
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
11.3.3
Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log.
The investigator will keep a Subject Identification Code list. This list remains with the 
investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
11.4
Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the sponsor or by the investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
11.5
Archiving and data retention
The investigator will maintain adequate records for the study, including CRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact 
UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The investigator will also notify UCB should he/she 
REDACTED
nd or 
nd or 
any ti
any ti
ncomp
ncomp
ect to 
ect to 
COPY 
This document
All e
ll e
app
app
cannot
ory r
y r
rts, inf
ts, in
ess
es
be
igato
igato
es
es
used
Arch
Arch
or
to
her 
her 
support 
C 
C 
n by th
by th
require
equir
r ma
m
any
n or 
n or
shou
shou
marketing 
qual
qua
d or su
d or su
regulato
egula
r su
r s
authorization 
prema
prema
ime fo
ime fo
plete d
plete 
alili
application
ded in
ded in
e dates
e date
and 
em
ect.
ct.
any 
mains
mains
extensions 
tion C
on C
ing an
ng an
or variations 
s in 
s in 
d.d.
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 64 of 240
relocate or move the study-related files to a location other than that specified in the sponsor’s 
trial master file.
11.6
Audit and inspection
The investigator will permit study-related audits mandated by UCB, and inspections by domestic 
or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and well-being of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the investigator will immediately 
inform UCB (or designee).
11.7
Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
investigator, institution, institution staff, or designees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study.
12
STATISTICS
Selected disposition, exposure, demographic, and Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Within cohort and infusion 
duration, presentation will include the IIL subject group and the OLL and RxL subject group.
Descriptive statistics will be displayed to provide an overview of the Baseline characteristics, 
PK, and safety results.
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan.
12.1
Definition of analysis sets
The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study drug 
LCM (oral and/or iv). Selected safety summaries will be presented for the SS.
The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of EP0060 
study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety data.
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS-iv having 
provided at least 1 measurable postdose plasma sample (with recorded sampling time) on at least 
1 study day with documented iv LCM intake times and without important protocol deviations 
impacting the interpretability of the PK analysis.
12.2
General statistical considerations
All computations for the non-PK analyses will be performed using SAS® version 9.1 or later 
(SAS Institute, NC, USA).
REDACTED 
graphi
graph
s ove
s ove
COPY
s of 
s of
mplian
mplia
This document
The P
he 
pro
pro
cannot
fety S
ety S
y drug
drug
P
be 
and
nd
S
used 
t (SS) 
(SS) 
d/or
d/or
to
finit
ini
support
l meth
met
itio
ti
any 
ho
h
marketing
erall, 
erall,
e IIL su
e IIL s
ayed t
ayed 
authorization
nce 
ce 
c, and
, and
application 
tory re
tory re
he spon
e spo
e ma
ma
and any 
c
ator w
ator 
extensions
, the
the
atory 
tory 
cord
ord
or
on 
on
e
variations 
he
going
going
n of
of
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 65 of 240
Summary statistics will consist of frequency tables for categorical variables. For continuous 
variables, descriptive statistics (number of available observations, mean, median, standard 
deviation [SD], minimum, and maximum) will be tabulated. For PK parameters, the coefficient 
of variation (CV) and geometric mean may also be presented.
12.3
Planned pharmacokinetic analyses
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected. 
12.4
Planned safety analyses
Safety analyses will be presented by age cohort. 
Inferential statistical tests are not planned for the safety variables. In general, for continuous 
safety variables (eg, ECG measurements including QTc, and vital signs measurements), the 
descriptive analyses (n, mean, SD, median, minimum, maximum) for the actual measurement 
and its change from Baseline (defined as pre-iv LCM measurement) will be presented by 
day/time of collection for each infusion day. When analyzing categorical data, the number and 
percentage of subjects in each category will be presented. In addition, shift tables may be used to 
evaluate the number and percentage of subjects having a different post-iv LCM status when 
compared with their pre-iv LCM status.
12.5
Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary outcomes for an individual subject. The criteria for identifying 
important protocol deviations will be defined within the appropriate protocol-specific document. 
Important protocol deviations will be reviewed as part of the ongoing data cleaning process and 
data evaluation. All important deviations will be identified and documented prior to database 
lock to confirm exclusion from analysis sets.
12.6
Handling of dropouts or missing data
There will be no special procedures for handling withdrawals and missing data.
12.7
Planned interim analysis and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 20 subjects in Cohort 2. 
12.7.1
Definition of stopping rules
No formal stopping rule will be applied. The DMC may give a recommendation to stop the study 
after reviewing the safety data as described in Section 12.7.2. A recommendation for stopping 
should be based on the collective experience of the DMC members. After meeting to review data 
from each cohort, the DMC will provide a recommendation in writing regarding whether to 
continue or to stop the study. UCB will consider this recommendation and ensure the study 
investigators are informed of the sponsor’s decision on how to continue as described below.
REDACTED
viat
viat
ns fro
ns fro
omes 
omes 
e defin
e defin
e re
e r
COPY 
g a
g 
atio
tio
This document 
No f
o 
after
after
sh
sh
cannot 
1
form
form
be
subj
sub
used
im an
m an
a DM
DM
to 
nn
support 
proced
proce
ned i
ed 
any 
dro
dro
marketing
ned
ed
eviewe
eviewe
ations w
tions 
nalysis
alysi
authorization 
ons
ns
om the
m the
for an
for an
d w
d w
application
tegori
egor
addition
dditio
ifferent
feren
and 
he 
he 
will 
will 
i
any
easu
easu
actu
ac
extensions 
l, for c
 for c
ur
or variations 
d d 
on 
on 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 66 of 240
12.7.2
Data Monitoring Committee
The DMC members will be defined in the DMC charter. 
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion durations as follows:
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to receive 
iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of
30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped.
REDACTED 
nitiate
nitiate
jects 
jects 
COPY 
ill be 
ill be
nger 
nger 
This document cannot 

3
be
from
from
used 
ur
u
minu
minu
to
ratio
ratio
support 
oh
oh
ows: 
ws: 
oxima
oxim
any
sub
sub
hort 1
ort
marketing
≥1 m
≥1 m
ohort 2
ohort
minutes
inute
bje
bj
authorization
than 
than 
ed.d.
application 
s who 
who
tio
the
the inv
in
enrolle
nroll
6
and 
who
h
d
estiga
stiga
any 
o wo
o w
a
extensions
mme
me
ort 1 w
rt 1 w
or 
end
end
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 67 of 240
12.8
Determination of sample size
Approximately 100 subjects will be enrolled, which includes up to 2 cohorts of at least 
40 subjects for Cohort 1 and approximately 44 subjects for Cohort 2. No formal sample size 
calculation has been performed. The sample size was deemed clinically appropriate for the 
evaluation of safety, tolerability, and PK of iv LCM administration in pediatric subjects with 
epilepsy. 
13
ETHICS AND REGULATORY REQUIREMENTS
13.1
Informed consent
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject’s legal representative(s) in both oral and written form 
by the investigator (or designee). Subject’s legal representative(s) will have the opportunity to 
discuss the study and its alternatives with the investigator.
Prior to participation in the study, the written Informed Consent form should be signed and 
personally dated by the subject’s legal representative(s) and by the person who conducted the 
informed consent discussion (investigator or designee). The subject’s legal representative(s) 
must receive a copy of the signed and dated Informed Consent form. As part of the consent 
process, each subject’s legal representative(s) must consent to direct access to the subject’s 
medical records for study-related monitoring, auditing, IRB/IEC review, and regulatory 
inspection.
If the Informed Consent form is amended during the study, the investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.
The subject’s legal representative(s) may withdraw his/her consent to participate in the study at 
any time. A subject is considered as enrolled in the study when his/her legal representative(s) has 
signed the Informed Consent form. A CRF must not be started, nor may any study specific 
procedure be performed for a given subject, without having obtained written consent from
his/her legal representative(s) in order to participate in the study.
13.2
Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject or legal 
representative will be provided with a subject identification card in the language of the subject. 
The investigator will fill in the subject identifying information and medical emergency contact 
information. The investigator will instruct the subject to keep the card with him/her at all times.
REDACTED
nfor
nform
(s) mu
(s) mu
oring, 
ring
nd
nd
COPY
e(s) a
e(s) 
gnee)
gnee)
me
me
This document
Upon
pon
repr
repr
T
cannot 
g
on s
n s
be
e p
al re
al re
used
rmed 
med
perfo
perfo
to
t is c
is 
C
support
bility A
ility 
presen
presen
con
any 
rs in 
rs in 
A
marketing 
ded dur
ed dur
ble regu
le reg
by th
by th
authorization
). Th
 Th
ed Co
d Co
ust co
ust co
audit
audit
application 
sent fo
ent fo
nd by t
nd by
he s
he s
and 
othth
ill ha
ll ha
any
guag
guag
h ora
or
extensions 
ocal
ocal
igin in
gin in
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 68 of 240
13.3
Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copies of the protocol, Informed 
Consent form, Investigator’s Brochure, investigator’s curriculum vitae (if applicable), 
advertisement (if applicable), and all other subject-related documents to be used for the study to 
the IRB/IEC for its review and approval.
Before initiating a study, the investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The investigator should provide a final report to the IRB/IEC following study 
completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the investigator or the sponsor, as specified by 
the applicable regulatory requirements in each concerned country. Where applicable, 
investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.
13.4
Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.
The investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
REDACTED
p
ocol d
ocol 
igat
gator
or
s for 
s for 
COPY 
study 
study 
ppare
pare
This document
UCB
CB
stud
stud
a
cannot 
B s
B s
be 
a
n.n.
used
egula
gula
are to
are to
to
B/IE
B/IE
t
support 
ve) wil
e) w
ive inv
ve inv
EC
EC
any
sho
sho
marketing
r conti
cont
riodic p
iodic 
riate to
ate t
ould
oul
authorization
o
ent im
nt im
during
during
r to ob
r to ob
i
application
nges
ges
hers, a
hers, 
or stud
r stu
and 
s in
s in
any
appro
appr
extensions 
me
le),
e),
for th
for th
or 
ed 
ed 
variations 
will
will
r to 
r to 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 69 of 240
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
13.5
Protocol amendments
Protocol changes may affect the legal and ethical status of the study and may also affect the 
evaluations of sample size and the likelihood of the study fulfilling its primary objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.
14
FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the investigator and/or contract 
research organization agreements, as applicable.
15
REFERENCES
Aicardi J. Syndromic classification in the management of childhood epilepsy. J Child Neurol. 
1994;9(Suppl 2):14-18.
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, et al. Gabapentin as 
add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, 
placebo-controlled study. Gabapentin Pediatric Study Group. Epilepsia. 1999;40:1147-54.
Arkilo D, Gustafson M, Ritter FJ. Clinical experience of intravenous lacosamide in infants and 
young children. Eur J Paediatr Neurol. 2016;20(2):212-7.
CDC growth curves. Girls: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c022.pdf. 
Boys: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c021.pdf. 2000. 
CHMP/EWP/566/98 Guideline on clinical investigation of medicinal products in the treatment of 
epileptic disorders (EMA) Rev 2, 20 Jan 2010.
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.
Columbia University Medical Center. Columbia-Suicide Severity Rating Scale (2008). 
http://www.cssrs.columbia.edu/. Accessed on 03 Jul 2014.
Commission on Classification and Terminology of the International League Against Epilepsy. 
Proposal for revised classification of epilepsies and epileptic syndromes. 
Epilepsia.1989;30:389-99.
Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al. A placebo-controlled 
trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial 
Seizure Study Group. Neurology. 1999;53:1724-31.
Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized 
trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP 
Study Group. Neurology. 1999;52:1338-44.
REDACTED
ric Stu
ric St
al exp
al exp
. 2016
. 201
ww
ww
COPY 
J, Hal
J, Ha
l seiz
seiz
This documen
rial 
ial 
Seiz
Sei
cannot
ia.19
a.19
chown
hown
of
o
be
or re
or re
98
98
used 
co
co
on Cla
n Cl
vi
to
y
olum
olum
support 
for gu
for gu
Medic
Medi
b
any 
on
v 2, 2
v 2, 2
marketing 
.cdc.go
cdc.go
harts/da
arts/d
n clin
 clin
authorization
zures:
zures:
udy G
udy G
perienc
erien
;20(2
20(2
application 
hood e
hood 
sall G
all G
and any 
an
an
extensions 
nd/o
nd/o
or variations 
ust
ust
ng 
ng 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 70 of 240
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. 
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. 
Neurology. 2006;66:1654-60.
Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother. 
2007;7:179-93.
Herman ST, Pedley TA. New options for the treatment of epilepsy. JAMA. 1998;280:693-4.
Institute of Medicine. Epilepsy across the spectrum: promoting health and understanding. 
Washington, DC: The National Academies Press; 2012.
Lamictal Pediatric Partial Seizure Study Group. Neurology. 1999;53:1724-31.
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epilepsy: A systematic review and meta-analysis. Neurology. 2011; 77(10): 1005–12.
Perucca E. Established antiepileptic drugs. Baillieres Clin Neurol. 1996;5:693-722.
Rheims S, Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset 
seizures. Neuropsychiatr Dis Treat. 2013;9:629-37.
Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 
1959-2009. Epilepsia. 2009;50(Suppl 3):93-130.
Welsh SS, Lin N, Topjian AA, Abend NS. Safety of intravenous lacosamide in critically ill 
children. Seizure. 2017;52:76-80.
REDACTED
e cen
e ce
130.
130.
NS. S
NS. S
COPY
tent
ten
.
ent
ent
This document cannot be used to support any marketing authorization 
ury of
ury o
Safety 
afety 
application 
; 7
rol. 19
ol. 1
al in the
 in th
and
ewto
wto
77(1
77(1
any
31
31
on C
on
extensions
:693
69
standin
tandi
or 
93
variations 
ther.
her.
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 71 of 240
16
APPENDICES
16.1
Protocol Amendment 1
Rationale for the amendment
The primary purpose of this substantial amendment is to add further clarification regarding the 
design of the study, the definition of the clinical situation in which a subject will qualify for 
enrollment in this study, and to provide further clarification regarding the PK assessments in 
accordance with the US Food and Drug Administration (FDA) request. It is clarified that this 
study will enroll approximately 75 subjects ≥4 to <17 years of age and that another 
Phase 2/3 study is planned to investigate the use of iv LCM in subjects with epilepsy ≥1 month 
to <4 years of age. EP0060 will initially enroll older pediatric subjects (Cohort 1), which will 
include at least 20 subjects ≥12 to <17 years of age. After the first 10 subjects in each cohort 
have completed their iv LCM treatment over infusion durations of 30 to 60 minutes, the 
enrollment will be temporarily put on hold for the DMC to review the available safety and 
tolerability data. Based on their review, the DMC will recommend the target infusion duration to 
be used (30 minutes to 60 minutes or 15 to 30 minutes) for the remaining subjects in the cohort, 
whether the study/cohort should be stopped, and whether the next cohort can be initiated.
Additional changes have been implemented for consistency with other protocols in the LCM 
pediatric program.
Furthermore, administrative changes including the update of the study team and update of the 
Sponsor Declaration have been made.
At the time of approval of this amendment, no subjects were enrolled in EP0060.
Modifications and changes
Global changes
The following changes were made throughout the protocol:
x Text has been modified to clarify that approximately 75 subjects ≥4 to <17 years of age with 
epilepsy will be included in EP0060 and that another study is planned to investigate the use 
of iv LCM in subjects with epilepsy ≥1 month to <4 years of age.
x Text has been modified to allow an age staggered approach to enrollment. The enrollment 
will begin with the older pediatric subjects (Cohort 1: at least 20 subjects ≥12 to <17 years of 
age) followed sequentially by younger pediatric subjects (Cohort 2: at least 20 subjects ≥8 to
<12 years of age, and Cohort 3: at least 20 subjects ≥4 to <8 years of age). 
x Text has been modified to clarify that after completion of the first 10 subjects in each cohort, 
the enrollment will be temporarily put on hold for the DMC to review the available safety 
and tolerability data. Based on their review, the DMC will recommend the target infusion 
duration for the remaining subjects in the cohort, whether the study/cohort should be stopped, 
and whether the next cohort can be initiated.
x Inclusion Criterion #2 has been amended as diaries are not used in this study. 
x Inclusion Criterion #3 has been amended to clarify that subjects from ≥4 to <17 years of age 
can be enrolled in the study.
REDACTED 
th
ent, no
nt, n
COPY 
te
he up
he up
This document
a
cannot 
ea
ext ha
xt ha
the e
the e
be
ow
ars o
ars o
used
with t
ith t
wed 
wed
to
mod
mod
support
to
ded in
ded in
ects wi
cts w
ifi
if
any 
clari
clari
marketing 
e thro
e thro
authorization 
pdate 
pdate 
o subj
subj
application
mai
xt coh
xt coh
with o
with 
and
e targ
tar
ining
ning
any
ailabl
ailab
rget
rge
extensions
y ≥1
≥1 m
, whic
whic
in eac
n eac
minut
minut
or variations 
his 
is 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 72 of 240
x Inclusion Criterion #4 has been deleted as it is no longer applicable based on the amended 
age of the subjects in the study. 
x Inclusion Criterion #5 (new numbering) has been added to clarify the clinical situation in 
which a subject will qualify for enrollment in this study.
x Inclusion Criterion #10 has been reworded to clarify the allowed use of prescribed oral 
VIMPAT depending on subject’s weight.
x Inclusion Criterion #11 has been reworded to clarify that intake of the prescribed total daily 
dose of prescribed oral VIMPAT must be confirmed for at least 3 days prior to first infusion.
x Inclusion Criterion #12 has been reworded to clarify requirements in case of concomitant 
AEDs.
x Exclusion Criterion #2 has been deleted as any subject expected to be hospitalized longer 
than 5 days may enter the study, but may not receive iv LCM in EP0060 longer than 5 days.
x Exclusion Criterion #8 (new numbering) has been revised to clarify that subjects who have a 
medical condition that could reasonably be expected to interfere with oral LCM absorption 
are not excluded from the study.
x Exclusion Criterion #11 (new numbering) has been amended to clarify that subjects are 
excluded from the study with creatinine clearance of less than 30mL/min. 
x Exclusion Criterion #18 has been deleted as vigabatrin is permitted during the study. 
x Exclusion Criterion #19 (new numbering) has been amended to specify that subjects with 
known cardiac sodium channelopathy are excluded from the study.
x Text has been modified to clarify the equation to be used to calculate the total volume of 
fluid according to the subject’s weight.
x Text has been modified regarding concomitant treatments so that subjects who have been 
treated with ethosuximide are not excluded from the study, treatment with vigabatrin or 
ethosuximide and with neuroleptics is allowed during the course of the study, any doses of 
anxiolytics or hypnotics are allowed for nonepilepsy indications, and use of benzodiazepines 
is not restricted.
x Text has been revised to clarify the procedures by visit; details of prior and concomitant 
medications recording; timing of the Telephone Contact assessments; morning or evening 
timing of some procedures during the study visits; and timing of infusion, blood sampling, 
vital signs, and ECG measurements; and to clarify the required subject positions during vital 
signs and ECG measurements.
x Text has been modified to indicate that the LCM metabolite SPM 12809 will also be 
analyzed. Furthermore, additional PK assessments may be obtained at the discretion of the 
investigator, especially in the event of a relevant treatment-emergent AE.
x Text has been revised to clarify actions in case of pregnancy.
x Text has been revised to clarify the version of the C-SSRS that needs to be completed by 
subjects who are ≥6 years of age.
as vi
as v
ing) h
ng) h
thy are
thy are
y the
y the
COPY
en a
en 
nce of
nce of
viga
vig
This document
T
canno
l sign
sig
igns a
gns a
Te
Te
be
of so
of s
gns
gns
used
n rere
ns rec
s rec
om
to 
evi
evi
support
neur
neu
otics ar
tics a
any
are n
are n
urol
uro
marketing
e equa
e equa
weight.
eight.
ding c
ing 
authorization 
f l
abatri
batri
has be
has be
e excl
e excl
application
re w
e w
ended 
ended
les
ess th
s t
and
ify th
fy th
wit
wit
any
60 lo
60 l
t
extensions 
ncomi
ncom
spital
pita
o
infu
nfu
variations 
daily 
aily 
usi
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 73 of 240
x The use of some terms has been revised: the terms “inpatient” and “BMI” have been deleted, 
and the terms “hospital” and “hospitalization” have been replaced with “health care facility” 
and “admission to the health care facility,” respectively, where appropriate.
x The Clinical Project Manager has been changed and contact details have been updated.
x The Sponsor Declaration has been updated as the protocol will be signed electronically.
x Other changes made in this amendment are to provide clarification, are administrative in 
nature, or are to correct errors. 
Specific changes
Change #1
Title page
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE AS REPLACEMENT FOR ORAL 
LACOSAMIDE IN CHILDREN (≥1 MONTH TO <17 YEARS OF AGE) WITH EPILEPSY
Has been changed to:
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE AS REPLACEMENT FOR ORAL 
LACOSAMIDE IN CHILDREN (≥4 TO <17 YEARS OF AGE) WITH EPILEPSY
Change #2
STUDY CONTACT INFORMATION
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
REDACTED 
OSA
OS
17 YE
17 YE
COPY 
INVE
INV
SAM
AM
This document 
Ha
Ha
cannot 
Phon
Pho
t
n
an
an
an
be 
b
used to support
UCB
UC
8
or
su
ort any 
ny
a
marketing 
ION
ON
authorization 
EST
S
MIDE 
IDE 
EARS 
ARS 
application 
LA
LA
S OF A
OF 
STIG
TIG
and
HE S
E S
ACE
ACE
any 
SA
SA
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 74 of 240
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Change #3
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949
Canada: +1 877 582 8842
Japan: +81 3 6864 7400
Email
Global: DS_ICT@ucb.com (for interventional clinical studies)
Japan: JDSO@ucb.com
Has been changed to:
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949
Canada: +1 877 582 8842
Email
Global: DS_ICT@ucb.com (for interventional clinical studies)
Change #4
LIST OF ABBREVIATIONS
BMI and CRO have been deleted and FDA has been added.
Change #5
Section 1 SUMMARY
EP0060 is a Phase 2/3, multicenter, open-label, inpatient study to evaluate the safety and 
tolerability of adjunctive intravenous (iv) lacosamide (LCM) infusions as replacement for oral 
LCM in pediatric subjects with epilepsy where the subject is currently taking oral LCM and 
needs to undergo a procedure, be admitted to an epilepsy monitoring unit (EMU) or hospital, or 
other situations where iv administration is clinically appropriate. Up to 75 subjects, who are 
participating in a long-term, open-label study with LCM (SP848, EP0034, EP0012, or other 
24h)
24h)
CT
of the
of the
6
DA
COPY
terve
erv
CO
This document
Secti
ecti
E
cannot 
ange 
nge
i
be used 
EV
EV
O hav
O hav
to 
VIA
VIA
support any
_ICT
_IC
an marketing 
e Wo
Wo
6949
949
7 582 8
582
T@
T
m
authorization 
on
or
or
or
au
application 
tional c
ional
ica
and any y extensions 
ten
e
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 75 of 240
future study) or who are currently prescribed VIMPAT® (LCM) will be enrolled. Pediatric 
subjects entering into EP0060 from a long-term, open-label study will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly 
into EP0060 will temporarily switch from their prescribed VIMPAT oral treatment to the iv 
LCM formulation. Subjects will be enrolled from approximately 40 sites in North America, 
Europe, Asia Pacific, and Latin America. Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s)
administered over target durations of 30 minutes or 15 minutes in pediatric subjects ≥1 month to 
<17 years with epilepsy. 
EP0060 will be comprised of up to 3 cohorts. 
x Approximately 25 subjects will be enrolled into Cohort 1 in order to receive iv LCM, which 
should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of Cohort 1, enrollment into EP0060 will be temporarily put on hold to allow 
for a Data Monitoring Committee (DMC) review of the safety and tolerability data from 
Cohort 1. Based on the review of the Cohort 1 data, the DMC will make a recommendation for 
the target infusion duration to be evaluated in Cohort 2. 
x EITHER approximately 25 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible,
x OR approximately 25 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
The DMC will reconvene after the completion of Cohort 2. If the Cohort 2 target infusion 
duration was 30 minutes but no longer than 60 minutes, enrollment into the study will be stopped 
once Cohort 2 has completed. If the Cohort 2 target infusion duration was 15 but no longer than 
30 minutes, the DMC will make a recommendation for the target infusion duration to be 
evaluated in Cohort 3.
x EITHER approximately 25 additional subjects will be enrolled into Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 25 additional subjects will be enrolled into Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of Cohort 3, the DMC will reconvene to review the final data to provide their 
overall impression.
This design will result in a total exposure of at least approximately 50 pediatric subjects (up to 
75 pediatric subjects) to assess the safety of iv LCM administered over a range of infusion 
durations.
EP0060 is comprised of the following: Screening and/or Baseline Period (up to 7 days); 
Treatment Period (up to 5 days); an End-of-Study/Final Visit (1 day); and a Follow-Up
Period/Telephone Contact (up to 2 days). During the Screening Period (Day -1), oral LCM 
tablets will be administered in accordance with each subject’s oral LCM dosage regimen. During 
REDACTED
nger 
nger 
ects w
ects w
ger tha
ger th
om
om
COPY 
rt 2. 
rt 2. 
ts wil
s wi
This document 
his
his
75 p
75 p
d
cannot 
mpl
mpl
ll imp
l imp
s de
s de
be 
pleti
pleti
used
mate
mate
f 30
f 30
to 
n 
l
support 
ately 2
tely 
of 15
of 15
any
ke a r
e a 
marketing 
mpletion
pletio
ger than
er th
he Coh
he Co
re
authorization
ll be 
ll be 
than 3
than 3
will be
will be
an 60 
n 60 
application 
mpor
po
and tol
nd to
C w
C will 
ill
and 
orari
rar
any 
minu
min
extensions 
ive iv
ve iv
or 
mon
mo
variations 
ion(s)
on(s)
nth
nt
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 76 of 240
the Treatment Period, subjects will receive iv LCM infusion twice daily (bid) at approximately 
12-hour intervals. The daily dose of iv LCM will be the same as the subject's current stable daily 
dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood 
samples will be obtained for pharmacokinetic (PK) analysis, and safety assessments will be 
collected (physical and neurological exams, pulse rate, blood pressure, and 12-lead 
electrocardiogram [ECG]). An End-of-Study/Final Visit will be conducted the day after the last 
dose of iv LCM after completion of or withdrawal from the Treatment Period. A safety 
follow-up assessment will be collected during the Follow-Up Period by phone or in person, 1 to
2 days after the last dose of iv LCM in the Treatment Period. 
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, only subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were prescribed VIMPAT should continue antiepileptic 
drug (AED) treatment at the discretion of the treating physician.
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM) infusions as replacement for oral LCM in pediatric subjects 
≥4 to <17 years of age with epilepsy. A separate Phase 2/3 study investigating the use of iv LCM 
as replacement for oral LCM therapy in pediatric subjects with epilepsy ≥1 month to <4 years of 
age is planned. EP0060 will include subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) who need to undergo a procedure, be 
admitted to an epilepsy monitoring unit (EMU) or health care facility, or other situations where 
iv administration is clinically appropriate. Approximately 75 subjects, who are participating in a 
long-term, open-label study with LCM (SP848, EP0034, EP0012, or other future study) or who 
are currently prescribed VIMPAT® (LCM) will be enrolled. Pediatric subjects entering into 
EP0060 from a long-term, open-label study will temporarily suspend their participation in that 
study to receive iv LCM treatment in EP0060. Subjects who enroll directly into EP0060 will 
temporarily switch from their prescribed VIMPAT oral treatment to the iv LCM formulation. 
Subjects will be enrolled from approximately 40 sites in North America, Europe, Asia Pacific, 
and Latin America. Additional sites or regions may be added if deemed necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s)
in pediatric subjects ≥4 to <17 years with epilepsy, after temporarily switching from the 
equivalent stable oral LCM dose. EP0060 is planned to include up to 3 age-based cohorts of at 
least 20 subjects per cohort: ≥12 to <17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to 
<8 years (Cohort 3). A Data Monitoring Committee (DMC) will review the safety and 
tolerability data for each cohort to make recommendations for the progression of subsequent 
cohort enrollment and iv infusion durations to be evaluated. 
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
REDACTED
urr
eedin
eedin
EMU)
MU)
ate. Ap
ate. A
CM (S
CM (S
LC
L
COPY 
se 2
e 
subjec
ubjec
rently
rentl
This document 
h
EP0
EP0
canno
s (Co
(C
ability
bility
ort e
ort e
be
bject
bjec
oh
oh
used
ects 
cts 
ble or
ble o
tst
to 
ive 
ve 
s ≥4
s ≥4
support 
rom 
om 
ditiona
ition
e of E
of
any
presc
presc
ap
a
marketing
SP84
P84
CM) w
CM) w
bel stud
el stu
t in E
t in E
authorization
cts
ly taki
y tak
g tube
g tube
) or he
) or he
Approx
pprox
48
48
application
the sa
the s
for ora
for or
ststudy 
udy
s with
with
and any extensions
s. Af
. A
P0060
P0060
sume o
ume o
nue a
ue a
or 
fte
ft
variations 
1 t
1 to
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 77 of 240
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. During the Treatment Period, subjects will 
receive iv LCM infusions twice daily (bid) at approximately 12-hour intervals for up to 5 days. 
The daily dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM 
(2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood samples will be 
obtained for pharmacokinetic (PK) analysis, and detailed safety assessments will be performed. 
An End-of-Study/Final Visit will be conducted the day after the last dose of iv LCM after 
completion of or withdrawal from the Treatment Period. A safety follow-up Telephone Contact 
should occur 1 to 2 days after the End-of-Study/Final Visit. 
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, only subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were prescribed VIMPAT should continue antiepileptic 
drug (AED) treatment at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
ubject
ubject
no lon
o lon
subje
subje
nge
ng
COPY 
enr
en
ew of 
ew of
will m
ill m
This document 
x
O
cannot 
ITHER
THE
infus
infu
be
p
nd C
nd C
used
n of 
n of 
ut on
ut on
to 
ute
th
support
ubjec
bjec
Cohort
Cohor
es wh
s wh
any
n be i
be 
t
marketing
ects 
cts 
er than
r than
i
authorization
f t
make r
make r
ts will
 will
nger th
ger th
s w
application
v L
v L
ver pos
er po
lment i
ment 
the sa
he sa
and
<17 ye
7 y
LCM
LCM
any 
ea
extensions
s. Af
. A
P0060
P0060
sume o
ume o
nue a
ue a
or 
fte
ft
variations 
tact 
act 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 78 of 240
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Change #6
Section 2 INTRODUCTION, last paragraph
The results of EP0060 will provide safety and PK data regarding the use of the iv LCM 
formulation in pediatric subjects ≥1 month to <17 years with epilepsy.
Has been changed to:
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation as replacement for oral LCM in pediatric subjects ≥4 to <17 years with
epilepsy.
Change #7
Section 3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of adjunctive iv LCM 
infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy, after temporarily switching 
from the equivalent stable oral LCM dose. An additional objective is to evaluate the PK of 
iv LCM in pediatric subjects with epilepsy.
Has been changed to:
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy, after temporarily switching from 
the equivalent stable oral LCM dose. An additional objective is to evaluate the PK of iv LCM 
replacement in pediatric subjects with epilepsy.
REDACTED 
raph
raph
fety an
fety an
mon
mon
COPY 
This document
v LC
LC
H
cannot 
arar
on(s) i
n(s) i
m the 
m the 
CM
CM
be 
ry ob
ry ob
used 
UDY 
UDY
to support any 
de
d
emen
emen
marketing
nth to 
nth to
de saf
e sa
authorization 
nd PK
d PK
application 
pedia
ediatrt
urations
ration
and 
sub
ub
any 
bjec
bje
extensions 
arget i
rget i
or variations 
et t 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 79 of 240
Change #8
Section 4.2 Pharmacokinetic variable(s)
The PK variables will include plasma concentration of LCM and its metabolite, SPM12809. 
Has been changed to:
The PK variables will include plasma concentration of LCM and its main metabolite, 
SPM 12809.
Change #9
Section 5.1 Study description 
EP0060 is a Phase 2/3, multicenter, open-label, inpatient study to evaluate the safety and 
tolerability of adjunctive iv LCM infusions as replacement for oral LCM in pediatric subjects 
with epilepsy where the subject is currently taking oral LCM and needs to undergo a procedure, 
be admitted to an EMU or hospital, or other situations where iv administration is clinically 
appropriate. Up to approximately 75 subjects, who are participating in long-term, open-label 
studies with LCM or who are currently prescribed VIMPAT, will be enrolled. Pediatric subjects 
entering into EP0060 from a long-term, open-label study will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly 
into EP0060 will temporarily switch from their prescribed oral VIMPAT treatment to the 
iv LCM formulation. Subjects will not be prescribed or maintained on VIMPAT for the purposes 
of participating in EP0060. Subjects will be enrolled from approximately 40 sites in North
America, Europe, Asia Pacific, and Latin America. Additional sites or regions may be added if 
deemed necessary.
EP0060 will be comprised of up to 3 cohorts. 
x Approximately 25 subjects will be enrolled into Cohort 1 in order to receive iv LCM, which 
should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of Cohort 1, enrollment into EP0060 will be temporarily put on hold to allow 
for a Data Monitoring Committee (DMC) review of the safety and tolerability data from 
Cohort 1. Based on the review of the Cohort 1 data, the DMC will make a recommendation for 
the target infusion duration to be evaluated in Cohort 2. 
x EITHER approximately 25 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 25 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
The DMC will reconvene after the completion of Cohort 2. If the Cohort 2 target infusion 
duration was 30 minutes but no longer than 60 minutes, enrollment into the study will be stopped 
once Cohort 2 has completed. If the Cohort 2 target infusion duration was 15 but no longer than 
30 minutes, the DMC will make a recommendation for the target infusion duration to be 
evaluated in Cohort 3.
REDACTED 
r pr
r pr
rescrib
rescrib
be en
be en
atin A
atin A
COPY
tudy
tudy
tment 
tment
resc
res
This document 
d
cannot 
HER
E
fusion
usion
OR
OR
be 
R ap
R ap
used
on t
on t
usion 
sion 
to
ing 
ng 
thth
support 
Cohort 
ohort 
Co
C
any 
wili
uratio
urati
marketing 
3 cohor
coho
ll be 
ll b
authorization 
in E
in 
cribed
ribed
bed or
ed or
nrolled
rolled
meric
meric
application 
mi
ting in
ing in
 will b
will b
will tem
will te
n EP0
EP
and
ds to
s to
inist
nist
any
in pe
in pe
o un
o u
extensions 
he saf
e sa
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 80 of 240
x EITHER approximately 25 additional subjects will be enrolled into Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 25 additional subjects will be enrolled into Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of Cohort 3, the DMC will reconvene to review the final data to provide their 
overall impression.
This design will result in a total exposure of approximately 50 pediatric subjects (up to 
approximately 75 pediatric subjects) to assess the safety of iv LCM administered over a range of 
infusion durations. 
EP0060 is comprised of the following: Screening and/or Baseline Period (up to 7 days); 
Treatment Period (up to 5 days); an End of Study/Final Visit (1 day); and a Follow-Up
Period/Telephone Contact (up to 2 days). During the Screening Period (Day -1), oral LCM 
tablets will be administered in accordance with each subject’s LCM dosage regimen. For 
subjects enrolled in a long-term, open-label study, the oral LCM will be administered from the 
long-term, open-label study supply. For subjects prescribed VIMPAT and enrolling directly into 
EP0060, oral LCM will be administered from the subject’s prescribed VIMPAT supply. 
Subjects will be under medical care at a healthcare facility for the duration of the iv LCM 
infusion treatment in EP0060. If necessary, the Screening and/or Baseline Visit can occur on the 
same day as the first iv LCM infusion. In both cases, it is required that all screening procedures 
are performed and the results of examinations (ie, ECG) are available to allow verification of 
subject eligibility. During the Treatment Period, subjects will receive iv LCM infusion twice 
daily (bid) at 12-hour intervals. The daily dose of iv LCM will be the same as the subject's 
current stable daily dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). During the 
Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, and safety 
assessments will be collected (physical and neurological exams, pulse rate, blood pressure, and 
12-lead ECG). An End-of-Study/Final Visit will be conducted the day after the last dose of 
iv LCM after completion of or withdrawal from the Treatment Period. A safety follow-up
assessment will be collected during the Follow-Up Period by telephone or in person 1 to 2 days 
after the last dose of iv LCM in the Treatment Period.
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were prescribed VIMPAT should continue AED treatment 
at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions as replacement for oral LCM in pediatric subjects ≥4 to <17 years of age with 
epilepsy. EP0060 will include subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) who need to undergo a procedure, be 
admitted to an EMU or health care facility, or other situations where iv administration is 
clinically appropriate. Approximately 75 subjects, who are participating in long-term, open-label 
REDACTED
s (ie, 
s (ie,
Period,
eriod
ily dos
ily do
M (2 to
M (2 t
l b
l
COPY 
cili
cil
reenin
eenin
ases, 
ses, 
This document
Has
Has
E
cannot
scre
cre
sched
ched
be
accor
cco
etio
eti
used
dis
dis
en-lab
lab
ord
ord
to 
y d
y
sco
sco
support
d du
d du
LCM 
CM in
durat
durat
any
with
with
durin
uri
marketing
to 12
12
be obta
e obta
ical an
cal an
Final V
Final
d
authorization
g
it is r
it is r
ECG)
ECG)
d, subj
subj
se of 
e of 
12m
2m
application 
PAT
AT
scribed
cribe
for the
or th
g and/
and/
and
be a
be a
T an
T an
any 
y
ge reg
ge re
dm
d
extensions 
7 days
days
ollow
low
1), 
1),
or
ran
ran
variations 
nge
ng
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 81 of 240
studies with LCM or who are currently prescribed VIMPAT, will be enrolled. Pediatric subjects 
entering into EP0060 from a long-term, open-label study will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly 
into EP0060 will temporarily switch from their prescribed oral VIMPAT treatment to the iv 
LCM formulation. Subjects will not be prescribed or maintained on VIMPAT for the purposes of 
participating in EP0060. Subjects will be enrolled from approximately 40 sites in North America, 
Europe, Asia Pacific, and Latin America. Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 3 age-based cohorts of at least 20 subjects per cohort: ≥12 to 
<17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to <8 years (Cohort 3). A DMC will 
review the safety and tolerability data for each cohort to make recommendations for the 
progression of subsequent cohort enrollment and iv infusion durations to be evaluated. Details 
regarding the DMC are provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. For subjects enrolled in a long-term, open-label 
study, the oral LCM will be administered from the long-term, open-label study supply. For 
subjects prescribed VIMPAT and enrolling directly into EP0060, oral LCM will be administered 
from the subject’s prescribed VIMPAT supply. 
Subjects will be under medical care at a healthcare facility for the duration of the iv LCM 
infusion treatment in EP0060. If necessary, the Screening and/or Baseline Visit can occur on the 
same day as the first iv LCM infusion. In this case, it is required that all screening procedures are 
performed and the results of examinations (ie, ECG) are available to allow verification of subject 
eligibility. During the Treatment Period, subjects will receive iv LCM infusion bid at 
approximately 12-hour intervals for up to 5 days. The daily dose of iv LCM will be the same as 
the subject's current stable bid dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (physical and neurological exams, pulse rate, BP, 12-lead ECG, 
clinical hematology and chemistry, and Columbia-Suicide Severity Rating Scale [C-SSRS] when 
applicable). An End-of-Study/Final Visit will be conducted the day after the last dose of iv LCM 
after completion of or withdrawal from the Treatment Period. A safety follow-up Telephone 
Contact should occur 1 to 2 days after the End-of-Study/Final Visit.
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were prescribed VIMPAT should continue AED treatment 
at the discretion of the treating physician.
1), o
1), o
men. F
men. F
ed fro
ed fro
nrollin
nrollin
AT
AT
COPY 
). 
).
This document
Cont
Cont
T
cannot
hem
em
cable)
able)
r com
r com
be
s wi
w
mat
ma
used 
ent 
nt
eatme
atme
will
will
to 
ou
t sta
t st
support
of ex
of ex
Treatm
reatm
ur int
r int
any 
f ne
n
infusi
nfus
marketing
ng d
g d
T suppl
suppl
e at a h
e at a 
neces
ece
authorization 
ral LC
ral LC
For su
or su
om the
m the
dire
dire
application and any extensions
DMC
MC
for the
or the
aluate
uate
or
: ≥
: ≥
C w
C
variations 
≥12
≥12
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 82 of 240
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
REDACTED 
w th
w th
w, the 
w, the 
nal sub
nal sub
but no
but no
COPY 
t 2, en
t 2, e
he a
he
This document 
x
E
cannot 
ilyly
t 1, C
1, C
ollow
ollow
be 
leti
y pu
y pu
used
minu
inu
ion 
ion
to
s in 
in 
utet
support 
3 can
can
20 subj
0 sub
Co
C
any
pped
pped
n b
marketing 
o lolo
ubjects
ubjec
onger t
onger
d
authorization 
nrol
ro
availab
vaila
DMC
DMC
bjects 
jects 
onge
nge
application
enroll
enrol
er a du
er a d
ollme
llm
and 
l
any extensions 
, 
target 
arget
or
get
ge
variations 
et
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 83 of 240
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age). 
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Change #10
Section 5.1.1 Study duration per subject
The maximum iv LCM exposure per subject will be up to 5 days with a total study duration of up 
to 15 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, 
and Telephone Contact/Follow-Up up to 2 days after last dose of iv LCM.
The end of the study is defined as the date of the last contact of the last subject in the study.
Has been changed to:
The maximum iv LCM exposure per subject will be up to 5 days with a total study duration of up 
to 15 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, 
and a safety follow-up Telephone Contact 1 to 2 days after the Final Visit).
The end of the study is defined as the date of the last contact of the last subject in the study.
Change #11
Section 5.1.2 Planned number of subjects and site(s)
Up to 75 subjects currently participating in long-term, open-label studies with LCM or who are 
currently prescribed VIMPAT will be enrolled at approximately 40 sites. 
In each cohort, the following target number of subjects will be enrolled in each age group:
x At least 4 subjects ≥1 month to <4 years of age
x At least 4 subjects ≥4 to <8 years of age
x At least 4 subjects ≥8 to <12 years of age
x At least 4 subjects ≥12 to ≤16 years of age 
In total, across all cohorts, at least 8 subjects (for a 2-cohort study) or 12 subjects (for a 3-cohort 
study) will be enrolled in each age group.
Has been changed to:
Approximately 75 subjects currently participating in long-term, open-label studies with LCM or 
who are currently prescribed VIMPAT will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 20 subjects from ≥12 to <17 years of age
x Cohort 2: at least 20 subjects from ≥8 to <12 years of age
REDACTED 
bjects
bject
ating
ating
COPY
st con
st con
This document
Appr
Appr
wh
wh
cannot
will b
ill b
s bee
bee
be
ross 
ss
be
be
used
ubjec
bjec
s al
s al
to 
cts
support 
4 to <8
4 to <
s ≥8 t
≥8 t
any 
nth to
th to
marketing
g in lo
g in lo
e enrol
e enro
et num
et nu
authorization 
s and
and
application 
with
, 1 day
1 da
he Fina
he Fin
tact of
act o
nd 
th a t
h a 
any extensions
urati
rati
ge/Fin
e/Fin
ect in
ct in
or 
tion
io
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 84 of 240
x Cohort 3: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in any of the 3 cohorts.
COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 85 of 240
Change #12
Section 5.2 Table 5-1: Schedule of study assessments
Table 5-1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitb
End-of-Study Period
Visit
V1a
V1ba
V2
V3
Final Visitc
TCd
Study Day
-7
to -1
-1
1
2 - 5
2 - 6
2 - 9
AM
PM
AM
PM
Written informed consent
X
Inclusion/exclusion criteria
X
Xe
X
X
Demographics
X
Medical procedures
X
Procedure historyf
X
Medical history/updatef
X
Diagnosis of epilepsyf
X
Childbearing potentialf
X
LCM dosing historyg
X
Prior and concomitant medicationsh
X
X
X
X
X
X
X
X
X
Concomitant AEDs/VNS settings 
X
X
X
X
X
X
X
X
Pregnancy testingi
X
X
Withdrawal criteria
X
X
X
X
X
X
AE reportingj
X
X
X
X
X
X
X
X
X
ILAE seizure classification 
X
D
CT
DA
DA
DA
DA
DA
R
COPY 
OP
C
This document 
ficat
cat
en cannot 
ot
atio
tio
ca
be 
e used 
ed
u
to 
o support 
X
t
p
X
pp
up
s
any y
ny
a
marketing 
ing
eti
rk
m
authorization 
tio
ori
ho
au
application 
M
P
ioio
atio
lic
a
X
ap
a
and 
an
any 
U
a
extensions 
en
or variations 
on thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 86 of 240
Physical examination (complete)
X
X
Table 5-1:
Schedule of study assessments (continued)
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitb
End of Study Period
Visit
V1a
V1ba
V2
V3
Final Visitc
TCd
Days in study
-7
to -1
-1
1
2 - 5
2 - 6
2 - 7
AM
PM
AM
PM
Neurological examination (complete)
X
X
Clinical chemistry and hematologyk
X
X
X
X
12-lead ECG
X
Xl
Xl
Xl
Xl
Xl
X
X
Vital signs
X
Xl
Xl
Xl
Xl
Xl
X
X
Body weight, height, and BMI
X
Blood sample for LCM PKm
X
X
X
X
X
Admission to the unitn
X
X
Oral LCM administrationo
X
X
X
X
Intravenous LCM infusion
X
X
X
X
X
C-SSRSp
X
Xq
X
X
Xb
X
Signs and symptoms of depression
X
X
X
X
X
X
X
X
Discharge from the unit
X
AE=adverse event; AED=antiepileptic drug; BMI=body mass index; BP=blood pressure; C-SSRS=Columbia-Suicide Severity Rating Scale; 
ECG=electrocardiogram; ILAE=International League against Epilepsy; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; TC=Telephone Contact; 
V=Visit; VNS=vagus nerve stimulation
a Visit 1b only applies when Screening and Baseline occur on separate days. 
b If an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. The 
C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.
c A Final Visit must be completed the day after the last dose of iv LCM for all subjects who complete or withdraw prematurely from EP0060. For subjects 
REDACTED 
D
CTE
DA
DA
DA
DA
DA
R
COPY 
Xl
OP
C
This document
sho
be co
be co
cannot
im
Scree
Scree
is need
s need
ould 
ould 
be 
=Inte
nte
mulat
mulat
used
c drug
drug
tern
ern
ed 
ed to support 
X
t
X
p
up
s
any 
ny
a
marketing 
X
ng
eti
X
rk
m
authorization 
Xl
tio
ori
ho
ut
application 
PM
PM
on
atio
lic
a
X
ap
a
and 
M
nd any 
U
Vis
Vi
a
extensions 
Unsc
nsc
ns or variations 
on
X
at
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 87 of 240
who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and refer to the long-term, open-label studies taper regimen.
d The Telephone Contact assessment should be performed 1 to 2 days after the last dose of iv LCM in the Treatment Period during the Follow-Up Period (2 
to 7 days after Visit 2/Day 1). During the contact, the site should inquire as to whether the subject noted any change at the site of the infusion.
e Verification that the subject continues to meet inclusion/exclusion criteria if Screening and Baseline occur on separate days.
f Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be collected for direct-enroll subjects who were prescribed 
VIMPAT prior to entering the study. Medical history update will be collected for subjects from the long-term open-label studies. 
g Lacosamide dosing history will include date, time, and quantity during the last 3 days.
h Prior medications will only be collected for direct-enroll subjects. Concomitant medications from the long-term open-label studies will be followed, as well 
as the recording of new concomitant medications during EP0060.
i Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening Visit for direct-enroll subjects who are prescribed VIMPAT 
and urine testing for subjects enrolled in long-term, open-label studies. Urine pregnancy testing (or serum pregnancy test if no urine sample can be 
obtained) will be conducted on all subjects of childbearing potential at the Final Visit. 
j Ongoing AEs from the long-term open-label studies will be followed, as well as recording of new AEs during EP0060. 
k Laboratory assessments will be performed for subjects who are directly enrolled into EP0060. Screening laboratory assessments may be conducted up to 
the day of the infusion provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion.
l Vital Signs will be performed 5 minutes prior to infusion and at 5, 10, 20, 45, 60 minutes, and 2 hours from the start of each iv administration. Noninvasive 
BP (systolic and diastolic) and pulse rate will be measured at study visits in a sitting position after at least 3 minutes at rest, when feasible. 12-lead ECG 
will be performed 5 minutes prior to infusion and at 15, 30, 60 minutes, and 2 hours from the start of each iv administration. Care should be taken to assure 
proper lead placement and quality ECG recordings. Subjects should rest in a supine position at least 5 minutes prior to each ECG recording and should be 
motionless during the recording.
m Samples for PK will be drawn after ECG and vital signs have been taken on Day 1 (within 1 hour prior to the first iv LCM dose and 1 to 4 hours after the 
second iv LCM dose) and on the Final Treatment Visit (within 1 hour prior to the first iv LCM dose and 1 to 4 hours after the second iv LCM dose) from 
the opposite arm in which the solution for infusion was administered.
n Admission to the hospital to participate in the study should take place at least the day prior to the start of the first iv LCM infusion. However, when 
necessary for the wellbeing of the subject or when the investigator deems it appropriate, the hospitalization and the first iv LCM infusion can start on the 
same day.
o On Day -1, oral LCM will be administered in accordance with each subject’s LCM dosage regimen. 
p For all subjects ≥6 years of age, the “since last visit” version of the C-SSRS assessment should be completed for all visits after the initial 
(Screening/Baseline) assessment. Signs and symptoms of depression for patients <6 years of age will also be assessed whenever a C-SSRS assessment is 
performed.
q The C-SSRS assessment (see Section 10.1.1.1) does not need to be completed twice if Screening/Baseline assessments are done on the same day.
Has been changed to:
REDACTED
nd 2 h
nd 2 
st in a 
t in a 
en take
en take
hin 1 h
hin 1 h
ini
in
COPY
riteri
riter
0 minu
0 mi
sittin
sittin
h
This document cannot be used to 
.1.1
support 
” ve
ve
mptoms o
ptoms
1) do
1) d
any 
ce wit
ce wi
ersio
ers
marketing 
hour p
ur 
stered.
tered.
e place 
place
tigator 
igator
authorization
ute
g posi
g posi
ours fr
urs fr
supine
upine
n on D
on D
pr
pr
application 
new AE
ew A
60. Scre
0. Scr
prior to
prior t
es, and
s, an
i
and
dire
ire
erum 
erum 
any 
m
ect
ect
extensions 
ays
ys.
l subje
subje
-label
label
m op
op
or
te of
e o
variat
dies tap
es tap
ng the
the
f
ations 
on
at
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 88 of 240
Table 5-1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitc
End-of-Study Period
Visit
V1a
V1ba
V2
V3b
Final Visitd
TCe
Study Day
-7 to -1
-1
1
2 to 5
2 to 6
2 to 9
Written informed consent
X
Inclusion/exclusion criteria
X
Xf
Demographics
X
Medical procedures
X
X
X
X
X
X
X
Procedure historyg
X
Medical history/updateg
X
X
X
X
X
X
X
Diagnosis of epilepsyg
X
Childbearing potentialg
X
LCM dosing historyh
X
Prior and concomitant medicationsi
X
X
X
X
X
X
X
Concomitant AEDs/VNS settings 
X
X
X
X
X
X
Pregnancy testingj
X
X
Withdrawal criteria
X
X
X
X
X
X
AE reportingk
X
X
X
X
X
X
X
ILAE seizure classification 
X
Physical examination (complete)
X
X
Neurological examination (complete)
X
X
Clinical chemistry and hematologyl
X
X
X
X
REDACTED 
X
D
CT
CT
CT
CT
CT
DA
R
COPY 
OP
C
This document
and 
nd h
en cannot 
letet
on (co
n (co
ot
he
he
ca
be 
te)
te)
e used 
ed
u
to 
o support 
X
t
p
X
pp
up
s
any y 
a
marketing 
g
ing
X
rk
m
authorization 
tio
or
au
a
application 
io
X
lic
p
ap
and 
an
any y
any extensions 
sched
ched
Visitc
Visitc
or r variations 
on
v
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 89 of 240
Table 5-1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitc
End-of-Study Period
Visit
V1a
V1ba
V2
V3b
Final Visitd
TCe
Study Day
-7 to -1
-1
1
2 to 5
2 to 6
2 to 9
12-lead ECG
X
Xm
Xm
Xm
X
X
Vital signs
X
Xn
Xn
Xn
X
X
Body weight and height
X
PK blood samplingo
X
X
X
Admission to the unitp
X
X
Oral LCM administrationq
X
X
X
X
Intravenous LCM infusionr
X
X
X
C-SSRSs
X
Xt
X
X
Xc
X
Discharge from the unit
X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C-SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogram; 
ILAE=International League against Epilepsy; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; TC=Telephone Contact; V=Visit; VNS=vagus 
nerve stimulation
a Visit 1b only applies when Screening and Baseline occur on separate days. 
b If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed each day of iv LCM treatment in EP0060. 
c If an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. The 
C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.
d A Final Visit must be completed the day after the last dose of iv LCM for all subjects who complete or withdraw prematurely from EP0060. For subjects 
who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and refer to the long-term, open-label studies taper regimen.
e The Telephone Contact assessment should be performed 1 to 2 days after the Final Visit (2 to 7 days after Visit 2/Day 1). During the contact, the site 
should inquire as to whether the subject noted any change at the site of the infusion.
f Verification that the subject continues to meet inclusion/exclusion criteria if Screening and Baseline occur on separate days.
g Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be collected for direct-enroll subjects who were prescribed 
VIMPAT prior to entering the study. Medical history update will be collected for subjects from the long-term open-label studies. 
h Lacosamide dosing history will include date, time, and dosage information during the last 3 days.
REDA
Xt
DACTED 
D
CT
CT
CT
CT
CT
DA
R
COPY 
OP
C
This document
histo
histo
cannot
cont
ont
al histo
l histo
ring th
ing th
be
nt 
e subj
e subj
i
used 
y afa
he subj
e subj
shou
shou
to 
if th
f th
after 
after
support 
occu
occu
sessme
essm
ments n
ments n
the U
he U
any 
ou
ou
ur o
ur
mark
ure; C
re; C-S
us;
us; L
rketing 
g
ing
rk
authorization 
tio
X
or
X
au
a
application 
io
X
lic
p
ap
and 
an
any y
any extensions 
sched
ched
Visitc
Visitc
or r variations 
on
v
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 90 of 240
Table 5-1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitc
End-of-Study Period
Visit
V1a
V1ba
V2
V3b
Final Visitd
TCe
Study Day
-7 to -1
-1
1
2 to 5
2 to 6
2 to 9
i Prior medications will only be collected for direct-enroll subjects. Concomitant medications from the long-term open-label studies will be followed, as well 
as the recording of new concomitant medications during EP0060 for all enrolled subjects.
j Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening Visit for direct-enroll subjects who are prescribed VIMPAT 
and urine testing for subjects enrolled in long-term, open-label studies. Urine pregnancy testing (or serum pregnancy test if no urine sample can be 
obtained) will be conducted on all subjects of childbearing potential at the Final Visit. 
k Ongoing AEs from the long-term open-label studies will be followed, as well as recording of new AEs during EP0060. 
l Laboratory assessments will be performed for subjects who are directly enrolled into EP0060. Screening laboratory assessments may be conducted up to 
the day of the infusion provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion.
m 12-lead ECG will be performed approximately 20 minutes prior to each infusion and at approximately 15, 30, 60 minutes, and 2 hours from the start of 
each iv administration. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should be at rest at least 5 minutes prior 
to each ECG recording and should be motionless during the recording, when feasible.
n Vital signs will be performed approximately 10 minutes prior to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diastolic) and pulse rate will be measured at study visits after at least 3 minutes at rest, when feasible.
o Samples for PK will be drawn after ECG and vital signs have been taken. Plasma samples will be obtained from the opposite arm in which the solution for 
infusion was administered for the first iv LCM infusion (Day 1): predose (within 1 hour prior to iv LCM infusion) and postdose (within 1 to 4 hours after 
end of iv LCM infusion), and for the final iv LCM infusion (Day 2 to 5/Early Termination): predose (within 1 hour prior to iv LCM infusion) and postdose 
(within 1 to 4 hours after end of iv LCM infusion). Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in 
the event of a relevant treatment-emergent AE.
p Admission to the health care facility to participate in the study should take place at least the day prior to the start of the first iv LCM infusion. However, 
when necessary for the wellbeing of the subject or when the investigator deems it appropriate, the admission to the health care facility and the first iv LCM 
infusion can start on the same day.
q On Day -1, oral LCM will be administered in accordance with each subject’s LCM dosage regimen. 
r LCM will be administered twice daily at approximately 12-hour intervals, once in the morning and once in the evening, for up to 5 days.
s All subjects ≥6 years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent visits. 
t The C-SSRS assessment (see Section 10.7.5) does not need to be completed twice if Screening/Baseline assessments are done on the same day.
REDACTED
nfusio
nfusi
ement 
ement 
ng, wh
ng, wh
each in
each in
) and p
) and p
bee
bee
COPY
cord
cor
d into E
d into E
ion cri
on cr
on
This document cannot
e Sec
Sec
be
age an
age a
cti
cti
used
t a
mplete t
lete 
mes
mes 6
d
to
in
appro
appr
support 
n the
the
or when
r whe
n acco
acco
any 
on
on
he stu
he s
marketing
pulse
ulse
n taken
n taken
): predo
: pred
(Day 2 
Day 2
nal bl
nal b
authorization
iteria p
iteria 
n and at
and at
and qu
nd qu
en feas
en fea
nfusion
fusion
e ra
e ra
application 
it for
fo
g (or ser
(or se
ng of new
g of n
P0060
0060
and 
ong
ng
r d
r d
any y
term
ter
any extensions 
sched
ched
Visitc
Visitc
or r variations 
on
v
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 91 of 240
Change #13
Section 5.2 Table 5-2: Timing of infusion, blood sampling, and measurement of vital signs and ECG on Treatment Days 
(Infusion Day 1 to Day 5)
Table 5-2:
Timing of infusion, blood sampling, and measurement of vital signs and ECG on Treatment Days 
(Infusion Day 1 to Day 5)
Approxim
ate time 
(min/hrs)
T0
T12hb
-3min t
o
-59min
-5mi
n
T0 
(Start 
of 
infusio
n)
+5mi
n
+15mi
n
+30mi
n
(End of 
infusion)
a
+60mi
n
+1h t
o
+4h
+2
h
-5mi
n
T12
h
+5mi
n
+15mi
n
+30mi
n
+60mi
n
+2
h
Pulse ratec
X
X
X
X
X
X
X
X
X
X
X
X
Blood 
pressurec
X
X
X
X
X
X
X
X
X
X
X
X
12-lead 
ECG
X
X
X
X
X
X
X
X
X
X
Blood 
sampling 
LCM PK 
Xd
Xd
ECG=electrocardiogram; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; T=time
a Depending on the target duration defined for the cohort and patient tolerability, end of infusion can be at 15, 30, or 60 minutes or whenever the infusion is 
stopped (if prematurely terminated).
b T12 will be approximately 12 hours after T0.
c Pulse rate and blood pressure will be taken predose and post dose at least once daily, where clinically appropriate.
d Samples for PK will be drawn after ECG and vital signs have been taken on Day 1 (within 1 hour prior to the first iv LCM dose and 1 to 4 hours after the 
second iv LCM dose) and on the Final Treatment Visit (within 1 hour prior to the first iv LCM dose and 1 to 4 hours after the second iv LCM dose) from the 
opposite arm in which the solution for infusion was administered.
X
D
AC
AC
AC
AC
AC
AC
R
COPY 
OPY
CO
C
This document cannot be 
for
for
used
G and
and
al Trea
Trea
inin
to
pred
pred
d
support
mid
mi
hort an
ort an
os
any y
de; PK
de; P
d
ny marketing 
X
ng
tin
authorization 
tio
riz
X
th
application 
-5mi
5m
n
ap
cat
ap
ap
ap
and 
nd any 
ny extensions 
nd EC
nd EC
or
on T
on 
variations 
on
T
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 92 of 240
Has been changed to:
Table 5-2:
Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points referred to 
iv infusion 
Vital signsa
12-lead 
ECGb
PK blood samplingc
-59min to -3min
X
-20min
X
-10min
X
T0 (start of infusion)
+5min
X
+10min
X
+15min
X
+20min
X
+30min 
X
+45min
X
+60min
X
X
+1h to +4hd
X
+2h
X
X
AE=adverse event; BP=blood pressure; ECG=electrocardiogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
a Noninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before and after the start of each iv LCM infusion.
b A 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should 
be at rest at least 5 minutes prior to each ECG recording and should be motionless during the recording, when 
feasible.
c Samples for PK will be drawn after ECG and vital signs have been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusion was administered for the first iv LCM infusion (Day 1) and the 
final iv LCM infusion (Day 2 to 5/Early Termination), predose and postdose, at the time points indicated in the 
table. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE. Depending on the target duration defined for the cohort and subject 
tolerability, end of infusion can be at 15, 30, or 60 minutes, or whenever the infusion is stopped (if prematurely 
terminated).
d Time points are in reference to T0 (start of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.
Change #14
Section 5.3 Rationale for study design and selection of dose
EP0060 is an open-label, multicenter, inpatient study to investigate the safety and tolerability of 
adjunctive iv LCM as replacement for oral LCM therapy in pediatric subjects with epilepsy aged 
RED
G=ele
G=ele
EDACTED 
X
ED
AC
ED
COPY 
Y
X
CO
This document 
wi
cannot 
y,y
ated).
ted).
me poin
e poin
thin 
hin 
be 
ev
ev
, end
, end
used
sion 
on 
al bloo
l bloo
vant 
ant
to
which
hich
(D
(D
support
ior to 
or to
drawn a
drawn a
h th
h t
any
the 
the
en to a
en to 
e
marketing
ectroc
ectroc
me
nd puls
nd pul
ime po
me po
e i
e in
authorization 
n
za
X
ho
a
application 
ati
p
p
and 
X
d
a
any y
ny
a
extensions 
ion
ten
e
or 
or variations 
on
tio
ar
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 93 of 240
≥1 month to <17 years. The results of EP0060 will provide safety and PK data regarding the use 
of the iv LCM formulation in pediatric subjects. The EP0060 design is based on the study design 
for SP757, which evaluated iv LCM replacement in adults with partial-onset seizures, as well as 
based on design elements of other pediatric iv AED studies.
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial-onset seizures in subjects ≥16 years of age (depending on country-specific 
labeling) with epilepsy when oral administration is temporarily not feasible. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for subjects enrolling from the long-term 
open-label studies and for subjects currently prescribed VIMPAT and enrolling directly into 
EP0060. 
The planned pediatric iv LCM labeling will be consistent with the approved adult iv LCM 
labeling and will also include infusion durations of 15 to 60 minutes depending on the evaluation 
of iv LCM PK, safety, and tolerability in pediatric subjects enrolled into EP0060. EP0060 will be 
comprised of up to 3 cohorts, and will first evaluate a target infusion duration of 30 minutes but 
no longer than 60 minutes whenever possible (Cohort 1). After a DMC review of the safety and 
tolerability data from subjects in Cohort 1, the DMC will make a recommendation for the target 
infusion duration to be evaluated in Cohort 2: EITHER 15 minutes but no longer than 30 minutes 
whenever possible, OR 30 minutes but no longer than 60 minutes whenever possible. If the 30 to 
60 minutes infusion duration is repeated, enrollment into the study will be stopped once Cohort 2 
has completed. If the Cohort 2 infusion is initiated at 15 to 30 minutes duration, the DMC will 
either recommend further evaluation at the 15 to 30 minutes infusion duration in Cohort 3, or to 
repeat evaluation of the 30 to 60 minutes infusion duration in Cohort 3. After completion of the 
enrollment of approximately 25 subjects in Cohort 3, the DMC will reconvene to review the final 
data to provide their overall impression.
This design will result in a total exposure of at least 50 pediatric subjects (up to 75 pediatric 
subjects) to assess the safety of iv LCM administered over a range of infusion durations. Taken 
together, the iv LCM dosing scheme and planned target infusion durations being evaluated in
EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for administration of a 
range of pediatric doses at infusion durations that are the same as those approved for adults and 
adolescents.
Has been changed to:
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM as 
replacement for oral LCM therapy in pediatric subjects with epilepsy aged ≥4 to <17 years. A 
separate Phase 2/3 study investigating the use of iv LCM as replacement for oral LCM therapy in
pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. The results of EP0060 
will provide safety and PK data regarding the use of the iv LCM formulation in pediatric subjects 
(≥4 to <17 years of age). The EP0060 design is based on the study design for SP757, which 
REDACTED
e (Coh
e (Co
, the D
the D
hort 2
hort 2
but no
but no
ate
ate
COPY 
5 to
5 t
subjec
subje
ate a
ate a
This documen
Has
Has
EP
EP
cannot
f ped
ped
scent
cent
s b
s b
be
to 1
to 1
dia
di
used
ss th
 th
v LCM
LCM
12m
12m
to 
ult 
the
he
support
ly 25
y 2
erall im
rall im
t in a
in
any
60 mi
60 m
25 s
5
marketing
o lon
lon
ed,d, enro
enro
sion is 
ion is
ion at 
on a
authorization
c
a targe
a targe
hort 1)
hort 1
DMC 
DMC 
2: EIT
: EIT
ng
ng
application 
h the ap
the a
0 minu
min
ts enr
s enr
and
g
d enr
enr
any 
ed 
ed
from
from
ol
extensions
tio
e Phas
Pha
der ra
der ra
l studi
studi
d in 
in
or
ons 
ns 
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 94 of 240
evaluated iv LCM replacement in adults with partial-onset seizures, as well as based on design 
elements of other pediatric iv AED studies.
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial-onset seizures in subjects ≥16 years of age (depending on country-specific 
labeling) with epilepsy when oral administration is temporarily not feasible. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for subjects enrolling from the long-term 
open-label studies and for subjects currently prescribed VIMPAT and enrolling directly into 
EP0060. 
EP0060 will initially enroll older pediatric subjects (Cohort 1), which will include at least 
20 subjects ≥12 to <17 years of age. Cohort 2 (at least 20 subjects ≥8 to <12 years of age) and 
Cohort 3 (at least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC 
recommendation. After the first 10 subjects in each cohort have received iv LCM over infusion
durations of 30 to 60 minutes, the enrollment will be temporarily put on hold for the DMC to 
review the available safety and tolerability data. Based on their review, the DMC will 
recommend the target infusion duration for the remaining subjects in the cohort (ie, 30 to 
60 minutes or 15 to 30 minutes), if the study/cohort should be stopped, and if the next cohort can 
be initiated, and if a new iv LCM study in younger pediatric subjects (≥1 month to <4 years of 
age) can be initiated.
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥4 to <17 years of age over a range of infusion 
durations. Taken together, the iv LCM dosing scheme and planned target infusion durations 
being evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for 
administration of a range of pediatric doses, and include infusion durations that are the same as 
those approved for adults and adolescents.
Change #15
Section 6.1 Inclusion criteria
2. Subject/legal representative is considered reliable and capable of adhering to the protocol 
(eg, able to understand and complete diaries), visit schedule, and medication intake according 
to the judgment of the investigator.
3. Subject is male or female from ≥1 month to <17 years of age. Note: For preterm infants 
<1 year old, the corrected gestational age should be used (calculated by subtracting the 
number of weeks born before 37 weeks of gestation from the chronological age).
5. Subject has, in the opinion of the investigator, adequate seizure control for participation in 
EP0060, and is able to comply with all study requirements including hospitalization, multiple 
REDACTED
he rem
he re
udy/co
dy/co
y in yo
y in yo
COPY 
oho
oh
be tem
be tem
Base
Base
This document
tot
3
cannot 
ubject/
bject
(eg, a
(eg, 
be
1 Inc
1 In
used 
5
to support
of ped
of pe
ults and
ts an
any
v LC
L
toto 12
12
d
marketing 
sure of
sure o
n subje
n sub
LCM
LCM
authorization
mp
ed on 
ed on 
mainin
mainin
ohort s
ohort s
ounge
unge
application
ts ≥8 
s ≥8 
w sequ
w sequ
have re
ave 
porar
porar
h
and 
h wil
h wil
t
any 
lin
lin
extensions
ng
es (2 t
s (2 
EP006
EP006
m the l
the l
ing d
ng
or
ge o
ge o
variations 
as 
e 3 3 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 95 of 240
blood draws, and iv infusions. Subject (or parent[s] or legal representative) is willing to 
comply with all study requirements.
10. Subject has been prescribed oral VIMPAT at a dose of 2mg to 12mg/kg/day or 100mg to 
600mg/day. 
11. Subject has been prescribed oral VIMPAT for the treatment of epilepsy for at least 1 month 
prior to Screening and has not been prescribed or maintained on VIMPAT for the purposes of 
participating in EP0060. Prescribed oral VIMPAT dose must be stable for at least 7 days, and 
intake of the prescribed total daily dose confirmed for at least 3 days prior to participation.
12. Subject is on a stable dosage regimen of at least 1 AED. The daily dosage regimen of AED 
therapy must be kept constant for a period of at least 1 week prior to Screening. VNS is 
allowed, but settings must be kept constant for a period of at least 1 week prior to Screening.
Have been changed to:
2. Subject/legal representative is considered reliable and capable of adhering to the protocol, 
visit schedule, and medication intake according to the judgment of the investigator.
3. Subject is male or female from ≥4 to <17 years of age.
4. Subject has, in the opinion of the investigator, adequate seizure control for participation in 
EP0060, and is able to comply with all study requirements including admission to the health 
care facility, multiple blood draws, and iv infusions. Subject (or parent[s] or legal 
representative) is willing to comply with all study requirements.
10. Subject has been prescribed oral VIMPAT at a dose of 2mg/kg/day to 12mg/kg/day (for 
subjects <50kg) or 100mg/day to 600mg/day (for subjects ≥50kg). 
11. Subject has been prescribed oral VIMPAT for the treatment of epilepsy for at least 1 month 
prior to Screening and has not been prescribed or maintained on VIMPAT for the purposes of 
participating in EP0060. Prescribed oral VIMPAT dose must be stable for at least 7 days, and 
intake of the prescribed total daily dose confirmed for at least 3 days prior to first infusion.
12. If the subject is on a concomitant AED, the daily dosage regimen of AED therapy must be 
kept constant for a period of at least 1 week prior to Screening. VNS is allowed, but settings 
must be kept constant for a period of at least 1 week prior to Screening.
The following inclusion criterion has been deleted:
4. Subject must be a minimum of 4kg in body weight.
And the following inclusion criterion has been added:
5. Subject is participating in a long-term, open-label study with LCM or is currently prescribed 
oral VIMPAT and needs to undergo a procedure, is admitted to an EMU or health care 
facility, or other situations where iv administration of LCM is clinically appropriate.
Change #16
Section 6.2 Exclusion criteria
6. Subjects who do not have a diagnosis of epilepsy.
REDACTED
all stu
all st
MPAT 
MPAT
600mg
600mg
VIM
VIM
COPY
qu
qu
quirem
quire
fusion
usion
This document
o
canno
he f
e f
Subje
Subje
ora
ora
be 
mu
fol
fo
sed
g in
g in
ust b
ust b
to 
nc
nc
support 
oncom
nco
period o
eriod
tant fo
tant f
any
al da
l da
omi
m
marketing
MPAT
MPAT
een pre
en pre
cribed o
ribed
aily
ail
authorization
ns. Su
ns. S
udy req
dy req
at a d
at a d
g/day 
/day 
application 
seizur
seizu
ments i
ments
ub
and 
dhe
h
of the
of the
any 
ering
erin
extensions
n of
n of
g. VNS
. VN
rior to
rior to
or 
f A
f A
variations 
of 
of 
s, and 
and 
tion.
ion.
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 96 of 240
9. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.
12. Subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2 times the upper limit of normal (ULN), or creatinine 
clearance less than 50mL/min.
21. Subject has a known sodium channelopathy, such as Brugada syndrome.
Have been changed to:
5. Subject does not have a diagnosis of epilepsy.
8. Subject has a medical condition that could reasonably be expected to interfere with drug 
distribution, metabolism, or excretion.
11. Subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2 times the upper limit of normal (ULN), or creatinine 
clearance less than 30mL/min.
19. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
And the following exclusion criteria have been deleted:
2. Subject, in the investigator’s opinion, would be expected to stay in the hospital or on iv LCM 
longer than 5 days.
18. Subject has been treated with vigabatrin for at least 12 months prior to entering EP0060 and 
has experienced any toxicity issues with this treatment. Note: Any subject who is currently 
treated with vigabatrin, and has received vigabatrin for a period of less than 12 months, is 
excluded from EP0060. Subjects who have received vigabatrin in the past must have 
documentation of an assessment for visual field defects after completion of vigabatrin 
therapy.
Change #17
Section 7.2 Treatment(s) to be administered
Treatment Period (up to 5 days)
During the Treatment Period, iv LCM will be administered twice daily at 12-hour intervals, once 
in the morning and once in the evening. The iv LCM dose will be equivalent (mg-for-mg) to the 
subject’s current stable oral LCM dose or prescribed oral VIMPAT dose (always in bid regimen) 
of 2 to 12mg/kg/day or 100 to 600mg/day. The first iv LCM dose will be given on Day 1.
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to administration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; 
iv LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal 
saline (NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total 
volume of fluid intake/day of 100mL/kg body weight. Intravenous LCM administration should 
be completed within 4 hours after dilution.
For subjects enrolled into Cohort 1, iv LCM should be infused as follows:
for at 
for at
ith thi
h thi
ceived
ceived
s who
s who
f
COPY
expec
expe
This document
each 
each
vo
vo
cannot 
m
ibrate
brate
targe
targe
be
rre
mg/k
mg/k
used
and o
nd o
ent 
ent s
to
ent P
ent 
support 
to
to b
o 5 da
5 d
up
Pe
P
any 
be a
be
marketing 
o hav
hav
or visua
r visu
authorization 
least 
least 
is trea
s trea
d vigab
viga
ve
ve
application 
Bruga
rug
delete
delet
cted to
ted to
and 
gad
gad
any
mal (U
mal (U
extensions 
with d
ith d
se (A
se (A
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 97 of 240
x Over a target duration of 30 minutes but no longer than 60 minutes whenever possible. 
After review of the Cohort 1 data, the DMC will make a recommendation for the target infusion 
duration to be evaluated in Cohort 2: 
x EITHER 15 minutes but no longer than 30 minutes whenever possible, 
x OR 30 minutes but no longer than 60 minutes whenever possible. 
If the 30 minutes but no longer than 60 minutes infusion duration is repeated, enrollment into the 
study will be stopped once Cohort 2 has completed. If the Cohort 2 infusion is initiated at 
15 minutes but no longer than 30 minutes duration, the DMC will make a recommendation for 
the target infusion duration to be evaluated in Cohort 3:
x EITHER 15 minutes but no longer than 30 minutes whenever possible, 
x OR 30 minutes but no longer than 60 minutes whenever possible. 
When necessary for the safety of the subject or when the investigator deems it appropriate, the 
iv LCM dose can be modified after 1 day, once the Day 1 PK samples are taken.
A subject cannot receive iv LCM for more than 5 days in EP0060. Once the subject has 
completed the Treatment Period (up to 10 infusions from Day 1 to Day 5 of iv LCM), the subject 
will need to discontinue EP0060. If a subject requires iv LCM treatment for more than 5 days, 
the subject will need to discontinue EP0060. Subjects who were enrolled in a long-term, 
open-label study may be eligible to resume participation in that study, according to the protocol 
requirements. If subjects need to discontinue LCM, the subjects should be tapered off LCM 
gradually as specified in their long-term, open-label study. This taper should occur as a part of 
the long-term, open-label study.
Subjects who were prescribed oral VIMPAT should continue AED treatment at the discretion of 
the treating physician. 
Has been changed to:
Treatment Period (up to 5 days)
During the Treatment Period, iv LCM will be administered bid at approximately 12-hour 
intervals, once in the morning and once in the evening, for up to 5 days. The iv LCM dose will 
be equivalent (mg-for-mg) to the subject’s current stable oral LCM dose or prescribed oral 
VIMPAT dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 600mg/day. The first 
iv LCM dose will be given on Day 1.
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to administration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; 
iv LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal 
saline (NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total 
volume of fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
REDACTED 
rtici
rtic
e LCM
e LCM
open
open
VIM
VIM
COPY
s iv 
s iv
ects w
ects 
cipa
ipa
This document 
ach
ch
volu
volu
iviv
cannot
rated
ated
arget d
rget 
h do
h do
be 
se w
e w
d i
d i
used 
g f
e (al
(alwa
wa
will
will
to 
for
for-
support 
days
ay
rt
Period, 
eriod
morni
morn
any 
s)s)
marketing 
MPAT s
PAT 
authorization
who
who
ation i
tion i
M, the
M, the
label
label
application 
60. On
0. On
y 1 to D
y 1 to
LCM tr
CM t
o we
o w
and 
dee
ee
es are
s are
any 
ems i
ms
extensions 
at
or
ion 
on 
variations 
o the 
 the 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 98 of 240
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.
For the first 10 subjects ≥12 to <17 years of age enrolled into Cohort 1, iv LCM should be 
infused over a duration of 30 minutes but no longer than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in Cohort 1 and subsequent cohort(s) will be 
based on DMC recommendation: 
x 30 minutes but no longer than 60 minutes whenever possible,
x OR 15 minutes but no longer than 30 minutes whenever possible.
Further details on the timing on DMC recommendations regarding infusion duration are provided 
in Section 12.7.2.
When necessary for the safety of the subject or when the investigator deems it appropriate, the 
iv LCM dose can be modified after the first infusion, once the Day 1 PK samples have been 
taken. 
A subject cannot receive iv LCM for more than 5 days in EP0060. If a subject requires iv LCM 
treatment for more than 5 days, the subject may continue on iv VIMPAT, but he/she will need to 
discontinue EP0060. Subjects who were enrolled in a long-term, open-label study may be 
eligible to resume participation in that study, according to the protocol requirements. If subjects 
need to discontinue LCM, the subjects should be tapered off LCM gradually as specified in their 
long-term, open-label study. This taper should occur as a part of the long-term, open-label study.
Subjects who were prescribed oral VIMPAT should continue AED treatment at the discretion of 
the treating physician.
Change #18
Section 7.8.1 Permitted and prohibited concomitant treatments (medications and therapies)
Only stable use of amphetamines and sedative antihistamines are permitted during the study. 
Also, only stable low doses of anxiolytics or hypnotics are allowed for nonepilepsy indications.
The following concomitant medications that influence the central nervous system are prohibited 
during EP0060:
x Neuroleptics
x MAOIs
Subjects who have been treated with ethosuximide are excluded from the study. Concomitant use 
of either vigabatrin or ethosuximide during the course of the study is prohibited.
Therapy which becomes necessary in the investigator’s opinion during the course of the study 
must not be refused to a subject even if described above as therapy that is expressly not 
permitted. In such cases, the subject’s participation in EP0060 will be discontinued.
Has been changed to:
Stable use of amphetamines and sedative antihistamines is permitted during the study. 
REDACTED 
be 
be 
uld occ
uld oc
PAT s
PAT 
COPY
a lon
a lon
ording 
rdin
tap
tap
This document
of eit
of ei
T
cannot 
AOIs
OIs
bjects
jects
be
eptic
epti
used 
cs
cs
to
com
om
support
tamin
amin
doses o
oses 
ita
it
any
proh
proh
marketing authorization 
g to 
to
pered o
ered 
cur as
cur as
shoul
houl
application
60. If a
0. If 
iv VIM
iv VIM
g term,
term
o the
the
and 
K 
K 
any
ms it 
ms i
samp
samp
extensions 
tion ar
on ar
t a
t a
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 99 of 240
Use of MAOIs is prohibited during EP0060.
Therapy which becomes necessary in the investigator’s opinion during the course of the study 
must not be refused to a subject even if described above as therapy that is expressly not 
permitted. In such cases, the subject’s participation in EP0060 may be discontinued.
Change #19
Section 7.8.2 Rescue medication
The use of oral or rectal benzodiazepines is restricted to intermittent use as rescue medication.
Has been deleted 
Change #20
Section 8 STUDY PROCEDURES BY VISIT
The following subheadings have been added:
8.1 Screening/Baseline Period
8.2 Treatment Period
8.4 End-of-Study Period
Change #21
Section 8.1
Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline
Prior to the conduct of any study related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments may be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 1a). Screening may also occur 1 day prior to Day 1 (Visit 1b) 
provided all test results are available and reviewed to assess inclusion and exclusion criteria prior 
to enrollment/treatment in the study. Oral LCM will be administered in accordance with each 
subject’s current stable LCM dosage regimen of 2 to 12mg/kg/day or 100 to 600mg/day. For 
subjects enrolled in a long-term open-label study, the oral LCM will be taken from the long-term 
open-label study supply. For subjects who have been prescribed VIMPAT, oral LCM will be 
taken from the subject’s prescribed VIMPAT supply.
When necessary for the well-being of the subject or when the investigator deems it appropriate, 
the hospitalization, screening laboratories, and the first iv LCM infusion can start on the same 
day provided all results are available and reviewed for inclusion/exclusion criteria prior to the 
start of infusion/treatment.
REDACTED 
(D
(
COPY 
This document
j
subje
subje
op
op
cannot
d all
all
rollme
ollme
ject’
ect’
be
s pr
pr
ll te
ll t
used 
ring
ng
he Scr
e Scr
rio
rio
to 
C
g th
g th
support
. The 
The
Inform
Infor
C-app
app
any 
se 
se 
Bs
Bs/IE
/IE
marketing 
Day 
Day -7
elated p
lated
 of th
of
authorization application and any extensions 
edicic
or 
cati
ati
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 100 of 240
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria and the results of the following pretreatment assessments at Visit 1a:
x Height, weight, and body mass index (BMI)
x Medical procedures
x Procedure history
x Diagnosis of epilepsy
x Childbearing potential
x Medical history update for subjects from long-term open-label studies, or complete medical 
history for subjects receiving prescribed VIMPAT
x Lacosamide dosing history (including time and quantity during the last 3 days)
x Prior and concomitant medication(s) assessment 
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening 
Visit for subjects who are prescribed VIMPAT and urine testing for subjects enrolled in 
long-term, open-label studies
x Withdrawal criteria
x Complete neurological examination
x Complete physical examination
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse) assessment
x 12-lead ECG 
x AE reporting (AEs occurring since signature of Informed Consent form). Ongoing AEs from 
the long-term open-label studies will be followed, as well as recording of new AEs during 
EP0060.
x ILAE (International League against Epilepsy) seizure classification
x Admission to the unit
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
x Signs and symptoms of depression for subjects <6 years of age
x The following assessments will be carried out at Visit 1b if Screening and Baseline occur on 
separate days:
x Verification that the subject continues to meet the inclusion criteria
x Lacosamide dosing history (including time and quantity during the last 3 days)
REDACTED COPY
and u
and u
This document 
C
x
cannot 
ral LC
al LC
C-S
be
sion 
sion
used 
ernatio
rnatio
to support 
ccurrin
curr
n-label
labe
any marketing 
try and
ry and
essme
essm
authorization application 
will be 
will be
rine tes
ne te
and 
nt, and
t, and
any extensions
lete m
ete m
days)
days)
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 101 of 240
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x AE reporting (AEs occurring since signature of Informed Consent form)
x Blood sample for clinical chemistry and hematology 
x Withdrawal criteria
x Vital signs (BP and pulse) assessment
x 12-lead ECG
x Admission to the unit
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
x Signs and symptoms of depression for subjects <6 years of age
Has been changed to:
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline
Prior to the conduct of any study-related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments may be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 1a). When necessary for the well-being of the subject or when
the investigator deems it appropriate, the Screening and/or Baseline Visit can occur on the same 
day as the first iv LCM infusion (Day 1) provided all test results are available and reviewed to 
assess inclusion and exclusion criteria prior to enrollment/treatment in the study. Oral LCM will 
be administered in accordance with each subject’s current stable LCM dosage regimen of 2 to 
12mg/kg/day or 100 to 600mg/day. For subjects enrolled in a long-term open-label study, the 
oral LCM will be taken from the long-term open-label study supply. For subjects who have been 
prescribed VIMPAT, oral LCM will be taken from the subject’s prescribed VIMPAT supply.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. The following pretreatment assessments will be carried out at 
Visit 1a:
x Height and weight 
x Medical procedures
x Procedure history
x Diagnosis of epilepsy
REDACTED
y wil
y wi
d the s
d the s
s pare
s pare
nsent 
nsent 
tten
tten
COPY
y -1) 
1)
ures, a
res, 
l
This document
Visit
Visit
x
cannot 
subjec
subje
eria 
eria 
be
l
VIM
VIM
used
r 100
100
l be t
 be 
to
acco
acc
support
ppro
pro
infusio
nfusi
exclusi
xclusi
ord
any
sit 1
sit 1
opri
opr
marketing 
for
for
n Asse
n Asse
Period,
eriod
asses
asse
)
authorization
a com
a com
l be gi
be g
subjec
ubjec
ent/leg
nt/leg
rm.
rm
application 
Screen
cree
and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 102 of 240
x Childbearing potential
x Medical history update for subjects from long-term open-label studies, or complete medical 
history for subjects receiving prescribed VIMPAT
x Lacosamide dosing history (including formulation, date, and time of use, and dose and unit 
during the last 3 days)
x Prior and concomitant medication(s) assessment (prior medications will only be collected for 
direct-enroll subjects; concomitant medications from the long-term open-label studies will be 
followed, as well as the recording of new concomitant medications during EP0060 for all 
enrolled subjects)
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening 
Visit for subjects who are prescribed VIMPAT and urine testing for subjects enrolled in 
long-term, open-label studies
x Withdrawal criteria
x Complete neurological examination
x Complete physical examination
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG 
x AE reporting (AEs occurring since signature of Informed Consent form). Ongoing AEs from 
the long-term open-label studies will be followed, as well as recording of new AEs during 
EP0060.
x ILAE (International League against Epilepsy) seizure classification
x Admission to the unit
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
x The following assessments will be carried out at Visit 1b if Screening and Baseline occur on 
separate days:
x Verification that the subject continues to meet the inclusion criteria
x Lacosamide dosing history (including formulation, date, and time of use, and dose and unit 
during the last 3 days)
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
hema
hema
sment
men
COPY 
This document 
x
cannot
parate
arate
Veri
Veri
be
llow
llow
used 
for sub
or sub
to
inis
inis
support
ague
gu
nitit
tra
t
any 
ue a
ue
marketing 
ce signa
e sign
es will
s wil
authorization 
tology
tology
application and
or su
su
any
testin
testi
ubje
ubj
extensions 
of last
f last
o
or a
or a
variations 
for 
for 
will b
will b
all
all
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 103 of 240
x AE reporting (AEs occurring since signature of Informed Consent form)
x Blood sample for clinical chemistry and hematology 
x Withdrawal criteria
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG
x Admission to the unit
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
Change #22
Section 8.2
Visit 2 (Day 1)
Intravenous LCM infusion treatment will begin at this visit and the following assessments will be 
carried out. Screening laboratory assessments may be conducted up to the day of the infusion
provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion.
x Confirmation of inclusion criteria and exclusion criteria
x Intravenous LCM infusion
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x Withdrawal criteria
x AE reporting
x 12-lead ECG (prior to iv LCM infusion and at 15, 30, 60 minutes, and 2 hours from the start 
of iv LCM infusion)
x Vital signs of BP and pulse rate (5 minutes prior to iv LCM infusion and at 5, 10, 20, 45, 
60 minutes, and 2 hours from the start of iv LCM infusion)
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM 
infusion may not be used for PK blood sampling.) 
x C-SSRS (for subjects ≥6 years of age)
x Signs and symptoms of depression for subjects <6 years of age
x Intravenous LCM infusion and the following assessments will be carried out during the 
evening (PM) at approximately 12 hours after the start of the AM infusion:
x Intravenous LCM infusion
x Concomitant medication(s) assessment
REDACTED 
assess
asses
t (id
(iden
en
COPY 
ion
o
on crit
n cr
This document 
x
cannot 
e t
fusion
usion
C-S
be 
amp
m
the i
the i
used
and 
and 
mple
mple
to
BP a
P a
2
support
iv LC
v L
)
and
and
any 
CM
C
marketing 
ntif
tif
authorization 
terer
sment
smen
fica
fica
application
he fo
e fo
ed up t
d up 
riteria p
iteria
riaia
and 
ollll
any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 104 of 240
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x AE reporting
x 12-lead ECG (prior to iv LCM infusion and at 15, 30, 60 minutes, and 2 hours from the start 
of iv LCM infusion)
x Vital signs of blood pressure and pulse rate (5 minutes prior to iv LCM infusion and at 5, 10, 
20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Withdrawal criteria
x Signs and symptoms of depression for subjects <6 years of age
Has been changed to:
Section 8.2.1 Visit 2 (Day 1)
Intravenous LCM infusion treatment will begin at this visit, and iv LCM will be administered bid 
at approximately 12-hour intervals, once in the morning and once in the evening, for up to 
5 days. Screening laboratory assessments may be conducted up to and including the day of the 
infusion provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion. 
The following assessments will be carried out:
x Intravenous LCM infusion
x Medical procedures and medical history update
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x Withdrawal criteria
x AE reporting
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered at the time points described in Section 9).
An indwelling cannula used for the iv LCM infusion may not be used for PK blood
sampling.) 
x C-SSRS (for subjects ≥6 years of age)
x The second iv LCM infusion will be administered at approximately 12 hours after the start of 
the first infusion, and the following assessments will be carried out:
x Intravenous LCM infusion
x AE reporting
REDACTED 
y upda
y upda
s) asse
s) asse
t (ide
t (ide
COPY 
This document
s
x
cannot
ere th
re th
An ind
An ind
sam
sam
be
samp
sam
used 
f BP
BP
ately 5
tely 5
to
BP a
P a
support 
ximate
imat
nd 2 ho
d 2 ho
any marketing
entifi
entifi
authorization 
ate
essme
ssme
application 
in t
n t
to and
to an
lusion 
usion
and
CM w
CM w
the
the
any 
wi
extensions or variations 
10, 
10, 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 105 of 240
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Withdrawal criteria
Change #23
Section 8.3
Visit 3 (Day 2 to Day 5)
Assessments for Visit 3 (Day 2 to 5) are the same as those described for Visit 2 (Day 1) in 
Section 8.2.
Has been changed to:
Section 8.2.2 Visit 3 (Day 2 to Day 5)
If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. Blood samples for LCM PK will be obtained before 
and after the final iv LCM infusion at the time points described in Section 9. In addition, during 
the course of the study, additional blood samples for PK analysis can be taken at the discretion of 
the investigator, especially in the event of a relevant treatment-emergent AE.
Change #24
Section 8.4 Unscheduled Visit
The following assessments will be carried out during the Unscheduled Visit:
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x 12-lead ECG
x Blood pressure and pulse rate
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM 
infusion may not be used for PK blood sampling)
x Withdrawal criteria
x C-SSRS (for subjects ≥6 years of age). The C-SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE.
x Signs and symptoms of depression for subjects <6 years of age
REDACTED
eleva
eleva
COPY
mp
m
nts des
nts de
 for P
for P
This document
ini
cannot 
d p
Blood 
lood 
whe
whe
be 
press
pres
used 
CG
to support
assess
asses
gs
any
) asse
) ass
marketing 
e carrie
carr
authorization
PK an
PK a
nt trea
t trea
application
sit 3 
it 3
(Day 2 
Day 2
for LC
for L
cribed
cribe
and 
m
any extensions 
Day 1
Day 1
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 106 of 240
Has been changed to: 
Section 8.3 Unscheduled Visit
The following assessments will be carried out during the Unscheduled Visit:
x Medical procedures and medical history update
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x 12-lead ECG
x BP and pulse rate
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM 
infusion may not be used for PK blood sampling)
x Withdrawal criteria
x C-SSRS (for subjects ≥6 years of age). The C-SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE.
Change #25
Section 8.5 Final Visit (Day 2 to 6)/Termination Visit
The following assessments will be carried out the day after the last dose of iv LCM for subjects 
who complete the study, discontinue the study or withdraw from the study prematurely:
x Concomitant medication(s) assessment
x Pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x Complete physical examination
x Complete neurological examination
x Blood sample for clinical chemistry and hematology
x 12-lead ECG
x Blood pressure and pulse rate
x Withdrawal criteria
x Oral LCM administration
REDACTED 
)/Ter
)/Ter
COPY 
SSRS 
SSRS
This document
B
x
cannot 
plele
Compl
omp
Bl
Bl
be 
ete
ete
used 
ett
ett
ing
ng
to
ting
ting
support 
r subje
subje
D(s) as
(s) a
any 
s) asse
) ass
marketing
rmina
rmin
arried o
rried
nue the
ue th
authorization application 
assess
ssess
and 
arm
ar
cannu
cannu
any 
rm op
m o
extensions or variations 
)
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 107 of 240
x C-SSRS (for subjects ≥6 years of age) if the Unscheduled Visit is due to an AE
x Signs and symptoms of depression for subjects <6 years of age 
x Discharge from the unit
Has been changed to:
Section 8.4.1 Final Visit (Day 2 to 6)/Termination Visit
The following assessments will be carried out the day after the last dose of iv LCM for subjects 
who complete the study, discontinue the study, or withdraw from the study prematurely:
x Medical procedures and medical history update
x Concomitant medication(s) assessment
x Pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x Complete physical examination
x Complete neurological examination
x Blood sample for clinical chemistry and hematology
x 12-lead ECG
x BP and pulse rate
x Withdrawal criteria
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age) 
x Discharge from the unit
Change #26
Section 8.6
Follow-Up Period (Day 2 to Day 9)
One or 2 days after the last dose of iv LCM in the Treatment Period, a safety 
follow-up/telephone assessment will be conducted during the Follow-Up Period (2 to 9 days 
after Visit 2/Day 1). The following assessments will be collected:
Concomitant medication(s) assessment
AE reporting
Oral LCM administration
During the contact, the site should inquire as to whether the subject noted any change at the site 
of the infusion.
REDACTED
hema
hema
COPY 
t
This document 
ftere
Con
Con
annot
2 da
da
w-up/
up/
r Vi
r Vi
be 
ys
ys
used 
Fo
Fo
to support 
unit
nit
any 
years o
ears 
marketing authorization 
ology
ology
application and 
and
nd
any 
d tim
d tim
extensions or variations 
jects 
ects
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 108 of 240
Has been changed to:
Section 8.4.2 Telephone Contact (Day 2 to Day 9)
One or 2 days after the Final Visit, a safety follow-up/telephone assessment will be conducted 
during the End-of-Study Period (2 to 9 days after Visit 2/Day 1). The following assessments will 
be collected:
x Medical procedures and medical history update
x Concomitant medication(s) assessment
x AE reporting
x Oral LCM administration
During the contact, the site should inquire as to whether the subject noted any change at the site 
of the infusion.
Change #27
Section 9 ASSESSMENT OF PHARMACOKINETICS
Blood samples for the determination of LCM and SPM12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of study medication and the time of blood sampling 
must be recorded.
During the Treatment Period, plasma samples will be taken for LCM determination after ECG 
and vital signs have been taken from the opposite arm in which the solution for infusion was 
administered on Day 1 and Day 5/Early Termination at the following time points: 
x Predose (within 1 hour prior to iv LCM dose)
x Post dose (within 1 to 4 hours after end of iv LCM infusion)
x Final Treatment Visit (within 1 hour prior to the first iv LCM dose and 1 to 4 hours after the 
second iv LCM dose)
The study-related blood loss (including any losses in the maneuver), per study subject, will not 
exceed 3% of the total blood volume during a period of 4 weeks and will not exceed 1% at any 
single time. The total volume of blood is estimated at 80 to 90mL/kg body weight; 3% is 2.4mL 
of blood per kg of body weight. With today’s microanalytical techniques, plasma samples for 
drug level determinations can be small, with less than 1mL needed.
Details of plasma sample collection and processing, sample labeling, and shipment will be 
provided in the laboratory manual. 
Has been changed to:
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of study medication and the time of blood sampling 
must be recorded.
REDACTED
tudy 
tudy
sample
sampl
m the o
m the o
l
COPY
PM12
PM1
edures
dures
m
This document
eta
et
prov
prov
H
cannot 
pe
pe
evel d
vel d
ails 
ails 
be 
Th
er kg
er kg
used
b
he tot
he tot
he to
he t
to
bloo
loo
support 
t (with
(with
ose)e)
d
any
our
ours a
s a
marketing 
oppo
oppo
ly Term
y Ter
o iv LC
 iv L
authorization
s (see
s (se
medic
medic
es wil
s wi
os
application 
2809 c
809 
e S
and any extensions 
y chan
y chan
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 109 of 240
During the Treatment Period, plasma samples will be taken for LCM and SPM 12809
determination after ECG and vital signs have been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusion was administered, at the following time 
points:
First iv LCM infusion (Day 1):
x Predose (within 1 hour prior to iv LCM dose)
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
x Final iv LCM infusion (Day 2 to 5/Early Termination):
x Predose (within 1 hour prior to iv LCM dose)
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
Additional blood samples for PK analysis can be taken at the discretion of the investigator, 
especially in the event of a relevant treatment-emergent AE.
The study-related blood loss (including any losses in the maneuver), per study subject, will not 
exceed 3% of the total blood volume during a period of 4 weeks and will not exceed 1% at any 
single time. The total volume of blood is estimated at 80 to 90mL/kg body weight; 3% is 2.4mL 
of blood per kg of body weight. With today’s microanalytical techniques, plasma samples for 
drug level determinations can be small, with less than 1mL needed.
Details of plasma sample collection and processing, sample labeling, and shipment will be 
provided in the laboratory manual.
Change #28
Section 10.1.1.1 Signs and symptoms of depression
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The investigator should be aware of common warning signs that might be a signal for 
risk of depression. For common signs and symptoms of depression in children, reference should 
be made to the current version of the Diagnostic and Statistical Manual of Mental Disorders. 
Each subject’s parent(s)/legal representative(s)/caregiver(s) (in accordance with local regulation) 
should also be advised accordingly and effort should be made at clinic visits to specifically 
assess potential depression.
Section has been deleted
Change #29
Section 10.1.6 Pregnancy, bullets 
x The subject should be withdrawn from the study.
x The subject should immediately stop the intake of iv LCM or be down-titrated as instructed 
at the early discontinuation visit. 
REDACTED
essin
essin
COPY
analy
anal
than 1
than 
This document
Cha
Cha
Se
S
cannot 
 h
an
be 
has
has
used
dvis
dvis
al dep
al dep
to
nt(s
nt(
sed
ed
support
r sh
s
ommon
mmo
t versio
versi
(s)/le
s)/
any
or an
or a
hould
hould
marketing 
oms of
ms o
any
any
authorization
1mL
mL
g, sam
, sam
application 
r), 
),
s and w
and w
90mL/k
0mL/
tical tec
cal te
mL ne
L n
and 
per
per
any
the 
the
extensions 
e i
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 110 of 240
x A Safety Follow-Up Visit should be scheduled 1 to 2 days after the subject has discontinued 
her iv LCM infusion.
Have been changed to:
x The subject may need to discontinue iv LCM. The decision to stop the intake of iv LCM will 
be at the discretion of the investigator. 
x A Safety Follow-Up Visit should be scheduled 1 to 2 days after the subject has discontinued 
her iv LCM infusion.
Change #30
Section 10.7.1 Vital signs, body weight, height and BMI 
Noninvasive measurements of BP (systolic and diastolic) and pulse rate will be performed at 
clinic visits in a sitting position after at least 3 minutes at rest, when feasible, according to the 
tabular schedule of study assessments (Section 5.2). Body weight will be determined without 
shoes and wearing light clothing, and height will be measured without shoes; body weight and 
height, will be assessed according to the tabular schedule of study procedures (Section 5.2).
Has been changed to:
Section 10.7.1 Vital signs, body weight, and height
Noninvasive measurements of BP (systolic and diastolic) and pulse rate will be performed after 
at least 3 minutes at rest, when feasible, according to the tabular schedule of study assessments 
(Section 5.2). Body weight will be determined without shoes and wearing light clothing, and 
height will be measured without shoes; body weight and height will be assessed according to the 
tabular schedule of study procedures (Section 5.2).
Change #31
Section 10.7.2 12-lead ECG, paragraph 2
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest in a supine position at least 5 minutes prior to each recording and should be 
motionless during the recording, when feasible.
Has been changed to:
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 5 minutes prior to each recording and should be motionless during the 
recording, when feasible.
Change #32
Section 10.7.5 Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
REDACTED 
and di
and di
accord
accord
termin
termi
es; b
es; b
COPY 
eight
ight
This document
recor
ecor
cannot 
hould
hould
uld re
uld re
rd
be
n ch
n c
used
upip
ring th
ng th
ha
h
to
ine 
ine
support 
ECG, p
CG,
to ass
o as
any marketing
body w
body 
(Sectio
(Secti
authorization 
iastoli
astol
ding to
ding t
ed w
ed w
application
ithout
ithou
tudy pr
udy p
and 
asib
asi
ill be 
ll be 
t
any
ill b
ill b
ible, 
ble
extensions 
be
b
or variations 
ed 
ed 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 111 of 240
as to assess suicidal ideation and behavior that may occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5-1). 
The C-SSRS is not validated and will not be used for subjects <6 years of age. Signs and 
symptoms of depression for subjects <6 years of age will also be assessed whenever a C-SSRS 
assessment is performed. Subjects should be monitored for any changes in mood, ideas, or 
behavior for warning signs of depression. The investigator should be aware of common warning 
signs that might be a signal for risk of depression. For common signs and symptoms of 
depression in children younger than 6 years old, reference should be made to the current version 
of the Diagnostic and Statistical Manual of Mental Disorders. Parents and caregivers should also 
be advised accordingly and effort should be made at clinic visits to specifically assess potential 
depression.
Has been changed to:
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5-1). All subjects who 
are ≥6 years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and 
will complete the “Since Last Visit” version at subsequent visits. If a subject becomes 6 years of 
age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first 
visit at which the subject is 6 years of age and the “Since Last Visit” version used at subsequent 
visits.
The C-SSRS is not validated for subjects <6 years of age and will not be used for this population. 
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The investigator should be aware of common warning signs that might be a signal for 
risk of depression. For common signs and symptoms of depression in children younger than 
6 years old, reference should be made to the current version of the Diagnostic and Statistical 
Manual of Mental Disorders. Parents and caregivers should also be advised accordingly and 
effort should be made at clinic visits to specifically assess potential depression.
Change #33
Section 12 STATISTICS
Selected disposition, exposure, demographic, and Baseline summaries will be presented by 
cohort and all subjects overall. Descriptive statistics will be displayed to provide an overview of 
the Baseline characteristics, pharmacokinetic, and safety results. For categorical variables, these 
will consist of the number and percentage of subjects in each category. The denominator and 
percentage will be based on the number of subjects appropriate for the purpose of analysis. For 
continuous variables, display of descriptive statistics will generally include n (number of 
subjects), mean, standard deviation (SD), median, minimum, and maximum.
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan.
Has been changed to:
REDACTED 
he
s <6 y
<6 y
chang
chan
be a
be a
COPY 
quen
qu
on of t
on of t
e “Si
e “Si
This document
perce
perce
co
co
cannot
nd a
nd a
aselin
selin
l con
con
be
spos
po
all
all
used
ATIS
TIS
osit
osit
to 
T
support 
nic
any
aren
aren
c visi
c visi
marketing
g
aware 
aware
s and s
and 
made to 
ade to
nts
nts
authorization
th
ince L
ince L
years o
ears o
es in
es in
application
(Tab
(Tab
ersion o
ersion
visits. 
visits
he C
e C
and 
use
use
 stud
stud
l
any
(Col
(Co
ed fo
ed
extensions
s po
 po
l
or
ould
ould
otet
variations 
ersion
rsion
d a
d
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 112 of 240
Selected disposition, exposure, demographic, and Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Descriptive statistics will 
be displayed to provide an overview of the Baseline characteristics, PK, and safety results.
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan.
Change #34
Section 12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM plasma concentrations, including but not limited to geometric 
mean and coefficient of variation (CV%), will be computed for pre-infusion and post-infusion
time points on each infusion day where LCM plasma is collected.
If an adequate number of samples are collected on Day 5, then statistical comparisons between 
trough plasma concentrations from Day 1 and Day 5 as well as post-infusion plasma 
concentrations from Day 1 and Day 5 will be performed.
Has been changed to:
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected.
Change #35
Section 12.5
Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK/PD outcomes 
(if applicable) for an individual subject. The criteria for identifying important protocol deviations 
will be defined within the appropriate protocol-specific document. Important protocol deviations 
will be reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prior to database lock to confirm exclusion from 
analysis sets.
Has been changed to:
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary safety outcomes (if applicable) for an 
individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol-specific document. Important protocol deviations will be 
reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prior to database lock to confirm exclusion from 
analysis sets.
REDACTED 
9 pl
9 p
ol de
ol de
COPY
ma co
ma c
pre
pre-ini
plasm
las
This document
withi
with
rev
rev
d
cannot
t p
ngful 
gful 
ividua
vidua
ini
be 
proto
prot
used 
chan
han
to suppor
appro
ppr
t of the
of th
ntified
ntifie
any
al sub
al sub
rop
rop
marketing 
eviatio
eviati
eviatio
viatio
uct, o
uct, o
j
authorization 
nfus
fu
ma are
ma ar
application 
ncentra
ncentr
usion
sion
and
nfus
fus
any
comp
com
ion
io
extensions 
geom
geom
d post
post
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 113 of 240
Change #36
Section 12.7
Planned interim analysis and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of each cohort.
Has been changed to:
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 10 subjects in each cohort. 
Change #37
Section 12.7.1Definition of stopping rules
No formal stopping rule will be applied. The DMC may give a recommendation to stop the study 
after reviewing the safety data for Cohort 1 or Cohort 2. A recommendation for stopping should 
be based on the collective experience of the DMC members. After meeting to review data from 
each cohort, the DMC will provide a recommendation in writing, regarding whether to continue 
or to stop the study. UCB will consider this recommendation and ensure the study investigators 
are informed of the sponsor’s decision on how to continue as described below.
Has been changed to:
No formal stopping rule will be applied. The DMC may give a recommendation to stop the study 
after reviewing the safety data as described in 12.7.2. A recommendation for stopping should be 
based on the collective experience of the DMC members. After meeting to review data from each 
cohort, the DMC will provide a recommendation in writing regarding whether to continue or to 
stop the study. UCB will consider this recommendation and ensure the study investigators are 
informed of the sponsor’s decision on how to continue as described below.
Change #38
Section 12.7.2 Data Monitoring Committee
The DMC members will be defined in the DMC charter. After completion of Cohort 1, 
enrollment into EP0060 will be temporarily put on hold to allow for a DMC review of the safety 
and tolerability data from Cohort 1. Based on the review of the Cohort 1 data, the DMC will 
make a recommendation for the target infusion duration to be evaluated in Cohort 2. 
The DMC will reconvene after the completion of Cohort 2. If the Cohort 2 target infusion 
duration was 30 minutes but no longer than 60 minutes, enrollment into the study will be stopped 
once Cohort 2 has completed. If the Cohort 2 target infusion duration was 15 minutes but no 
longer than 30 minutes, the DMC will make a recommendation for the target infusion duration to 
be evaluated in Cohort 3. After completion of Cohort 3, the DMC will reconvene to review the 
final data to provide their overall impression.
Has been changed to:
The DMC members will be defined in the DMC charter. 
REDACTED 
e DMC
e DM
ed in 1
ed in 
the DM
the DM
omme
omme
COPY
ntinu
ntinu
This document
urara
once
once
lolo
cannot 
eco
c
DMC 
DMC 
ation
ation
be 
lity
omm
omm
used
ers
o EP0
EP0
y da
y da
to
s wi
s w
support 
Monito
Monit
ll
any marketing
endat
enda
s recom
s reco
on how
on ho
authorization 
C m
C may
a
12.7.2
12.7.
MC m
MC m
ti
application 
m
g, rega
g, rega
and en
and e
e as des
as de
and
ndatio
dati
meeti
eeti
any
ndatio
ndati
on
on
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 114 of 240
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
REDACTED 
ubjects
ubject
no long
o long
subjec
subje
nge
nge
COPY 
enr
n
availa
avail
 DM
DM
This document
inin
x
cannot 
ws: 
ws: 
EITH
EITH
be
Coho
Coho
used
n of 
n of 
ut on 
ut on
to 
te
f thth
support
ubjec
bjec
Cohort
Cohor
es wh
s wh
any 
be
be i
cts
marketing 
ects 
cts
er than
r than
d,
ini
authorization
MC wi
C wi
ts will
 will
ger th
ger th
s wi
wi
application 
du
du
ment in
ment 
able sa
ble s
ll
and
lled t
ed t
urati
rat
any 
o
extensions
et in
t in
or 
nfu
nf
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 115 of 240
Change #39
Section 12.8
Determination of sample size
No formal sample size calculation has been performed. The sample size was deemed clinically 
appropriate for the evaluation of safety, tolerability, and PK of iv LCM administration in 
pediatric subjects with epilepsy.
Has been changed to:
Approximately 75 subjects will be enrolled, which includes up to 3 cohorts of at least 
20 subjects. No formal sample size calculation has been performed. The sample size was deemed 
clinically appropriate for the evaluation of safety, tolerability, and PK of iv LCM administration 
in pediatric subjects with epilepsy.
Change #40
Section 17SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
Clinical Project Manager
_____________________________
Date/Signature
Clinical Trial Biostatistician
 MPH
_____________________________
Date/Signature
Study Physician
, MD
_____________________________
Date/Signature
Clinical Program Director
_____________________________
Date/Signature
Has been changed to (and became Section 18):
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document 
as
as
I co
I co
annot 
s bee
be
be
be used
am D
am D
u
to support any marketing authorization 
_
application 
l and a
and a
urrent G
rrent 
and any extensions
was
dminis
mini
or
s de
s de
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 116 of 240
16.2
Protocol Amendment 2
Rationale for the amendment
The primary purpose of this substantial amendment is to maximize the patient pool used in the 
evaluation of the safety of iv LCM in pediatric subjects. Thus, enrollment has been opened to 
include OLL and RxL subjects who are on a stable dose of oral LCM and elect to receive iv 
LCM as well as IIL subjects who are not currently taking LCM and initiate adjunctive LCM 
treatment using iv LCM. This amendment has also included the option for RxL and IIL subjects 
to continue oral LCM treatment in SP848, if clinically appropriate, after completion of iv LCM 
in EP0060. Given this option for RxL and IIL subjects, 2 visits were added to the study design. If 
required, a Transition Visit has been add for RxL and IIL subjects transitioning to SP848 and 
requiring up to 7 days for scheduling of additional assessments to be performed during EP0060. 
If not transitioning to SP848, an additional telephone contact visit has been added approximately 
30 days after last infusion to collect final safety data. 
In order to provide treatment continuity, a short-term oral LCM solution may be dispensed to 
RxL and IIL subjects eligible for SP848 enrollment in the event that additional time is needed to 
schedule the Transition Visit.
Enrollment from EP0012 has been removed as has enrollment from future pediatric studies.
The study design was changed to merge the previous Cohort 1 (≥12 to <17 years of age) and 
Cohort 2 (≥8 to <12 years of age) into 1 cohort spanning the age range of ≥8 to <17 years of age 
while maintaining the combined planned enrollment for this age group. The decision to combine 
these 2 age groups is supported by the following 3 considerations: PK modeling, growth chart 
information, postmarketing safety assessment of iv LCM use, and a recent publication (Arkilo, et 
al 2016). 
x In the oral and iv LCM PK pediatric modeling CL0266, simulations of iv LCM infused 
over durations of 15 to 60 minutes suggest that exposure is similar to oral administration. 
These results are consistent with the LCM PK profile and bioequivalence of iv and oral 
LCM established in adults. Thus, using the weight-based dosing adaptations for LCM 
adjunctive therapy, it is predicted that the LCM concentration at steady-state in pediatric 
subjects with partial-onset seizures will be similar to that in adults for both oral and iv 
LCM. Based on the PK modeling, the use of iv LCM is expected to be 
 in the 
pediatric patient population down to 4 years of age. 
x Based on the Centers for Disease Control and Prevention (CDC) growth charts for 
weight-for-age percentiles (2 years to 20 years of age), the ages at which a child reaches 
the 50th percentile at a weight of 50kg are 13.82 years for boys and 14.21 years for girls 
(http://www.cdc.gov/growthcharts, 2000). Therefore, average pediatric patients weighing 
50kg are approximately 2 to 3 years younger than the currently approved lower limit for 
age for VIMPAT (16 years [EU] or 17 years [US]). Based on PK modeling, LCM 
exposure in pediatric subjects weighing 50kg or more is predicted to be the same as 
exposure observed in adults.
x Postmarketing data were evaluated for the period from 01 Aug 2008 to 30 Nov 2015, and 
49 cases were identified for iv LCM formulation use in the pediatric population (in 
REDACTED 
evio
evi
hort sp
hort sp
enrol
enrol
e follo
e follo
ssess
ssess
COPY 
enrol
enrol
ious
iou
This document cannot
Base
ase
wei
wei
t
be 
atr
ed
ed
used
Based
sed
ric p
ric p
to
th pa
h p
support
nsis
nsis
d in adu
in ad
rapy, i
rapy, i
art
any
60 m
60 m
isten
ste
marketing
sment
ment
K pedi
K ped
i
authorization 
us Coh
s Coh
pannin
annin
llmen
lmen
wing 
wing 
application
oluti
lut
t that a
that 
ment 
ment
and 
tion
tion
any
n ad
n ad
extensions
of iv
f iv
study 
tudy 
g to SP
to SP
med du
ed d
d
or
subj
sub
v L
variations 
M 
bje
bje
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 117 of 240
patients 4 to <16 years of age). Based on review of these cases, no new safety concerns 
were identified. 
x Arkilo and colleagues examined use of iv LCM in 47 infants and children from 4 months 
to <12 years of age, and this study included use in nonapproved indications (ie, status 
epilepticus) (Arkilo, et al 2016). Evaluation of adverse effects was not possible for the 
11 subjects in status epilepticus. Five of remaining 36 subjects experienced sedation, and 
no new safety concerns were noted in this evaluation. 
Taken together, along with our knowledge of the safety of oral LCM in children down to 4 years 
of age, enrollment of children ≥8 to <17 years of age within the same cohort should not present a 
significant safety risk and should allow earlier benefit of access to the iv LCM option of 
treatment for those subjects who are ≥8 to <12 years of age. Initiation of the assessment of safety 
in patients ≥4 to <8 year olds will remain dependent on review of safety data from Cohort 1 by 
the DMC.
To accommodate these changes, revisions have been made to the inclusion/exclusion criteria, 
schedule of assessments, LCM dosing, and statistical analyses. 
Additional changes have been implemented for consistency with other protocols in the LCM 
pediatric program and updated language in protocol template regarding monitoring for potential 
drug-induced liver injury events.
Furthermore, administrative changes including the update of the study team have been made.
At the time of approval of this amendment, no subjects were enrolled in EP0060.
Modifications and changes
Global changes
The following changes were made throughout the protocol:
x Define the 3 subject populations that are eligible for enrollment into EP0060:
 Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or 
other pediatric study).
 Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
 Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv
LCM as adjunctive treatment in EP0060. Initiation of LCM monotherapy is not 
permitted in IIL subjects.
x Revise the subject population who will receive iv LCM as follows:
 Replacement for oral LCM treatment (OLL and RxL subjects): 
◦ 
Clinical need administration: Subjects currently taking prescribed oral LCM (or 
any enteric LCM administration, eg, LCM administration by feeding tube) who 
need to undergo a procedure and are treated at an EMU or health care facility, or 
other situations where iv administration is clinically appropriate and oral 
REDACTED 
no sub
no sub
COPY 
he up
he up
This document
x
cannot
L
be
Initi
Init
LC
L
used 
ib
mmerc
merc
i
to 
bed
ed-
support 
M (O
(
as par
as pa
atric stu
tric st
L
any 
ulal
OLL
OL
marketing 
hrough
rough
ation
atio
authorization
pdate 
date 
bjects
bjects
application 
h other
h oth
e regar
 rega
and 
usioio
any 
on/ex
on/e
extensions 
ot p
on of 
on of 
essmen
ssmen
from C
from 
or
pres
pre
variations 
4 yea
yea
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 118 of 240
administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
◦ 
Elective administration: Subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv 
LCM administration at an EMU or healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
 Adjunctive iv LCM treatment initiation (IIL subjects):
◦ 
Clinical need administration: Subjects not currently taking LCM who need to 
undergo a procedure, be treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration 
is not feasible (ie, surgery). In these subjects, the maximum number of iv doses of 
LCM is 10.
◦ 
Elective administration: Subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
x Enrollment from EP0012 has been removed.
x New published data regarding use of iv LCM in children was added to the Introduction.
x As a result of extending the eligible subject population to subjects initiating treatment, the 
primary study objective was modified as follows to remove stable oral LCM dose:
 The primary objective of this study is to evaluate the safety and tolerability of iv 
LCM infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy.
x Safety variables were clarified as either primary or other variables.
x Text was added to clarify that IIL subjects will not receive oral LCM during the 
Screening/Baseline Period.
x The design of the study was changed such that the Screening, Baseline, Treatment Period, 
and Final Visit may occur in 1 day, provided the subject only requires 1 iv infusion, 
results of examinations (ie, ECG, laboratory measurements) are available to allow 
verification of subject eligibility prior to infusion, and time permits for completion of 
Final Visit assessments.
x The age-staggered approach to enrollment has been modified from 3 cohorts to 2 cohorts 
while maintaining the overall number of planned subjects, which also modified the 
timing of the DMC reviews as follows:
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
REDACTED
d as fo
d as f
study
study
ric sub
ric su
ed a
ed a
COPY
M in c
M in 
ect po
ct po
This document 
EP00
P00
enro
enro
a
cannot
whil
hil
timi
tim
0060
060
be
age
age
ile m
ile m
used
sit as
it as
ge-
to
of s
of 
support 
udy
udy
may occ
ay oc
minatio
minatio
sub
any 
od.
od
y wa
y w
marketing 
as eithe
s eith
hat IIL
hat IIL
d
authorization
opula
opula
ollows
ollows
y is to 
is to 
bjects
ects
application 
hildren
ildren
ti
and
ility.
lity.
any 
M and
M an
In
I
extensions
other
ther
admin
admin
ber o
ber o
or
d to
d t
r
variations 
toto
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 119 of 240
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes.
x OR Cohort 2 should be stopped, 
x AND whether to initiate the assessment of safety in younger pediatric subjects (≥1 month to 
<4 years of age).
x Modifications for the number and dose of iv LCM treatment(s) were incorporated as follows:
 The number of required infusions was reduced from 2 to 1.
 Text was added to clarify the starting iv LCM dose to be administered to subjects 
initiating adjunctive LCM therapy.
x Include the option for RxL and IIL subjects to continue oral LCM treatment after completion 
of iv LCM; if determined clinically appropriate; these subjects will be given the option to 
continue oral LCM treatment in SP848.
 Inclusion of this option added a Transition Visit for arrangement of SP848 entry 
assessments.
REDACTED 
subjec
subjec
no
no lolo
d infu
d infu
m a
m
COPY
, the 
, the
Based
Base
This document cannot 
The
The

be
catio
catio
used
r toto
of age)
f age)
to 
o in
o in
support
s but n
but 
uld be 
ld be 
any 
itiona
tiona
marketing
usion
sio
a 15 to
15 to
faster i
faster
60 m
60 m
authorization
d on
d on
cts wi
cts wi
onger t
nger 
on r
on
application
a dur
a dur
DMC w
DMC 
on th
n th
and 
led to
ed to
any extensions 
get in
get in
or variations 
on of 
n of 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 120 of 240
 Oral LCM solution will be dispensed only to those RxL and IIL subjects who are 
interested and eligible to enroll in SP848 in the event the additional time is required for 
arrangement of the Transition Visit.
x The options for RxL and IIL subjects to continue LCM treatment in SP848 resulted in 
changing the study periods as follows:
 For all subjects:
◦ 
Screening and/or Baseline Period (up to 7 days),
◦ 
Treatment Period 
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
◦ 
End-of-Study/Final Visit (1 day), 
◦ 
End-of-Study/Telephone Contact 1 (1 to 3 days),
 
Additional visits or contacts as follows:
◦ 
RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
-Transition Visit which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
◦ 
- RxL and IIL subjects who do not continue LCM treatment in SP848
-End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
x Modifications to maximum study duration were incorporated as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848.  
x Anticipated regions for the study were updated to North America and Europe with possibility 
for expansion into other regions.
x The following changes and clarifications were made to planned assessments:
 All pregnancy tests will be conducted on urine samples.
REDACTED 
o not c
not c
one Co
one C
COPY 
ncurre
ncurre
This document cannot 
App
App
be
u
the 
the 
used
mate
ate
bject
bject
to 
tely
tely
support
OLL
OLL
e oral L
oral 
n-lalabel
bel
a
any 
L gr
L g
marketing 
dy dura
y dur
authorization
ent w
nt w
contin
contin
ontact
ntac
application 
to con
to con
wit
wi
and any extensions 
imatel
matel
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 121 of 240
 Medical history or medical history update will only occur at Screening/Baseline.
 Information regarding ILAE classification will no longer be collected.
 LCM dosing information since the Treatment Period will be collected at TC1, Transistion 
Visit (if applicable), and TC2 (if applicable).
 Information will be collected regarding use of ketogenic diet.
 The PK samples (predose [OLL and RxL] and postdose [all subjects]) remained required 
for the first LCM infusion. Collection of PK samples (both predose and postdose for all 
subjects) from an additional iv LCM dose was changed to optional.
 If an Unscheduled Visit is due to an AE, the C-SSRS should be performed and collection 
of a PK blood sample is at the discretion of the investigator.
 Admission and discharge from unit were removed as hospitalization is not required for 
treatment.
 Seizure history was added at Screening for RxL and IIL subjects.
 Brief physical and brief neurological examinations were added during the Treatment
Period.
 Clarification was added that brief physical examination, brief neurological examination, 
hematology/chemistry laboratory assessments, and C-SSRS should only be collected 
once per day during the Treatment Period. 
 Text was added to clarify that the C-SSRS assessment should be performed once if the 
Screening and Baseline visits occur on the same day. If the Screening/Baseline and first 
infusion occur on the same day, the C-SSRS should be performed twice (predose and 
postdose).
 A Transition Visit was added to occur within 7 days of the Final Visit for RxL and IIL 
subjects who are eligible and choose to continue LCM treatment in SP848
◦ 
The Final Visit and Transition Visit can occur on the same day.
◦ 
Transition Visit in EP0060 and Visit 1 of SP848 should occur on the same day.
 Dispensing and collection of oral LCM solution was added for RxL and IIL subjects who 
are eligible and elect to continue oral LCM treatment in SP848. 
 An additional telephone contact was added 30 days after last dose for RxL and IIL
subjects who do not continue oral LCM treatment in SP848.
 Text was added to allow use of a local laboratory except for Final Visit. Central 
laboratory must be used for Final Visit.
 Text was added to permit the use of local laboratory results obtained for routine 
diagnostic and medical care whenever possible if collected no more than 24 hours prior to 
Screening/Baseline Visit in order to minimize blood loss associated with the study.
 Text was added to clarify the approach for LCM taper for RxL and IIL subjects.
REDACTED 
eriod.
eriod
 C-SS
S
occur
occur
day, t
day, t
COPY 
exami
exam
ments
ments
This document cannot
subj
subj

T
be
add
add
used 
ng a
g a
gible a
ible a
to 
and
and
support
t and 
and
Visit 
Visit 
any
le an
le an
T
marketing 
o
the C
the C
ded to
ded t
d
authorization
min
s, and
, and
SRS a
SRS a
on th
on th
application 
j
e added
adde
nation
ation
and 
ects.
ects.
any 
n is
n i
extensions 
d and c
and 
is no
s n
or variations 
uired 
red 
or all
or all
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 122 of 240
 Time windows were added for collection of ECG and vital signs during the 2 hours after 
the start of infusion.
 Corrections were made in table to align with assessments listed in Section 8 of protocol.
x The inclusion and exclusion criteria were modified as follows:
 Inclusion Criteria were reordered for a more logical flow. 
 An Inclusion Criterion was added (#4 in Amendment 2) which describes the study 
population to be enrolled, ie, OLL, RxL and IIL subjects. 
 Inclusion Criterion #4 (Amendment 1) has been amended such that adequate seizure 
control is no longer required as enrollment can now include subjects initiating adjunctive 
LCM treatment. The remainder of the previous criterion is now included in Amendment 2 
Inclusion Criteria 6 and 7. 
 Inclusion Criterion #5 (Amendment 1) has been removed as enrollment can now include 
subjects initiating adjunctive LCM treatment.
 Inclusion Criteria # 7 and #8 have been combined with Inclusion Criteria #10 and #11. In 
Amendment 2, these are contained within Inclusion Criterion 5. 
 Inclusion Criterion #9 (Amendment 1) has been deleted as only 1 dose is required. 
 Inclusion Criteria #10 and #11 (Amendment 1) have been reworded to incorporate and 
update the wording regarding stability of LCM dose from Inclusion Criterion #11 into 
Inclusion Criterion #10. These criteria were then folded into Inclusion Criterion 5 in 
Amendment 2. 
 Inclusion Criterion #12 (Amendment 1) has been deleted to remove requirements of 
concomitant AEDs.
 Inclusion Criteria #5 (Amendment 2) includes requirements for subjects initiating 
adjunctive LCM treatment, including stable dose of other AEDs and permitted types of 
epilepsy.
 Exclusion Criterion #3 has been revised to clarify investigator’s assessment of 
hypotension and bradycardia.
 Exclusion Criteria #5 and #16 (Amendment 1) have been deleted as epilepsy diagnosis is 
addressed within inclusion criteria.
 Exclusion Criterion #6 (now Exclusion Criterion 5 in Amendment 2) has been reworded 
to clarify that subjects taking monoamine oxidase A inhibitors are excluded.
 Exclusion Criterion #8 (now Exclusion Criterion 7 in Amendment 2) has been revised to 
include medical condition impacting absorption since short-term oral LCM will be 
provided to eligible subjects entering SP848.
 Exclusion Criterion #11 was removed and replaced by Exclusion Criterion #20. This 
criterion updates LFT exclusion criteria in line with current UCB standards. 
 Exclusion Criterion #17 (Amendment 1) has been deleted as felbamate is permitted in the 
long-term open-label studies for OLL subjects who may enroll in EP0060. 
REDACTED
y of L
y of L
eria w
eria w
endm
endm
COPY
een d
een 
ent 1
ent 1
This document 

cannot
Excl
xcl
to c
to c
be 
es
lus
lu
used
on Cr
n Cr
sed 
sed 
to 
 an
an
support 
rion
ion #
nd br
nd b
any
ment, 
ment,
marketing
ment 
ment 
endm
endm
i
authorization
1) hav
1) hav
LCM d
LCM d
were th
ere th
application
nclusi
nclus
riterion
iterio
deleted 
eleted
and any 
llmen
lmen
extensions
seizu
eiz
ting ad
ing a
d in A
d in A
or 
ur
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 123 of 240
 Exclusion Criterion #17 has been added since LCM has not been evaluated in the 
treatment of status epilepticus.
 Exclusion Criterion #18 has been added to clarify that subjects with only Type IIA1 or 
Type IIA2 should not be enrolled.
 Exclusion Criterion #19 was added to clarify that subjects with Dravet’s syndrome are 
excluded from this study.
 Exclusion Criterion #21 has been added to clarify that subjects enrolling to initiate 
adjunctive LCM treatment should not have received LCM during the past 3 months.
x Withdrawal criteria were modified in the following 4 ways:
 Clarification was added that treatment should not go beyond 10 doses.
 A withdrawal criterion was added such that any subject who initiated adjunctive LCM 
treatment and required a dose adjustment during the study should be withdrawn.
 Addition language was added to incorporate Sponsor language surrounding LFT results 
and monitoring for PDILI events.
 Clarification was added about the ability of subjects requiring more than 10 iv doses 
return to or enroll in the long-term open-label study pending discussion with and 
agreement from the Medical Monitor.
x Language regarding IMP labeling, handling and storage requirements, and drug 
accountability was updated to reflect new standard Sponsor text.
x Description of the short-term oral LCM supply was added, including under what 
circumstances it would be dispensed to RxL and IIL subjects.
x Language was added regarding oral dosing of LCM for RxL and IIL subjects who require 
short-term oral LCM supply in order to arrange for SP848 enrollment.
x Prohibited medications were updated to include cannibidiols not approved or indicated for 
epilepsy by local health authorities.
x Numbering of subjects was clarified for RxL and IIL subjects.
x Text was added to clarify reporting requirements for any suspected transmission of an 
infectious agent via a medicinal product to align with updated standard Sponsor text across 
programs.
x Potential Hy’s law was added as an AE of special interest to align with updated standard 
Sponsor text across programs.
x New Sponsor text was added surrounding LFT monitoring to provide further detail regarding 
the evaluation, investigations, and follow up of PDILI events. This text is to align with FDA 
guidance for PDILI monitoring; addition of this language was not initiated on the basis of 
any new hepatic safety signal for LCM.
x A new analysis set was added to include all subjects who receive LCM (oral or iv).
ing an
ing a
new 
ew stst
LCM
LCM
nsed
nsed
COPY
j
el stu
el stu
This document
x
N
cannot
tentia
entia
Spons
Spons
be 
ms.
ms.
used
ded t
d 
agent
agent
to 
d toto
support
we
th aut
h aut
bjects w
jects w
any 
ere up
ere up
h
marketing
d to Rx
d to R
oral do
oral d
n orde
n ord
authorization 
nd stor
nd stor
tandar
tandar
supp
supp
application 
g
requiri
equir
dy pend
y pen
and 
ge su
e su
any 
d a
d 
be w
be w
extensions 
adj
adj
o
ths.
ths
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 124 of 240
x The planned PK and safety analyses were updated to include evaluation based on whether 
subject was receiving replacement treatment (OLL and RxL subjects) or initiating treatment 
(IIL subjects).
x The use of the term “admitted” has been replaced with “treated” to accurately reflect that 
treatment can occur at an EMU or healthcare facility and admission to a hospital is not 
required.
x Other changes made in this amendment are to provide clarification, are administrative in 
nature, or are to correct errors.
Specific changes
Change #1
Title page
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE AS REPLACEMENT FOR ORAL 
LACOSAMIDE IN CHILDREN (≥4 TO <17 YEARS OF AGE) WITH EPILEPSY
Has been changed to:
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥4 TO <17 YEARS 
OF AGE) WITH EPILEPSY
Change #2
STUDY CONTACT INFORMATION 
Sponsor Study Physician
Name:
 MD
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
REDACTED
COSA
COSA
COPY 
O INV
O INV
A
This document cann
P
not 
n
an
be used to suppo
UC
UC
po
su
rt
port any 
a
marketing 
TION 
ION
authorization
VEST
VEST
AMIDE
AMID
application 
PLA
PLA
GE) WI
E) W
TI
and 
THE S
HE S
C
any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 125 of 240
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Change #3
STUDY CONTACT INFORMATION 
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
REDACTED
Drive
Driv
7, USA
7, USA
67 (ma
7 (ma
riangl
riangl
R
COPY 
c.c.
OPY
This document cannot 
an
be used 
:
d to 
t
support 
er
su
sup
su
any y mark
arketing 
le Par
e Par
ting
rket
ma
authorization 
, Suite
Suit
A
ail)l)
rk
application 
ic
ap
and any extensions 
on
en
or r
or variations 
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 126 of 240
Change #4
STUDY CONTACT INFORMATION 
Clinical Trial Biostatistician
Name:
 MPH 
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Trial Biostatistician
Name:
MPH 
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Change #5
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949
Canada: +1 877 582 8842
Email
Global: DS_ICT@ucb.com (for interventional clinical studies)
REDACTED
ate Dr
ate Dr
617, U
617, U
167 (m
167 (
Trian
Trian
COPY 
Inc.
nc.
OP
This document cannot 
Fax
Fax
ca
be
ous 
us 
b
used 
ER
ER
s ad
ad
ed to 
RSE
RSE
support any
any
ny ma
ma keting 
ngle P
ngle P
et
marke
m
authorization 
ive, S
ive, S
USA
USA
mail)
mail)
application 
ic
ap
and 
d any y
a
extensions 
en
e
or r variations 
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 127 of 240
Has been changed to:
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949 or +1 866 890 3175
Email
Global: DS_ICT@ucb.com (for interventional clinical studies)
Change #6
LIST OF ABBREVIATIONS
ICH has been revised; DS, ILAE, and RDC have been deleted; and EDC, IIL, OLL, PDILI, PS, 
and RxL were added.
Change #7
Section 1 SUMMARY
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM) infusions as replacement for oral LCM in pediatric subjects 
≥4 to <17 years of age with epilepsy. A separate Phase 2/3 study investigating the use of iv LCM
as replacement for oral LCM therapy in pediatric subjects with epilepsy ≥1 month to <4 years of 
age is planned. EP0060 will include subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) who need to undergo a procedure, be 
admitted to an epilepsy monitoring unit (EMU) or health care facility, or other situations where 
iv administration is clinically appropriate. Approximately 75 subjects, who are participating in a 
long-term, open-label study with LCM (SP848, EP0034, EP0012, or other future study) or who 
are currently prescribed VIMPAT® (LCM) will be enrolled. Pediatric subjects entering into 
EP0060 from a long-term, open-label study will temporarily suspend their participation in that 
study to receive iv LCM treatment in EP0060. Subjects who enroll directly into EP0060 will 
temporarily switch from their prescribed VIMPAT oral treatment to the iv LCM formulation. 
Subjects will be enrolled from approximately 40 sites in North America, Europe, Asia Pacific, 
and Latin America. Additional sites or regions may be added if deemed necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥4 to <17 years with epilepsy, after temporarily switching from the 
equivalent stable oral LCM dose. EP0060 is planned to include up to 3 age-based cohorts of at 
least 20 subjects per cohort: ≥12 to <17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to 
<8 years (Cohort 3). A Data Monitoring Committee (DMC) will review the safety and 
tolerability data for each cohort to make recommendations for the progression of subsequent 
cohort enrollment and iv infusion durations to be evaluated. 
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
st
s as re
s as r
eparate
parate
n pedi
n pedi
subje
subje
ion
io
COPY 
tudy 
udy 
This document
quiu
least
east
<8
<
canno
mary
mary
diatric
diatric
ivale
val
be 
me
y o
y o
used
h 
e enro
e enro
eric
eric
to
from
fro
suppor
IMPA
MP
m, ope
m, op
CM tre
M tr
any
p
ith LC
ith L
PAT
PA
marketing
ects c
cts 
on by fe
n by fe
unit (E
unit (
ropria
opri
authorization
to ev
to ev
eplace
eplace
te Pha
te Pha
iatric 
atric 
cu
cu
application and any
IIL, 
IIL,
extensions or variations 
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 128 of 240
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. During the Treatment Period, subjects will 
receive iv LCM infusions twice daily (bid) at approximately 12-hour intervals for up to 5 days. 
The daily dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM 
(2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood samples will be 
obtained for pharmacokinetic (PK) analysis, and detailed safety assessments will be performed. 
An End-of-Study/Final Visit will be conducted the day after the last dose of iv LCM after 
completion of or withdrawal from the Treatment Period. A safety follow-up Telephone Contact 
should occur 1 to 2 days after the End-of-Study/Final Visit. 
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, only subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were prescribed VIMPAT should continue antiepileptic 
drug (AED) treatment at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
REDACTED
j
60 min
60 mi
in Coh
n Coh
he DM
he DM
, the 
, the 
COPY 
p
0 subje
0 subj
ects i
cts i
This document
temp
emp
Co
Co
cannot
than 
han 
er com
er com
be
,
subj
sub
6
used 
r C
at le
at le
to 
Coh
Coh
support
s but n
but 
be stop
e stop
any 
itiona
tiona
marketing
e DMC
DMC
tional s
ional
es but 
s bu
authorization
e
inin Co
Co
nutes w
nutes 
ohort 1
hort 1
MC rev
C re
application
stud
tu
T should
shou
cian.
ian.
cts ≥1
cts ≥
h
and
nrolle
olle
udy
dy
any 
ately 1
ately 
d
extensions
perfo
erf
M aft
M af
elepho
lepho
or
will 
will
or
variations 
s. 
s. 
LCM
LCM
l be
l b
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 129 of 240
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥4 to <17 years of 
age with epilepsy. Investigation the use of iv LCM in pediatric subjects with epilepsy ≥1 month 
to <4 years of age is planned. 
EP0060 will include approximately 75 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other 
pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
REDACTED
of i
of 
pen
pen-lal
VIM
VIM
COPY 
oxima
oxim
f inf
inf
This document 
S
cannot 
Initi
Init
a
be
mme
mme
used 
stutu
ibed
bed
to
y a
udy)
udy
support 
M 
M (OL
(OL
as par
as pa
any
ately
ately
marketing
MPAT
MPAT
se of iv
se of i
y 7
authorization
ately
tely
fusion
usion
bel st
bel st
®
application 
pediatri
ediatr
ly 75
y 7
and 
ssib
sib
any
with 
with
ible,
ble
extensions 
with a t
ith a t
possib
ossib
h
or
dati
dat
variations 
om
tion
io
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 130 of 240
care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2.
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥4 to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including at least 20 subjects who are ≥4 to <8 years. Within Cohort 1, at least 
20 subjects will be ≥12 to <17 years of age and at least 20 subjects will be ≥8 to <12 years of 
age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each 
cohort to make the following recommendations: the progression of the current cohort, including 
iv infusion durations to be evaluated, and progression to initiate enrollment in the next cohort 
(Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age (as detailed 
further below). 
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
REDACTED
ou
e subj
e sub
48. Su
8. Su
ddition
ddition
COPY 
nt in
nt 
ch fro
ch fro
up wi
p wi
This document cannot
0 is c
0 is c
x
F
be
ow).
ow)
used
ions
ons
sep
epara
ar
to 
foll
oll
ns to
ns to
support
0
o <17 y
<17 
ng Com
g Com
llowi
low
any
t 1 
t 1
subje
subj
marketing 
o evalu
o eva
ars with
s wit
inc
in
authorization
om
ill ini
ill ini
jects f
ects f
ubject
ubject
nal sit
al sit
application 
will tem
will te
EP0060
P006
m thei
m thei
and
y. In t
In t
any 
nd ele
nd ele
h
extensions
d to 
d to
ations 
ions
ot feas
t feas
LCM 
CM 
or 
u
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 131 of 240
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses (over 
approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day 
(subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose if the last LCM infusion was performed 
in the morning, and time permits completion of assessments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LCM after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the 
Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
e of iv 
e of iv
twice d
wice 
nical n
nical 
e adm
e adm
COPY 
y ini
will be 
will be
This document
in th
n th
con
co
cannot 
ng g 
rawal 
wal
it can
t can
be 
g of 
g of
used
atmen
men
afety
afety
to 
t
support
ubject
bjec
0kg) an
kg) a
any 
60
60
weig
weig
t
marketing
minist
minis
bject's c
bject's
y). The 
. The
00m
00m
authorization 
v LCM
LCM
daily 
daily 
eed a
eed a
t
application
resul
resu
ill be a
ll be 
ccordan
cord
admin
admin
and
Visit
Visit
ltlt
any 
1
w ver
ve
t a
t
extensions
usio
usio
ay occ
y occ
12-lele
or 
on
on
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 132 of 240
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue antiepileptic drug (AED) treatment at the discretion of the treating 
physician. For RxL and IIL subjects who will discontinue use of LCM, the subject should 
complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper 
regimen or taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
REDACTED
l disc
l disc
r refer
r refer
 treati
treati
here 
here 
COPY 
D) tre
D) tre
This document
3
x
cannot 
tly 
ly
ot
ho wil
o wi
Inves
Inves
0
be 
n du
du
y be
y be
used 
pprox
prox
urat
urat
to support 
first 20
rst 2
these s
hese 
any 
ur
ur
marketing
at le
at le
ohort 1
ohort
to <12 
o <12
ration
rati
authorization
eatme
eatme
ontinu
ntinu
r to th
to th
ing ph
ng ph
application 
ontinue
ontinu
and any 
ly app
y ap
extensions
dy
in the
n the
or
and
an
variations 
d
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 133 of 240
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped,
x AND whether to initiate the assessment of safety in younger pediatric subjects (≥1 month to 
<4 years of age).  
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Change #8
Section 2 INTRODUCTION, first paragraph
Epilepsy is the second most prevalent neurological disorder in the world. More than 40 million 
people suffer from epilepsy–about 1% of the world’s population (Dichek, 1999). Although some 
forms of epilepsy may respond to surgical treatment and others may not require any treatment at 
all, most patients with epilepsy require appropriate pharmacological therapy (Perucca, 1996). 
The Institute of Medicine of the National Academies recently provided a review of the burdens 
of epilepsy, global incidence and prevalence of epilepsy, classification systems for seizure types 
and syndromes, gaps in information about epilepsy, and general recommendations (Institute of 
Medicine, 2012). In the past 2 decades, several new options for the medical treatment of epilepsy 
have been introduced, including novel AEDs and vagus nerve stimulation (VNS).
Has been changed to:
Epilepsy is the second most prevalent neurological disorder in the world. It is estimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most 
patients with epilepsy require appropriate pharmacological therapy (Perucca, 1996). The Institute 
of Medicine of the National Academies recently provided a review of the burdens of epilepsy, 
global incidence and prevalence of epilepsy, classification systems for seizure types and 
REDACTED
of i
of 
1 visi
1 visi
es, vita
s, vita
COPY 
oxima
oxim
inf
inf
This document
Has
as
Ep
Ep
cannot 
e, 2
, 2
been i
een i
s b
s b
be
mes
mes
201
201
used 
Med
ed
obal in
obal in
s g
s g
to
th
edici
dic
support
sy–
y ab
ab
respon
espon
h epil
epil
any 
revale
reval
bou
b
marketing 
rst par
st pa
authorization
ately
tely
fusion
usion
it with
with
al sign
al sign
application 
ger ped
er pe
ly 7
y 7
and any
with 
with
extensions 
Su
the
the
e an in
an in
h
or
ubje
ubje
variations 
ould 
uld 
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 134 of 240
syndromes, gaps in information about epilepsy, and general recommendations (Institute of 
Medicine, 2012). In the past 2 decades, several new options for the medical treatment of epilepsy 
have been introduced, including novel AEDs and vagus nerve stimulation (VNS).
Change #9
Section 2 INTRODUCTION, fifth paragraph
Intravenous formulations are particularly helpful as short-term replacement of oral formulations 
for patients unable to take oral products (eg, preoperative and postoperative patients, patients 
with acute gastrointestinal disorders). Such formulations allow patients to be maintained on the
same AED on their stable dose when they are unable to take the drug orally.
Has been changed to:
Intravenous formulations are particularly helpful as short-term replacement of oral formulations 
for patients unable to take oral products (eg, preoperative and postoperative patients, patients 
with acute gastrointestinal disorders). Such formulations allow patients to be maintained on the 
same AED on their stable dose when they are unable to take the drug orally. Intravenous 
formulations may also be helpful in the initiation of treatment in certain situations when the 
patient is unable to take oral medications.
Change #10
Section 2 Introduction, sixth paragraph
The iv formulation of LCM is approved in the US, EU, and several countries worldwide at doses 
of 200 to 400mg/day as adjunctive therapy in the treatment of partial-onset seizures in subjects 
with epilepsy when oral administration is temporarily not feasible. Intravenous LCM is approved 
in patients ≥16 years of age and for infusion durations of 15 to 60 minutes depending on the 
country-specific labeling.
Has been changed to: 
In the US, the iv formulation of LCM is approved in patients ≥17 years of age at a maximum 
dose of 400mg/day as monotherapy and adjunctive therapy in the treatment of partial onset 
seizures in subjects with epilepsy when oral administration is temporarily not feasible. In EU, the 
iv formulation is approved in patients ≥16 years at a maximum dose of 600mg/day as 
monotherapy (EU CHMP positive opinion received on 11 Nov 2016) and at a maximum dose of 
400mg/day as adjunctive therapy in the treatment of partial onset seizures in subjects with 
epilepsy when oral administration is temporarily not feasible. Intravenous LCM is approved in 
patients ≥16 years of age and for infusion durations of 15 to 60 minutes depending on the 
country-specific labeling.
Change #11
Section 2 INTRODUCTION, new seventh paragraph
REDACTED 
ph
ph
ved i
ved i
COPY 
This document
patie
patie
cou
cou
cannot 
rap
ap
g/day 
g/day 
epsy 
epsy 
be 
on 
on 
py (
py (
used
ay y 
jects w
ects w
n is 
is
to
as m
as 
support 
to:
o:
mulatio
ulati
any 
fo
fo
marketing
in the
n th
erapy in
rapy 
ation is 
ion i
or inf
or in
authorization 
e
application 
ien
e drug 
drug
t in ce
t in c
and
erativ
rativ
nts t
nts 
any
ent of 
nt of
ve
extensions
at
ained 
ined 
or
ient
ien
variations 
ation
ation
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 135 of 240
Recently, a retrospective evaluation was conducted to examine the use of iv LCM in 47 infants 
and children from 4 months to <12 years of age (Arkilo et al, 2016). The median age across the 
47 children was 6.5 years, and 18 children were <3 years of age. Intravenous LCM was 
administered as adjunctive treatment along with ≥2 other AED. Lacosamide dose levels ranged 
from 1 to 11mg/kg, and the infusion was given over 30 minutes. Fifteen of the children were 
administered iv LCM either as replacement treatment for oral maintenance dose (n=10) or to 
initiate maintenance dose (n=5). For the remaining children, iv LCM was used to treat acute 
exacerbation of seizure frequency (n=18), status epilepticus (n=11) or epilepsia partialis continua 
(n=3). Children were observed for at least 48 hours after infusion. The 11 children with status 
epilepticus were not able to respond to inquiries about adverse effects. Of the remaining 
36 subjects, 5 experienced adverse effect of sedation which resolved in all 5 within 24 hours. No 
other observable adverse effects were noted. No cardiac events were noted during the infusions 
for the 80% of children who had ECG evaluation during the infusion. This study shows an initial 
positive benefit-risk profile for the use of iv LCM in infants and children from 4 months to 
<12 years of age. 
Has been added
Change #12
Section 2 INTRODUCTION, seventh paragraph (now eighth paragraph)
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation as replacement for oral LCM in pediatric subjects ≥4 to <17 years with 
epilepsy.
Has been changed to:
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment 
initiation in pediatric subjects ≥4 to <17 years with epilepsy.
Change #13
Section 3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy, after temporarily switching from 
the equivalent stable oral LCM dose. An additional objective is to evaluate the PK of iv LCM 
replacement in pediatric subjects with epilepsy. 
Has been changed to:
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy. An additional objective is to 
evaluate the PK of iv LCM in pediatric subjects with epilepsy.
REDACTED
olerab
olerab
ral LC
al LC
COPY 
aragr
ragr
This document
Has
Has
T
cannot
s)
uivale
ivale
acem
acem
be
o
in p
in p
used
UDY
D
objec
bjec
to 
DY
DY
support any
≥4
≥4 toto
marketing 
safety
safety
lacem
acem
authorization
raph
raph
ility, a
ility, 
CM in
CM in
application 
h (
h
and any
rom
om
extensions 
ng g
24 ho
24 ho
ng the 
g the 
udy sh
dy sh
m 4
m 4
or variations 
ntinua 
tinua 
atus
tus 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 136 of 240
Change #14
Section 4.1 Primary variable(s) (now Primary safety variables)
Safety and tolerability will be assessed using the following primary variables:
x Adverse events (AEs) reported spontaneously by the subject and/or caregiver (including 
parent/legal guardian) or observed by the investigator
x Subject withdrawals due to AEs
x Changes in 12-lead electrocardiograms (ECGs)
x Changes in vital sign measurements (blood pressure [BP] and pulse rate) 
Has been changed to:
Safety and tolerability will be assessed using the following primary variables:
x Adverse events (AEs) reported spontaneously by the subject and/or caregiver (including 
parent/legal guardian) or observed by the investigator
x Subject withdrawals due to AEs
Change #15
Section 4.2 Other safety variables
Other safety variables include the following:
x Changes in 12-lead electrocardiograms (ECGs)
x Changes in vital sign measurements (blood pressure [BP] and pulse rate)
x Changes in physical examinations
x Changes in neurological examinations
Has been added. 
This change also shifted the numbering of the Section describing the Pharmacokinetic variables 
from Section 4.2 to Section 4.3.
Change #16
Section 5.1 Study description
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions as replacement for oral LCM in pediatric subjects ≥4 to <17 years of age with 
epilepsy. EP0060 will include subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) who need to undergo a procedure, be 
admitted to an EMU or health care facility, or other situations where iv administration is 
clinically appropriate. Approximately 75 subjects, who are participating in long-term, open-label 
studies with LCM or who are currently prescribed VIMPAT, will be enrolled. Pediatric subjects 
entering into EP0060 from a long-term, open-label study will temporarily suspend their 
REDACTED 
ing:
ng:
grams
grams
t
COPY 
This document 
P00
P0
LCM
LCM
e
cannot 
e #
on 5.1
n 5.1
006
06
be
#16
#16
used 
o
to
 Sec
Se
support 
ted the
ed th
t
any
xamin
xami
marketing 
s (E
(
ts (blo
s (blo
ions
ons
authorization 
(ECG
ECG
application and 
r ca
c
any 
es
areg
areg
extensions 
s:
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 137 of 240
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly 
into EP0060 will temporarily switch from their prescribed oral VIMPAT treatment to the iv 
LCM formulation. Subjects will not be prescribed or maintained on VIMPAT for the purposes of 
participating in EP0060. Subjects will be enrolled from approximately 40 sites in North America, 
Europe, Asia Pacific, and Latin America. Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 3 age-based cohorts of at least 20 subjects per cohort: ≥12 to 
<17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to <8 years (Cohort 3). A DMC will 
review the safety and tolerability data for each cohort to make recommendations for the 
progression of subsequent cohort enrollment and iv infusion durations to be evaluated. Details 
regarding the DMC are provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. For subjects enrolled in a long-term, open-label 
study, the oral LCM will be administered from the long-term, open-label study supply. For 
subjects prescribed VIMPAT and enrolling directly into EP0060, oral LCM will be administered 
from the subject’s prescribed VIMPAT supply. 
Subjects will be under medical care at a healthcare facility for the duration of the iv LCM 
infusion treatment in EP0060. If necessary, the Screening and/or Baseline Visit can occur on the 
same day as the first iv LCM infusion. In this case, it is required that all screening procedures are 
performed and the results of examinations (ie, ECG) are available to allow verification of subject 
eligibility. During the Treatment Period, subjects will receive iv LCM infusion bid at 
approximately 12-hour intervals for up to 5 days. The daily dose of iv LCM will be the same as 
the subject's current stable bid dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (physical and neurological exams, pulse rate, BP, 12-lead ECG, 
clinical hematology and chemistry, and Columbia-Suicide Severity Rating Scale [C-SSRS] when 
applicable). An End-of-Study/Final Visit will be conducted the day after the last dose of iv LCM 
after completion of or withdrawal from the Treatment Period. A safety follow-up Telephone 
Contact should occur 1 to 2 days after the End-of-Study/Final Visit.
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were prescribed VIMPAT should continue AED treatment 
at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
m the
m th
g direc
g dire
suppl
suppl
at a h
at a h
COPY 
ral LC
ral LC
or su
or su
This document
The m
he 
com
com
lol
cannot
mple
mple
act sho
ct sho
e ma
ma
be
. An
An
leti
let
used 
be 
be 
ology
ology
n E
n E
to 
nt 
e per
pe
support
terval
erva
able bid
ble bi
Peri
Peri
any 
mi
m
ent Pe
ent P
l
marketing
health
healt
ssary, t
ssary,
ion. In
on. In
minat
ina
authorization
ubject
bject
 long
 long
ectly in
tly in
ly.y. 
h
application 
M wil
M wi
and any extensions
d. D
. D
or 
Det
D t
variations 
2 to 
 to 
will
ill
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 138 of 240
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).  
REDACTED 
ubjects
ubject
no long
o long
subjec
subje
nge
nge
COPY 
enr
n
availa
avail
 DM
DM
This document
inin
x
cannot 
ws: 
ws: 
EITH
EITH
be
Coho
Coho
used
n of 
n of 
ut on 
ut on
to 
te
f thth
support
ubjec
bjec
Cohort
Cohor
es wh
s wh
any 
be i
be 
cts
marketing 
ects 
cts
er than
r than
d,
ini
authorization
MC wi
C wi
ts will
 will
ger th
ger th
s wi
wi
application 
dur
du
ment in
ment 
able sa
ble s
ll
and
lled t
ed t
urati
rat
any 
o
extensions
et in
t in
or 
nfu
nf
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 139 of 240
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. 
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥4 to <17 years of age with epilepsy. EP0060 will include 
approximately 75 subjects. The following subjects will be eligible for enrollment in EP0060:
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants 
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescribed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM 
is 10.
 Elective administration: subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.
REDACTED
s cl
s c
e subj
e subj
subjec
subjec
ad
ad
COPY
dmini
dmin
t an EM
t an E
clini
lin
This document
Pedia
edi
part
part
E
cannot
a
iatr
iatr
be
Elec
le
adj
ad
used
ery). 
ry).
ecti
ecti
to
trati
trat
I
support 
d admin
admi
re, be t
e, be t
ion
i
any 
eatme
eatme
marketing
cts c
s c
dminist
minist
U or he
U or h
LCM 
LCM
authorization
MU
MU
nically
cally
jects, 
ects, 
cur
cu
application
jects)
jects)
aking p
aking 
stration
tratio
U or
U or
and 
)
any
tted i
ted 
extensions
pply (
pply (
s adju
adju
i
or variations 
cipant
ipant
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 140 of 240
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40 subjects who are ≥8 to <17 years and Cohort 2 including at least 20 subjects who are ≥4 to 
<8 years. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age and at least 
20 subjects will be ≥8 to <12 years of age. A DMC will review the safety and tolerability data for 
each cohort to make the following recommendations: the progression of the current cohort, 
including iv infusion durations to be evaluated, and progression to initiate enrollment in the next 
cohort (Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age. 
Details regarding the DMC are provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily 
REDACTED 
(1 
(1 
lows:
lows:
are eli
are e
COPY 
toto
This document 
an n 
from
from
LC
L
annot 
for 
or
rther t
ther t
last
last
be 
nts)
r com
r com
used
he
he
ubject
bject
s) ar
) ar
to
e Sc
 Sc
support 
udy/Te
udy/T
LCM).
CM).
any 
cts wh
cts w
marketing 
ch can 
h can
sit)
sit)
authorization 
3 day
3 day
gible
gible
application 
n): up 
): up
and 
: up
up
any 
p to 
p to
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 141 of 240
dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day 
(subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead 
ECG, clinical hematology and chemistry, and Columbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose if the last LCM infusion was performed 
in the morning, and time permits completion of assessments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LCM after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the 
Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL and 
IIL subjects who directly enrolled and will discontinue use of LCM, the subject should complete 
the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen or 
taper at the discretion of the treating physician.
REDACTED
o allo
o allo
n Visit
Visit
t cont
t con
uld o
uld o
COPY 
ose to
ose to
ent w
ent w
This document cannot
t
x
A
be
Sub
Sub
h
used 
ximate
imate
to 
pen
en-
support 
y
he OLL
e OL
me ora
me or
lab
l
any 
s:s:
marketing
occur 
ccur 
e as fo
as f
authorization
o c
with t
with t
w con
w con
it in E
it in E
inue L
nue L
application
tion
ion
hould o
hould
contin
conti
h
and
ise, t
se, t
on o
n o
any 
se
se
nfusio
nfusi
he
extensions
ale [C
e [C
ast LC
st LC
essm
essm
or 
2-lel
C
variations 
ead
ea
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 142 of 240
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).  
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
REDACTED 
years
years
M sho
M sho
ssible
ssible
COPY 
This document
O
x
cannot
appr
ppr
uration
ratio
OR
OR
be 
prox
prox
used
, can
can
s but
s but
to
rect
rect
support 
y 15
15
15 min
5 mi
om an 
m an 
tly
tl
any 
5 ad
5 ad
marketing 
e.
cts in C
cts in 
 and C
and C
authorization 
s of ag
of ag
ould be
uld b
application 
n Coho
Coh
and 
uld 
ld
any
pinio
pinio
d rec
d re
extensions 
th a ta
h a ta
ects wh
cts w
ten
estiga
stiga
or variations 
datio
datio
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 143 of 240
Change #17
Section 5.1.1 Study duration per subject, first paragraph
The maximum iv LCM exposure per subject will be up to 5 days with a total study duration of up 
to 15 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, 
and a safety follow-up Telephone Contact 1 to 2 days after the Final Visit).
Has been changed to:
For clinical need administration, the planned maximum iv LCM exposure will be up to 10 doses 
(or up to 5 days). For elective administration, the planned maximum iv LCM exposure will be up 
to 2 consecutive doses (over approximately 24 hours). 
For OLL subjects, the planned maximum total study duration assuming clinical need 
administration will be approximately 16 days (up to 7 days for screening, up to 5 days of 
treatment, 1 day for discharge/Final Visit, and a safety follow-up Telephone Contact 1 at 1 to 3 
days after the Final Visit). 
For RxL and IIL subjects who will continue LCM treatment in SP848, the planned maximum 
total study duration assuming clinical need administration will be approximately 23 days to 
allow arrangement for assessments to transition to SP848 (up to 7 days for screening, up to 
5 days of treatment, 1 day for discharge/Final Visit, safety follow-up Telephone Contact 1 at 1 to 
3 days after the Final Visit, and the Transition Visit at 1 to 7 days after the last dose). The Final 
Visit and the Transition Visit may occur on the same day or separate days, depending on 
availability and scheduling.
For RxL and IIL subjects who will not continue LCM treatment in SP848, the planned maximum 
total study duration (assumes clinical need administration) will be approximately 45 days to 
allow for further safety follow-up (up to 7 days for screening, up to 5 days of treatment, 1 day for 
discharge/Final Visit, safety follow-up Telephone Contact 1 at 1 to 2 days after the Final Visit, 
and safety follow-up Telephone Contact 2 at 30 days [±2 days] after the last dose).
For those subjects electively receiving iv LCM, the above maximum total study durations are 
reduced by 4 days. 
Change #18
Section 5.1.2 Planned number of subjects and site(s)
Approximately 75 subjects currently participating in long-term, open-label studies with LCM or 
who are currently prescribed VIMPAT will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 20 subjects from ≥12 to <17 years of age
x Cohort 2: at least 20 subjects from ≥8 to <12 years of age
x Cohort 3: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in any of the 3 cohorts.
REDACTED 
e sa
e sa
contin
contin
l need
l need
p to
p to
COPY
safet
safe
sit at 1
sit at 
ame
am
This document 
he
he
x
annot 
ma
ma
re cur
e cur
e foll
foll
be 
ately
ately
used 
Plan
Plan
to support any 
eceiv
eceiv
marketing 
d ad
ad
o 7
o 7 day
da
up Tel
up Te
Contac
onta
authorization
1 toto
e day 
e day 
nue LC
ue LC
adm
dm
application 
848
be appr
e app
p to 7
p to 7 d
y follow
follo
o 7 d
o 7
and 
48, th
8, t
any
ne C
ne C
extensions 
e w
need 
need
to 5 d
to 5 d
Co
C
or
will 
will
variations 
dose
dose
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 144 of 240
Has been changed to:
Approximately 75 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12 to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in either of the 2 cohorts.
Change #19
Section 5.1.3 Anticipated regions and countries
The study will be conducted at selected sites from North America, Europe, Asia Pacific, and 
Latin America. Additional sites may be added as deemed necessary.
Has been changed to:
The study will be conducted at selected sites from North America and Europe. Additional sites 
may be added as deemed necessary.
Change #20
Table 5-1
Schedule of study assessments
REDACTED 
ssess
sses
COPY 
rtht
This document cannot be used to support any marketing authorization 
smen
smen
application 
merica 
merica
and 
op
op
any 
e, As
e, As
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 145 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitc
End-of-Study Period
Visit
V1a
V1ba
V2
V3b
Final Visitd
TCe
Study Day
-7 to -1
-1
1
2 to 5
2 to 6
2 to 9
Written informed consent
X
Inclusion/exclusion criteria
X
Xf
Demographics
X
Medical procedures
X
X
X
X
X
X
X
Procedure historyg
X
Medical history/updateg
X
X
X
X
X
X
X
Diagnosis of epilepsyg
X
Childbearing potentialg
X
LCM dosing historyh
X
Prior and concomitant medicationsi
X
X
X
X
X
X
X
Concomitant AEDs/VNS settings 
X
X
X
X
X
X
Pregnancy testingj
X
X
Withdrawal criteria
X
X
X
X
X
X
AE reportingk
X
X
X
X
X
X
X
ILAE seizure classification 
X
Physical examination (complete)
X
X
Neurological examination (complete)
X
X
Clinical chemistry and hematologyl
X
X
X
X
12-lead ECG
X
Xm
Xm
Xm
X
X
REDACTED 
D
CT
CT
CT
CT
CT
DA
R
COPY 
OP
C
This document 
en cannot
hemato
mato
ot 
om
om
ot
a
be 
mple
mple
e used 
ed
u
to 
o support 
X
t
p
X
pp
up
s
any y 
a
marketing 
g
ing
X
rk
m
authorization 
tio
ori
u
a
application 
X
ion
lic
p
ap
and 
an
any y
any extensions
edule
dule
Visit
Visitc
ex
or variations 
on
va
v
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 146 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitc
End-of-Study Period
Visit
V1a
V1ba
V2
V3b
Final Visitd
TCe
Study Day
-7 to -1
-1
1
2 to 5
2 to 6
2 to 9
Vital signs
X
Xn
Xn
Xn
X
X
Body weight and height
X
PK blood samplingo
X
X
X
Admission to the unitp
X
X
Oral LCM administrationq
X
X
X
X
Intravenous LCM infusionr
X
X
X
C-SSRSs
X
Xt
X
X
Xc
X
Discharge from the unit
X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C-SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogram; 
ILAE=International League against Epilepsy; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; TC=Telephone Contact; V=Visit; VNS=vagus 
nerve stimulation
a Visit 1b only applies when Screening and Baseline occur on separate days. 
b If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed each day of iv LCM treatment in EP0060. 
c If an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. The 
C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.
d A Final Visit must be completed the day after the last dose of iv LCM for all subjects who complete or withdraw prematurely from EP0060. For subjects 
who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and refer to the long-term, open-label studies taper regimen.
e The Telephone Contact assessment should be performed 1 to 2 days after the Final Visit (2 to 7 days after Visit 2/Day 1). During the contact, the site 
should inquire as to whether the subject noted any change at the site of the infusion.
f Verification that the subject continues to meet inclusion/exclusion criteria if Screening and Baseline occur on separate days.
g Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be collected for direct-enroll subjects who were prescribed 
VIMPAT prior to entering the study. Medical history update will be collected for subjects from the long-term open-label studies. 
h Lacosamide dosing history will include date, time, and dosage information during the last 3 days.
i Prior medications will only be collected for direct-enroll subjects. Concomitant medications from the long-term open-label studies will be followed, as well 
as the recording of new concomitant medications during EP0060 for all enrolled subjects.
j Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening Visit for direct-enroll subjects who are prescribed VIMPAT 
and urine testing for subjects enrolled in long-term, open-label studies. Urine pregnancy testing (or serum pregnancy test if no urine sample can be 
REDA
C-SSR
SS
LCM
LCM
DACTED 
X
D
CT
CT
CT
CT
CT
DA
COPY 
OP
C
This document 
r su
su
for sub
r sub
cannot 
ill i
ll 
y be co
be co
conco
onco
ubje
ubje
be
tudy.
dy
incl
inc
used
s to m
to m
diagn
diagn
M
to
oted
oted
support
che
h
last do
last d
should 
hould
e perfo
perfo
an
any
d wil
d wi
edule
edul
marketing
RS
M=laco
M=laco
separate
epara
for Vis
for V
l b
authorization 
tio
ori
S=Co
=Co
u
application 
ion
lic
p
ap
and 
an
any y
any extensions
edule
dule
Visit
Visitc
X
ex
or variations 
on
va
v
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 147 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitc
End-of-Study Period
Visit
V1a
V1ba
V2
V3b
Final Visitd
TCe
Study Day
-7 to -1
-1
1
2 to 5
2 to 6
2 to 9
obtained) will be conducted on all subjects of childbearing potential at the Final Visit. 
k Ongoing AEs from the long-term open-label studies will be followed, as well as recording of new AEs during EP0060. 
l Laboratory assessments will be performed for subjects who are directly enrolled into EP0060. Screening laboratory assessments may be conducted up to 
the day of the infusion provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion.
m 12-lead ECG will be performed approximately 20 minutes prior to each infusion and at approximately 15, 30, 60 minutes, and 2 hours from the start of 
each iv administration. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should be at rest at least 5 minutes prior 
to each ECG recording and should be motionless during the recording, when feasible.
n Vital signs will be performed approximately 10 minutes prior to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diastolic) and pulse rate will be measured at study visits after at least 3 minutes at rest, when feasible.
o Samples for PK will be drawn after ECG and vital signs have been taken. Plasma samples will be obtained from the opposite arm in which the solution for 
infusion was administered for the first iv LCM infusion (Day 1): predose (within 1 hour prior to iv LCM infusion) and postdose (within 1 to 4 hours after 
end of iv LCM infusion), and for the final iv LCM infusion (Day 2 to 5/Early Termination): predose (within 1 hour prior to iv LCM infusion) and postdose 
(within 1 to 4 hours after end of iv LCM infusion). Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in 
the event of a relevant treatment-emergent AE.
p Admission to the health care facility to participate in the study should take place at least the day prior to the start of the first iv LCM infusion. However, 
when necessary for the wellbeing of the subject or when the investigator deems it appropriate, the admission to the health care facility and the first iv LCM 
infusion can start on the same day.
q On Day -1, oral LCM will be administered in accordance with each subject’s LCM dosage regimen. 
r LCM will be administered twice daily at approximately 12-hour intervals, once in the morning and once in the evening, for up to 5 days.
s All subjects ≥6 years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent visits. 
t The C-SSRS assessment (see Section 10.7.5 ) does not need to be completed twice if Screening/Baseline assessments are done on the same day.
REDACTED
(withi
(with
5/Early
5/Early
d samp
samp
y shoul
y shoul
ves
ve
COPY
d at ap
d at a
will be 
will b
sma s
sma s
This document cannot be used to support 
ge du
ge du
ce Last 
Last
) does n
does n
any 
2-h
ne/Scre
e/Scr
urin
marketing 
ld tak
d tak
stigator
tigator
with each
th ea
hour
hou
authorization
me
sample
sample
n 1 hou
1 hou
y Term
Term
les for
es for
ke
k
application
mately 
ately
G reco
record
r
proxima
roxim
measur
easu
and
ng lab
g la
infusi
fus
any 
ring EP
ing E
bor
bo
extensions
edule
dule
Visit
Visitc
ex
or variations 
on
va
v
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 148 of 240
Has been changed to:
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
Written informed consent
X
Inclusion/exclusion criteria
X
Xi
Demographics
X
Medical procedures
X
X
X
X
X
X
X
X
Procedure historyj
X
Medical history/updatej
X
X
Diagnosis of epilepsyj
X
Seizure historyk
X
Childbearing potentialj
X
LCM dosing historyl
X
X
LCM dosing information since 
Treatment Period
X
X
X
Prior and concomitant medicationsm
X
X
X
X
X
X
X
X
X
Concomitant AEDs/VNS settings/ 
ketogenic diet 
X
X
X
X
X
X
Xn
Xn
Urine pregnancy testing (as 
applicable)
X
X
X
Withdrawal criteria
X
X
X
X
X
X
REDACTED 
D
CT
AC
DA
R
COPY 
Y
X
OP
C
This document t cannot 
nn
c
be 
e used
X
d
us
u
to 
X
to support t
up
su
any y
a
marketing 
ning
n
rk
m
authorization 
on
tio
ori
au
application 
io
lic
ap
and 
nd
an
an
an
any 
i
1 to
1 to
y extensions 
End
End
s
al
isit
site
ns
or 
o variations 
on thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 149 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
AE reporting
X
X
X
X
X
X
X
X
X
Physical examination (complete)
X
X
Physical examination (brief)
X
Xo
Xo
X
Neurological examination 
(complete)
X
X
Neurological examination (brief)
X
Xo
Xo
X
Clinical chemistry and hematologyp
X
Xq
X
12-lead ECG
X
X
Xr
Xr
X
Vital signs
X
X
Xs
Xs
X
X
Body weight and height
X
PK blood sampling
Xt
Xu
Intravenous LCM infusionv
X
X
C-SSRSw
X
Xx
Xo
Xo
Xd
X
Additional items for RxL and IIL subjects continuing into SP848
Dispense transitional supply of 
oral LCM solutiong
Xy
Collect transitional supply of 
oral LCM solution
X
Visit 1 SP848 assessments 
(documented in SP848) 
X
REDACTED 
X
ED
AC
AC
AC
AC
AC
Xs
ED
COPY 
Y
Xo
CO
This document
SP84
P84
en cann
ments
ment
48)
48
not 
o
n
be 
f f 
e used 
us
u
to 
s co
co
to support 
Xx
ort
u
ontin
onti
up
any 
ny
a
marketing 
n
eti
Xt
ma
authorization 
n
on
za
X
ho
a
application 
X
on
lic
and 
nd
nd
nd
nd
and any 
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 150 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C-SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogram; IIL=initiating iv 
LCM; iv=intravenous; LCM=lacosamide; OLL=open-label LCM; PK=pharmacokinetics; RxL=prescribed commercial LCM; TC=Telephone Contact; V=Visit; 
VNS=vagus nerve stimulation
a
The Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion, if necessary. In this case, it is required that all Screening 
procedures are performed and the results of examinations (ie, ECG, laboratory measurements) are available to allow verification of subject eligibility.
b
Visit 1b only applies when Screening and Baseline occur on separate days. 
c
If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed for each infusion of iv LCM treatment in EP0060, unless otherwise 
noted (see footnote o).  
d
If an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. If the 
Unscheduled Visit is due to an AE, the C-SSRS assessment should be completed and collection of a blood sample for LCM PK analysis is at the discretion 
of the investigator.
e
A Final Visit must be completed for all subjects who complete or withdraw prematurely from EP0060. If the last iv infusion of LCM for the study occurs in 
the morning, the Final Visit may occur on the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the following day 
(ie, last infusion in evening). For subjects who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and either refer to the 
long-term, open-label studies taper regimen or taper at the discretion of the treating physician for those subjects who enrolled directly.
f
The Telephone Contact 1 Visit assessment should be performed 1 to 3 days after the Final Visit. During the contact, the site should inquire as to whether the 
subject noted any change at the site of the infusion.
g
The Transition Visit will only be conducted for RxL and IIL subjects who will continue LCM treatment in SP848. This visit can occur at the same time as 
the Final Visit or on another day up to and including 7 days after the Final Visit and should occur at the same time as Visit 1 for SP848. 
h
The Telephone Contact 2 Visit will only be conducted for RxL and IIL subjects who will not continue LCM treatment in SP848.
i
Verification that the subject continues to meet inclusion/exclusion criteria if Screening and Baseline occur on separate days.
j
Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be collected for RxL and IIL subjects at Screening. For OLL 
subjects, a medical history update will be performed in order to collect medical history that was not captured during the course of the prior study. 
k
Subject or caregiver (including parent/legal guardian) will be asked how many seizures the subject has had over the past 4 weeks as a historical baseline for 
RxL and IIL subjects.
l
For OLL and RxL subjects, LCM dosing history will include date, time, and dosage information during the last 3 days.
m
Prior medications will only be collected for direct-enroll subjects. 
n
At Telephone Contact follow-up calls, only concomitant AED and ketogenic diet information will be gathered (ie, settings for VNS will not be gathered).
o
During the Treatment Period, brief physical examination, brief neurological examination, and C-SSRS should be performed once per day and after an 
infusion.
p
Screening laboratory assessments may be conducted up to and including the day of the infusion provided they are reviewed and meet inclusion/exclusion 
REDACTED
ed. A
ed. A
compl
compl
r withd
r withd
last in
last in
ue us
ue us
COPY 
comple
comple
Ad
Ad
This document 
atory a
ory a
cannot 
be c
e c
llow
ow-up
u
Period
Period
be
CM d
CM d
coll
col
used
nt/lega
/lega
os
to
e per
e per
l
support 
ng 7
g 7
ducted 
ucted 
t inclus
inclu
is of ep
s of e
f
any
nd IIL
d IIL
7 day
7 da
marketing 
nfus
fus
se of LC
e of L
retion o
retion 
med 1 t
med 1 
authorization 
ditiona
dition
eted an
ted an
draw pr
aw pr
usion
sion
application 
f necess
nece
nts) are 
nts) are
ed for 
ed for
and
ng 
ng
ed com
d com
any 
Scal
Sca
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 151 of 240
Table 5‒1:
Schedule of study assessments
Assessments
Screening/
Baseline
Treatment Period
Unscheduled 
Visitd
End-of-Study Period
Visit
V1aa
V1bb
V2
V3c
Final 
Visite
TC1f
Transition 
Visitg
TC2h
Study Day
-7 to 
1
-1 to 
1
1
2 to 5
1 to 6
2 to 9
1 to 13
29 to 
37
criteria prior to the infusion. For all subjects, local laboratory results obtained for routine diagnostic and medical care can be used whenever possible if 
collected no more than 24 hours prior to Screening/Baseline Visit in order to minimize blood loss associated with the study. Use of the central or local 
laboratory is at the discretion of the investigator for all visits except the Final Visit. The central laboratory must be used for laboratory samples collected at 
the Final Visit.
q
If Screening and Baseline Visits are not performed on the same day, repetition of laboratory assessments at Baseline is at the discretion of the investigator.
r
A 12-lead ECG will be performed approximately 20 minutes prior to each infusion and at approximately 15, 30, 60 minutes, and 2 hours from the start of 
each iv administration. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should be at rest (sitting or supine) at 
least 3 minutes prior to each ECG recording and should be motionless during the recording, when feasible.
s
Vital signs will be performed approximately 10 minutes prior to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diastolic) and pulse rate will be measured at study visits after at least 3 minutes at rest, when feasible.
t
Plasma samples will be obtained from a different region of the body from the region in which the solution for infusion was administered for the first iv LCM 
infusion (Day 1): predose for OLL and RxL subjects (within 1 hour prior to iv LCM infusion) and postdose for all subjects (within 1 to 4 hours after end of 
iv LCM infusion). If the postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK sample will be drawn after 
ECG and vital signs have been taken. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the event of a 
relevant treatment-emergent AE.
u
If the subject has more than 1 iv LCM infusion, it is optional to also collect plasma samples for the final iv LCM infusion (Day 2 to 5/Early Termination): 
predose for all subjects (within 1 hour prior to iv LCM infusion) and postdose for all subjects (within 1 to 4 hours after end of iv LCM infusion). If the 
postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK sample will be drawn after ECG and vital signs 
have been taken. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the event of a relevant 
treatment-emergent AE.
v
During the Treatment Period subjects will receive at least 1 dose of iv LCM. If more than 1 infusion is needed, infusions will occur bid at approximately 
12-hour intervals up to either 2 doses (elective administration) or 10 doses (clinical need administration). 
w
All subjects ≥6 years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent visits. If the subject is <6 years of age, assessment for signs of 
depression will be conducted as described in Section 10.7.5 of the protocol.
x
The C-SSRS assessment does not need to be completed twice if Screening/Baseline assessments are done on the same day. If Screening/Baseline and Visit 2 
occur on the same day, 2 assessments should be completed with 1 predose and 1 after infusion.
y
For RxL and IIL subjects who are eligible and wish to enroll in SP848, a short-term oral LCM solution will be dispensed to allow continuity of LCM 
treatment while visits and assessments are scheduled for starting SP848. Subjects (or their caregivers) will administer the oral LCM solution twice a day 
according to the investigator’s instructions until the subject returns for the Transition Visit.
REDACTED
usion
usio
lse rate
lse rate
y from 
from
our prio
our pri
ilar tim
ilar tim
les f
les f
COPY 
n an
n a
nd qual
nd qua
g the re
g the re
n a
n a
This document 
its an
s an
investi
nvest
cannot 
es no
s no
assess
assess
cts wh
ts wh
and
and
be
s des
des
not n
not
used
es 6 y
s 6 y
and th
and th
cr
to
e the
e th
support 
ana
an
ceive at 
eive a
ive adm
ve ad
“
any
and v
nd 
alysis
alys
marketing 
me f
e 
or PK a
or PK 
al to also
to al
usion)
usion
i
authorization
ecord
cord
and at a
nd at a
e will b
will b
the reg
the reg
or to iv
r to iv
for E
for E
application 
abor
bor
y assess
y asses
at appro
appr
ity ECG
ty EC
ini
and
d m
d m
ssociat
sociat
rato
rato
any
me
medic
d
ny 
any extensions 
T
ns
si
to 6
o 6
te
or 
of
of
variations 
on
f St
S
va
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 152 of 240
Change #21
Table 5-2 Timing of infusion, blood sampling, and measurement of vital signs and ECG on 
Treatment Days (Infusion Day 1 to Day 5)
Table 5-2:
Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points referred to 
iv infusion 
Vital signsa
12-lead ECGb
PK blood samplingc
-59min to -3min
X
-20min
X
-10min
X
T0 (start of infusion)
+5min
X
+10min
X
+15min
X
+20min
X
+30min
X
+45min
X
+60min
X
X
+1h to +4hd
X
+2h
X
X
AE=adverse event; BP=blood pressure; ECG=electrocardiogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
a Noninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before and after the start of each iv LCM infusion.
b A 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should 
be at rest at least 5 minutes prior to each ECG recording and should be motionless during the recording, when 
feasible.
c Samples for PK will be drawn after ECG and vital signs have been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusion was administered for the first iv LCM infusion (Day 1) and the 
final iv LCM infusion (Day 2 to 5/Early Termination), predose and postdose, at the time points indicated in the 
table. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE. Depending on the target duration defined for the cohort and subject 
tolerability, end of infusion can be at 15, 30, or 60 minutes, or whenever the infusion is stopped (if prematurely 
terminated).
d Time points are in reference to T0 (start of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.
REDACTED 
X
D
CTE
DA
R
COPY 
OP
C
This document
term
term
d Tim
Ti
cannot
dditi
diti
of a r
of a r
erabil
erabil
mini
be
M inf
M in
on
on
used
will be
will b
m in 
m in
to 
nut
support
xima
ima
ormed a
rmed
uld be ta
d be t
tes pr
es p
any
T
tolic) a
tolic)
mate
ate
marketing 
ng
r
ECG=ele
CG=e
T=tim
T=tim
rk
authorization 
tio
X
ori
ut
application 
X
on
lic
p
ap
and 
nd any 
ny
any
ny
ny
ny extensions 
X
ns
ns
ex
or r variations 
pling
lingc
tio
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 153 of 240
Has been changed to:
Table 5-2:
Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points in relation 
to iv LCM infusion  
Vital signsa
12-lead ECGb
PK blood samplingc
-59min to -3min
Xd
-20min (±10 min)
X
-10min (±5 min)
X
T0 (start of infusion)
+5min (±2 min)
X
+10min (±2 min)
X
+15min (±5 min)
X
+20min (±5 min)
X
+30min (±5 min)
X
+45min (±5 min)
X
+60min (±10 min)
X
X
+1h to +4he
X
+2h (±15 min)
X
X
AE=adverse event; BP=blood pressure; ECG=electrocardiogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
a Noninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before and after the start of each iv LCM infusion.
b A 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should 
be at rest (sitting or supine) at least 3 minutes prior to each ECG recording and should be motionless during the 
recording, when feasible.
c If the postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK 
sample will be drawn after ECG and vital signs have been taken. Plasma samples will be obtained a different 
region of the body from the region in which the solution for infusion was administered for the first iv LCM 
infusion (Day 1). If the subject has more than 1 iv LCM infusion, it is optional to also collect plasma samples for 
the final iv LCM infusion (Day 2 to 5/Early Termination), predose and postdose, at the time points indicated in the 
table. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE. Depending on the target duration defined for the cohort and subject
tolerability, end of infusion can be at 15, 30, or 60 minutes, or whenever the infusion is stopped (if prematurely 
terminated).
d For the first LCM infusion, the predose PK sample is required for OLL and RxL subjects and not required for IIL 
subjects. For optional PK sample collection of a subsequent LCM infusion, the predose sample should be collected 
from all subjects.
e Time points are in reference to T0 (start of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.
RED
G=elec
G=elec
me
m
EDACTED 
X
D
CT
ED
COPY 
Y
X
OP
This document
For 
For 
sub
su
cannot
f a re
a re
ability
bility
rminat
mina
thth
be
C
tiona
tiona
lele
used
fro
ro
. If the
If the
M inf
M in
to 
aft
om th
om t
support
least 
east
e is tak
 is tak
ter EC
er E
any 
the
h
en to a
en to 
t 3 m
t 3
marketing
ctroc
roc
nd pulse
d puls
me poin
me po
he ind
e in
au
car
car
authorization 
at
X
hor
au
application 
tio
pli
p
a
and 
an
any 
ny
a
extensions 
on
en
ex
or 
or variations 
on
on
on
on
ria
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 154 of 240
Change #22
Section 5.3 Rationale for study design and selection of dose, first 4 paragraphs
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM as 
replacement for oral LCM therapy in pediatric subjects with epilepsy aged ≥4 to <17 years. A 
separate Phase 2/3 study investigating the use of iv LCM as replacement for oral LCM therapy in 
pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. The results of EP0060 
will provide safety and PK data regarding the use of the iv LCM formulation in pediatric subjects 
(≥4 to <17 years of age). The EP0060 design is based on the study design for SP757, which 
evaluated iv LCM replacement in adults with partial-onset seizures, as well as based on design 
elements of other pediatric iv AED studies.
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial-onset seizures in subjects ≥16 years of age (depending on country-specific 
labeling) with epilepsy when oral administration is temporarily not feasible. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for subjects enrolling from the long-term 
open-label studies and for subjects currently prescribed VIMPAT and enrolling directly into 
EP0060. 
EP0060 will initially enroll older pediatric subjects (Cohort 1), which will include at least 
20 subjects ≥12 to <17 years of age. Cohort 2 (at least 20 subjects ≥8 to <12 years of age) and 
Cohort 3 (at least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC 
recommendation. After the first 10 subjects in each cohort have received iv LCM over infusion 
durations of 30 to 60 minutes, the enrollment will be temporarily put on hold for the DMC to
review the available safety and tolerability data. Based on their review, the DMC will 
recommend the target infusion duration for the remaining subjects in the cohort (ie, 30 to 
60 minutes or 15 to 30 minutes), if the study/cohort should be stopped, and if the next cohort can 
be initiated, and if a new iv LCM study in younger pediatric subjects (≥1 month to <4 years of 
age) can be initiated.
Have been changed to:
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥4 to <17 years. A separate Phase 2/3 study investigating 
the use of iv LCM in pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. 
The results of EP0060 will provide safety and PK data regarding the use of the iv LCM 
formulation in pediatric subjects (≥4 to <17 years of age). The EP0060 design is based on 
components of the study design for SP757, which evaluated iv LCM replacement in adults with 
partial-onset seizures, as well as based on design elements of other pediatric iv AED studies. In 
an effort to maximize the patient pool used in the evaluation of the safety of iv LCM in pediatric 
subjects, Protocol Amendment 2 has opened enrollment to also include OLL and RxL subjects 
who are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who 
REDACTED
g/day
g/da
y pres
y pres
diatric
diatric
Co
C
COPY
the l
the 
LCM 
LCM
ay f
ay f
This document
he u
he u
The
The
f
cannot
0 is a
0 is a
iatric 
atric 
use
us
be
en c
used
iated
ated
ch
ch
to
a ne
a ne
support
and
and
nfusion
fusion
0 minu
0 minu
w
any
the e
the e
d to
d t
marketing
c su
su
ohort 2
hort 2
<8 yea
<8 ye
0 subj
0 sub
authorization
M dos
dos
for su
or su
scribed
ribed
ubj
ubj
application 
M p
M p
doses o
oses 
0060 c
0060 
ong
ng-ter
te
oses
ses
and
valua
valu
plas
pla
any 
le.e.
ate
extensions 
n 
ve the
ve the
n coun
coun
or
des
des
variations 
bjects
jects
h h 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 155 of 240
are not currently taking LCM and initiate adjunctive LCM treatment using iv LCM. This 
expansion of the subject population occurred prior to the start of study enrollment. Protocol 
Amendment 2 has also included the option for RxL and IIL subjects to continue oral LCM 
treatment after completion of iv LCM, if determined clinically appropriate, in SP848. If required, 
a short-term supply of oral LCM solution will be provided for RxL and IIL subjects transitioning 
to start SP848 to ensure continuity of LCM treatment while allowing flexibility to schedule a 
clinical visit to initiate SP848. For RxL and IIL subjects who do not continue into SP848 (either 
by choice or not clinically appropriate), an additional telephone contact approximately 30 days 
after last dose of iv LCM IMP is added in order to collect final safety data. 
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial-onset seizures in subjects ≥16 years of age (depending on country-specific 
labeling) with epilepsy when oral administration is temporarily not feasible, which can also
include initiation of LCM treatment. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day 
(subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatric subjects (Cohort 1) and will include at least 
20 subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 (at 
least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC recommendation. 
After the first 20 subjects (Cohort 1) or 10 subjects (Cohort 2) have received iv LCM over 
infusion durations of 30 to 60 minutes, the DMC will review the available safety and tolerability 
data. Based on their review, the DMC will recommend the target infusion duration for the 
remaining subjects in the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 
minutes [only for subjects who would directly benefit from an increased infusion rate, in the 
opinion of the Investigator; otherwise 30 to 60 minutes]), if the study/cohort should be stopped, 
and if the next cohort can be initiated, and if a new iv LCM study in younger pediatric subjects 
(≥1 month to <4 years of age) can be initiated (Section 12.7.2).
Change #23
Section 6.1 Inclusion criteria 
To be eligible to participate in EP0060, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject or by the parent(s) or legal 
REDACTED
er is 
er is
ose of 
ose of 
hose u
ose 
hould 
hould
COPY
CM d
CM d
ay for 
ay for
s lo
s lo
This document 
Ch
Ch
cannot
 n
onth t
nth t
be 
he 
next 
next 
sed
for sub
or su
 Inv
Inv
to
in t
in t
support
Coh
Coh
to 60 
to 60
eview
eview
he
h
any
g
s of a
s of 
hort
ho
marketing 
d r
40 old
40 old
ge and
ge an
authorization
r OL
OL
ower. 
wer.
f 2mg/
2mg/
used in
sed i
rema
ema
application
ses o
es o
60 can
60 can
g-term,
term
oses be
ses b
LL a
LL a
and
plasm
lasm
of
of
any 
uated 
ated
ma
extensions
rapy
apy
ntry
ntry-s
hich c
hich c
or 
y i
variations 
er r 
ays 
ys 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 156 of 240
representative. The Informed Consent form or a specific Assent form, where required, will be 
signed and dated by minors.
2. Subject/legal representative is considered reliable and capable of adhering to the protocol, 
visit schedule, and medication intake according to the judgment of the investigator.
3. Subject is male or female from ≥4 to <17 years of age. 
4. Subject has, in the opinion of the investigator, adequate seizure control for participation in 
EP0060, and is able to comply with all study requirements including admission to the health 
care facility, multiple blood draws, and iv infusions. Subject (or parent[s] or legal 
representative) is willing to comply with all study requirements.
5. Subject is participating in a long-term, open-label study with LCM or is currently prescribed 
oral VIMPAT and needs to undergo a procedure, is admitted to an EMU or health care 
facility, or other situations where iv administration of LCM is clinically appropriate.
6. Subject is an acceptable candidate for venipuncture and iv infusion.
Subjects who are participating in a long-term, open-label study with LCM must fulfill the 
following additional inclusion criteria:
7. Subject is currently enrolled in a long-term, open-label study, receiving oral LCM for the 
treatment of epilepsy.
8. Subject has been on a stable bid dosage regimen of oral LCM for the last 3 days in their 
long-term, open-label study.
9. Subject is expected to benefit from participation in EP0060, in the opinion of the 
investigator.
Subjects who are currently prescribed oral VIMPAT and enroll directly into EP0060 must fulfill 
the following additional inclusion criteria:
10. Subject has been prescribed oral VIMPAT at a dose of 2mg/kg/day to 12mg/kg/day (for 
subjects <50kg) or 100mg/day to 600mg/day (for subjects ≥50kg). 
11. Subject has been prescribed oral VIMPAT for the treatment of epilepsy for at least 1 month 
prior to Screening and has not been prescribed or maintained on VIMPAT for the purposes of 
participating in EP0060. Prescribed oral VIMPAT dose must be stable for at least 7 days, and 
intake of the prescribed total daily dose confirmed for at least 3 days prior to first infusion.
12. If the subject is on a concomitant AED, the daily dosage regimen of AED therapy must be 
kept constant for a period of at least 1 week prior to Screening. VNS is allowed, but settings 
must be kept constant for a period of at least 1 week prior to Screening.
Has been changed to:
To be eligible to participate in EP0060, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject or by the parent(s) or legal 
representative. The Informed Consent form or a specific Assent form, where required, will be 
signed and dated by minors.
REDACTED 
im
particip
artic
d o
d
COPY 
ab
men o
men o
This document 
Has
as
To
To
cannot
con
con
must be
ust be
s b
be
ubje
bje
nst
ns
used
e pres
pre
ect
ect
to
EP0
EP
support 
g
scribed
cribe
g and h
and h
00
00
any
ora
or
/day 
/day 
marketing 
oral VI
oral VI
riteria:
teria
ral V
al V
authorization 
of ora
of ora
pation
pation
application 
h 
study, r
tudy,
and 
LCM
LCM
any extensions 
ently p
ntly p
r heal
heal
appro
ppr
or variations 
health
alth
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 157 of 240
2. Subject is male or female from ≥4 to <17 years of age.
3. Subject has a diagnosis of epilepsy with partial-onset seizures or primary generalized 
tonic-clonic seizures.
4. Subject meets 1 of the following criteria:
 OLL subject: Subject is currently receiving oral LCM as adjunctive or monotherapy as 
participants in an open-label long-term study (SP848, EP0034, or other pediatric study); 
OR,
 RxL subject: Subject is currently receiving prescribed oral LCM from commercial supply 
(eg, VIMPAT) as adjunctive or monotherapy; OR, 
 IIL subject: Subject is not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
5. Subject is an OLL or RxL subject and meets both of the following criteria: 
 Subject has been administered LCM for the treatment of epilepsy for at least 2 weeks 
prior to Screening; AND, 
 Subject has been administered (OLL) or prescribed (RxL) oral LCM at a dose of 
2mg/kg/day to 12mg/kg/day (for subjects <50kg) or 100mg/day to 600mg/day (for 
subjects ≥50kg). Open-label study drug LCM (OLL) or prescribed oral LCM dose (RxL) 
must be stable for at least 3 days prior to first LCM infusion.
-OR-
Subject is an ILL subject and is on a stable dosage regimen of at least 1 AED. The daily 
dosage regimen of concomitant AED therapy must be kept constant for a period of at least 2 
weeks prior to Screening.
6. Subject is an acceptable candidate for venipuncture and iv infusion.
7. Subject is, in the opinion of the investigator, able to comply with all study requirements. 
Subject (or parent[s] or legal representative) is willing to comply with all study requirements.
Change #24
Section 6.2 Exclusion criteria
Subjects are not permitted to enroll in EP0060 if any of the following criteria are met:
1. Subject has previously received iv LCM in this study. 
2. Subject has any medical, neurological, or psychiatric condition that, in the opinion of the 
investigator, could jeopardize the subject’s health or compromise the subject’s ability to 
participate in EP0060.
3. Subject has clinically significant hypotension or bradycardia.
4. Subject ≥6 years of age has a lifetime history of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as 
REDACTED 
g LC
g LC
or to f
or to f
on a s
on a 
E
COPY
cribe
crib
<50kg
<50k
LCM
CM
This document 
2.2.
cannot
ts are
s are
Subj
Subj
be
2 Ex
Ex
used 
xclc
to support 
on of
n o
] or leg
or le
any
ndida
ndid
f th
f
marketing
stabl
stabl
ED the
ED th
date
dat
authorization
g) o
) o
M (OL
M (OL
first L
irst L
-O
l
application
epilep
epile
d (RxL
(RxL
or 1
or 1
and
g crit
crit
any 
ter
t
extensions 
ci
LCM 
CM 
ot per
t per
or
al s
al s
variations 
y););
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 158 of 240
indicated by positive responses (“Yes”) to either Question 4 or Question 5 of the C-SSRS at 
Screening.
5. Subject does not have a diagnosis of epilepsy.
6. Subject is taking monoamine oxidase inhibitors (MAOIs).
Subjects who are participating in a long-term, open-label study with LCM are not permitted to 
enroll in EP0060 if any of the following additional criteria are met:
7. Subject has any ongoing AE in their long-term, open-label study that, in the opinion of the 
investigator, could jeopardize or would compromise the subject’s ability to participate 
EP0060.
Subjects who are currently prescribed oral VIMPAT are not permitted to directly enroll in 
EP0060 if any of the following additional criteria are met:
8. Subject has a medical condition that could reasonably be expected to interfere with drug 
distribution, metabolism, or excretion.
9. Subject has a known hypersensitivity to any component of the investigational medicinal 
product (IMP).
10. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of participation in EP0060. 
a) Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30μg ethinylestradiol per intake (or 50μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, 
oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also an acceptable method of contraception. 
b) The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.
11. Subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2 times the upper limit of normal (ULN), or creatinine 
clearance less than 30mL/min.
12. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart block at rest or a QT prolongation greater than 450ms).
13. Subject has hemodynamically significant heart disease (eg, heart failure).
14. Subject has an arrhythmic heart condition requiring medical therapy.
15. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.
16. Subject has only nonepileptic events, including psychogenic seizures, which could be 
confused with seizures. If both epileptic and nonepileptic events are present, epileptic events 
must be distinguished from nonepileptic phenomena.
REDACTED
etho
etho
estrad
estrad
enzym
nzym
be used
use
ble m
ble m
COPY
does
doe
in EP0
n EP0
od
od
This document 
14.
14. S
cannot
 seco
seco
Subj
Subj
be
t has
t has
used
el gr
gr
ess th
ess th
to 
alan
grea
grea
support
of ch
f ch
nine 
nine
any
 and 
 and
hild
hil
marketing
ed 
metho
metho
d the co
the c
be edu
be ed
authorization 
00
includ
nclu
diol pe
iol pe
me indu
e ind
in c
in c
application
e inv
inv
not pra
ot pra
060.
060.
and 
ves
ves
any
interf
inter
extensions 
p
y enro
y enro
or 
tete
variations 
f the 
the
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 159 of 240
17. Subject has been treated with felbamate for at least 12 months prior to entering EP0060 and 
has experienced any toxicity issues with this treatment. Note: Any subject who is currently 
treated with felbamate, and has received felbamate for a period of less than 12 months, is 
excluded from EP0060. 
18. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressive or 
neurodegenerative disease (malignant brain tumor or Rasmussen syndrome).
19. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
Has been changed to:
Subjects are not permitted to enroll in EP0060 if any of the following criteria are met:
1. Subject has previously received iv LCM in this study. 
2. Subject has any medical, neurological, or psychiatric condition that, in the opinion of the 
investigator, could jeopardize the subject’s health or compromise the subject’s ability to 
participate in EP0060.
3. Subject has clinically significant hypotension or bradycardia in the opinion of the 
investigator.
4. Subject ≥6 years of age has a lifetime history of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as 
indicated by positive responses (“Yes”) to either Question 4 or Question 5 of the C-SSRS at 
Screening.
5. Subject is taking monoamine oxidase A inhibitors (MAOI-A). 
For OLL subjects, enrollment in EP0060 is not permitted if any of the following additional 
criteria are met:
6. Subject has any ongoing AE in their long-term, open-label study that, in the opinion of the 
investigator, could jeopardize or would compromise the subject’s ability to participate 
EP0060 or the subject meets any of the criteria for required withdrawal from the long-term 
open-label study.
For RxL and IIL subjects, enrollment in EP0060 is not permitted if any of the following 
additional criteria are met:
7. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.
8. Subject has a known hypersensitivity to any component of the investigational medicinal 
product (IMP).
9. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of participation in EP0060. 
a) Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30μg ethinylestradiol per intake (or 50μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, 
REDACTED 
ha
to eith
to eith
dase A
dase A
P
COPY 
of suic
f su
as su
as su
This document
p
9.9.
cannot
rpti
rpti
Subjec
ubjec
pro
pro
be
t has
has
ion
ion
used
eria a
ria 
s a
s a
to
subj
sub
support
ard
t meet
mee
jej
any
E in 
E in
dize o
dize o
marketing 
A i
P0060 i
0060 i
n the
n th
authorization 
cid
uicida
uicida
her Qu
er Qu
inhi
inhi
application 
ia in th
a in t
de at
de a
and
the s
he 
any
n the 
n the
sub
su
extensions 
met:
met:
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 160 of 240
oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also an acceptable method of contraception. 
b) The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.
10. Subject has creatinine clearance less than 30mL/min.
11. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart block at rest or a QT prolongation greater than 450ms).
12. Subject has hemodynamically significant heart disease (eg, heart failure).
13. Subject has an arrhythmic heart condition requiring medical therapy.
14. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.
15. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressive or 
neurodegenerative disease (malignant brain tumor or Rasmussen syndrome).
16. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
17. Lacosamide is intended for treatment of generalized convulsive status epilepticus. 
18. Subject has exclusively typical absence (Type IIA1) or atypical absence (Type IIA2) seizures 
(no other generalized seizure types are reported).
19. Subject has diagnosis of Dravet’s syndrome.
20. Subject has >2 upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
For enrolled subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a 
Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the Case Report form (CRF).
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re-screening.
For IIL subjects, enrollment in EP0060 is not permitted if the following additional criterion 
is met:
21. Subject has been treated with LCM within the last 3 months prior to Screening.
REDACTED
ener
ener
ce (Typ
e (Typ
are re
are re
s syn
s syn
COPY 
o
pathy,
pathy,
ral
ral
This document 
d
cannot
eat th
at th
releva
eleva
disc
disc
be
ect h
ect h
h
used 
gnos
no
d and r
and 
to
je
osis 
osis
support
bilir
bili
diagnos
iagno
ects w
cts w
any
xULN
xUL
irub
irub
marketing
nd
ndrom
rom
rmal (U
mal 
rtate a
rtate 
N
authorization 
, s
lized c
zed c
ype IIA
ype IIA
eporte
porte
application
s sys
sy
y other 
othe
asmuss
smus
such 
uch 
and
rious
ous
yste
yste
any 
s bl
s b
extensions
inv
inv
n 450m
450m
or 
ves
ves
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 161 of 240
Change #25
Section 6.1 Withdrawal criteria
Subjects are free to withdraw from EP0060 at any time, without prejudice to their continued 
care.
Subjects must be withdrawn from EP0060 if any of the following events occur:
1. Subject experiences intolerable AEs and AEs associated with iv administration that, in the 
opinion of the investigator, preclude further participation in EP0060.
2. The subject requires more than 5 days of iv LCM dosing.
3. The sponsor or a regulatory agency requests withdrawal of the subject.
4. Subject has corrected QT interval (QTc) ≥500ms that is confirmed by a cardiologist over 
read on any ECG.
5. Subject becomes pregnant during the study, as evidenced by a positive serum or urine 
pregnancy test.
6. Subject develops a second- or third-degree atrioventricular (AV) block or another clinically 
relevant change in medical condition (or ECG) as determined by the investigator, or if the 
investigator feels it is in the interest of the subject to withdraw.
7. For subjects ≥6 years of age, subject has actual suicidal ideation since last visit as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Children’s Since 
Last Visit” version of C-SSRS. The subject should be referred immediately to a Mental 
Healthcare Professional and must be withdrawn from EP0060.
8. Subject is unwilling or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in EP0060.
9. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.
10. In the case of liver function test (LFT) results of transaminases (AST, ALT, or both) 
≥3x ULN to <5xULN and total bilirubin ≥2xULN or transaminases (AST, ALT, or both) 
≥5xULN, the study medication must be immediately discontinued and the subject withdrawn 
from the study. The LFTs will be repeated as soon as possible, and in no case more than 
1 week later.
Participation in EP0060 may be discontinued for any of the following reasons:
11. Subject experiences convulsive status epilepticus.
12. Subject has any clinically relevant change in medical or psychiatric condition (if, in the 
opinion of the investigator, the change in condition warrants discontinuation from EP0060).
13. Subject requires a medication that is not permitted by the protocol (see Section 7.8.1).
14. Subject and/or delegated caregiver is noncompliant with EP0060 procedures or medication, 
in the opinion of the investigator.
15. Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality 
REDACTED
tu
Questi
Quest
ubject 
bject 
e with
e wit
 con
 con
COPY
ct to 
ct to
ual su
al su
This document 
2.
cannot 
ubject 
bject
Sub
Sub
be
on in
on in
used 
dy. T
y. T
er.r.
to 
udy
The
Th
support
nction
ction
LN and
N an
dy me
y me
any 
t
marketing
ntinue
ntinue
n EP00
EP0
drawa
draw
authorization
uicida
uicida
ion 4 o
on 4 
t shou
shou
hdraw
draw
application 
(AV) b
(AV)
mined b
mined 
withdr
withd
and
itive
ive
any 
ve se
e s
extensions 
ardiol
ardio
or variations 
he e
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 162 of 240
(ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring 
of LFTs should continue until resolved (ie, <3xULN or stable condition). The investigator is 
to decide whether or not to stop the study medication.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
Investigators should also attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. Withdrawal assessments will be recorded in EP0060. For subjects returning to a 
long-term, open-label study, withdrawal assessments from the long-term open-label study should 
be evaluated separately from the EP0060 withdrawal assessments. For subjects considered as lost 
to follow up, the investigator should make efforts (at least 1 phone call and 1 written message to 
the subject), and document his/her efforts (date and summary of the phone call and copy of the 
written message in the source documents), to complete the final evaluation. All results of these 
evaluations and observations, together with a narrative description of the reason(s) for removing 
the subject, must be recorded in the source documents. The Case Report form (CRF) must 
document the primary reason for withdrawal or discontinuation.
Has been changed to:
Subjects are free to withdraw from EP0060 at any time, without prejudice to their continued 
care. The following criteria for subject withdrawal from EP0060 are outlined below. Additional 
discontinuation criteria for potential drug-induced liver injury are presented in Section 6.3.1.
Subjects must be withdrawn from EP0060 if any of the following events occur:
1. Subject experiences intolerable AEs and AEs associated with iv administration that, in the 
opinion of the investigator, preclude further participation in EP0060.
2. The subject requires more than 10 iv LCM doses.
3. The sponsor or a regulatory agency requests withdrawal of the subject.
4. Subject has corrected QT interval (QTc) ≥500ms that is confirmed by a cardiologist over 
read on any ECG.
5. Subject becomes pregnant during the study, as evidenced by a positive urine pregnancy test.
6. Subject develops a second- or third-degree atrioventricular (AV) block or another clinically 
relevant change in medical condition (or ECG) as determined by the investigator, or if the 
investigator feels it is in the interest of the subject to withdraw.
7. For subjects ≥6 years of age, subject has actual suicidal ideation since last visit as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Children’s Since 
Last Visit” version of C-SSRS. The subject should be referred immediately to a Mental 
Healthcare Professional and must be withdrawn from EP0060.
8. Subject is unwilling or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in EP0060.
9. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.
Participation in EP0060 may be withdrawn for any of the following reasons:
REDACTED
f any 
any 
and A
and A
de fur
de fu
0 iv
0 iv
COPY
from 
rom 
d liver
d live
This document
H
8.8.
cannot
ub
a pos
a pos
Last V
ast V
He
He
be
bject
bject
used
nge i
ge 
or fee
or fee
to 
ps a 
s a
inin
support 
egnant 
gnan
a sec
a se
any
terv
terv
marketing 
v LCM
v LCM
ency re
ncy r
val
va
authorization
r inj
inj
of the 
of the 
AEs
Es as
as
ther p
her p
application 
hout pr
out p
EP0060
P006
njury
jury
and any 
as
as
form 
form
extensions
er
n mes
n mes
nd cop
nd cop
All resu
l resu
son(
on
or
ed a
ed 
variations 
g to a
to a
shou
shou
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 163 of 240
10. Subject experiences generalized convulsive status epilepticus.
11. Subject has any clinically relevant change in medical or psychiatric condition (if, in the 
opinion of the investigator, the change in condition warrants discontinuation from EP0060).
12. Subject requires a medication that is not permitted by the protocol (see Section 7.8.1).
13. Subject and/or delegated caregiver is noncompliant with EP0060 procedures or medication, 
in the opinion of the investigator.
14. Subject who initiated adjunctive LCM treatment in EP0060 and requires a change in LCM 
dose during the Treatment Period.
15. Subject electively administering LCM requires more than 2 iv doses. If, in the opinion of the 
Investigator, there is a clinical need to administer more than 2 iv doses, the subject may 
remain in the study. The Investigator should document the clinical need in the medical 
record/source documents. 
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance. Investigators should also attempt to obtain information on subjects in the 
case of withdrawal. Withdrawal assessments, which are the same as those for Final Visit, will be 
recorded in EP0060. For subjects considered as lost to follow up, the investigator should make 
efforts (at least 1 phone call and 1 written message to the subject/subject’s parent or legal 
guardian), and document his/her efforts (date and summary of the phone call and copy of the 
written message in the source documents), to complete the final evaluation. All results of these 
evaluations and observations, together with a narrative description of the reason(s) for removing 
the subject, must be recorded in the source documents. The Case Report form (CRF) must 
document the primary reason for withdrawal.
For subjects returning to a long-term, open-label study, withdrawal assessments from the 
long-term open-label study should be evaluated separately from the EP0060 withdrawal 
assessments. The Medical Monitor may provide guidance on whether the subject should return to 
continued treatment within the long-term open-label study (OLL subject), be allowed to enroll in 
SP848 (RxL and IIL subjects), or withdraw completely. For the particular withdrawal criterion of 
requiring more than 10 iv doses or if the route of LCM administration (iv) is the sole reason for 
withdrawal of consent, subjects may be allowed to return to their long-term open-label study 
(OLL subjects) or enroll in SP848 (RxL and IIL subjects) after discussion with and agreement 
from the Medical Monitor. If an OLL subject is advised to withdraw from the long-term 
open-label study (EP0034 or SP848), the subject will be required to return to the long-term 
open-label study to complete the required withdrawal and safety follow-up assessments.
Change #26
Section 6.3.1 Potential drug-induced liver injury IMP discontinuation criteria
Has been added:
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
REDACTED 
om
om
a narr
a narr
ce doc
ce doc
drawa
drawa
m, op
m, op
COPY
o the
o th
summ
sum
mple
mpl
This document 
Cha
ha
Sec
Se
cannot 
ang
ang
be
stud
stud
used
al M
l M
udy (E
dy (E
to
enro
enro
on
support 
ts),
s)
v doses
dos
t, subje
, subj
oll i
oll
any
long
lon
, or w
, or
marketing 
pen
pen-lala
e evalu
eval
or may 
r may
g t
authorization 
mar
mar
ete the
te th
rative 
ative
cumen
cumen
l.
application
in
e as th
e as t
w up, th
w up, t
subject
ubjec
ry of
ry o
and
to d
to d
nform
nform
any 
disc
dis
extensions 
opinio
opinio
subjec
ubjec
n th
n the
or variations 
CM 
CM 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 164 of 240
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator. 
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 10.6.2. If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The CRF must document the primary 
reason for IMP discontinuation.
Change #27
Section 7.1 Description of investigational medicinal product
Investigational medicinal product will be provided as LCM solution in glass iv vials (10mg/mL 
in a 20mL vial; each vial contains LCM 200mg). Both the iv vials and the carton containing the 
vials will be labeled for the study.
Has been changed to:
7.1.1
Lacosamide solution for infusion
Investigational medicinal product for infusion will be provided as LCM solution for infusion in 
glass iv vials (10mg/mL in a 20mL vial; each vial contains LCM 200mg). Both the iv vials and 
the carton containing the vials will be labeled for the study.
Further details regarding dilution and storage of LCM solution for infusion are provided in the 
IMP Handling Manual.
7.1.2
Lacosamide oral solution for RxL and IIL subjects transitioning to SP848
REDACTED
h PD
h PD
mplete.
plete.
or IMP
or IMP
source
sourc
COPY
MP mu
P m
on on 
n on
DI
This documen
glass
lass
the 
the
cannot
Laco
aco
estiga
stiga
s i
s i
be 
 c
os
os
sed
eled 
led
chan
ha
to
h vi
h v
d fo
fo
support
f inv
f inv
nal pro
al pr
vial 
vial
any 
ves
marketing 
e d d
authorization
subj
subj
ILI sh
LI sh
. All r
All r
P disc
disc
docu
docu
application
rness)
rness
n 10.6.
10.6
st be d
t be d
ec
and 
LN
LN
sympt
ympt
)
any 
N, to
N, t
extensions
hout
ou
etion o
tion o
or
and
and
ut c
t c
variations 
d ri
d ri
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 165 of 240
Lacosamide syrup/oral solution will be provided in a polyethylene terephthalate bottle 
(10mg/mL in 200mL bottle). The bottle will be labeled for the study. Study medication will be 
measured and administered via a dosing syringe.
Lacosamide oral solution will only be distributed to those RxL and IIL subjects who are eligible 
and choose to participate in SP848. This supply, if required, will be dispensed at Visit 2 in the 
event that additional time is needed to coordinate scheduling of Visit 1 of SP848, and any 
remaining oral LCM solution will be returned to the site at the Transition Visit.
Change #28
Section 7.2 Treatment(s) to be administered
Treatment Period (up to 5 days)
During the Treatment Period, iv LCM will be administered bid at approximately 12-hour 
intervals, once in the morning and once in the evening, for up to 5 days. The iv LCM dose will 
be equivalent (mg-for-mg) to the subject’s current stable oral LCM dose or prescribed oral 
VIMPAT dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 600mg/day. The first 
iv LCM dose will be given on Day 1.
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to administration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv 
LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline 
(NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total volume of 
fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.
For the first 10 subjects ≥12 to <17 years of age enrolled into Cohort 1, iv LCM should be 
infused over a duration of 30 minutes but no longer than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in Cohort 1 and subsequent cohort(s) will be 
based on DMC recommendation: 
x 30 minutes but no longer than 60 minutes whenever possible,
x OR 15 minutes but no longer than 30 minutes whenever possible.
Further details on the timing of DMC recommendations regarding infusion duration are provided 
in Section 12.7.2.
When necessary for the safety of the subject or when the investigator deems it appropriate, the 
iv LCM dose can be modified after the first infusion, once the Day 1 PK samples have been 
taken. 
REDACTED
mini
min
sion d
sion d
diluen
diluen
uent s
uent 
ay
ay S
COPY
vering
verin
iously
iously
This document
x
O
F
cannot
n DM
DM
30 mi
30 mi
be
on of
on o
M
used
bjbj
durati
durati
f i
f
to
ject
ect
support
≥20k
≥20k
ministra
inistr
any
to ≤2
to ≤
kg
k
marketing 
sh
Segar 
Segar 
100mL
00mL
≤20
≤2
authorization
y unu
y un
stratio
tratio
duratio
uratio
nts: de
ts: de
hould
oul
application 
M d
100 to
00 to
the iv
the i
us
and
ys. T
s. T
dose
ose
any
imate
imat
The
Th
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 166 of 240
A subject cannot receive iv LCM for more than 5 days in EP0060. If a subject requires iv LCM 
treatment for more than 5 days, the subject may continue on iv VIMPAT, but he/she will need to 
discontinue EP0060. Subjects who were enrolled in a long-term, open-label study may be 
eligible to resume participation in that study, according to the protocol requirements. If subjects 
need to discontinue LCM, the subjects should be tapered off LCM gradually as specified in their 
long-term, open-label study. This taper should occur as a part of the long-term, open-label study.
Subjects who were prescribed oral VIMPAT should continue AED treatment at the discretion of 
the treating physician. 
Has been changed to:
7.2.1
Treatment Period 
During the Treatment Period, subjects will receive at least 1 dose of iv LCM at the dose levels 
noted below. The first iv LCM dose will be given on Day 1. If more than 1 infusion is given, iv 
LCM will be administered bid at approximately 12-hour intervals, once in the morning and once 
in the evening, for up to 10 doses (or up to 5 days) for clinical need administration or up to 2 
consecutive doses (over approximately 24 hours) for elective administration. 
Specific dosing regimens for subjects who will receive iv LCM replacement therapy for oral 
treatment (OLL and RxL subjects) or for subjects who will initiate adjunctive LCM treatment 
(IIL subjects) are as follows:
x Replacement for oral treatment: For OLL and RxL subjects, the iv LCM daily dose 
will be equivalent (mg-for-mg) to the subject’s current oral LCM dose or prescribed oral 
LCM (ie, VIMPAT) dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 
600mg/day. The first infusion must be equivalent to the subject’s stable oral LCM dose.
x Adjunctive LCM treatment initiation: For IIL subjects, the iv LCM daily dose will be 
2mg/kg/day for subjects <50kg or 100mg/day for subjects ≥50kg. As LCM is given bid, 
the actual dose for the first infusion will be LCM 1mg/kg (subjects weighing <50kg) or 
50mg (subjects weighing ≥50kg). For these subjects, the LCM dose should remain 
unchanged for the duration of the iv Treatment Period (see Section 6.3).
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to administration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv 
LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline 
(NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total volume of 
fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.
REDACTED 
OL
OL
he subj
e subj
s in bi
s in bi
must 
must
t in
t in
COPY 
o w
LL
LL
This document 
x
cannot
9%
9%
intake
ntake
x
be
mpa
pa
%)
%)
used 
on n 
atible 
tible 
atib
atib
to
def
n is n
is
support
durat
ura
ump sh
ump s
fined
fined
any
ng ≥5
g ≥
ation
atio
marketing 
nitiatio
itiatio
0kg or 
kg or
t infus
infu
50
5
authorization 
and R
and R
ject’s 
ect’s 
id reg
d reg
be eq
e eq
application 
inis
nis
M repla
M repl
initiat
initia
and
dmin
dmin
istra
stra
any 
in
n the 
n the
nisi
extensions 
t the d
the d
nfus
fus
or variations 
n of 
 of 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 167 of 240
For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 10 subjects ≥4 
to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer 
than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in each cohort will be based on DMC 
recommendation: 
x EITHER target infusion duration of 15 minutes but no longer than 30 minutes only in 
subjects who would directly benefit from an increased infusion rate, in the opinion of the 
Investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion, in the
opinion of the Investigator, cannot receive the faster infusion. These subjects should receive 
an infusion of 30 minutes but no longer than 60 minutes.
x OR all remaining subjects will have a target infusion duration of 30 minutes but no longer 
than 60 minutes
Further details on the timing of DMC recommendations regarding infusion duration are provided 
in Section 12.7.2.
For OLL and RxL subjects, the iv LCM dose can be modified after the first infusion when 
necessary for the safety of the subject or when the investigator deems it appropriate; however, 
modification should not occur until after the Day 1 PK samples have been taken. Modification of 
iv LCM dose is not permitted for IIL subjects.
A subject cannot receive iv LCM for more than 10 doses (up to 5 days) within the Treatment 
Period of EP0060 (or more than 2 consecutive doses [over approximately 24 hours] for elective 
administration. If a subject requires iv LCM treatment for more than 5 days, the subject may 
continue on iv VIMPAT, but he/she will need to discontinue EP0060. Upon 
completion/discontinuation of EP0060, OLL subjects are eligible to resume participation in their 
respective open-label study, according to the protocol requirements. If a subject is withdrawn 
from EP0060 due to requirement of more than 10 iv LCM doses, the subject may be allowed to 
return to their long term open-label study (OLL subjects) or enroll in SP848 (RxL and IIL 
subjects) after discussion with and agreement from the Medical Monitor. If an OLL subject 
meets any other “must withdrawal” criteria for the respective open-label study, the subject will 
return to the open-label study to complete the appropriate withdrawal assessments and safety 
follow-up.
For RxL and IIL subjects, AED treatment will continue at the discretion of the treating 
physician, upon completion/discontinuation of EP0060. If determined clinically appropriate, 
these subjects will be given the option to continue oral LCM treatment for up to 2 years in 
SP848. If LCM treatment is not continued in SP848 (either by choice or not clinically 
appropriate), RxL and IIL subjects will be followed for approximately 30 days after the Final 
Visit in order to collect safety data. All concomitant medications taken during this 30-day period, 
including prescribed AEDs, will be collected at TC2.
If subjects need to discontinue LCM, the subjects should be tapered off LCM either as specified 
in their long-term, open-label study or at the discretion of the treating physician for RxL and IIL 
subjects. For OLL subjects this taper should occur as a part of the long-term, open-label study 
and not as a part of EP0060.
REDACTED 
n 10
n 1
ive do
ive do
CM tre
CM tr
will ne
will ne
60, O
60, O
COPY 
K s
K 
10 d
0 d
This document 
Visit
si
incl
incl
cannot
 If LC
If LC
ropria
opria
it in
t in
be
p
ects w
ects w
used
L sub
sub
on co
on co
to 
bj
support
thdraw
hdra
l study
stud
any 
bel
be
h and 
and 
marketing
OLL 
OLL 
g to the
g to th
of more
f mo
el stu
el st
authorization 
doses 
oses 
oses [o
ses [o
reatme
eatme
ed to 
d to 
application 
er the
r th
r deem
deem
mples ha
ples h
and 
h
any 
on dur
on du
extensions 
ld 
s but n
s but n
or
rec
rec
variations 
e
the
the
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 168 of 240
Change #29
Section 7.2.2 Transition oral lacosamide
Oral LCM solution will only be distributed to those RxL and IIL subjects who are eligible and 
choose to participate in SP848.
For OLL and RxL subjects, the oral LCM daily dose will be equivalent (mg-for-mg) to the 
subject’s current oral LCM dose or prescribed oral LCM (ie, VIMPAT) dose (always in bid 
regimen) of 2 to 12mg/kg/day.
For IIL subjects, the oral LCM solution daily dose (always in bid) will be 2mg/kg/day for 
subjects <50kg or 100mg/day for subjects ≥50kg if the subject has been taking LCM for less than 
7 days. If the subject has reached 7 days of LCM exposure, an increase in dose titration can be 
initiated.
Has been added
Change #30
Section 7.5 Handling and storage requirements
The investigator (or designee) is responsible for the safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access.
Lacosamide is to be stored according to instructions on the label. Appropriate storage conditions 
must be ensured either by controlled room temperature and by completion of a temperature log 
in accordance with local requirements on a regular basis (eg, once a week), showing minimum 
and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of LCM.
The CPM (or designee) will transmit the out-of-range temperature (copy of the temperature log 
and duration of the out-of-range temperature, if available) to the Clinical Supply Manager. Based 
on discussion with a UCB Quality Assurance representative, the Clinical Supply Manager will 
then provide the CPM (or designee) with instructions for the site regarding use of LCM.
Has been changed to:
The investigator (or designee) is responsible for the safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access 
according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensured by controlling the temperature and by 
completion of a temperature log in accordance with local requirements on a regular basis, 
showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.
In the case of dispensing oral LCM solution, the investigator (or designee) will instruct the 
subject’s parent or guardian to store the IMP following the instructions on the label.
ructio
ructio
m tem
m tem
on a r
on a r
d over
d over
COPY
e safe 
e safe
pt in 
pt in
This document
pp
pp
comp
comp
sh
sh
cannot 
ide
d
ding to
ing to
prop
rop
be 
gato
de sto
de sto
used
ang
ang
tor (
or (
to 
ge
ge
support
rang
rang
CB Qu
B Qu
M (or d
(or 
any
ransm
ansm
ge t
marketing
r the 
r the
is note
s note
(or des
or de
authorization
a sec
a sec
ons on
ns on
mperat
perat
regula
egula
t
application 
and pr
and p
c
and any extensions
o
M for 
M for 
tration
ratio
or 
or 
or 
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 169 of 240
Changes #31 and #32
Section 7.6 Drug accountability, first and last paragraphs
First paragraph:
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost (due to breakage or wastage), not used, disposed of at the study site, or returned to 
the sponsor or designee must also be recorded on the appropriate forms. All supplies and 
pharmacy documentation must be made available throughout the study for UCB (or designee) to 
review.
Last paragraph:
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers) and unused LCM containers must be reconciled and returned to UCB (or designee), 
preferably in their original package. Investigational medicinal product intended for the study 
cannot be used for any other purpose than that described in this protocol.
Have been changed to:
First paragraph:
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
Last paragraph:
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired LCM must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
Change #33
Section 7.8.1 Permitted and prohibited concomitant treatments (medications and 
therapies), first and second paragraphs
Stable use of amphetamines and sedative antihistamines is permitted during the study. 
Use of MAOIs is prohibited during EP0060.
Have been changed to:
Stable use of amphetamines and sedative antihistamines is permitted during the study. 
Use of the following concomitant treatments (medications and therapies) is prohibited during 
EP0060:
REDACTED 
men
me
r wasta
r wast
esigne
esign
ation m
ation m
COPY 
d LCM
d LC
entat
nta
This document
Stabl
tab
Us
Us
cannot
7.8.
7.8.
apies)
pies)
blele
be 
#33
1
used 
3
to support
ding 
ing 
nal med
al me
cribed
ribed
any
used, d
used, 
tot
marketing 
ion o
on o
authorization 
M d
M d
tion d
ion d
age), 
age), 
ee mu
ee mu
must b
must b
application 
disp
disp
and 
intnt
ocol.
ocol.
any
o UC
o U
tende
tend
extensions 
ed (in
d (in
UC
UC
or
gne
gn
variations 
f 
d to
d to
nee)
ee)
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 170 of 240
x MAOI-A inhibitors
x Cannabidiols not approved or indicated for epilepsy by local health authority
Change #34
Section 7.10 Randomization and numbering of subjects
Subjects will not be randomized in EP0060. For a subject enrolled in a long-term, open-label 
study, the unique identification number assigned to them in that study will be used to identify 
them and maintain subject confidentiality throughout EP0060. Direct-enroll subjects prescribed 
VIMPAT will be assigned a unique identification number in EP0060.
Has been changed to:
Subjects will not be randomized in EP0060. For an OLL subject, the unique identification 
number assigned to them in that study will be used to identify them and maintain subject 
confidentiality throughout EP0060. A unique identification number in EP0060 will be assigned 
for RxL and IIL subjects.
Change #35
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline, first 
2 paragraphs
8.1.1
Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline 
Prior to the conduct of any study-related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments may be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 1a). When necessary for the well-being of the subject or when 
the investigator deems it appropriate, the Screening and/or Baseline Visit can occur on the same 
day as the first iv LCM infusion (Day 1) provided all test results are available and reviewed to 
assess inclusion and exclusion criteria prior to enrollment/treatment in the study. Oral LCM will 
be administered in accordance with each subject’s current stable LCM dosage regimen of 2 to 
12mg/kg/day or 100 to 600mg/day. For subjects enrolled in a long-term open-label study, the 
oral LCM will be taken from the long-term open-label study supply. For subjects who have been 
prescribed VIMPAT, oral LCM will be taken from the subject’s prescribed VIMPAT supply.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. The following pretreatment assessments will be carried out at 
Visit 1a:
REDACTED 
Da
D
o Day
o Day
ated p
ated p
thth
COPY 
Day 
ay
This document
oral 
oral 
pr
pr
cannot 
clulu
minist
inis
mg/kg
mg/kg
L
be 
irst 
rst
usio
usio
used 
r toto
r deem
deem
t iv
t iv
to
o D
o D
support
roved
rove
e Scree
Scre
ening 
ning
any
med Co
ed C
ed
marketing 
proc
proc
he stud
he stu
ECs) an
Cs) a
bject
bjec
authorization 
-1) Sc
1) S
y -1) S
1) S
ce
ce
application and 
d m
in EP
n EP
any
ue id
ue id
main
mai
extensions
pres
pres
de
d
or
nti
nt
scr
sc
variations 
el
tify
ify
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 171 of 240
Have been changed to:
8.1.1
Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline 
Prior to the conduct of any study-related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments may be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 2). 
The Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion 
(Day 1), if necessary, provided all test results (ie, 12-lead ECG and laboratory results) are 
available and reviewed to assess inclusion and exclusion criteria prior to enrollment/treatment in 
the study. For all subjects, laboratory results obtained for routine diagnostic and medical care can 
be used whenever possible if collected no more than 24 hours prior to Screening/Baseline Visit 
in order to minimize blood loss associated with the study. At the Screening/Baseline Visit, the 
use of a central or local laboratory is at the discretion of the investigator.
If Screening/Baseline do not occur on the same day as the first infusion, oral LCM will be 
administered for OLL and RxL subjects during the Screening/Baseline Period from their 
open-label study or prescribed LCM supply in accordance with each subject’s current stable 
LCM dosage regimen of 2 to 12mg/kg/day or 100 to 600mg/day. For IIL subjects, no LCM will 
be administered during the Screening Period.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. Demographic data will be collected at Visit 1a. The following 
pretreatment assessments will be carried out at Visit 1a:
Change #36
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline, bullets 6, 7, 
8, 9, 10, 15, 16, 20, and 21
x Medical history update for subjects from long-term open-label studies, or complete medical 
history for subjects receiving prescribed VIMPAT
x Lacosamide dosing history (including formulation, date, and time of use, and dose and unit 
during the last 3 days)
x Prior and concomitant medication(s) assessment (prior medications will only be collected for 
direct-enroll subjects; concomitant medications from the long-term open-label studies will be 
followed, as well as the recording of new concomitant medications during EP0060 for all 
enrolled subjects)
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
REDACTED
g the
g th
y in ac
in ac
ay or 
ay or 
Perio
Perio
dy w
dy
COPY 
of 
of
ay as 
ay as
he S
he
This document 
x
P
cannot 
y
acosam
cosa
durin
durin
be
for 
for 
used 
20, 
0, 
istory
istory
to 
1a
, an
an
support 
a and
and
any marketing 
will be
will be
Demog
emog
carrie
carrie
authorization
the 
he 
Screen
Screen
ccorda
corda
100 to
100 t
d.
application
ior to
ior to
the Scr
the Sc
e inves
 inve
e fir
fir
and 
to e
o e
agnos
gnos
any
tory 
tory
enro
enr
extensions 
ity
ay and
ay and
v LCM
LCM
or
y for
fo
variations 
e
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 172 of 240
x Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening 
Visit for subjects who are prescribed VIMPAT and urine testing for subjects enrolled in 
long-term, open-label studies
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG 
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
Have been changed to:
x Medical history update for OLL subjects from long-term open-label studies, or complete 
medical history for RxL and IIL subjects 
x For OLL and RxL subjects, LCM dosing history (including formulation, date, and time of 
use, and dose and unit during the last 3 days)
x Prior and concomitant medication(s) assessment (prior medications will only be collected for 
direct-enroll subjects)
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose),  
VNS settings, and/or use of ketogenic diet
x Urine pregnancy testing for subjects of childbearing potential 
x Vital signs (BP and pulse rate) assessment (measured on subjects who have rested [sitting or 
supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5.
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will continue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open-label study or prescribed oral LCM supply, 
respectively.
And
x Seizure history for RxL and IIL subjects
Has been added
Change #37
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline, bullets 18 
and 19
x ILAE (International League against Epilepsy) seizure classification
REDACTED
ildbe
ildb
ment (
ment (
n feasi
n feasi
jects
jects
COPY 
f dr
f d
bea
bea
This document 
C
cannot
ure 
ure 
s bee
bee
be 
e hi
e hi
used to 
d us
support
d the f
he f
L and R
and
using 
sing 
any
ed as 
ed as
i
marketing
s who 
s who
en feas
n fea
s of ag
of a
d
authorization 
aring p
ring p
(measu
(meas
ible)
ble)
application
ation
ion
gs, amo
s, am
and 
ons
ns
any
on, da
n, d
extensions 
or com
or com
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 173 of 240
x Admission to the unit
Have been deleted
Change #38
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline, Visit 1b 
bullets 2, 4, 6, 8, 9, 11, and 12
x Lacosamide dosing history (including formulation, date, and time of use, and dose and unit 
during the last 3 days)
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
Have been changed to:
x For OLL and RxL subjects, the LCM dosing history will be collected (including formulation, 
date, and time of use, and dose and unit during the last 3 days)
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose), 
VNS settings, and/or ketogenic diet
x Blood sample for clinical chemistry and hematology (Repetition of laboratory assessments is 
at the discretion of the investigator if Visit 1b is on a separate day from Visit 1a.)
x Vital signs (BP and pulse rate) assessment (measured on subjects who have rested [sitting or 
supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5.
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will continue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open-label study or prescribed oral LCM supply, 
respectively.
REDACTED 
dosing
dosing
unit d
unit d
t (ide
t (id
COPY 
This document
dmi
dmi
dosa
dosa
r
cannot
essi
essi
creeni
reen
mini
ini
be
S (fo
(f
ion
ion
used
h EC
EC
for
for
to
cond
ond
G
support
ulse ra
se r
3 mi
 minu
n
duc
d
any
estiga
estig
t
marketing
dentifi
dentifi
ietet
mistry
mistr
t
authorization 
g histo
g histo
during
uring
application and any extensions 
of last
f last
or
nd u
nd 
variations 
un
un
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 174 of 240
Change #39
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline, Visit 1b 
bullet 10
x Admission to the unit
Has been deleted
Change #40
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline, Visit 1b, 
new bullets (currently numbering) 11, 12, 13, 14, and 15
x Medical procedures
x Medical history update for OLL subjects, or complete medical history for RxL and IIL 
subjects
x Urine pregnancy testing for subjects of childbearing potential
x Brief physical examination
x Brief neurological examination
Have been added
Change #41
Section 8.2.1 Visit 2 (Day1), first paragraph
Intravenous LCM infusion treatment will begin at this visit, and iv LCM will be administered bid 
at approximately 12-hour intervals, once in the morning and once in the evening, for up to 
5 days. Screening laboratory assessments may be conducted up to and including the day of the 
infusion provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion. 
The following assessments will be carried out:
Has been changed to:
Intravenous LCM infusion treatment will begin at this visit. Subjects will receive at least 1 dose 
of iv LCM. If more than 1 infusion is given, iv LCM will be administered bid at approximately 
12-hour intervals, once in the morning and once in the evening, for up to 10 doses (or up to 5 
days) for clinical need administration or up to 2 consecutive doses (over approximately 24 hours) 
for elective administration. 
Screening laboratory assessments may be conducted up to and including the day of the infusion 
provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion. 
Section 8.1.1 details under what conditions laboratory results within 24 hours of signing the 
Informed Consent form can be used. 
The following assessments will be carried out:
ar
ar
COPY 
This document 
Scre
Scre
p
cannot 
inte
nte
for cl
for cl
elect
elect
be 
If m
f 
terv
terv
used 
CM in
CM in
mo
mo
to
ged
ge
support
e rerevie
vi
ents w
nts w
d t
d
any 
als
als
assess
sses
marketing 
ragrap
agrap
ent will
nt wil
s, on
s, o
authorization application and any 
y for R
y for 
extensions
e, Visi
e, Vis
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 175 of 240
Change #42
Section 8.2.1 Visit 2 (Day 1), bullets 2, 4, 7, 8, 9 and 10 for first infusion
x Medical procedures and medical history update
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or VNS settings
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered at the time points described in Section 9).
An indwelling cannula used for the iv LCM infusion may not be used for PK blood 
sampling.) 
x C-SSRS (for subjects ≥6 years of age)
Have been changed to:
x Medical procedures
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion) (conducted on subjects who 
have rested [sitting or supine] for at least 3 minutes prior to each ECG recording, when 
feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion) 
(measured on subjects who have rested [sitting or supine] for at least 3 minutes, when 
feasible)
x Blood sample for LCM PK (Blood draws will be performed from a region of the body that is 
different from the region where the iv LCM infusion will be administered at the time points 
described in Section 9. An indwelling peripheral cannula used for the iv LCM infusion may 
not be used for PK blood sampling.) 
x C-SSRS (for subjects ≥6 years of age) after infusion. For subjects <6 years, signs and 
symptoms of depression will be evaluated as described in Section 10.7.5.
Change #43
Section 8.2.1 Visit 2 (Day 1), bullets 11, 12, and 13
x Brief physical examination
x Brief neurological examination
REDACTED
catio
catio
diet
iet
inutes 
nutes 
m th
m the s
e s
r at
r a
COPY 
on
on
This document cannot 
e u
SSR
SSR
sym
sym
be
d 
used
used
used
om th
m th
inin S
to
or L
or L
support
s who 
who
LC
LC
any
rate
rat
5, 60
5, 60
h
marketing
start
art
at least 
least 
te (a
e (
authorization 
of dru
of dru
 prior
prior
rt o
rt o
application and any 
rib
rib
d for P
for 
extensions
sion 
ion 
 infus
infus
pposite
posit
bed 
bed
or 
an
variations 
15,5,
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 176 of 240
x For RxL and IIL subjects who are eligible and choose to participate in the long-term open 
label oral LCM study SP848 after completion of EP0060, a short-term oral LCM solution 
will be dispensed at Visit 2. This supply is to allow continuity of LCM treatment after the last 
iv LCM infusion and the scheduled Transition Visit.
Have been added
Change #44
Section 8.2.1 Visit 2 (Day 1), second paragraph
The second iv LCM infusion will be administered at approximately 12 hours after the start of the 
first infusion, and the following assessments will be carried out:
Has been changed to:
If a second iv LCM infusion is given, it will be administered at approximately 12 hours after the 
start of the first infusion, and the following assessments will be carried out:
Change #45
Section 8.2.1 Visit 2 (Day 1), bullets 3 and 4 for second infusion
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
Have been changed to:
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion) (conducted on subjects who 
have rested [sitting or supine] for at least 3 minutes prior to each ECG recording, when 
feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion) 
(measured on subjects who have rested [sitting or supine] for at least 3 minutes, when 
feasible)
Change #46
Section 8.2.1 Visit 2 (Day 1), bullets 6 and 7 for second infusion
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
REDACTED
prior
prior
tart of
tart of
pprox
pprox
minu
minu
COPY 
seco
seco
t
This document
Cha
ha
Sec
Se
cannot 
ang
ang
be 
e)e)
used 
ely 5
y 5
d on s
on s
to
BP a
P a
support
supin
upin
and
and
any 
y 2
y 2
rs from
rs fro
ne
marketing
utes, a
utes, a
20
20 m
authorization 
nd
nd
to iv L
o iv 
f iv LC
iv L
imate
mate
application 
d inf
inf
and 
ima
m
ied ou
ed ou
any 
mately
ate
extensions 
the st
the st
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 177 of 240
Have been added
Change #47
Section 8.2.1 Visit 2 (Day 1), last paragraph
If the subject has more than 1 iv LCM infusion, it is optional to also collect blood samples for 
LCM PK before and after the final iv LCM infusion at the time points described in Section 9. In 
addition, during the course of the study, additional blood samples for PK analysis can be taken at 
the discretion of the investigator, especially in the event of a relevant treatment-emergent AE.
Has been added
Change #48
Section 8.2.2 Visit 3 (Day 2 to Day 5)
If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. Blood samples for LCM PK will be obtained before 
and after the final iv LCM infusion at the time points described in Section 9. In addition, during 
the course of the study, additional blood samples for PK analysis can be taken at the discretion of 
the investigator, especially in the event of a relevant treatment-emergent AE. 
Has been changed to:
If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. If the subject has more than 1 iv LCM infusion, it is 
optional to also collect blood samples for LCM PK before and after the final iv LCM infusion at 
the time points described in Section 9. In addition, during the course of the study, additional 
blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE.
Change #49
Section 8.3 Unscheduled Visit, bullets 1, 3, 6, and 9
x Medical procedures and medical history update
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose) 
and/or VNS settings
x BP and pulse rate
x C-SSRS (for subjects ≥6 years of age). The C-SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE.
REDACTED
releva
eleva
er Da
er Da
A
COPY 
mp
m
nts des
nts de
 for P
for P
This document
a
x
cannot
dical
dical
Conc
Con
be
Un
Un
used 
nsc
nsc
to support
ysis 
sis 
ment
ent-e
any
ction
ctio
s can
ca
marketing
ay 1
y 1
Assessm
ssessm
tion 
ion 8.2
8
ples fo
ples 
authorization
PK an
PK a
nt trea
nt trea
1, a
application
isit 3 
isit 3
(Day 2
Day 2
s for LC
for L
cribed
cribe
and any extensions 
en
or
nt A
t A
variations 
9. In 
In 
aken 
aken
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 178 of 240
Has been changed to:
x Medical procedures
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x C-SSRS (for subjects ≥6 years of age). The C-SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE. For subjects <6 years, signs and symptoms of depression 
will be evaluated as described in Section 10.7.5.
Change #50
Section 8.3 Unscheduled Visit, bullets 5 and 7
x 12-lead ECG
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM 
infusion may not be used for PK blood sampling)
Has been deleted
Change #51
Section 8.3 Unscheduled Visit, bullets 10 and 11
x Brief physical examination
x Brief neurological examination
Have been added
Change #52
Section 8.3 Unscheduled Visit, final paragraph
Additional assessments can be performed at the investigator’s discretion, including collection of 
a blood sample for LCM PK if the reason for the unscheduled visit is an AE.
Has been added
Change #53
Section 8.4.1 Final Visit (Day 2 to 6 [now Day 1 to 6])/Termination Visit, first paragraph
The following assessments will be carried out the day after the last dose of iv LCM for subjects 
who complete the study, discontinue the study, or withdraw from the study prematurely:
REDACTED 
let
le
COPY 
An 
An
ng)
ng)
This document 
as
a
cannot 
nal a
al 
od sam
d sam
s b
s b
be 
ass
ass
used 
nsch
nsch
to support any 
ation
tion
marketing 
ts 10 an
s 10 an
authorization application 
d on th
d on 
dwellin
well
and any extensions 
dep
or
pre
pre
variations 
f the
f the
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 179 of 240
Has been changed to:
If the last iv infusion of LCM for the study occurs in the morning, the Final Visit may occur on 
the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the 
following day (ie, last infusion in evening).
The following assessments will be carried out after the last dose of iv LCM for subjects who 
complete the study, discontinue the study, or withdraw from the study prematurely:
Change #54
Section 8.4.1 Final Visit (Day 2 to 6 [now Day 1 to Day 6])/Termination Visit, bullets 1, 3, 4, 
8, 9, 10, 12, and 13
x Medical procedures and medical history update
x Pregnancy testing for subjects of childbearing potential
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose) 
and/or VNS settings
x Blood sample for clinical chemistry and hematology
x 12-lead ECG
x BP and pulse rate
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age) 
Have been changed to:
x Medical procedures
x Urine pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identification of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x Blood sample for clinical chemistry and hematology which must be analyzed at the central 
laboratory
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] for at least 3 minutes 
prior to each ECG recording, when feasible)
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x Oral LCM administration, if applicable:
 For OLL subjects, oral LCM administration will continue in accordance with each 
subject’s LCM dosage regimen using the subject’s open-label study LCM supply
REDACTED 
f age) 
f age)
COPY 
gy
gy
This document
3
x
cannot
or to 
r to 
BP a
BP a
be
d EC
d EC
used 
 fo
fo
G
o
or c
or c
support 
) assess
asse
/or use
or us
i
any 
or sub
or sub
marketing authorization application 
unt
and 
nt an
t an
any extensions 
bulle
bulle
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 180 of 240
 For RxL subjects who are not eligible or do not wish to continue LCM treatment in 
SP848, oral LCM administration may continue from the subject’s prescribed LCM supply 
at the physician’s recommended dosage regimen.
 For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM 
administration may continue from the short-term oral LCM solution that was dispensed at 
Visit 2. Additional assessments will be conducted at the Transition Visit, as outlined in 
Section 8.4.3.
x C-SSRS (for subjects ≥6 years of age) For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5.
Change #55
Section 8.4.1 Final Visit (Day 2 to 6)/Termination Visit, last bullet
x Discharge from the unit
Has been deleted
Change #56
Section 8.4.2 Telephone Contact (Day 2 to Day 9), section title
Has been changed to:
Section 8.4.2 Telephone Contact 1 (Day 2 to Day 9)
 
Change #57
Section 8.4.2 Telephone Contact (Day 2 to Day 9), first paragraph
One or 2 days after the Final Visit, a safety follow-up/telephone assessment will be conducted 
during the End-of-Study Period (2 to 9 days after Visit 2/Day 1). The following assessments will 
be collected:
Has been changed to:
One to 3 days after the Final Visit, a safety follow-up/telephone assessment will be conducted 
during the End-of-Study Period. The following assessments will be collected:
Change #58
Section 8.4.2 Telephone Contact (Day 2 to Day 9), first and last bullets
x Medical procedures and medical history update
x Oral LCM administration
REDACTED
Day 
Day
ay 2 t
ay 2 
COPY 
y 9)
y 9)
This document
Cha
Cha
Se
S
cannot 
he E
e E
an
be 
ys a
ys 
End
End
used
ang
ang
afte
afte
to 
ge
support
nal V
al V
y Perio
y Peri
any
act (
act 
Vis
Vi
marketing 
(D
(
authorization 
), sect
, sect
o Day
Day
application and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 181 of 240
Have been changed to:
x Medical procedures
x Information regarding LCM dosing since Final Visit
Change #59
Section 8.4.2 Telephone Contact (Day 2 to Day 9), new bullet
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
Has been added
Change #60
Section 8.4.3 Transition Visit (Day 1 to Day 13)
For RxL and IIL subjects who are eligible and wish to enroll in SP848, the Final Visit and 
Transition Visit may occur on the same day or may occur up to 7 days after the Final Visit. The 
Transition Visit for EP0060 should occur on the same day as Visit 1 in SP848.
The following assessments will be conducted at the Transition Visit if the visit is not conducted 
on the same day as the Final Visit:
x Collection of the short-term oral LCM solution, if dispensed at Visit 2 
x Information regarding LCM dosing since Final Visit
x Concomitant medication(s) assessment
x AE reporting
Additional assessments for enrollment in SP848 (Visit 1) are detailed within the SP848 protocol.
Has been added
Change #61
Section 8.4.4 Telephone Contact 2 (Day 29 to Day 37)
Thirty days (±2 days) after the Final Visit, a safety follow-up/telephone assessment will be 
conducted during the End-of-Study Period (29 to 37 days after Visit 2/Day 1). This assessment 
will only occur for those subjects who directly enrolled in EP0060 and will not be continuing 
LCM therapy in SP848. 
The following assessments will be collected:
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identification of drugs, amount, and time of last dose) 
and/or use of ketogenic diet
x AE reporting
REDACTED 
soluti
soluti
g sinc
g sinc
ssm
ssm
COPY 
 da
d
he Tra
he Tr
This document
LCM
CM
Th
T
cannot
ys
ys
cted d
ted d
l only 
only
M
be 
s (±2
s (±2
used 
Telep
Tele
to support any
ollm
ollm
marketing 
ment
ent
men
me
authorization 
ansi
ns
ion, if
on, if
e Fin
e Fin
application
SP848
SP84
o 7 day
o 7 da
as Visi
s Vis
sition
itio
and 
8
any extensions 
do
or
ose)
ose
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 182 of 240
x Information regarding LCM dosing since Telephone Contact 1
x Medical procedures
During the contact, the site should inquire as to whether the subject noted any change at the site 
of the infusion.
Has been added
Change #62
Section 9 ASSESSMENT OF PHARMACOKINETICS, first, second, third, and fourth 
paragraphs and first bullet point
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of study medication and the time of blood sampling 
must be recorded.
During the Treatment Period, plasma samples will be taken for LCM and SPM 12809 
determination after ECG and vital signs have been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusion was administered, at the following time 
points:
First iv LCM infusion (Day 1):
x Predose (within 1 hour prior to iv LCM dose)
Final iv LCM infusion (Day 2 to 5/Early Termination):
Have been changed to:
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of IMP and the time of blood sampling must be 
recorded.
During the Treatment Period, plasma samples will be taken for LCM and SPM 12809 
determination after ECG and vital signs have been taken. Plasma samples will be obtained from 
a different region of the body from the region in which the solution for infusion was 
administered, at the following time points: 
First iv LCM infusion (Day 1) – required samples:
x Predose (within 1 hour prior to iv LCM dose) for OLL and RxL subjects
Final iv LCM infusion (Day 2 to 5/Early Termination) – optional samples:
Change #63
Section 10.1.6 Pregnancy, second bullet
REDACTED 
M do
M do
arly T
arly T
COPY
was a
was a
This document
Final
Final
cannot
LCM
LCM
Predo
Predo
be 
d, a
d, a
M
used
er r 
on of 
on of
at th
at th
to
EC
EC
support 
st r
t r
Perio
Peri
G
any
les o
les 
recen
rec
marketing 
Terer
on of 
on of
of
authorization 
ose)
se)
rmin
min
application 
LCM a
LCM 
asma sa
sma 
dminist
minis
and 
tim
any
n eac
n ea
me of
e o
extensions
d fou
d fou
s will 
will 
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 183 of 240
x A Safety Follow Up Visit should be scheduled 1 to 2 days after the subject has discontinued 
her iv LCM infusion.
Has been changed to:
x A Safety Follow-Up Visit should be scheduled 1 to 3 days after the subject has discontinued 
her iv LCM infusion.
Change #64
Section 10.1.7 Suspected transmission of an infectious agent via a medicinal product
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
Has been added
Change #65
Section 10.1.8 (previously Section 10.1.7) Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the Drug Accountability or Study Drug Dosing module of the CRF. Any SAE or 
nonserious AE associated with excessive dosing must be followed as any other SAE or 
nonserious AE. These events are only considered AEs or SAEs if there are associated clinical 
signs and symptoms or if the act of taking the excess medicine itself is an AE or SAE (eg, 
suicide attempt).
Has been changed to:
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the CRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
Change #66
Numbering for Section 10.1.8 (Safety signal detection) is now Section 10.1.9
Change #67
Section 10.2.1 Definition of serious adverse event, Bullet 5
REDACTED 
verd
ver
n the 
n the 
Study
Study
sive d
sive d
ly c
ly c
COPY 
rdos
rdo
This document
Num
Num
cannot 
ange 
nge 
mb
be used
ated 
ted 
AE (e
AE (e
to
her S
her 
cl
support 
d that 
d that
Any SA
Any S
SA
SA
any marketing 
dos
os
conside
onside
aking t
aking
authorization 
se of i
e of 
proto
proto
y Drug
Drug
sing
sing
application and any 
v
lopath
lopat
extensions
duc
duc
via a m
ia a m
ately,
tely,
virirus
us
or 
ctct
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 184 of 240
x Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
(Important medical events may include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse.)
Has been changed to:
x Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 10.3], allergic bronchospasm requiring intensive treatment in an emergency room or 
at home, blood dyscrasias that do not result in inpatient hospitalization, or the development 
of drug dependency or drug abuse.)
Change #68
Section 10.2.3 Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. 
Information on SAEs obtained after clinical database lock will be captured through the Drug 
Safety database without limitation of time.
Has been changed to:
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events are provided in Section 10.6.2.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety database without limitation of time.
Change #69
Section 10.3 Adverse events of special interest, last bullet point
x Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow-up
information should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.
REDACTED 
ed, 
ed, 
nifican
nifican
nical d
nical d
f time.
f time
COPY 
nts
nts
, has
ha
This document
P
cannot 
e #
 #
ion 10
on 10
Po
P
be 
#69
#69
used 
itit
to
thou
hou
support 
ies 
es
DI
DILI e
LI
obtai
obta
any
clinic
clini
s to A
to
marketing 
it has 
t has
ca
authorization 
as a sta
s a sta
nt, or 
nt, or 
databa
ataba
application and any 
n e
n e
on, or 
n, or
extensions
f the
f the
y’s La
y’s L
eme
eme
or
dize
diz
e o
variations 
ze t
ze
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 185 of 240
Has been added
Change #70
Section 10.5 Anticipated serious adverse events, first paragraph
The following list of anticipated SAEs has been identified, as these events are anticipated to 
occur in the epilepsy population at some frequency that is independent of drug exposure. This 
original list will remain in effect for the duration of the protocol.
Has been changed to:
The following list of anticipated SAEs is anticipated to occur in the epilepsy population at some 
frequency that is independent of drug exposure. 
Change #71
Section 10.6 Laboratory measurements, first paragraph
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study assessments (Section 5.2). Samples will be prepared 
and evaluated by the local laboratory as described in the laboratory manual.
Has been changed to:
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study assessments (Section 5.2). To minimize risk from 
blood loss associated with this study, local laboratory results obtained for routine diagnostic and 
medical care can be used whenever possible if collected no more than 24 hours prior to 
Screening/Baseline Visit. Use of the central or local laboratory is at the discretion of the 
investigator for all visits except the Final Visit. The central laboratory must be used for 
laboratory samples collected at the Final Visit. Samples will be prepared and evaluated by a 
central laboratory as described in the laboratory manual.
Change #72
Section 10.6.1 Liver function tests (now Section 10.6.2)
Transaminases (AST, ALT, or both) ≥3xULN but <5xULN, in the presence of total bilirubin 
≥2xULN, or transaminases (AST, ALT, or both) ≥5xULN will result in immediate 
discontinuation of LCM and withdrawal of the subject from the study. The LFTs will be repeated 
as soon as possible, and in no case more than 1 week later.
Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality (ie, 
transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring of LFTs 
should continue until resolved (ie, <3xULN or stable condition). The investigator is to decide 
whether or not to stop the study medication. 
REDACTED 
matolo
matolo
udy as
udy as
y, loca
y, loca
COPY
nts (S
nts (
d in the
d in th
This document
as so
s so
Tr
Tr
cannot
na
LN, or
N, or
ontin
ntin
oo
be
ases
ases
use
1
ed 
Liv
Liv
to support
ribed 
bed
any 
h
at the 
t the
ini
marketing
al lab
al lab
ossible 
ssibl
he centr
cen
he Fin
e Fi
authorization 
he la
e la
ogy an
ogy an
ssessm
sessm
bo
b
application 
al chem
al chem
ection
ction
labor
abo
and any extensions 
pulatio
ulatio
or variations 
his s 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 186 of 240
In all cases of transaminases (AST, ALT, or both) ≥3xULN, testing for hepatitis A, B, and C will 
be done.
Referral to a specialist (ie, hepatologist or gastroenterologist) is at the discretion of the 
investigator. This is recommended especially if the transaminase abnormalities >3xULN persist 
after discontinuation of the study medication.
Has been deleted (see Change #73).
Change #73
Numbering for Section 10.6.2 (Pregnancy testing) is now Section 10.6.1.
Change #74
Section 10.6.2 Liver function tests and evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 10.6.2.2 with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 10.3), and, if applicable, also reported as an 
SAE (see Section 10.2.1). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 10‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 10.6.2.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 10.6.2.4).
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be
recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.
REDACTED 
nostic 
nostic
on labo
on labo
st (if 
st (if 
COPY
itete
e crite
e crit
n 10.3
10.3
This document 
mos
os
2 lab
lab
rere
cannot
are d
re d
ral lab
al lab
st ra
t ra
be 
me
me
do
do
used
resul
resul
edic
edic
to
dy s
dy s
support 
itoring
toring
site
sit
any 
ve
ve
se of t
e of 
marketing
appli
appl
sulted b
sulted
isease.
sease
estig
esti
authorization
), an
), an
testin
testin
orator
rator
i
application 
ed in
d in
g detai
deta
d spon
spon
rion fo
ion f
d
and 
S
any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 187 of 240
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 188 of 240
Table 10-3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptoms
a of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULN
b
NA
Hepatology consult.
c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 10.6.2.3);
recommended to 
occur at the site 
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.
d
≥5xULN
NA
NA
≥3xULN
NA
Yes
Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
Baseline) 
and
<5xULN
<2xULN
No
Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 10.6.2.2).
Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).
≥5xULN 
(and ≥2x 
Baseline) 
<2xULN
No
Discussion with
Medical Monitor 
required.
Immediate, 
permanent IMP 
discontinuation.
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see 
Section 10.6.2.3).
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d
REDACT
allow
allow
CTED
Fu
Fu
ED 
ED
CT
COPY
nent, 
nent
ontinu
ontin
This document cannot 
ca
be used to 
o support
c
equired
quired
s
any 
on w
on 
al Mo
al M
m
wit
marketing 
ws 
ws 
uation
uation
g
m
authoriza
urther 
rther 
– imm
imm
didi
authorization 
uati
at
za
a
application
tes
te
A
MP 
MP 
tion.
ion
io
and
emis
mi
and ad
nd ad
any
epeat
epea
istry
str
extensions
Ev
Ev
o
Mus
Mus
te
or 
va
or variations 
on
ari
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 189 of 240
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
.c Details provided in Section 10.6.2.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
COPY 
This document cannot be used to support any marketing authorization application and any extensions
Medi
edica
ca
r asses
asses
nation
ation
or variations 
on
care pr
are p
al
nclud
clud
thereof. 
3


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 190 of 240
10.6.2.1
Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 10.6.2.3) and SAE report (if applicable).
10.6.2.2
Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 10‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
10.6.2.3
Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 10‒4 (laboratory measurements) and Table 10‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
REDACTED
n req
n req
may ha
may ha
and 
and Ta
T
ation 
ation 
histo
histo
COPY 
tox
o
alterna
altern
qu
This document cannot be used to support
so be
o be
ements
ment
any
tored
tored
e s
marketing 
co
co
ory of 
ory of
se addi
e add
authorization 
ativ
ati
uired f
red f
ave be
ve be
able
ble 1
ollec
ollec
application
r sho
r sho
d consi
cons
to a sui
o a su
ive e
ve
and
supple
uppl
ou
any
0‒3 f
extensions 
hepat
hepat
te in
e in
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 191 of 240
Table 10-4: PDILI laboratory measurements
Virology-
related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology
Eosinophil count
Urinalysis
Toxicology screen
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Additional
Prothrombin time/INRa
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of normal
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
REDACTED 
n f
uate p
uate p
ED
CT
ED
COPY 
Y
fract
frac
O
This document cannot be 
ng g
used 
g add
add
to
sitivi
sitiv
support 
l d
s with A
with 
tis sym
is sym
ty
any 
 IgM
IgM
drug
drug-i
marketing 
tin
ar
reatine 
eatine
M=
M
authorization 
tionate
ionat
n
possibl
ossibl
at
ho
a
application 
tio
pl
a
and
ve an
ve an
a
any 
d
a
extensions 
teroph
teroph
s
en
e
or 
o variations 
on
tio
va
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 192 of 240
Table 10-5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
x 
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
x 
Adverse reactions to drugs
x 
Allergies
x 
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)
x 
Recent travel 
x 
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
10.6.2.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 10‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilization is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Has been added
Change #75
Section 10.7.2 12-lead ECG, second paragraph
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 5 minutes prior to each recording and should be motionless during the 
recording, when feasible.
REDACTED 
ne
TE
on
onsult,
sult
AC
RE
COPY 
a with
a wit
PY
CO
This document 
ectc
Ca
Ca
cannot 
nge #
nge #
tion
tion
be used 
dded
ded
to
he h
he h
support 
r inj
inj
should
houl
etermin
termin
hep
hep
any 
n
njury
njur
marketing 
,
g
ke
artate am
rtate a
authorization 
h co
co
on
iza
if don
f do
th
application
ersens
ersens
te, abdo
e, ab
ompr
omp
pp
and
ase
se
LT ele
LT ele
a
any 
e to th
to th
extensions 
1 antit
antit
or variations 
on thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 193 of 240
Has been changed to:
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 3 minutes prior to each recording and should be motionless during the 
recording, when feasible.
Change #76
Section 10.7.4 Complete physical examination (now Physical examination)
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. Clinically significant physical examination findings 
are to be reported as AEs.
Has been changed to:
10.7.4.1
Complete physical examination
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. Clinically significant physical examination findings 
are to be reported as AEs.
10.7.4.2
Brief physical examination
The brief physical examination will includes a review of the following body systems: 
cardiovascular, pulmonary, abdominal (hepato-gastrointestinal), and dermatologic.
Change #77
Section 10.7.5 Assessment of suicidality, first paragraph
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5-1). All subjects who 
are ≥6 years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and 
will complete the “Since Last Visit” version at subsequent visits. If a subject becomes 6 years of 
age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first 
visit at which the subject is 6 years of age and the “Since Last Visit” version used at subsequent 
visits.
Has been changed to:
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5‒1). If the Screening 
and Baseline visit is on the same day, the C-SSRS does not need to be completed twice. The 
C-SSRS should be performed once per day during the Treatment Period. If Screening/Baseline 
and Visit 2 occur on the same day, 2 assessments should be completed with 1 predose and 1 after 
infusion.
REDACTED 
rev
ato
ato-ga
ga
COPY 
view
view
This document
Suici
uic
Me
Me
cannot 
been
been
cid
cid
be 
h t
sed
study
tudy
the 
the 
to
Sinc
Sin
support
on an
n an
the tab
he ta
ill com
ll com
ce
any
bjects
bject
and
nd
marketing 
dality, 
ality
ined s
ined 
authorization 
w of th
w of th
astroin
stroin
application 
ato
ant ph
ant ph
and 
ory 
ory 
any extensions 
nation
nation
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 194 of 240
All subjects who are ≥6 years of age will complete the “Baseline/Screening” version of the 
C-SSRS at Visit 1 and will complete the “Since Last Visit” version at subsequent visits. If a 
subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS 
should be used at the first visit at which the subject is 6 years of age and the “Since Last Visit” 
version used at subsequent visits.
Change #78
Section 10.7.6 Complete neurological examination (now Neurological examination)
The complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and 
sensation. Clinically significant neurological examination findings are to be reported as AEs.
Has been changed to:
10.7.6.1
Complete neurological examination
The complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and 
sensation. Clinically significant neurological examination findings are to be reported as AEs.
10.7.6.2
Brief neurological examination
The brief neurological examination will include selected assessment of mental status, cranial 
nerves, and coordination/cerebellar function.
Changes #79 to #80
Section 11.3.1 Case Report form completion, first and third paragraphs
First paragraph:
The study is performed using remote data capture (RDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the electronic CRFs and in all 
required reports.
Third paragraph:
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator.
Have been changed to:
First paragraph:
The study is performed using electronic data capture (EDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the electronic CRFs and in all 
required reports.
inclu
inclu
unctio
unctio
COPY
crcr
e), coo
e), coo
mina
mina
This document
Hav
Hav
F
cannot
tions 
ions 
sword/
word/
be
grap
ap
used 
s.
ph:
ph:
to
f ac
f ac
support 
ed usin
d usin
cu
any
form 
form
marketing 
on.
authorization
ation 
ation 
ude sel
de sel
n
application 
assessm
sess
al nerv
l nerv
rdinat
dina
fi
and any 
r
extensions
neuro
neur
otor sy
tor sy
functio
unctio
repo
epo
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 195 of 240
Third paragraph:
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will need to be reapproved by the investigator.
Change #81
Section 11.3.2 Database entry and reconciliation, first paragraph
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. As the study is performed using RDC, the data are entered into the electronic CRFs 
once and are subsequently verified.
Has been changed to:
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. As the study is performed using EDC, the data are entered into the electronic CRFs 
once and are subsequently verified.
Change #82
Section 12 STATISTICS, first paragraph
Selected disposition, exposure, demographic, and Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Descriptive statistics will 
be displayed to provide an overview of the Baseline characteristics, PK, and safety results.
Has been changed to:
Selected disposition, exposure, demographic, and Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Within cohort and infusion 
duration, presentation will include the IIL subject group and the OLL and RXL subject group.
Change #83
Section 12.1 Definition of analysis sets, first paragraph
The Safety Set (SS) will include subjects who received at least 1 dose of iv LCM. The SS will be 
the primary analysis set for the analysis of safety data.
Has been changed to:
The Safety Set iv (SS-iv) will include subjects who received at least 1 dose of iv LCM. The SS 
will be the primary analysis set for the analysis of safety data.
The Safety Set (SS) will include subjects who received at least 1 dose of LCM (oral or iv). 
Selected safety summaries will be presented for the SS.
REDACTED 
graph
graph
ogra
ogra
COPY 
ta
This document
the p
he p
H
cannot
n 12.1
n 12.1
e Safe
Saf
be
#83
#83
used 
3
to 
on w
n 
support
osure, 
sure,
ration,
ration
n will
wi
any 
d
marketing
aphic, 
aphic,
s overa
overa
ew of t
w of 
authorization application
mpute
pute
ancies 
ncies
entere
enter
and
to a v
o a v
er
any extensions
ning 
ng
consi
consi
ctroni
troni
or 
nic
ni
g ch
g ch
variations 
icic
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 196 of 240
Change #84
Section 12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected.
Has been changed to:
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected. Data will be presented by 
cohort and infusion duration, and the IIL and OLL and RXL groups of subjects in EP0060 will 
also be presented.
Change #85
Section 12.4 Planned safety and other analyses (now titled Planned safety analyses), first 
paragraph
Safety analyses will be presented by cohort and infusion duration, cohorts overall, and all 
subjects overall. Within cohort and infusion duration, the OLL and RxL groups of subjects and 
the IIL subject group will also be presented.
Has been added
Change #86
Section 12.5 Handling of protocol deviations 
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary safety outcomes (if applicable) for an 
individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol-specific document. Important protocol deviations will be 
reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prior to database lock to confirm exclusion from 
analysis sets.
Has been changed to:
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary safety outcomes for an individual subject. The criteria for 
identifying important protocol deviations will be defined within the appropriate protocol-specific 
document. Important protocol deviations will be reviewed as part of the ongoing data cleaning 
process and data evaluation. All important deviations will be identified and documented prior to 
database lock to confirm exclusion from analysis sets.
REDACTED COPY
sion 
sion
ion, th
ion, 
This document 
mean
ea
iden
iden
d
cannot 
en
en
ortant 
rtant
anin
nin
be 
n c
n c
used
be id
e id
to
f the
the
den
support 
y co
c
riteria 
iteria
e protoc
proto
e on
e o
any
re d
re d
ondu
ond
marketing 
ol devia
 devi
dev
de
authorization 
he O
he 
application
anne
anne
duration
uratio
OLL
OL
and 
d
any extensions
po
resen
esen
n EP0
n EP0
or
ints
int
variations 
mite
mite
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 197 of 240
Change #87
Section 12.7 Planned interim analysis and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 10 subjects in each cohort. 
Has been changed to:
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 10 subjects in Cohort 2. 
Change #88
Section 12.7.2 Data Monitoring Committee. Paragraph 2 through end of section
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
REDACTED 
ubjects
ubjects
o long
o long
subjec
subjec
nge
nge
COPY
enr
n
ew of 
ew of
will ma
ill ma
This document
x
O
cannot
THER
HER
infusi
infusi
be
nd C
nd C
used
n of 
of 
ut on 
ut on 
Co
C
to 
f th
f th
support 
ubjec
bjec
Cohort 
ohor
es whe
s wh
any
be 
be
ctst
marketing 
ctsts
er than 
r than
ini
in
authorization
ak
ake r
e r
s will 
will
ger tha
ger tha
s wi
wi
application 
v L
er poss
er pos
ment in
ment i
the saf
he sa
rec
and
17 ye
7 y
LCM
LCM
any
of s
of
year
ea
extensions 
se
or variations 
tion o
ion o
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 198 of 240
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
Has been changed to:
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion durations as follows:
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the Investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the Investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
REDACTED
0 minu
0 min
cts in C
cts in
 Bas
 Bas
COPY 
ubje
ubj
ast 20 
ast 20
f age
f age
This document
x
F
cannot 
nfu
fu
OR
OR
be
app
pp
usio
usi
used
m an i
an i
pro
pro
to
utes 
utes
support
t no lo
no l
reased 
eased
bu
b
any 
llow
llow
marketing
sed on
ed on
0 a
0 addi
dd
authorization
e. For
e. For
utes bu
utes b
Cohor
Coho
application 
s ≥8 to
≥8 t
subjec
ubje
and 
sub
ub
any 
bjec
bje
extensions 
arget i
rget i
or variations 
et t 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 199 of 240
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the Investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the Investigator
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
Change #89
Section 12.8 Determination of sample size
Approximately 75 subjects will be enrolled, which includes up to 3 cohorts of at least 
20 subjects. No formal sample size calculation has been performed. The sample size was deemed 
clinically appropriate for the evaluation of safety, tolerability, and PK of iv LCM administration 
in pediatric subjects with epilepsy.
Has been changed to:
Approximately 75 subjects will be enrolled, which includes up to 2 cohorts of at least 40 subjects 
for Cohort 1 and at least 20 subjects for Cohort 2. No formal sample size calculation has been 
performed. The sample size was deemed clinically appropriate for the evaluation of safety, 
tolerability, and PK of iv LCM administration in pediatric subjects with epilepsy. 
Changes #90 and #91
Section 15 References
Dichek B. Epilepsy: an ancient ailment that still eludes a cure. Scrip Magazine. 1999;Feb:9-11.
Has been deleted and 
Arkilo D, Gustafson M, Ritter FJ. Clinical experience of intravenous lacosamide in infants and 
young children. Eur J Paediatr Neurol. 2016;20(2):212-7.
CDC growth curves. Girls: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c022.pdf. 
Boys: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c021.pdf. 2000. 
REDACTED 
 whic
whic
lation
lation
on of s
on of 
COPY 
This document 
as
a
Ark
Ark
cannot 
k B. E
k B. E
s be
s b
be
Re
Re
used
0 an
0 an
f
to support
ze wa
e wa
iv LCM
v LC
any 
be
ubject
bject
as
marketing 
e enr
e en
authorization 
ch incl
h incl
n has b
has b
afety
afety
application and
iatric
atric
any 
s
extensions 
th a ta
h a ta
or
ben
be
or variations 
fit
fit
tio
ene
ene
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 200 of 240
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epilepsy: A systematic review and meta-analysis. Neurology. 2011; 77(10): 1005–12.
Have been added
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 201 of 240
16.3
Protocol Amendment 3
Rationale for the amendment
The primary purpose of this substantial amendment is to lower the age of subjects from ≥4 years 
to ≥1 month in an effort to maximize the subject pool in the evaluation of iv LCM, to include age 
stratification within Cohort 2 to be most informative with regard to safety and PK, and to 
increase study enrollment from 75 to 100 subjects to reflect the inclusion of subjects down to 1 
month of age. Since initial conception of the study, substantial new safety and efficacy 
information on the lowest age group (≥1 month to <4 years of age) has been accumulated, 
reported, and published. The available safety information consists of postmarketing data (n=27 
patient cases), data from internal studies (n=15 patient cases), as well as from two published 
reports (n=15 and n=22 patient cases) (Arkilo et al, 2016; Welsh et al, 2017). These reports cover 
the age range from ≥1 month to <4 years of age and also cover the clinical spectrum from an 
open-label extension study with oral treatment to critically care patients receiving iv treatment. 
This data points to no specific risks in the age group after administration of Vimpat® and UCB, 
therefore, believes it is justified to open Cohort 2 to the lowest age group in agreement with the 
DMC outcome on safety of Cohort 1.
Additional changes include the following:
x Study contact information has been updated as applicable.
x Additional region to maximize enrollment has been included.
x Number of subjects included in the DMC process in Cohort 2 has been modified.
x The timing of the End-of-Study/Final Visit has been clarified.
x Wording regarding the taper of LCM for ILL subjects who discontinue use has been 
removed.
x US and EU regulatory authority approvals of LCM have been updated.
x Pharmacokinetic variables have been further defined as “Other”.
x Bicarbonate testing is optional for subjects weighing less than 8kg.
x New inclusion criterion has been added for all subjects.
x New exclusion criterion has been added for RxL and ILL subjects.
x Oral LCM should be administered approximately 12 hours after the final iv LCM infusion
has been clarified.
x PDILI language has been updated to most current UCB template.
x List of hematology PDILI laboratory measurements have been updated.
x List of chemistry PDILI laboratory measurements have been updated.
x Clarification has been added regarding the reading of 12-lead ECGs. 
x Definitions of analysis sets have been modified.
x Data presentations for planned pharmacokinetic and safety analyses have been revised.
REDACTED 
ha
MC pro
MC pro
nal Vi
nal Vi
LCM
LCM
COPY
applic
ppli
as bee
s bee
This document
x
L
x
cannot 
been
ee
PDILI
PDIL
be
CM 
M 
n c
n c
used
ion c
on c
sh
sh
to 
rit
support 
e
is optio
s opti
terio
erio
any 
s have
hav
marketing 
M for
M for I
ty app
ty ap
authorization
en inc
en inc
ocess i
cess i
isit ha
sit ha
application 
able.
able.
and
roup 
oup 
any
ceiv
ei
of Vi
of V
extensions 
ata 
publis
publis
hese
ese rer
ectrum
ctrum
ivin
vin
or
,
(n=
(n
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 202 of 240
x Minor typographical errors and clarifications have been made and are not listed in the 
summary of changes.
Modifications and changes
Global changes
The following changes have been made throughout the protocol:
x Text has been modified to lower the age of subject enrollment to ≥1 month of age.
x Approximately 100 subjects will be included in EP0060.
x Asia with the possibility of other regions has been added to study regions.
x Age stratification has been included within Cohort 2. Every attempt will be made to enroll 20 
subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to 
<2 years of age.
x Number of subjects in the DMC process in Cohort 2 has been revised.
 For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a 
duration of 30 minutes but no longer than 60 minutes whenever possible.
 After completion of the first 20 subjects in Cohort 2, the DMC will review the available 
safety and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC 
will make recommendations as follows: 
◦ 
EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a 
target infusion duration of 15 minutes but no longer than 30 minutes only in subjects 
who would directly benefit from an increased infusion rate, in the opinion of the 
investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion, in 
the opinion of the investigator, cannot receive the faster infusion. These subjects 
should receive an infusion of 30 minutes but no longer than 60 minutes. 
◦ 
OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes. 
◦ 
OR Cohort 2 should be stopped.
x The Final Visit can be conducted on the same day as the last dose of iv LCM if time permits 
to complete all assessments. Otherwise, the Final Visit should be conducted the day 
following the last dose of iv LCM.
x Text has been amended to include US and EU regulatory authority approvals of LCM for 
pediatric patients down to 4 years of age. 
 In the US, oral tablets and oral solution (syrup) of LCM are indicated for the treatment of 
partial-onset seizures in patients 4 years of age and older. As the safety of LCM injection 
for iv use has not been established in pediatric patients, LCM injection for iv use at 
infusion durations of 15 to 60 minutes is indicated for the treatment of partial-onset 
cts in
cts in
ohort 
ohort 
follow
follow
30 ad
30 ad
COPY
Coho
Coho
60 mi
60 m
This document
x
T
cannot
omp
omp
follow
ollow
T
be
nal V
nal V
l
used 
R Coho
Coho
V
to
n dur
du
support
an in
an in
ximate
imate
urat
ra
any 
s w
s w
invest
nves
f
marketing
dditio
dditio
f 15 mi
f 15 m
nefit
efit fro
fr
ma
who 
who
authorization
minut
nu
Coho
Coho
1 and
1 and
ws: 
s: 
application
n revi
n rev
o <8 ye
<8 y
rt 2, iv 
2, iv
utes
utes
and 
i
any 
l b
12 su
12 su
extensions 
be m
be m
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 203 of 240
seizures only in patients 17 years of age and older as an alternative when oral 
administration is temporarily not feasible. 
 Additionally, LCM has been approved in the EU (oral tablets, oral solution [syrup], and 
solution for iv infusion), as monotherapy and adjunctive therapy in the treatment of 
partial-onset seizures with or without secondary generalization in patients 4 years of age 
and older. The iv formulation at infusion durations of 15 to 60 minutes is approved as an 
alternative for patients when oral administration is temporarily not feasible.
x The Inclusion Criterion 8 has been added to enroll patients who weigh ≥4kg.
x The Exclusion Criterion 20a has been added to clarify RxL and IIL subject must not be 
currently participating in another study of IMP. 
x PDILI language has been modified with current UCB language to clarify which laboratory 
values IMP must be immediately and permanently discontinued.
x Text has been amended to clarify OLL subjects will not have a medical history performed in 
EP0060.
x The following changes were made to PDILI laboratory measurements:
 Hematocrit, hemoglobin, platelet count, RBC count, WBC count, and WBC differential 
count have replaced eosinophil count as hematology measurements. 
 ALT, AST, ALP, GGT, and albumin have been added to chemistry measurements.
x 12-lead ECG will be read by a central reader in addition to the initial review.
x Analyis sets have been defined as follows:
 The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study 
drug LCM (oral and/or iv). Selected safety summaries will be presented for the SS.
 The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of 
EP0060 study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of 
safety data.
 The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS-iv
having provided at least 1 measurable postdose plasma sample (with recorded sampling 
time) on at least 1 study day with documented iv LCM intake times and without 
important protocol deviations impacting the interpretability of the PK analysis.
Specific changes
Change #1
Title page
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥4 TO <17 YEARS 
OF AGE) WITH EPILEPSY
REDACTED
ave 
ave
reade
reade
follow
follo
ude
ud
COPY 
cou
co
matol
matol
e be
e b
This document
Cha
Cha
T
cannot 
ecific
cific
be 
ort
used
n at le
at le
tant p
ant 
to
vide
ide
support 
okineti
kineti
d a
d
any
) w
) w
LCM
LCM
marketing 
de subje
e subje
Selecte
elect
will 
will
authorization 
lo
een ad
een a
er in a
er in a
ws:s:
application 
asurem
surem
t, WBC
 WB
ogy m
gy m
and
dica
dic
any 
cal h
al
extensions
not b
not 
which
which
or 
be
b
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 204 of 240
Has been changed to:
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥1 MONTH TO <17 
YEARS OF AGE) WITH EPILEPSY
Change #2
STUDY CONTACT INFORMATION
Sponsor Study Physician
Name:
, MD
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Sponsor Study Physician
Name:
 MD
Address:
UCB BIOSCIENCES, GmbH.
Alfred-Nobel-Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Mobile:
Change #3
STUDY CONTACT INFORMATION
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
REDACTED 
D
TE
COPY
27
2
PY
C
This document 
STU
STU
cannot 
ang
ang
be 
il
be used 
le:e:
ed to 
o support 
frfr
40789
4078
G
su
s
any
BIO
BIO
ed
ed-N
mar
OSC
OS
ma keting 
eti
arke
authorization 
tio
riz
application 
09, US
9, US
app
and 
rier)
ier)
any extensions 
en
e
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 205 of 240
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Project Manager
Name:
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Not Applicable
Change #4
STUDY CONTACT INFORMATION
Clinical Trial Biostatistician
Name:
 MPH 
Address:
UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Trial Biostatistician
Name:
Address:
UCB BIOSCIENCES, GmbH.
REDACTED 
ED
O
COPY 
Y
CO
This document 
H
cannot 
Pho
Pho
t
ot
an
an
an
an
be used to support 
UCB
UC
8
rt
su
rt any y 
any marketing 
ON
authorization 
n
za
application 
, USA
 USA
pli
and 
er)r)
any extensions 
sio
xte
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 206 of 240
Alfred-Nobel-Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Fax:
Not Applicable
Change #5
Section 1 SUMMARY
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥4 to <17 years of 
age with epilepsy. Investigation the use of iv LCM in pediatric subjects with epilepsy ≥1 month 
to <4 years of age is planned. 
EP0060 will include approximately 75 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other 
pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2.
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
REDACTED 
urren
urrentltl
T) as a
) as 
ects: n
ects: n
60
60
COPY
eceiv
ce
bel lon
el lon
This document cannot 
n

be
oral
ora
nu
nu
used
rgo a
go 
re faci
e faci
l a
l a
to 
LCM
C
a p
a p
support
al LC
l L
ed adm
d adm
CM ad
M a
any
fol
fo
LCM
LC
marketing
not c
ot c
0. Initia
. Initia
ollow
ollo
authorization 
ng
ly rece
y rece
adjun
djun
cu
cu
application
bjec
jec
ng oral
ng ora
g-term
term
and 
cts
cts
any
with e
with e
extensions 
tolera
tolera
ts ≥4
s ≥4
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 207 of 240
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥4 to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including at least 20 subjects who are ≥4 to <8 years. Within Cohort 1, at least 
20 subjects will be ≥12 to <17 years of age and at least 20 subjects will be ≥8 to <12 years of 
age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each 
cohort to make the following recommendations: the progression of the current cohort, including 
iv infusion durations to be evaluated, and progression to initiate enrollment in the next cohort 
(Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age (as detailed 
further below). 
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
REDACTED
:
ogress
ogres
ation o
tion o
ng st
ng st
COPY 
st 2
st 
eview 
view 
the p
the p
This document cannot 
Add
Ad
be
End
End
used 
d-of
of-f S
to
ctive
tive
support 
d
need a
need 
e ad
e a
any
seli
sel
marketing
tudy p
tudy p
line 
line
authorization
th
progre
progre
sion to
ion to
of iv L
of iv L
application
who a
who 
s. With
Wit
subject
ubjec
he saf
he sa
and 
lity 
ty
ed to 
d to 
any 
y of i
y of
extensions
th
s will 
s will 
roxima
oxima
if dee
f dee
or 
h iv
h iv
variations 
ment
ment
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 208 of 240
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses (over 
approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day 
(subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose if the last LCM infusion was performed 
in the morning, and time permits completion of assessments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LCM after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the 
Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
REDACTED
will b
will 
rform
rform
Visit 
Visit
od an
od an
COPY
y
ant fo
ant f
This document 
The 
The
cannot
an
an
w-up T
up T
M tre
M tre
be 
on
d I
d
used
prov
prov
n and
and
to
ll be
ll b
i
support 
y
s. 
ects w
ects w
e c
any
las
la
follow
follo
marketing
and av
nd av
day as t
ay as 
comple
ompl
ast d
ast
authorization 
be obt
be obt
med.
med.
will d
will d
application
For 
or 
ects we
cts w
jects w
ects w
or at lea
r at le
and
n this
this
r IIL
IIL
any 
jec
je
ral LC
ral L
s
extensions
re tha
e tha
ur int
ur int
sec
ecutiv
uti
ects,
cts
or variations 
e
g
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 209 of 240
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue antiepileptic drug (AED) treatment at the discretion of the treating 
physician. For RxL and IIL subjects who will discontinue use of LCM, the subject should 
complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper 
regimen or taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
bjects
bjects
o longe
longe
nfusio
nfusio
m a 15
m a 15
ast
as
COPY
eview
evie
This document
recom
ecom
x
cannot 
comp
comp
toler
tole
be
n 60 
n 60 
used
t leas
leas
bject
bject
to 
oh
t
support 
stoppe
stopp
hort 2
hort 2
any
ona
on
t no lo
no l
marketing
5 to 
to
terer infu
infu
0 minu
0 min
nal su
al s
authorization 
will b
will b
er tha
er tha
on rate
n rate
o 3
o 3
application 
MC will
C wi
w, the D
 the 
and 
sub
ub
than 
than 
any
≥12 t
≥12 
bject
bje
extensions
oul
es tape
es tape
of ag
of ag
t
or 
ld d 
variations 
ng g 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 210 of 240
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped, 
x AND whether to initiate the assessment of safety in younger pediatric subjects (≥1 month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥1 month to <17 
years of age with epilepsy. Investigation the use of iv LCM in pediatric subjects with epilepsy ≥1 
month to <4 years of age is planned.
EP0060 will include approximately 100 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other 
pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2.
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
REDACTED 
curren
curre
PAT) a
AT) 
cts
ct
COPY 
y receiv
recei
abel l
abel l
This document cannot 
o
be
care
are
ora
or
used 
c L
dergo 
ergo 
re f
e f
to
ne
LCM
LCM
support 
oral L
oral L
eed ad
ed ad
any 
as fol
as fo
marketing 
s: not c
: not c
060. In
60. I
authorization 
long
long
ently r
ntly r
s adju
 adju
application 
g subje
subj
ving o
ing o
and 
c su
su
d any
ects 
ects
ubje
ubj
a
extensions 
nd tol
d tol
≥
or 
ated
ate
variations 
tudy i
udy i
ed
ed
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 211 of 240
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia. Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥1 month to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including approximately 44 subjects who are ≥1 month to <8 years. Within Cohort 1, 
at least 20 subjects will be ≥12 to <17 years of age and at least 20 subjects will be ≥8 to <12 
years of age. Within Cohort 2, every attempt will be made to enroll 20 subjects ≥4 to <8 
years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
A Data Monitoring Committee (DMC) will review the safety and tolerability data for each 
cohort to make the following recommendations: the progression of the current cohort, including 
iv infusion durations to be evaluated, and progression to initiate enrollment in the next cohort 
(Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age (as detailed 
further below).
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
REDACTED 
e,
l revie
l revie
dation
dation
and p
and p
evalu
evalu
R
COPY 
nd a
nd 
ll be m
l be m
and
and
This document cannot

E
be 
(2)
2)
E
used
Clin
linici
) El
El
to 
nt 
support 
d/or Ba
d/or B
Perio
Perio
any marketing
p
uation
uatio
ng
wing s
wing 
authorization
m
d 12 s
d 12 s
ew the
w th
ns: the
s: the
ogre
ogre
application
who a
who 
onth
nth to
east 20
ast 2
made t
ade t
and 
lity 
ty
s pla
s pla
any 
y of i
y of
extensions
ith
s will 
s will 
roxima
oxima
added
added
or 
h iv
h iv
variations 
ment
ment
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 212 of 240
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses [over 
approximately 24 hours]) for elective administration. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg bid (subjects weighing <50kg) or 50mg bid (subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg), or
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose of iv LCM if the last LCM infusion was 
performed in the morning, and time permits to complete all assessments. Otherwise, the Final 
Visit should be conducted the day following the last dose of iv LCM after completion of or 
withdrawal from the Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 
to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
REDACTED
hould
hould
ample
ample
be p
be p
COPY 
er i
er
g) or 5
) or 5
2mg/
2mg/
This document 
or R
or R
follo
follo
L
cannot
wil
wil
infus
infus
Rx
Rx
be 
Visi
is
ill b
ill
used 
IL sub
L sub
sit w
it w
to
Fina
Fina
su
Treatm
reatm
pport
and
nd
t
ed the d
d the
reatm
eatm
up
al V
l
any
same
ame
d tim
tim
marketing
per
perfor
for
al Visit
l Vis
eriod
riod
ma
e d
authorization
50
/kg/da
/kg/da
rema
rema
s will
will
application
dose o
ose o
mitted i
itted 
lower. 
ower
0mg
mg b
and 
o 2 2 
RxL s
RxL s
f
any 
y 12
12-
con
co
extensions
t s
creenin
reeni
. If m
If m
h
or
s ora
or
variations 
od d 
his tim
is tim
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 213 of 240
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue antiepileptic drug (AED) treatment at the discretion of the treating 
physician. For RxL and IIL subjects who will discontinue use of LCM, the subject should 
complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper 
regimen or taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would
REDACTED
ohort
ohor
d on th
d on th
tiona
tiona
COPY
es bu
es bu
This document
of 30
of 30
A
cannot 
ohort 
ohort
eive i
ive 
be
wheth
whet
used 
should
hould
to
minu
min
support
ger th
ger th
y 30 ad
30 ad
utet
any
fro
fr
ve the
e the
marketing
al subj
al sub
ut no l
ut no 
sed inf
ed in
rom 
rom
authorization 
1, the
1, the
this re
his re
application 
<17
1
ts will 
s wil
he first
e firs
t no lon
no lo
and 
17 y
7 y
any
bel s
bel 
ny extensions 
nt 
f the t
f the t
ubjec
ubjec
t
or 
inin
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 214 of 240
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped.
x AND whether to initiate the assessment of safety in younger pediatric subjects (≥1 month to 
<4 years of age). 
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Change #6
Section 2 INTRODUCTION, sixth paragraph
In the US, the iv formulation of LCM is approved in patients ≥17 years of age at a maximum 
dose of 400mg/day as monotherapy and adjunctive therapy in the treatment of partial onset 
seizures in subjects with epilepsy when oral administration is temporarily not feasible. In EU, the 
iv formulation is approved in patients ≥16 years at a maximum dose of 600mg/day as 
monotherapy (EU CHMP positive opinion received on 11 Nov 2016) and at a maximum dose of 
400mg/day as adjunctive therapy in the treatment of partial onset seizures in subjects with 
epilepsy when oral administration is temporarily not feasible. Intravenous LCM is approved in 
patients ≥16 years of age and for infusion durations of 15 to 60 minutes depending on the 
country-specific labeling. 
Has been changed to:
In the US, oral tablets and oral solution (syrup) of LCM are indicated for the treatment of 
partial-onset seizures in patients 4 years of age and older. As the safety of LCM injection 
for iv use has not been established in pediatric patients, LCM injection for iv use at
infusion durations of 15 to 60 minutes is indicated for the treatment of partial-onset 
seizures only in patients 17 years of age and older as an alternative when oral administration is 
temporarily not feasible. 
Additionally, LCM has been approved in the EU (oral tablets, oral solution [syrup], and 
solution for iv infusion), as monotherapy and adjunctive therapy in the treatment of 
partial-onset seizures with or without secondary generalization in patients 4 years of age 
and older. The iv formulation at infusion durations of 15 to 60 minutes is approved as an 
alternative for patients when oral administration is temporarily not feasible.
REDACTED 
ctiv
ctiv
 admi
admi
6 year
6 yea
nion r
nion 
the t
the t
COPY 
d in pa
d in p
ve t
ve
This document
olut
lut
part
par
a
cannot
rily 
ily 
ditiona
tiona
utio
tio
be
nly y i
y no
y no
used 
ot b
t b
ations 
tions 
in p
in
to 
res
been
bee
support 
and o
and o
s in p
s in p
any marketing
treatm
treatm
tempor
empo
nfusion
fusio
authorization 
atien
tie
therap
herap
inistra
nistra
rs at a
rs at a
eceiv
eceiv
application 
ents 
nts
and any 
nd
nd
extensions 
s to as
 to as
eter fo
eter f
d th
d th
or 
ont
on
r variations 
nth
nth
v
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 215 of 240
Change #7
Section 2 INTRODUCTION, ninth paragraph
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment 
initiation in pediatric subjects ≥4 to <17 years with epilepsy.
Has been changed to:
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment 
initiation in pediatric subjects ≥1 month to <17 years with epilepsy.
Change #8
Section 3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy. An additional objective is to 
evaluate the PK of iv LCM in pediatric subjects with epilepsy. 
Has been changed to:
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy. An additional objective is 
to evaluate the PK of iv LCM in pediatric subjects with epilepsy. 
Change #9
Section 4.3 Pharmacokinetic variable(s)
4.3 Pharmacokinetic variable(s)
The PK variables will include plasma concentration of LCM and its main metabolite, 
SPM 12809.
Has be changed to:
4.3 Other pharmacokinetic variable(s)
The other PK variables will include plasma concentration of LCM and its main metabolite, 
SPM 12809.
Change #10
Section 5.1 Study description
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥4 to <17 years of age with epilepsy. EP0060 will include 
approximately 75 subjects. The following subjects will be eligible for enrollment in EP0060:
REDACTED 
ate 
ate 
o <17 
o <17
c subje
c subj
COPY 
e the
the
This document 
Cha
Cha
cannot
2809
809
be
PK v
PK 
used 
armac
rma
to
d to
d t
support
lude p
ude p
o:
any 
e(s)
e(s)
marketing 
riable(
iabl
authorization 
e safet
safe
 years
years
ects w
ects w
application 
ler
An add
An ad
y.y.
and 
rabil
abil
any extensions 
men
or 
nt 
nt 
variations 
he e
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 216 of 240
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescribed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM 
is 10.
 Elective administration: subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40 subjects who are ≥8 to <17 years and Cohort 2 including at least 20 subjects who are ≥4 to 
<8 years. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age and at least 
20 subjects will be ≥8 to <12 years of age. A DMC will review the safety and tolerability data for 
each cohort to make the following recommendations: the progression of the current cohort, 
including iv infusion durations to be evaluated, and progression to initiate enrollment in the next 
REDACTED
on (II
on (I
subje
subj
an EM
an EM
ly ap
ly ap
COPY
facili
facil
This document 
ece
EP0
EP0
4
cannot
o co
co
in No
n No
essa
essa
be
r co
r co
ont
on
used
e Rx
Rx
rmul
mul
om
om
to 
stu
RxL
xL
support
ber o
er o
ring int
ng i
tudy 
udy
any
nt usi
nt us
of i
of
marketing
U
pprop
pprop
s, the m
, the m
n: sub
n: sub
authorization 
L subj
L subj
ects no
cts n
U or
U or
application 
ral LCM
al LC
ng tube
ng tub
ty. In th
y. In t
and
num
um
any 
oral
ora
mber
mbe
extensions 
LCM 
LCM 
be) wh
be) wh
ility, 
lity, 
l
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 217 of 240
cohort (Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age. 
Details regarding the DMC are provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily 
dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day 
REDACTED 
not co
not co
one Co
one Co
COPY 
ncurre
ncurre
This documen
up to
p to
(ov
(ov
d
cannot
g the T
the T
nfusion
fusion
o 1
o
be used
labe
abe
regim
egim
to 
s. F
s. F
el s
el s
support 
Final
Fina
red for
ed fo
For O
For
any
o allo
o allo
al V
l
marketing 
on
eline, T
line, 
s 1 iv 
1 iv
authorization
ent w
ent w
ontinu
ontinu
ntact
tact
application 
 to con
to co
witi
and any extensions 
utive 
utive 
or
up
up
variations 
up to
p to
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 218 of 240
(subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead 
ECG, clinical hematology and chemistry, and Columbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose if the last LCM infusion was performed 
in the morning, and time permits completion of assessments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LCM after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the 
Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL and 
IIL subjects who directly enrolled and will discontinue use of LCM, the subject should complete 
the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen or 
taper at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
REDACTED 
ws:
ws:
up w
up w
COPY
M tre
M tr
days (±
days (
This document
the E
he E
tap
tap
cannot 
cts sho
ts sh
subje
subje
EP
EP
be
SP8
SP8
used 
mate
at
bjec
bject
4
to
tely 
tely
support 
y
he RxL
e Rx
to con
to con
any 
s
marketing 
will res
will re
treatme
reatm
accor
acco
authorization
±2 d
2 d
application
f LCM
LC
nd Visi
d Vis
atment 
men
day
day
and 
M tr
M tr
Visit o
isit o
M
any 
reatm
rea
extensions
er
Visit sh
isit s
drawa
drawa
to 3 da
o 3 d
or
rform
for
variations 
on or 
on or 
e Fina
Fin
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 219 of 240
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥1 month to <17 years of age with epilepsy. EP0060 will 
ohort
ohor
ohort 2
hort 2
tiona
tiona
COPY
infus
infus
This document
safet
safet
def
de
cannot
years
years
s des
s des
be
wheth
whet
used 
t 2 sho
2 sho
to
minu
min
support
ger th
er th
y 15 ad
15 ad
utet
any 
fro
fr
ve the 
e the
marketing
al subj
al sub
ut no lo
ut no 
sed inf
ed in
from 
rom
authorization 
2, the
2, the
2. Bas
. Bas
j
application 
be enro
be enr
ed over
d ove
and any extensions
n infus
n infu
th a ta
h a ta
or 
j
variations 
ld d 
ri
ects
ects
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 220 of 240
include approximately 100 subjects. The following subjects will be eligible for enrollment in 
EP0060:
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants 
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescribed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM 
is 10.
 Elective administration: subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and oral administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible subjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia. Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40 subjects who are ≥8 to <17 years and Cohort 2 including approximately 44 subjects who are 
≥1 month to <8 years. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age and 
at least 20 subjects will be ≥8 to <12 years of age. Within Cohort 2, every attempt will be 
REDACTED
thcar
thcar
2.2.
initiat
initia
ion
io
COPY 
ntly tak
tly tak
on by
on by
This document
optio
ptio
site
site
n
cannot
LCM 
LCM 
M. Aft
Af
on
on
be
i
om th
om t
used
cts en
s en
n tha
n tha
to 
m 
support
nistrat
istra
treatme
eatm
num
num
any
ubjec
ubje
i
marketing 
n: subj
n: subj
t an EM
an E
cally a
ally 
t
authorization
y feed
y feed
e facil
e facil
ion (
on (
application 
iate
ate
imum n
mum
ing or
ng o
i
and
care 
are 
e an
e an
any 
d o
d 
ing tu
ng tu
faf
extensions 
oral
ora
or
ect
ect
variations 
tsts
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 221 of 240
made to enroll 20 subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 
subjects ≥1 month to <2 years of age.
A DMC will review the safety and tolerability data for each cohort to make the following 
recommendations: the progression of the current cohort, including iv infusion durations to be 
evaluated, and progression to initiate enrollment in the next cohort (Cohort 2) or separate study 
for the evaluation of iv LCM in children <4 years of age. Details regarding the DMC are 
provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x 
Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ 
Transition Visit, which can be concurrent with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ 
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatment Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessments or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice daily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily 
REDACTED 
ws:
ws:
re elig
re elig
h
COPY 
 to 3 
to 3
This documen
from
om
LCM
LC
P
cannot
her tim
er tim
last u
last u
m th
m t
be
r co
r com
used
bject
ect
s) are 
) are
mp
to 
Sc
Sc
t o
t o
support 
dy/Te
y/T
CM).
M).
creen
cree
any
s wh
s w
Tele
e
marketing 
h can be
can b
it)
who
who
authorization
days
days
gible a
ible a
application
: up 
up 
s)
and 
tot
any
p to 1
p to 
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 222 of 240
dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg bid (subjects weighing <50kg) or 50mg bid (subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg), or
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase.
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead 
ECG, clinical hematology and chemistry, and Columbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose of iv LCM if the last LCM infusion was 
performed in the morning, and time permits to complete all assessments. Otherwise, the Final 
Visit should be conducted the day following the last dose of iv LCM after completion of or 
withdrawal from the Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 
to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume participation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL and 
IIL subjects who directly enrolled and will discontinue use of LCM, the subject should complete 
the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen or 
taper at the discretion of the treating physician.
REDACTED
o allo
o allo
n Visit
Visit
t cont
t con
uld o
uld o
COPY 
ose to
ose to
ent w
ent w
This document cannot
t
x
A
be
Sub
Sub
h
used 
ximate
imate
to 
pen
en-
support 
y
he OLL
e OL
me ora
me or
lab
l
any 
s:s:
marketing
occur 
ccur 
e as fo
as f
authorization
o c
with t
with t
w con
w con
it in E
it in E
inue L
nue L
application 
CM 
M 
elepho
lepho
contin
conti
h
and
ents. 
nts. 
M aft
aft
a
any 
se
se
last L
last 
any
O
extensions
ale [C
e [C
ast LC
st LC
essm
essm
or 
2-lel
C
variations 
ead
ea
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 223 of 240
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped. 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
REDACTED 
≥1 mo
1 mo
ts in C
ts in C
minut
minut
COPY 
This document
O
x
m
cannot
appr
ppr
uration
ratio
OR
OR
be 
prox
prox
used
, can
can
s but
s but
to
rect
rect
support 
y 30
3
15 min
5 mi
om an 
m an 
tly
tl
any 
0 ad
ad
marketing
tes w
es 
cts in C
cts in 
 and C
and C
authorization 
onth
nth
Cohor
ohor
s wh
wh
application 
n Coho
Coh
and 
uld 
ld
any
pinio
pinio
d rec
re
extensions 
th a ta
h a ta
ects wh
cts w
ten
estiga
stiga
or variations 
datio
datio
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 224 of 240
Change #11
Section 5.1.2 Planned number of subjects and site(s)
Approximately 75 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12 to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in either of the 2 cohorts.
Has been changed to:
Approximately 100 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12 to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: every attempt will be made to enroll 20 subjects ≥4 to <8 years of age, 12 
subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
The remaining subjects may be enrolled in either of the 2 cohorts.
Change #12
Section 5.1.3 Anticipated regions and countries
The study will be conducted at selected sites from North America and Europe. Additional sites 
may be added as deemed necessary.
Has been changed to:
The study will be conducted at selected sites from North America, Europe, and Asia. Additional 
sites or regions may be added as deemed necessary.
Change #13
Table 5–1 Schedule of study assessments, Clinical chemistry and hematology, Unscheduled 
Visit column
Clinical chemistry and 
hematologyp
X
Xq
X
Has been changed to:
Clinical chemistry and 
hematologyp,q
X
Xr
X
REDACTED 
su
either
either
COPY 
s
enroll
enro
ubje
ubje
This documen
Cl
Cl
ent 
isisi
en
um
cannot
e #
e #
le 5
e 5–1
it c
t c
be 
#1
#13
used 
may
may
to 
ond
ay b
y b
support 
to:
to:
ducte
ducte
any
ele
el
essary
ssary
marketing 
and co
and c
lecte
ect
authorization 
l 2
ects ≥
cts ≥
r of th
of th
application 
ge, wit
ge, w
m ≥8 to
≥8 to
20 su
0 s
and any extensions or variations 
from
rom
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 225 of 240
Change #14
Table 5–1 Schedule of study assessments, footnote c
c If iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed for 
each infusion of iv LCM treatment in EP0060, unless otherwise noted (see footnote o).
Has been changed to:
c If iv LCM treatment is continued after Day 1, assessments for Visit 3 (excluding PK blood 
sampling [see footnote u]) must be completed for each infusion of iv LCM treatment in 
EP0060, unless otherwise noted (see footnote o).
Change #15
Table 5-1 Schedule of study assessments, footnote e
e A Final Visit must be completed for all subjects who complete or withdraw prematurely from 
EP0060. If the last iv infusion of LCM for the study occurs in the morning, the Final Visit may 
occur on the same day as the last infusion, time permitting. Otherwise, the Final Visit should 
occur on the following day (ie, last infusion in evening). For subjects who will discontinue use of 
LCM, the subject should complete the EP0060 Final Visit and either refer to the long-term, 
open-label studies taper regimen or taper at the discretion of the treating physician for those 
subjects who enrolled directly.
Has been changed to:
e A Final Visit must be completed for all subjects who complete or withdraw prematurely from 
EP0060. If the last iv infusion of LCM for the study occurs in the morning, The Final Visit may 
occur on the same day as the last dose of iv LCM, time permitting. Otherwise, the Final Visit 
should occur on the following day (ie, last infusion in evening). For subjects who will 
discontinue use of LCM, the subject should complete the EP0060 Final Visit and either refer to 
the long-term, open-label studies taper regimen for OLL subjects or taper at the discretion of 
the treating physician for RxL subjects those subjects who enrolled directly.
Change #16
Table 5-1 Schedule of study assessments, footnote j
j Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be 
collected for RxL and IIL subjects at Screening. For OLL subjects, a medical history update will 
be performed in order to collect medical history that was not captured during the course of the 
prior study.
Has been changed to:
j Procedure history, medical history, diagnosis of epilepsy, and childbearing potential will be 
collected for RxL and IIL subjects at Screening. For OLL subjects, a medical history update will 
be captured in the previous long-term open-label study and not in EP0060.
REDACTED
he dis
he di
or al
or al
COPY
ttit
ning). 
ning).
inal V
inal V
This document 
olle
ll
be pe
be pe
pr
pr
cannot 
1 S
1 S
cedure
cedur
ecte
ecte
be 
Sch
Sch
used 
6
to support 
e s
l studie
stud
for
or Rx
R
any 
day 
day (
ubje
bj
marketing 
ll subje
l subj
M for 
M for
ke
dose o
ose 
(ie
(
authorization
Visit 
Visit
cretion
retion
application
or wi
r w
the mo
he m
Otherw
Other
For su
For su
an
and 
with
ith
any extensions 
t in 
in
or
loo
loo
variations 
od
od
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 226 of 240
Change #17
Table 5-1 Schedule of study assessments, new footnote q
q Bicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for 
bicarbonate in subjects weighing less than 8kg in cases of suspected metabolic disturbances such 
as metabolic acidosis.
Has been added and subsequent footnotes have been renumbered.
Change #18
Table 5-1 Schedule of study assessments, footnote z
z For RxL and IIL subjects who are eligible and wish to enroll in SP848, a short-term oral LCM 
solution will be dispensed to allow continuity of LCM treatment while visits and assessments are 
scheduled for starting SP848. Subjects (or their caregivers) will administer the oral LCM 
solution twice a day according to the investigator’s instructions until the subject returns for the 
Transition Visit.
Has been changed to:
z For RxL and IIL subjects who are eligible and wish to enroll in SP848, a short-term oral LCM 
solution will be dispensed to allow continuity of LCM treatment while visits and assessments are 
scheduled for starting SP848. Subjects (or their caregivers) will administer the oral LCM 
solution twice a day, starting approximately 12 hours after the final iv LCM infusion,
according to the investigator’s instructions until the subject returns for the Transition Visit.
Change #19
Section 5.3 Rationale for study design and selection of dose
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥4 to <17 years. A separate Phase 2/3 study investigating 
the use of iv LCM in pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. 
The results of EP0060 will provide safety and PK data regarding the use of the iv LCM 
formulation in pediatric subjects (≥4 to <17 years of age). The EP0060 design is based on 
components of the study design for SP757, which evaluated iv LCM replacement in adults with 
partial-onset seizures, as well as based on design elements of other pediatric iv AED studies. In 
an effort to maximize the patient pool used in the evaluation of the safety of iv LCM in pediatric
subjects, Protocol Amendment 2 opened enrollment to also include OLL and RxL subjects who 
are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who are not 
currently taking LCM and initiate adjunctive LCM treatment using iv LCM. This expansion of 
the subject population occurred prior to the start of study enrollment. Protocol Amendment 2 
also included the option for RxL and IIL subjects to continue oral LCM treatment after 
completion of iv LCM, if determined clinically appropriate, in SP848. If required, a short-term 
supply of oral LCM solution will be provided for RxL and IIL subjects transitioning to start 
REDACTED 
d w
d w
ty of L
ty of L
or their
r thei
imate
imat
uction
uction
COPY 
wish
wis
This document
subje
subje
are
are
cannot 
ents
nt
-onse
onse
effort
ffort
be 
n in 
in 
ts of
ts of
used 
M in
M i
EP006
EP006
n pe
pe
o
th
in p
in p
support 
stud
tud
el, mult
l, mu
h epil
h epil
any 
dy d
dy
marketing
ns un
ns un
authorization 
h to en
h to e
LCM 
LCM 
ir care
r care
ly 12
y 12
application 
dmi
until t
until 
and
e vis
e vis
minis
inis
any
a sho
a sho
sits
i
extensions or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 227 of 240
SP848 to ensure continuity of LCM treatment while allowing flexibility to schedule a clinical 
visit to initiate SP848. For RxL and IIL subjects who do not continue into SP848 (either by 
choice or not clinically appropriate), an additional telephone contact approximately 30 days after 
last dose of iv LCM IMP is added in order to collect final safety data. 
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial-onset seizures in subjects ≥16 years of age (depending on country-specific 
labeling) with epilepsy when oral administration is temporarily not feasible, which can also 
include initiation of LCM treatment. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day 
(subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatric subjects (Cohort 1) and will include at least 
20 subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 (at 
least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC recommendation. 
After the first 20 subjects (Cohort 1) or 10 subjects (Cohort 2) have received iv LCM over 
infusion durations of 30 to 60 minutes, the DMC will review the available safety and tolerability 
data. Based on their review, the DMC will recommend the target infusion duration for the 
remaining subjects in the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 
minutes [only for subjects who would directly benefit from an increased infusion rate, in the 
opinion of the investigator; otherwise 30 to 60 minutes]), if the study/cohort should be stopped, 
and if the next cohort can be initiated, and if a new iv LCM study in younger pediatric subjects 
(≥1 month to <4 years of age) can be initiated (Section 12.7.2).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥4 to <17 years of age over a range of infusion 
durations. 
Taken together, the iv LCM dosing scheme and planned target infusion durations being 
evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for 
administration of a range of pediatric doses, and include infusion durations that are the same as 
those approved for adults and adolescents. 
Has been changed to:
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥1 month to <17 years. A separate Phase 2/3 study 
investigating the use of iv LCM in pediatric subjects with epilepsy ≥1 month to <4 years of age 
is planned. The results of EP0060 will provide safety and PK data regarding the use of the iv 
REDACTED
pedia
pedia
t least 
least 
will f
will f
) or 10
) or 10
es
es
COPY
onsta
onst
This document
admi
dmi
thos
tho
cannot
toget
oget
luated
uated
mini
in
be used
resu
esu
erab
rabili
ili
to 
sult
ult
support
; oth
oth
an be in
n be i
s of ag
of a
any
o wou
o wo
an
herw
her
marketing 
0 sub
su
, the D
the D
MC will
C wi
ie, 30
e, 30
l
authorization 
tric su
tric su
t 20 su
t 20 su
follow
follow
ubj
ubj
application
ubj
ubj
subject
ubjec
ase 3 pe
se 3 p
nt for a
t for
and
L subj
subj
bjec
jec
any 
bel
be
uated i
ated 
ec
extensions
 3
tration
ratio
the P
the P
wider
wide
el stu
l st
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 228 of 240
LCM formulation in pediatric subjects (≥1 month to <17 years of age). The EP0060 design is 
based on components of the study design for SP757, which evaluated iv LCM replacement in 
adults with partial-onset seizures, as well as based on design elements of other pediatric iv AED 
studies. In an effort to maximize the patient pool used in the evaluation of the safety of iv LCM 
in pediatric subjects, EP0060 has opened enrollment to include also OLL and RxL subjects who 
are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who are not 
currently taking LCM and initiate adjunctive LCM treatment using iv LCM. The expansion of 
the subject population occurred prior to the start of study enrollment. EP0060 also includes the 
option for RxL and IIL subjects to continue oral LCM treatment after completion of iv LCM, if 
determined clinically appropriate, in SP848. If required, a short-term supply of oral LCM 
solution will be provided for RxL and IIL subjects transitioning to start SP848 to ensure 
continuity of LCM treatment while allowing flexibility to schedule a clinical visit to initiate 
SP848. For RxL and IIL subjects who do not continue into SP848 (either by choice or not 
clinically appropriate), an additional telephone contact approximately 30 days after last dose of 
iv LCM IMP is added in order to collect final safety data. 
The iv LCM formulation at infusion durations of 15 to 60 minutes is approved at doses of 200 
to 400mg/day as adjunctive therapy in the treatment of partial-onset seizures in subjects ≥17
years of age (depending on country-specific labeling) with epilepsy when oral administration is 
temporarily not feasible, which can also include initiation of LCM treatment, for infusion 
durations of 15 to 60 minutes. Additionally in the EU, the iv formulation is also approved 
in pediatric subjects down to 4 years of age at maximum weight-based doses depending on 
weight band and whether LCM is administered as monotherapy or adjunctive therapy, for 
infusion durations of 15 to 60 minutes. An infusion duration of at least 30 minutes for 
administration >200mg per infusion (ie, >400mg/day) is preferred.
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day 
(subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatric subjects (Cohort 1) and will include at least 
20 subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 will 
enroll approximately 44 subjects (with every attempt to enroll 20 subjects ≥4 to <8 years of 
age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age) and will 
follow sequentially based on DMC recommendation. After completion of the first 20 subjects 
(Cohort 1) and after completion of 20 subjects (Cohort 2) have received iv LCM over infusion 
durations of 30 to 60 minutes, the DMC will review the available safety and tolerability data. 
Based on their review, the DMC will recommend the target infusion duration for the remaining 
subjects in the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 minutes [only 
REDACTED
at 
stered
stered
An in
An in
(ie, >
(ie, >
e for
e for
COPY 
ati
ation
he EU
he EU
max
max
This document
0 su
su
enr
enr
cannot
reas
eas
0060 w
060 w
ubj
ub
be
at in
at in
se
se
used
des 
es 
kg)
g), w
, w
nit
nit
to 
ay o
y o
s the
th
support
g
00mg/
0mg/
kg/day
kg/da
or 60
or 6
any
owe
ow
es of 
es of
d
marketing
r pedi
r ped
tudies a
udies
0mg/da
mg/d
weve
wev
authorization
U, 
ximum
ximu
as m
as m
fusio
usio
>400m
400m
application
nset se
nset s
ilepsy 
ilepsy
of LCM
f LC
the i
the i
and 
s is ap
is ap
any
ays
ays
extensions 
CM
nsure 
nsure 
it to in
t to in
choice
hoice
ys af
s a
or 
M 
M
variations 
the 
he
M, i
M, i
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 229 of 240
for subjects who would directly benefit from an increased infusion rate, in the opinion of the 
investigator; otherwise 30 to 60 minutes]), if the study/cohort should be stopped, and if the next 
cohort can be initiated, and if a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age) can be initiated (Section 12.7.2).
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥1 month to <17 years of age over a range of 
infusion durations. 
Taken together, the iv LCM dosing scheme and planned target infusion durations being 
evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for 
administration of a range of pediatric doses, and include infusion durations that are the same as 
those approved for adults and adolescents. 
Change #20
Section 6.1 Inclusion criteria, second criterion
2. Subject is male or female from ≥4 to <17 years of age.
Has been changed to:
2. Subject is male or female from ≥1 month to <17 years of age.
Change #21
Section 6.1 Inclusion criteria
8.  Subject weighs ≥4kg.
Has been added.
Change #22
Section 6.2 Exclusion criteria
20a. Subject is currently participating in another study of an IMP.
Has been added.
Change #23
Section 6.3.1 Potential drug-induced liver injury IMP discontinuation criteria, first 
paragraph and bullets
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
REDACTED COPY 
<17 ye
<17 y
This document
Secti
Secti
pa
pa
cannot 
ange
ange
be 
a
used
urre
rre
adde
dde
to 
rent
ent
support 
n crite
n crit
any marketing authorization 
ears
ars
application 
rs of 
s of
and any extensions
fo
the sa
he sa
or 
or 
or 
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 230 of 240
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and 
right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever 
(without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator. 
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Has been changed to:
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be immediately and permanently discontinued. In addition, all concomitant medications 
and herbal supplements that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and 
right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever 
(without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below requires discussion with Medical Monitor to decide whether 
subject is allowed to continue on IMP at the discretion of the investigator.
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Change #24
Section 7.2.1 Treatment Period, fifth paragraph
For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 10 subjects ≥4 
to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer 
than 60 minutes whenever possible. 
REDACTED
and p
and p
ing:
ing:
COPY
ed. In
ed. I
cessar
cessa
This document 
C
cannot 
ubj
ub
<2xU
<2xU
(e(e
be 
bject
bject
used
rion 
on 
owed
wed
to 
ar 
n b
support
ensiti
nsit
drant p
rant p
altern
alter
any 
AST 
AST
ivi
marketing 
d coexi
d coex
es imm
es imm
ma
authorization
ry sh
y sh
erman
erman
application 
ust be a
ust be
additio
additi
shou
hou
and
ndern
nder
any 
LN
ympto
ympt
ne
extensions 
n of th
of th
N, to
N, to
or variations 
and 
nd 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 231 of 240
Has been changed to:
For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 20 subjects 
≥1 month to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but 
no longer than 60 minutes whenever possible. 
Change #25
Section 7.2.1 Treatment Period, final paragraph
If subjects need to discontinue LCM, the subjects should be tapered off LCM either as specified 
in their long-term, open-label study or at the discretion of the treating physician for RxL and IIL 
subjects. For OLL subjects this taper should occur as a part of the long-term, open-label study 
and not as a part of EP0060.
Has been changed to:
If subjects need to discontinue LCM, OLL subjects should be tapered off LCM either as 
specified in their long-term, open-label study or at the discretion of the treating physician for 
RxL and IIL subjects. For OLL subjects, this taper should occur as a part of the long-term, 
open-label study and not as a part of EP0060.
Change #26
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline, fourth 
paragraph, sixth bullet
x Medical history update for OLL subjects from long-term open-label studies, or complete 
medical history for RxL and IIL subjects 
Has been changed to:
x Medical history update for OLL subjects from long-term open-label studies, or Complete 
medical history for RxL and IIL subjects (a medical history update will be captured in 
the previous long-term open-label study for OLL subjects) 
Change #27
Section 8.2.1 Visit 2 (Day 1), third paragraph, final bullet
For RxL and IIL subjects who are eligible and choose to participate in the long-term open-label 
oral LCM study SP848 after completion of EP0060, a short-term oral LCM solution will be 
dispensed at Visit 2. This supply is to allow continuity of LCM treatment after the last iv LCM 
infusion and the scheduled Transition Visit.
Has been changed to:  
For RxL and IIL subjects who are eligible and choose to participate in the long-term open-label 
oral LCM study SP848 after completion of EP0060, a short-term oral LCM solution will be 
dispensed at Visit 2. This supply is to allow continuity of LCM treatment after the last iv LCM 
REDACTED 
y -7 to
to
OLL 
OLL 
COPY 
This document
al
dispe
dispe
inin
cannot 
8.2.2
RxL an
xL an
l LC
LC
be 
2.1 V
2.1 V
used 
7
to support 
ate
ate
or RxL
r RxL
ong
ong-tet
e fo
e fo
any 
e for
e for
a
marketing 
L subje
subje
IIL sub
IL su
authorization 
o Day 
o Day 
application
of th
of th
ur as a 
r as a
and
ed off 
d off
he
h
any extensions
as sp
s sp
r RxL
r RxL
pen
en-lab
la
or 
pec
pe
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 232 of 240
infusion and the scheduled Transition Visit. Oral LCM solution administration should begin 
approximately 12 hours after the final iv LCM infusion.
Change #28
Section 8.4.1 Final Visit (Day 1 to 6)/Termination Visit, first paragraph
If the last iv infusion of LCM for the study occurs in the morning, the Final Visit may occur on 
the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the 
following day (ie, last infusion in evening).
Has been Changed to:
If the last iv infusion of LCM for the study occurs in the morning, The Final Visit may occur on 
the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the 
following day (ie, last infusion in evening).
Change #29
Section 8.4.1 Final Visit (Day 1 to 6)/Termination Visit, second paragraph, Oral LCM
administration, if applicable bullet, third dash
For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM administration 
may continue from the short-term oral LCM solution that was dispensed at Visit 2. Additional 
assessments will be conducted at the Transition Visit, as outlined in Section 8.4.3.
Has been changed to:
For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM administration
may continue from the short-term oral LCM solution that was dispensed at Visit 2, should begin 
approximately 12 hours after the final iv LCM infusion regardless of when the Final Visit 
occurs. Additional assessments will be conducted at the Transition Visit, as outlined in 
Section 8.4.3.
Change #30
Section 10.6.2 Liver function tests and evaluation of PDILI, seventh paragraph
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. 
Has been changed to:
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings.
Change #31
Table 10-2 Laboratory tests, Clinical chemistry column, bicarbonate
REDACTED 
wi
wi
M solut
M solut
nsition
nsitio
COPY 
Vis
Vi
ish t
ish
This document 
as
a
Wh
Wh
d
cannot
MP
tinued
inued
s be
s be
be
P is s
P is s
used 
2 Liv
Liv
to support any 
he
h
ts wil
ts wi
marketing 
gible an
ible a
oral LC
ral L
he fin
e fin
authorization 
to enr
o enr
tion th
ion th
n Visi
n Vis
application 
second
econ
and any extensions 
Visi
isit m
t m
shou
shou
or variations 
on 
on 
on th
on th
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 233 of 240
a Bicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for 
bicarbonate in subjects weighing less than 8kg in cases of suspected metabolic disturbances 
such as metabolic acidosis. 
Has been added.
Change #32
Table 10-3 Required investigations and follow up for PDILI, Immediate Actions column 
for ≥3xULN for ALT or AST
Immediate, temporary or permanent, IMP discontinuation.
Has been changed to:
Immediate, temporary or permanent, IMP discontinuation.
Change #33
Table 10-4 PDILI laboratory measurements, hematology measurements
Hematology
Eosinophil count
Has been changed to:
Hematology
Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
WBC differential count
Change #34
Table 10-4 PDILI laboratory measurements, chemistry measurements
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
Has been changed to:
REDACTED 
TE
DA
RE
COPY 
Y
CO
This document 
um
cannot
istry
try
be
be 
PD
be used 
DIL
DIL
to support 
renti
rent
po
any 
ia
an marketing 
ng
ke
m
authorization 
n
riz
uth
application 
measu
meas
pl
and any extensions or variations 
mn 
mn 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 234 of 240
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
ALT
AST
ALP
GGT
Albumin
Change #35
Section 10.7.3 Overall ECG interpretation
An immediate initial review of the ECGs will be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically significant, then the ECG 
should be repeated in 1 hour, unless circumstances require a more rapid assessment. If the 
clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, the subject must be withdrawn from EP0060 (see Section 6.3). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the 
complete clinical picture and whether this finding influences the subject’s participation in 
EP0060.
Has been changed to:
An immediate initial review of the ECGs will be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically significant, then the ECG 
should be repeated in 1 hour, unless circumstances require a more rapid assessment. If the 
clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, the subject must be withdrawn from EP0060 (see Section 6.3). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the 
complete clinical picture and whether this finding influences the subject’s participation in 
EP0060. Additionally, the ECGs will be sent to a central reader for review.
REDACTED 
stig
sti
stance
stance
irmed 
rmed
be wi
be w
rdiol
rdiol
COPY
nduct
nduc
this re
this 
igato
ga
This document
prese
prese
inv
inv
cannot 
y sig
sig
cally n
ally n
estiga
stig
be
epea
pe
ign
ign
used 
or q
r q
ed by 
d by 
eate
eate
to
l r
qua
qua
support 
to:
to:
review
eview
any 
heth
het
marketing
logist
logis
CG abn
CG ab
ECG fin
CG f
ther 
ther
authorization 
ead
ead
tor to b
or to 
es requ
s requ
d by th
by th
thdra
hdra
t
application 
ed loca
d loc
ding
ding
and any y extensions 
on
te
or 
or variations 
on
on
on
on
ari
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 235 of 240
Change #36
Section 12.1 Definition of analysis sets
The Safety Set iv (SS-iv) will include subjects who received at least 1 dose of iv LCM. The SS 
will be the primary analysis set for the analysis of safety data.
The Safety Set (SS) will include subjects who received at least 1 dose of LCM (oral or iv). 
Selected safety summaries will be presented for the SS.
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS having 
provided at least 1 measurable postdose plasma sample (with recorded sampling time) on at least 
1 study day with documented LCM intake times.
Has been changed to:
The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study drug 
LCM (oral and/or iv). Selected safety summaries will be presented for the SS.
The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of EP0060 
study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety data.
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS-iv having 
provided at least 1 measurable postdose plasma sample (with recorded sampling time) on at least 
1 study day with documented iv LCM intake times and without important protocol deviations 
impacting the interpretability of the PK analysis.
Change #37
Section 12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected. Data will be presented by 
cohort and infusion duration, and the IIL and OLL and RxL groups of subjects in EP0060 will 
also be presented.
Has been changed to:
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected. Data will be presented by 
cohort and infusion duration, and the IIL and OLL and RxL groups of subjects in EP0060 will 
also be presented. 
Change #38
Section 12.4 Planned safety analyses, first paragraph
REDACTED
time
time
analy
analy
COPY
ill inc
ill in
sampl
ampl
This documen
alalso
so
ent
oho
h
also
so
en canno
metric
etric
infusi
nfusi
ort a
ort a
ca
be
e sta
e sta
c m
c m
used
hang
ang
atiti
to support
w
LCM 
LCM 
uration,
ration
any 
nd 
nd
ill be
ill be
marketing 
inetic 
netic
d SP
d S
authorization
le (w
le (w
and w
and w
ysis
sis.
application 
ceived
ceive
set for 
set for
lude a
ude 
iti h
and 
of f 
for the
or the
any 
EP0
EP
extensions
avin
vin
me) o
me) o
or 
ng
ng
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 236 of 240
Safety analyses will be presented by cohort and infusion duration, cohorts overall, and all 
subjects overall. Within cohort and infusion duration, the OLL and RxL groups of subjects and 
the IIL subject group will also be presented.
Has been changed to:
Safety analyses will be presented by age cohort and infusion duration, cohorts overall, and all 
subjects overall. Within cohort and infusion duration, the OLL and RxL groups of subjects and 
the IIL subject group will also be presented. 
Change #39
Section 12.5 Handling of protocol deviations, first sentence
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary safety outcomes for an individual subject.
Has been changed to:
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary safety outcomes for an individual subject.
Change #40
Section 12.6 Handling of dropouts or missing data
In Protocol Amendment 2, Section 12.6 Handling of dropouts or missing data was erroneously 
moved to become Section 17.1. This section has been restored to its original position and 
subsequent sections have been renumbered.
Change #41
Section 12.7 Planned interim analysis and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 10 subjects in Cohort 2. 
Has been changed to:
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 20 subjects in Cohort 2. 
Change #42
Section 12.7.2 Data Monitoring Committee, fourth paragraph through end of section
REDACTED 
ssing 
ssing 
Hand
Hand
sectio
sectio
mbe
mbe
COPY 
This document 
e 
cannot
mal in
al in
wed b
wed b
first 
first 
be 
c
int
int
sed
cts 
ts 
chan
ha
to 
C afaf
inin
support 
erim 
rim
lysis is
ysis i
after 
fter
any 
m an
a
marketing 
on 
red.
red.
authorization 
data
data
dling o
ing o
n has
has
application 
which 
which
dividua
dividu
and any 
ect.
ect.
extensions 
ally 
ally 
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 237 of 240
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
Has been changed to:
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows:
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped.
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).
REDACTED 
≥1 m
ts in C
ts in C
minut
minut
COPY 
in y
in
This document cannot 
OR 
OR
i
be
from
from
used 
an i
n 
minu
minu
to
tes
inc
inc
support
ately
tely
s as fo
as f
s but 
but 
any 
ly y 30
3
marketing
tes w
es 
cts in C
cts in 
1 and C
and C
authorization 
month
onth
Cohor
ohor
s wh
w
application 
unger p
nger
and 
ohor
ho
es, 
s, 
any 
r
ort 2 
rt 2
extensions
ectly
ctly
ns
not dir
ot dir
xt
or 
y b
variations 
rget 
get 
thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 238 of 240
Change #43
Section 12.8 Determination of sample size
Approximately 75 subjects will be enrolled, which includes up to 2 cohorts of at least 40 subjects 
for Cohort 1 and at least 20 subjects for Cohort 2. No formal sample size calculation has been 
performed. The sample size was deemed clinically appropriate for the evaluation of safety, 
tolerability, and PK of iv LCM administration in pediatric subjects with epilepsy. 
Has been changed to:
Approximately 100 subjects will be enrolled, which includes up to 2 cohorts of at least 
40 subjects for Cohort 1 and approximately 44 subjects for Cohort 2. No formal sample size 
calculation has been performed. The sample size was deemed clinically appropriate for the 
evaluation of safety, tolerability, and PK of iv LCM administration in pediatric subjects with 
epilepsy. 
Change #44
Section 15 REFERENCES
Welsh SS, Lin N, Topjian AA, Abend NS. Safety of intravenous lacosamide in critically ill 
children. Seizure. 2017;52:76-80.
Has been added.
REDACTED COPY
intra
intr
This document cannot be used to support any marketing authorization application 
venous
enou
and any extensions
ample 
mple
ate fo
ate fo
ic subj
c sub
or variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 239 of 240
17
DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name
Date/Signature
REDACTED COPY 
D
PY
This document cannot be used to support any marketing authorization
Date/S
ate/
application 
Sig
Si
pp
and any extensions
be 
ation 
ation
ents w
nts w
or
trea
tre
variations thereof. 


UCB
30 Apr 2018
Clinical Study Protocol
Lacosamide
EP0060
Confidential
Page 240 of 240
18
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


Approval Signatures
Name:
EP0060-protocol-amend-3
Version:
2. 0
Document Number:
CLIN-000115394
Title:
EP0060 Protocol Amendment 3
Approved Date:
07 May 2018
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 04-May-2018 08:42:15 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 04-May-2018 17:49:43 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 07-May-2018 07:24:42 GMT+0000
DACTED 
REDA
DA
OPY
App
App
CO
CO
This document cannot be used to supp
pport 
pp
any marketing 
ma
ma
n
p
uthorization 
n
ori
Nam
Ca
aut
ut
application 
p
roval
ova
a
and any extensions or variations thereof. 

SAP_000.pdf: 
UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 1 of 66
STATISTICAL ANALYSIS PLAN 
Study: EP0060
Product: Lacosamide
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN 
(≥1 MONTH TO <17 YEARS OF AGE) WITH EPILEPSY
SAP/Amendment Number
Date
Final SAP
11 August 2017
SAP Amendment 1
02 July 2018
SAP Amendment 2
21 June 2019
Confidentiality Statement
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED COPY 
This document cannot be used to
pub
pub
to support 
the pr
he pr
blis
bli
any 
C
a
marketing 
C
authorization application and any 
CH
LEPS
LEPS
extensions 
E SAF
SAF
HIL
HIL
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 2 of 66
TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................6 
1 
INTRODUCTION .............................................................................................................8 
2 
PROTOCOL SUMMARY.................................................................................................8 
2.1 
Study objectives.............................................................................................................8 
2.1.1 
Primary objective...................................................................................................8 
2.1.2 
Additional objective...............................................................................................8 
2.2 
Study variables...............................................................................................................8 
2.2.1 
Primary safety variables ........................................................................................8 
2.2.2 
Other safety variables ............................................................................................8 
2.2.3 
Other pharmacokinetic variables ...........................................................................8 
2.3 
Study design and conduct ..............................................................................................8 
2.4 
Determination of sample size.......................................................................................11 
3 
DATA ANALYSIS CONSIDERATIONS......................................................................11 
3.1 
General presentation of summaries and analyses ........................................................11 
3.2 
General study level definitions ....................................................................................12 
3.2.1 
Analysis time points ............................................................................................12 
3.2.1.1 
First and last dose of iv LCM....................................................................12 
3.2.1.2 
Relative day and time................................................................................12 
3.2.2 
Analysis periods...................................................................................................13 
3.2.3 
Study visit labeling ..............................................................................................13 
3.2.4 
Exposure duration................................................................................................14 
3.2.5 
Age and Age at first diagnosis.............................................................................14 
3.2.6 
Time since first epileptic seizure and last status epilepticus ...............................14 
3.2.7 
Body mass index (BMI).......................................................................................14 
3.3 
Definition of Baseline values.......................................................................................14 
3.4 
Protocol deviations.......................................................................................................15 
3.5 
Analysis sets.................................................................................................................15 
3.5.1 
Safety Set.............................................................................................................15 
3.5.2 
Safety Set iv.........................................................................................................15 
3.5.3 
Pharmacokinetic-Per Protocol Set .......................................................................15 
3.6 
Treatment assignment and treatment groups ...............................................................15 
3.7 
Center pooling strategy................................................................................................15 
3.8 
Coding dictionaries ......................................................................................................15 
3.9 
Changes to protocol-defined analyses .........................................................................15 
4 
STATISTICAL/ANALYTICAL ISSUES.......................................................................16 
4.1 
Adjustments for covariates ..........................................................................................16 
4.2 
Handling of dropouts or missing data..........................................................................16 
REDACTED 
M
......
......
......
....
......
......
COPY 
...
.....
......
..
This document 
3.7
3.7
3.3
cannot 
3
T
be
Sa
Sa
used 
sets
et
afety 
afety
f
to 
tsts.
support 
ex x
eline v
eline
ations
tions
any
lept
lep
(BM
(B
marketing 
......
.......
....
diagnos
agno
ptic
pti
authorization 
.
......
.....
......
....
......
.....
application 
.....
.......
.....
........
....
....
..
and
......
....
.
any 
......
.....
extensions 
.........
......
.....
.........
or 
.....
....
variations 
..8
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 3 of 66
4.2.1 
General imputation rule for incomplete dates .....................................................16 
4.2.2 
Handling of prior and concomitant medications with missing data ....................16 
4.2.3 
Handling of adverse events with missing data ....................................................17 
4.2.4 
Handling of study medication with missing data ................................................18 
4.2.5 
Handling of epilepsy diagnosis with missing data ..............................................18 
4.3 
Interim analyses and data monitoring..........................................................................18 
4.4 
Multicenter studies.......................................................................................................20 
4.5 
Multiple comparisons/multiplicity...............................................................................20 
4.6 
Use of an efficacy subset of study participants............................................................20 
4.7 
Active-control studies intended to show equivalence..................................................20 
4.8 
Examination of subgroups ...........................................................................................20 
5 
STUDY POPULATION CHARACTERISTICS.............................................................20 
5.1 
Study participant disposition........................................................................................20 
5.2 
Protocol deviations.......................................................................................................21 
6 
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................21 
6.1 
Demographics and other Baseline characteristics........................................................21 
6.2 
Medical history ............................................................................................................22 
6.3 
Potential Drug-Induced Liver Injury (PDILI)..............................................................22 
6.4 
History of epilepsy.......................................................................................................22 
6.4.1 
History of seizure types .......................................................................................22 
6.4.2 
History of seizure characteristics.........................................................................23 
6.4.3 
Historical seizure counts......................................................................................23 
6.5 
Prior and concomitant medications..............................................................................23 
6.5.1 
Concomitant Non-AEDs......................................................................................23 
6.5.2 
Concomitant AEDs..............................................................................................23 
6.6 
VNS setting and ketogenic diet....................................................................................23 
6.7 
Medical procedures......................................................................................................24 
7 
MEASUREMENTS OF TREATMENT COMPLIANCE...............................................24 
8 
SAFETY ANALYSES.....................................................................................................24 
8.1 
Extent of exposure .......................................................................................................24 
8.2 
Adverse events.............................................................................................................24 
8.3 
Clinical laboratory evaluations ....................................................................................26 
8.4 
Vital signs, physical findings, and other observations related to safety......................27 
8.4.1 
Vital signs ............................................................................................................27 
8.4.2 
Electrocardiograms (ECGs).................................................................................29 
8.4.3 
Complete physical examination...........................................................................31 
8.4.4 
Complete neurological examination....................................................................31 
8.4.5 
Assessment of suicidality ....................................................................................31 
REDACTED 
DI
....
........
......
.....
cterist
cterist
COPY 
......
....
ILI)
LI)
This document 
8.4.4
cannot
Adv
Adv
Cl
C
be
ent o
nt 
used 
M
ANA
ANA
of
to
ENT
EN
support 
E
ketoge
ketog
edures
dures
T
any 
E
Ds
Ds.
marketing 
tic
.......
.....
cations
ation
EDs
EDs
authorization 
......
......
......
....
......
.....
cs.
application 
..
TE
TERIS
RI
........
....
......
.....
and 
.......
.....
any 
.....
....
..
extensions 
......
....
......
...
......
....
or 
......
variations 
20
20
20
2
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 4 of 66
9 
PHARMACOKINETICS AND PHARMACODYNAMICS ..........................................31 
9.1 
Pharmacokinetics .........................................................................................................31 
9.1.1 
Pharmacokinetics Analysis..................................................................................32 
9.2 
Pharmacodynamics ......................................................................................................32 
10 EFFICACY ANALYSES ................................................................................................32 
11 REFERENCES ................................................................................................................33 
12 APPENDICES .................................................................................................................34 
12.1 
List of Other significant AEs of VIMPAT ..................................................................34 
12.2 
Marked abnormality criteria for laboratory data..........................................................37 
12.2.1 
Hematology..........................................................................................................37 
12.2.2 
Chemistry.............................................................................................................38 
12.2.3 
Required Investigations and follow up for PDILI ...............................................43 
12.2.4 
PDILI laboratory measurements..........................................................................44 
12.3     Additional PDILI information .....................................................................................46 
12.4     List of MedDRA Preferred Term for PDILI................................................................47 
13 AMENDMENTS TO THE STATISTICAL ANALYSIS PLAN....................................50 
13.1 
AMENDMENT 1.........................................................................................................50 
13.2 
AMENDMENT 2.........................................................................................................65 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE.....................................................66 
REDACTED 
TURE
TUR
COPY 
......
....
....
....
This document cannot be used to support any marketing authorization 
......
......
E PAG
E PA
application 
..
.......
.....
S P
S PLA
LA
......
.....
and 
.......
.....
any 
.....
....
..
extensions 
......
....
......
...
......
....
or 
.....
variations 
34
34
3
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 5 of 66
LIST OF TABLES
Table 8‒1: Vital signs abnormality criteria.........................................................................28 
Table 8‒2: ECG abnormality criteria..................................................................................29 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 6 of 66
LIST OF ABBREVIATIONS
AE
adverse event
AED
antiepileptic drug
AV
Atrioventricular
bid
twice daily
BP
Blood pressure
CRF
case report form
C-SSRS
Columbia-Suicide Severity Rating Scale
CV
coefficient of variation
DBP
diastolic blood pressure
DILI
drug-induced liver injury
DMC
Data Monitoring Committee
ECG
electrocardiogram 
eCRF
electronic Case Report Form
EMU
epilepsy monitoring unit
ETV
Early Termination Visit
iv
Intravenous
ILAE
International League Against Epilepsy
IIL
Initiating intravenous lacosamide Group
LCM
lacosamide
LOQ
limit of quantification
MA
markedly abnormal
MedDRA
Medical Dictionary for Regulatory Activities
OLL
Open-label lacosamide Group
PDILI
potential drug-induced liver injury
REDACTED 
ni
ctrocar
trocar
elec
elec
COPY
iver
ive
itorin
torin
This document 
MA
MA
cannot 
OQ
be used to support any marketing 
ctro
ro
epile
epil
authorization
ng Co
ng Co
rdiogr
rdiogr
onic
onic
application 
njury
njury
and any
cale
cal
extensions 
lele
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 7 of 66
PK
pharmacokinetic(s)
PK-PPS
Pharmacokinetic Per Protocol Set
PT
preferred term
RxL
Prescription lacosamide (eg, VIMPAT) Group
SAP
Statistical Analysis Plan
SBP
systolic blood pressure
SD
standard deviation
SOC
system organ class
SS
Safety Set
SS-iv
Safety Set iv
TEAE
treatment-emergent adverse event
TEMA
treatment-emergent marked abnormalities
ULN
upper limit of normal
VNS
vagus nerve stimulation
WHODD
World Health Organization Drug Dictionary
ntnt-em
e
per lim
per lim
vag
va
COPY
ergen
ergen
eme
em
This document cannot be used to support any marketing
gus n
gus n
Wo
W
authorization 
mergen
rgen
mit of
mit of
application 
t adve
adv
and any extensions or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 8 of 66
1
INTRODUCTION
This Statistical Analysis Plan (SAP) defines the scope of statistical analyses and provides a 
detailed description of statistical methodology for the statistical analyses to support the final 
clinical study report for EP0060. This SAP is based upon the following documents: (Final 
Protocol: 16Dec2014, Protocol Amendment 1: 21Jul2015, Protocol Amendment 2: 30Nov2016,
Protocol Amendment 3: 30Apr2018).
2
PROTOCOL SUMMARY
2.1
Study objectives
2.1.1
Primary objective
The primary objective of the study is to evaluate the safety and tolerability of intravenous (iv)
Lacosamide (LCM) infusion(s) in pediatric study participants ≥1 month to <17 years with 
epilepsy.
2.1.2
Additional objective
An additional objective of the study is to evaluate the pharmacokinetics (PK) of iv LCM in 
pediatric study participants with epilepsy.
2.2
Study variables
2.2.1
Primary safety variables
Safety and tolerability will be assessed using the following primary variables:
x
Adverse events (AEs) reported spontaneously by the study participant and/or caregiver 
(including parent/legal guardian) or observed by the investigator
x
Study participant withdrawals due to AEs
2.2.2
Other safety variables
Other safety variables include the following:
x
Changes in 12-lead electrocardiogram (ECGs)
x
Changes in vital sign measurements (blood pressure [BP] and pulse rate)
x
Changes in physical examinations
x
Changes in neurological examinations
2.2.3
Other pharmacokinetic variables
The other PK variables will include plasma concentration of LCM and its main metabolite, 
SPM 12809.
2.3
Study design and conduct
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv
LCM infusions in pediatric study participants ≥1 month to <17 years of age with epilepsy. Based 
on a local protocol amendment only patients between ≥1 month to <16 years of age will be 
enrolled in Ukraine. The study will include approximately 100 study participants.
The following patients will be eligible for enrollment in EP0060:
REDACTED
the f
the f
aneou
aneou
or obs
or ob
ue t
ue t
COPY 
This document 
M
2.3
2.3
cannot 
ther 
her P
M 12
12
be used 
hys
y
n neu
n neu
to
ysica
sica
support
ectroc
ctro
ign me
gn me
l
any
he fo
he f
ca
marketing 
o AEs
o AEs
bleles
fol
fo
authorization 
ollowi
ollow
usly by
sly b
erved
rved
application
neti
neti
and 
tics
ics
any extensions 
traven
raven
17 yea
7 yea
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 9 of 66
x
Open-label LCM (OLL) patients: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other 
pediatric study).
x
Prescribed-LCM (RxL) patients: currently receiving prescribed oral LCM from commercial 
supply (eg, VIMPAT) as adjunctive or monotherapy
x
Initiating iv LCM (IIL) patients: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL study 
participants.
Study participants can receive iv LCM as follows:
x
Replacement for oral LCM treatment (OLL and RxL study participants):
-
Clinical need administration: study participants currently taking prescribed oral LCM (or 
any enteric LCM administration, eg, LCM administration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health care 
facility, or other situations where iv administration is clinically appropriate and oral 
administration is not feasible (ie, surgery). In these study participants, the maximum 
number of iv doses of LCM is 10.
-
Elective administration: study participants currently taking oral LCM (or any enteric
LCM administration, eg, LCM administration by feeding tube) who elect to receive iv
LCM administration at an EMU or healthcare facility. In these study participants, the 
maximum number of iv doses of LCM is 2.
x
Adjunctive iv LCM treatment initiation (IIL study participants):
-
Clinical need administration: study participants not currently taking LCM who need to 
undergo a procedure, be treated at an EMU or health care facility, or other situations 
where iv administration is clinically appropriate and oral administration is not feasible 
(ie, surgery). In these study participants, the maximum number of iv doses of LCM is 10. 
-
Elective administration: study participants not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these study participants, the 
maximum number of iv doses of LCM is 2.
EP0060 is composed of the following study periods:
x
For all study participants:
-
Screening and/or Baseline Period (up to 7 days),
-
Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days (iv LCM will be 
administered bid at approximately 12-hour intervals, once in the morning and 
once in the evening, for up to 10 doses or up to 5 days).
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
-
End-of-Study/Final Visit (1 day),
REDACTED
lthc
lthc
M is 2
M is 2
ion (II
on (II
study
study
ed
ed
COPY
urren
urren
ation b
ation b
hcar
car
This document cannot
Trea
Trea
be
eeni
eeni
used
dy par
y par
to
ed 
ed o
support
nt usi
nt us
ber of 
er of
of th
of
any 
n:n: stud
stu
i
marketing
y pa
pa
d at an E
at an 
linicall
nical
y part
y par
authorization
by fe
y f
re faci
e faci
2.
IL stutu
parti
arti
application
parti
parti
ly takin
y tak
feed
feed
and 
unit
ni
lly ap
ly ap
any
ng tu
ng t
it (
t (E
extensions 
cribed
ribed
b
or variations 
study 
tudy 
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 10 of 66
-
End-of-Study/Telephone Contact 1 (1 to 3 days),
x
Additional visits or contacts as follows:
-
RxL and IIL study participants who are eligible and choose to continue oral LCM for 
up to 2 years in SP848
o
Transition Visit, which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
-
RxL and IIL study participants who do not continue LCM treatment in SP848
o
End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
The maximum study durations are as follows:
x
Approximately 16 days:
-
Study participants in the OLL group will resume participation in their respective 
study and either resume oral LCM treatment or follow taper regimen as described in
the long-term, open-label study accordingly.
x
Approximately 23 days:
-
Study participants in the RxL or IIL groups who, if determined clinically appropriate, 
are given the option to continue oral LCM treatment in SP848.
x
Approximately 45 days:
-
Study participants in the RxL or IIL groups who will not continue oral LCM 
treatment in SP848.
EP0060 is planned to include up to 2 age-based cohorts and will begin with Cohort 1, including 
at least 40 study participants ≥8 to <17 years of age. Within Cohort 1, at least 20 study 
participants will be ≥12 to <17 years of age and at least 20 study participants will be ≥8 to <12 
years of age. For the first 20 study participants in Cohort 1, iv LCM should be infused over a 
duration of 30 minutes but not longer than 60 minutes whenever possible.
The Data Monitoring Committee (DMC) will review the safety and tolerability data from the
first 20 study participants completed in Cohort 1. Based on this review, the DMC will make 
recommendations as follows:
x
EITHER approximately 30 additional study participants will be enrolled in Cohort 1 with 
target infusion duration of 15 minutes but no longer than 30 minutes only in study 
participants who would directly benefit from an increased infusion rate, in the opinion of the 
Investigator. Study participants who will not directly benefit from a 15 to 30 minute infusion
duration, in the opinion of the Investigator, cannot receive the faster infusion. These study 
participants should receive an infusion of 30 minutes but not longer than 60 minutes,
x
OR approximately 30 additional study participants will be enrolled in Cohort 1 with a target 
infusion duration of 30 minutes but not longer than 60 minutes,
x
OR study should be stopped,
REDACTED
al LC
al L
RxL or
RxL o
COPY 
groups
roups
LCM
LCM
This document
I
ca
p
nnot
get in
et in
partic
artic
ca
Inv
Inv
be
R ap
R ap
used
rtici
ici
ons a
ns a
to 
ng C
g
cipa
ipa
support 
0 stu
st
ut n
ut not
Com
Com
any
 year
 yea
tudy
tud
marketing 
r 
2 age
2 age b
o <17 
 <17
authorization
s wh
wh
M tre
M tre
IIL g
IIL 
application
tape
tap
ho
and
ation 
tion 
per
per
any extensions
v infu
infu
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 11 of 66
x
AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 study participants ≥1 month to <8 years of age will be enrolled 
to receive iv LCM. For the first 20 study participants in Cohort 2, iv LCM should be infused over 
a duration of 30 minutes but not longer than 60 minutes whenever possible. 
After completion of the first 20 study participants in Cohort 2, the DMC will review the 
available safety and tolerability data from Cohort 1 and Cohort 2. Based on this review, the 
DMC will make recommendations as follows:
x
EITHER approximately 30 additional study participants will be enrolled in Cohort 2 with a 
target infusion duration of 15 minutes but not longer than 30 minutes only in study 
participants who would directly benefit from an increased infusion rate, in the opinion of the 
Investigator. Study participants who will not directly benefit from a 15 to 30 minute infusion, 
in the opinion of the Investigator, cannot receive the faster infusion. These study participants
should receive an infusion of 30 minutes but no longer than 60 minutes,
x
OR approximately 30 additional study participants will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but not longer than 60 minutes,
x
OR Cohort 2 should be stopped.
The design will result in a total exposure of approximately 100 pediatric study participants to 
assess the safety and tolerability of iv LCM over a range of infusion durations. A completer for 
this study is defined as a study participant who completes at least 1 visit with iv LCM treatment 
and the associated assessments for that visit (eg, PK samples, vital signs, 12-lead ECG). The 
study participant should have ‘Completed study participant’ selected as a status at termination.
2.4
Determination of sample size
Approximately 100 study participants will be enrolled, which includes up to 2 cohorts of at least 
40 study participants for Cohort 1 and approximately 44 study participants for Cohort 2. No 
formal sample size calculation has been performed. The sample size was deemed clinically 
appropriate for the evaluation of safety, tolerability, and PK of iv LCM administration in 
pediatric study participants with epilepsy.
The following cohorts are planned:
x
Cohort 1: at least 40 study participants from ≥8 to <17 years of age, with at least 20 study 
participants from ≥12 to <17 years of age and at least 20 study participants from ≥8 to <12 
years of age
x
Cohort 2: approximately 44 study participants from ≥1 month to <8 years of age; every 
attempt will be made to enroll 20 study participants ≥4 to <8 years of age, 12 study 
participants ≥2 to <4 years of age, and 12 study participants ≥1 month to <2 years of age
The remaining study participants may be enrolled in either of the 2 age cohorts.
3
DATA ANALYSIS CONSIDERATIONS
3.1
General presentation of summaries and analyses
Statistical analysis and generation of tables, figures, study participant data listings, and statistical 
outputs will be performed using SAS Version 9.1 or higher. All summaries will be descriptive; 
o co
o co
t (eg,
eg, P
d d stud
stud
mple
mple
COPY
mate
mate
a rang
a ran
omp
om
This document 
p
Th
Th
cannot
hort 2
rt 2
attemp
ttemp
par
par
be
f age
ag
2
used 
ea
s from
from
ge
ge
to
st 4
st 4
support
s with
wit
s are pl
are p
any 
as 
as
of saf
of sa
h
marketing 
siziz
s will b
s will 
and 
nd ap
ap
s bee
s be
authorization
ge o
e o
mpletes
pletes
PK sa
PK sa
dy par
y par
ze
ze
application 
s,
y y 100
100
of in
of in
and
ed in 
d in 
any 
s,
C
extensions 
dy y
n
opini
opini
0 min
0 min
se e stu
stu
or 
wi
w
variations 
ith
ith
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 12 of 66
no statistical hypothesis testing is planned. All tables and listings will use Courier New font size 
9.
For categorical parameters, the number and percentage of study participants in each category will 
be presented. The denominator for percentages will be based on the number of study participants
appropriate for the purpose of the analysis. Unless otherwise noted, all percentages will be 
displayed to 1 decimal place. No percentage will be displayed for zero counts, and no decimal 
will be presented when the percentage is 100%. For continuous parameters, descriptive statistics 
will include number of study participants (n), mean, standard deviation (SD), median, minimum, 
and maximum, unless otherwise stated. For PK parameters, the coefficient of variation (CV) and 
geometric mean may also be presented.
Decimal places for descriptive statistics will always apply the following rules:
x
“n” will be an integer
x
Mean, SD, and median will use 1 additional decimal place compared to the original data
x
CV[%] will be presented with 1 decimal place
x
Minimum and maximum will have the same number of decimal places as the original value
However, the maximum number of decimals displayed will not exceed 4.
All summaries, unless otherwise stated, will be presented overall for all study participants and by 
age cohorts (≥1 month to <8 years and ≥8 to <17). Selected tables will be provided in addition 
by study participant groups (OLL and RxL, combined, and IIL) and target infusion duration (15-
30 minutes, and 30-60 minutes).
A complete set of listings containing all documented data and relevant derived data (eg, change 
from Baseline) will be generated.
3.2
General study level definitions
3.2.1
Analysis time points
3.2.1.1
First and last dose of iv LCM
Unless otherwise noted, all references to the first dose of iv LCM in this SAP refer to the first 
dose of iv LCM during EP0060. Unless otherwise noted, all references to the last dose of iv
LCM in this SAP refer to the last dose of iv LCM in this study.
3.2.1.2
Relative day and time
Relative Day is defined as the day relative to the first infusion of study drug.
If the current date occurred on or after the day of first dose of iv LCM and prior to or on the day 
of last iv LCM dose, the relative day will be calculated as the current date minus the date of first 
dose of iv LCM plus 1 (eg, the day of first dose will be Day 1).
If the current date occurred prior to the first dose of iv LCM, the relative day will be calculated
as date of first dose of iv LCM minus the current date (eg, the day prior to first dose will be 
Day -1).
REDACTED 
<17
<17
co
comb
mb
all do
all do
COPY 
d w
d 
resente
resen
7). S
7)
This document 
f lala
dose
dose
cannot
Da
Da
e curr
curr
ast
ast i
be 
ay i
ay
used 
P rere
Rel
Re
to 
ring
efer
efer
support
st d
st d
d, all re
all 
ng EP
g E
any
oint
oin
dos
do
marketing 
ocu
cu
l defin
defi
nts
nts
authorization 
ed o
ed 
Select
elect
bined,
ined,
ume
ume
application 
imal pl
mal p
l not ex
not e
d ove
ove
and any 
to the
to th
extensions or
CV
CV
variations 
tics
tics
imum
mum
V) a
V)
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 13 of 66
If the current date occurred after the last dose of iv LCM, the relative day will be calculated as 
the current date minus the date of last dose of iv LCM including a “+” to denote post-treatment 
days (eg, the day after the last dose will be Day +1). 
Relative day will not be calculated for partial dates.
Time will also be collected to ascertain if the event/sample/collection was before or after the first
iv LCM even if it happened on the same day.
In order to have a better insight into the times of AEs, concomitant antiepileptic drugs (AED),
laboratory samples, ECG and vital signs collections relative to the administration of study 
medication, the relative time will be displayed in hours and minutes for relative times ≤24 hours 
before and after first iv LCM administration. For relative times >24 hours the relative times will 
be displayed in days as described above.
3.2.2
Analysis periods
This study consists of a Screening and/or Baseline Period, an iv Treatment Period and a Post-iv
Treatment Period.
Screening and/or Baseline Period
This is defined as the period of time from Day -7 to Day 1 prior to the iv LCM first dose which 
means that the first visit can occur before or on the same day as the first iv LCM infusion.
iv Treatment Period
Treatment days are as follows:
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
The iv Treatment Period is defined as the period of time from the iv LCM first dose date and 
time to the iv LCM last dose date and time, inclusive.
Post-iv Treatment Period
This is defined as the period of time after the end date and time of the iv Treatment Period to the 
last contact with the study participant.
Listings will also include “Unscheduled Visit” as applicable.
3.2.3
Study visit labeling
Visits will be labeled in table summaries (according to the schedule outlined in Section 5.2 of the 
protocol) as follows:
x
“Visit X (Descriptor)” for scheduled visits during the Screening/Baseline Period
x
“Visit X” for scheduled visits during the iv Treatment Period
x
“Final Visit”
x
“Telephone Contact 1”
x
“Telephone Contact 2”
x
“Transition Visit”
REDACTED 
10 do
10 do
conse
conse
COPY
y
same 
same
This document 
x
cannot
ll 
ol) as
l) as
“Vis
“Vis
be
be la
be l
used 
inin
Stud
Stu
to
nclu
nclu
support 
riod of
od o
tudy pa
udy p
d
any marketing
ecutiv
ecuti
as the p
s the
and ti
and t
authorization 
oses or
ses or
application 
prior to
rior to
day as
day a
and 
e
any 
nt Pe
nt Pe
extensions
s ≤2
≤2
ive tim
ve ti
or 
y y 
24
24
variations 
D),
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 14 of 66
3.2.4
Exposure duration
Exposure duration refers to the first and last dose of iv LCM. The date of first infusion of study 
medication is defined as the first study medication infusion date according to the standard case 
report form (CRF) page.
The date of last infusion of study medication is defined as the last infusion of study medication 
reported on the standard trial termination CRF. 
The number of days of exposure is defined as the treatment stop date minus the treatment start 
date +1 day. Days with unknown or zero dosing which occur prior to the last infusion of study 
medication in the study should be included in the calculation.
3.2.5
Age and Age at first diagnosis
Age will be given in years and will be derived applying the rules for missing data imputation
(see Section 4.2.1 and the SDTM derivation definition). The age at first diagnosis will be given 
in years and will be derived applying all rules for missing data imputation (see Section 4.2.1)
with the following formulas:
Missing or partial epilepsy diagnosis date will be derived applying all rules for missing data 
imputation (see Section 4.2.1) and age at first diagnosis will use the following formulas, where 
applicable.
The following formula will be applied where birthdate is a complete date: 
(Date of first diagnosis of epilepsy – Date of birth) / 365.25
The following formula will be applied where birthdate is a partial date:
(Enrollment age in years) – [(Informed consent date – Epilepsy diagnosis date) / 365.25], if the 
value is negative then age at diagnosis will be set to zero.
3.2.6
Time since first epileptic seizure and last status epilepticus
Time since first epileptic seizure and time since last status epilepticus will be given in years and 
will be derived applying all rules for missing date imputation (see Section 4.2.1) with the 
following formula (respectively): 
(Date of informed consent - Date of first epileptic seizure) / 365.25 
(Date of informed consent - Date of last status epilepticus) / 365.25
3.2.7
Body mass index (BMI)
BMI will be calculated using the formula:
BMI = weight (kg) / (height (m))2
3.3
Definition of Baseline values
Baseline for laboratory variables (blood chemistry, hematology), vital signs, body weight, and 
quantitative electrocardiography (ECG) variables is defined as the last value prior to the first 
infusion of study drug (pre-iv LCM measurement). Individual laboratory variables should all 
come from the same timepoint. Same applies to the individual vital sign variables, except for 
weight. Both scheduled and unscheduled assessments from the central laboratory are considered.
REDACTED
f birth
f birth
where b
here 
med co
med co
isis
COPY 
thdate
hdate
This document 
3.3
3.3
B
cannot
ll be
l be
BMI =
BMI 
be 
e c
e c
used
rme
me
Bo
Bo
to 
d
ed
support
 rul
rul
ectively
ctive
d cons
cons
any
re an
re an
ules f
les
marketing
onse
nse
will be
will be
pileptic
lepti
nd
authorization
e is a
is a
h) / 36
) / 36
birthd
birthd
ent
ent
application
ng all 
ng all
use the
use th
a c
and 
ion
o
any
agno
agn
n (
n (se
s
extensions 
data
data i
nos
nos
or
stu
st
variations 
tart 
art 
tudy
udy
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 15 of 66
3.4
Protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary outcomes for an individual study participant. The criteria for 
identifying important protocol deviations will be defined within the appropriate protocol-specific 
document. Important protocol deviations will be reviewed as part of the ongoing data cleaning 
process and data evaluation. Important deviations will be identified and documented prior to 
database lock to confirm exclusion from analysis sets.
3.5
Analysis sets
3.5.1
Safety Set
The Safety Set (SS) will include study participants who received at least 1 dose of EP0060 study 
drug LCM (oral and/or iv). Selected safety summaries will be presented for the SS. If the SS and 
the SS-iv consist of the same number of study participants, tables will only be presented for the 
SS-iv.
3.5.2
Safety Set iv
The Safety Set iv (SS-iv) will include study participants in the SS who received at least 1 dose of 
EP0060 study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety 
data.
3.5.3
Pharmacokinetic-Per Protocol Set 
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all study participants in the SS-iv
having provided at least 1 measurable post-dose plasma sample (with recorded sampling time) 
on at least 1 study day with documented iv LCM intake times and without important protocol 
deviations impacting the interpretability of the PK analysis.
3.6
Treatment assignment and treatment groups
This is an open-label study with a single treatment arm. Study participants are summarized based 
on the age-based cohorts defined as:
•
≥8 to <17 years (Age Cohort 1)
•
≥1 month to <8 years (Age Cohort 2)
3.7
Center pooling strategy
No pooling of centers is planned for this study. 
3.8
Coding dictionaries
Medical history and AEs will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) version 16.1. Medications will be coded using the World Health Organization Drug 
Reference List (WHODD SEP/2013). Medical procedures will not be coded.
3.9
Changes to protocol-defined analyses
There are no changes to analyses specified in the protocol.
REDACTED
PPS
PS) w
st-dose
dose
d d iviv L
ility 
ility o
COPY 
Set 
et
This document
Me
Refe
Refe
3
cannot 
ical hi
cal hi
edDR
dDR
be used 
n
f cent
cent
to 
ter
ter
support
Coho
Coho
ears (
ars (A
any
ed as
ed a
t
marketing
of th
f th
nt an
nt and
singl
sing
authorization 
will in
will in
e plas
e plas
LCM
CM i
he
he
application
S 
S who
wh
nalysis
nalysi
and any extensions 
f EP0
EP0
e SS. 
SS. 
e pre
e pr
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 16 of 66
4
STATISTICAL/ANALYTICAL ISSUES
4.1
Adjustments for covariates
No statistical testing is planned; therefore, this section is not applicable for this study.
4.2
Handling of dropouts or missing data
No imputation of missing values for analysis parameters is planned unless otherwise noted. 
Imputations for missing or partial values for dates for AEs and concomitant medications will be 
applied to determine if an event is to be considered treatment-emergent or concomitant. Across 
safety and PK analysis, only reported data will be used. 
4.2.1
General imputation rule for incomplete dates
Where necessary for the calculation of derived variables, partial dates will be completed using 
the earliest calendar date based on the partial date provided. This rule is valid for all partial dates 
with the exception of the following:
x
Start and stop dates of concomitant medication
x
Start and stop date of adverse events
x
Start and stop dates of study medication
x
Date of epilepsy diagnosis
Completely missing dates will not be replaced and the corresponding derived variables will be 
set to missing.
4.2.2
Handling of prior and concomitant medications with missing data
Any medications with incomplete start and end dates will be handled according to the following 
rules for classification as prior and concomitant and for the calculation of relative study days.
Such imputations will only be performed for these classifications and calculations; in the listings 
all data will be shown as recorded on the electronic case report form (eCRF).
Imputation of Partial Start Dates
x
If only the month and year are specified and the month and year of first dose is not the same 
as the month and year of the start date, then use the 1st of the month.
x
If only the month and year are specified and the month and year of first dose is the same as 
the month and year of the start, then use the date of first dose.
x
If only the year is specified, and the year of first dose is not the same as the year of the start 
date, then use January 1 of the year of the start date.
x
If only the year is specified, and the year of first dose is the same as the year of the start date, 
then use the date of first dose.
x
If the start date is completely unknown and the stop date is unknown or not prior to the date 
of first dose, then use the date of first dose.
Imputation of Partial Stop Dates
x
If only the month and year are specified, then use the last day of the month.
REDACTED
d and
d an
conco
conco
art a
art a
COPY 
d t
d t
This document 
I
cannot
ly t
y t
ate, th
te, th
If o
If o
be 
the
the
used
month
onth
and 
and 
to 
d y
h
support
Date
Date
nd yea
nd yea
year o
year 
any 
d d
tes
tes
marketing
and en
nd en
oncomi
ncom
formed
orme
d on t
on
authorization 
the co
he co
omita
mita
application and any extensions 
comple
omple
d for 
for 
or variations 
 be
be
cross 
cross 
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 17 of 66
x
If only the year is specified, then use December 31 of that year.
x
If the stop date is completely unknown, do not impute the stop date.
In the event of ambiguity or incomplete data which makes it impossible to determine whether a 
medication was concomitant or not, the medication will be considered as concomitant.
4.2.3
Handling of adverse events with missing data
Any AEs with incomplete onset and outcome (end) dates/times will be handled according to the 
following rules for classification as treatment-emergent. Such imputations will only be 
performed for these classifications; in the listings all data will be shown as recorded on the 
eCRF. 
Imputation of Partial Onset Dates
x
If only the month and year are specified and the month and year of first dose of iv LCM is
not the same as the month and year of onset, then use the 1st of the month.
x
If only the month and year are specified and the month and year of first dose of iv LCM is
the same as the month and year of onset, then use the date/time of first dose of iv LCM.
x
If only the year is specified, and the year of first dose of iv LCM is not the same as the year 
of onset, then use January 1 of the year of onset.
x
If only the year is specified, and the year of first dose of iv LCM is the same as the year of 
onset, then use the date/time of first dose.
x
If the AE onset date is completely unknown, then use the date of first dose of iv LCM.
x
If the onset time of the event is unknown, impute it as 00:00 unless the known part of the 
onset date is the same as the date of first iv LCM dose; in this case impute the time of first 
dose of iv LCM dose.
Imputation of Partial End Dates
x
If only the month and year are specified, then use the last day of the month.
x
If only the year is specified, then use December 31 of that year.
x
If the AE resolved and the resolution date is completely unknown, then do not impute the 
resolution date.
With respect to AEs, events with missing intensity will be assumed to be severe. Events with 
missing relationship to iv LCM per the investigator will be assumed to be related.
Data handling for worsened AEs is provided below. The standard AE CRF has the outcome of 
“worsened” to be used when there is an increase in the intensity of an AE. The definition of 
“worsened” is when the AE is still present but at a heightened intensity. CRF instructions dictate 
to complete a new AE screen with the event term of the worsened event.  
Note that the outcome of “worsened” is not allowed terminology within the CDISC standards. In 
the SDTM.AE, the data is mapped to the outcome “Not Recovered/Not Resolved”. The outcome 
of “Worsened” will be kept in SDTM.SUPPAE. For study participant data listings, the 
convention will be to use the mapped SDTM terminology of “Not Recovered/Not Resolved”.
REDACTED 
known
know
nknow
nknow
e of
e of
COPY 
first d
rst d
This document 
wo
w
“wor
“wor
toto
cannot 
rela
el
handl
handl
orsen
rsen
be 
t to
latio
latio
used 
ate.
to A
o A
to
ved 
ved 
support 
earar
pecifie
ecifie
d and
an
any 
r are 
r ar
marketing 
wn
wn
f first 
first i
authorization
dose
ose o
wn, the
n, the
n, im
, im
application
me of 
e of
v LCM
LCM
of
and 
of fir
of fir
f f
f f
any 
month
onth
extensions 
n t
dose 
ose 
or 
the
he
variations 
the
the
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 18 of 66
4.2.4
Handling of study medication with missing data
No imputation should be performed for missing study medication start dates. This field on the 
CRF should not be partial or missing.
For partial or missing date of last dose of study medication, the following imputation rules will 
be applied for the purpose of calculating overall exposure:
x
If the day is missing (but month and year available), impute the last dose date as the 
minimum of the last day of the month or the date of last contact reported on the trial 
termination CRF; if day and month are both missing (only year available), impute the last 
dose date as the minimum of the last day of the year or the date of last contact on the trial 
termination CRF.
x
If a study participant died and has a partial or missing last administration date, the date is to 
set to the date of death. If there is a partial date of last dose and the month/year are prior to 
the month and year of the date of death, follow partial date imputation rules.
x
If the last dose date is completely missing and no information could be obtained from data 
cleaning exercises, the last dose date should be imputed as the date of last contact according 
to the study termination CRF. A review of the data for study participants with completely 
missing last dose dates should be performed to ensure that the imputation does not result in 
an unrealistic value for duration of exposure. 
x
Imputed date of last dose dates should only be used for calculation of the duration of 
exposure. The date as recorded on the CRF should be presented in study participant data 
listings (no imputed dates should be included in study participant data listings).
4.2.5
Handling of epilepsy diagnosis with missing data
Imputation methods should be applied for missing or partial epilepsy diagnosis date. 
x
If the month and year are available, the diagnosis date is imputed as the later of the 
following dates: the first day of the month, the study participant’s birthdate, or the date of 
the first seizure (if available).
x
If only a year is available, the later of the following dates will be imputed: January 1st of
the year, the study participant’s birthdate, and the date of the first seizure.
x
Completely missing dates will not be replaced and the corresponding derived variables 
will be set to missing.
4.3
Interim analyses and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 study participants in Cohort 1 and after 
completion of the first 20 study participants in Cohort 2.
No formal stopping rule will be applied. The DMC may give a recommendation to stop the study 
after reviewing the safety data as described below. A recommendation for stopping should be 
based on the collective experience of the DMC members. After meeting to review data from each 
cohort, the DMC will provide a recommendation in writing regarding whether to continue or to 
REDACTED
y be
y be
CRF sh
RF sh
includ
nclud
y diag
y diag
COPY 
sur
su
e u
e u
This document 
evie
vi
comp
comp
N
cannot 
ormal
ormal
iewe
ewe
be used
tely 
ely m
e set t
set t
to 
st
m
support 
avai
vai
s availa
avail
tudy p
udy 
any
st day
t da
ilab
ilab
marketing
gnos
no
d for m
d for m
availab
availa
y
authorization 
used fo
sed fo
hould 
ould
ded in
ed in
osis
sis
application
e date
e dat
dy part
dy par
hat the
at th
and 
uld b
uld b
any 
thth
n rule
n rul
extensions
the 
he
date, t
ate, t
h/ye
h/ye
or
e la
e la
e trtr
variations 
last
ast
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 19 of 66
stop the study. UCB will consider this recommendation and ensure the study investigators are 
informed of the sponsor’s decision on how to continue as described below.
The DMC members will be defined in the DMC charter. 
EP0060 will begin with Cohort 1, where at least 40 study participants ≥8 to <17 years of age will 
be enrolled to receive iv LCM. Within Cohort 1, at least 20 study participants will be ≥12 to <17 
years of age and at least 20 study participants will be ≥8 to <12 years of age. For the first 20
study participants in Cohort 1, iv LCM should be infused over a duration of 30 minutes but not
longer than 60 minutes whenever possible.
After completion of the first 20 study participants in Cohort 1, the DMC will review the safety 
and tolerability data from these study participants. Based on this review, the DMC will make 
recommendations as follows:
x
EITHER approximately 30 additional study participants will be enrolled in Cohort 1 with 
target infusion durations as follows:
-
15 minutes but not longer than 30 minutes only in study participants who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator; 
OR,
-
30 minutes but not longer than 60 minutes in study participants who would not 
directly benefit from an increased infusion rate, in the opinion of the Investigator
x
OR approximately 30 additional study participants will be enrolled in Cohort 1 with a target 
infusion duration of 30 minutes but not longer than 60 minutes,
x
OR study should be stopped,
x
AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 study participants ≥1 month to <8 years of age will be enrolled 
to receive iv LCM. For the first 20 study participants in Cohort 2, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 study participants in Cohort 2, the DMC will review the 
available safety and tolerability data from Cohort 1 and Cohort 2. Based on this review, the 
DMC will make recommendations as follows: 
x
EITHER approximately 30 additional study participants will be enrolled in Cohort 2 with
target infusion durations as follows:
-
15 minutes but not longer than 30 minutes only in study participants who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator; 
OR,
-
30 minutes but not longer than 60 minutes in study participants who would not 
directly benefit from an increased infusion rate, in the opinion of the Investigator
x
OR approximately 30 additional study participants will be enrolled in Cohort 2 with target 
infusion duration of 30 minutes but not longer than 60 minutes, 
x
OR Cohort 2 should be stopped.
REDACTED
rticip
rticip
long
long
nitia
nitia
COPY 
s s inin
PY
sion r
ion 
This document cannot
1
be 
nfus
15
15
used
pprox
prox
usion
sion
to 
com
om
support 
first 
rst 20
olerabil
erabi
mme
mm
any 
0
no lon
o lon
marketing 
ated.
ted.
udy par
dy pa
0 stud
stu
authorization 
atete
antnts w
s w
ger tha
r tha
application
 opin
 opin
tudy pa
udy p
pp
e, in
e in
and 
partic
artic
an
i
any extensions
the s
he 
will m
will 
in C
n C
or 
sa
sa
variations 
not
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 20 of 66
4.4
Multicenter studies
No multicenter analysis is planned therefore this section is not applicable for this study. 
4.5
Multiple comparisons/multiplicity
No statistical testing is planned; therefore, this section is not applicable for this study.
4.6
Use of an efficacy subset of study participants
No efficacy data are collected; therefore, this section is not applicable for this study.
4.7
Active-control studies intended to show equivalence
This section is not applicable for this study.
4.8
Examination of subgroups
For analyses, the study participant groups and the target infusion duration groups will be
combined to create a 4-level subgroup:
x
OLL and RxL study participants/15 – 30 minutes
x
OLL and RxL study participants/30 – 60 minutes
x
IIL study participants/15 – 30 minutes
x
IIL study participants/30 – 60 minutes
5
STUDY POPULATION CHARACTERISTICS
5.1
Study participant disposition
Study participants who were screen failures, broken down by primary reason for screening 
failure will be presented overall for all study participants screened.
A summary of disposition of study participants will be provided for all screened study 
participants. The date of first study participant in (date of first Screening visit), date of last study 
participant out (date of last visit (in clinic) for last study participant), number of study 
participants screened, and the number of study participants in each analysis set (SS-iv, SS and
PK-PPS) will be summarized overall, by country and by investigator site. Study participants who 
transferred sites will be summarized according to their original site. 
A summary of disposition of analysis sets will be provided for all study participants screened:
x
The number and percentage of study participants in the SS-iv
x
The number and percentage of study participants in the SS
x
The number and percentage of study participants in the PK-PPS
A summary of disposition and discontinuation reasons will be presented for all study participants
in the SS-iv and the SS. The summary will be presented by age cohort, all study participants and 
by subgroup. The following information is included:
x
The number and percentage of study participants starting the study
x
The number and percentage of study participants completing the study 
REDACTED
ARA
RA
ition
ition
failure
failure
all
all
COPY 
AC
This document
A su
A su
in 
in
canno
The 
he 
x
Th
T
be 
nu
nu
n
sed
ispo
spo
umb
umb
to 
osi
osi
support 
the n
he n
arized 
rized
be sum
e sum
any
y
sisit (in
t (in
num
n
marketing 
es, ,
study p
tudy 
partici
partic
y par
y pa
uthorization 
CTER
CTER
, bro
bro
application and any 
ro
ro
extensions 
oups
oups
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 21 of 66
x
The overall number and percentage of study participants discontinuing and the number 
and percentage of study participants discontinuing by primary reason for discontinuation
A summary of discontinuations due to AEs for the SS-iv will present the number and percentage 
of study participants who discontinued this study due to AEs broken down by type of AE. The 
table will be presented by age cohort, all study participants and by subgroup and will be repeated 
for the SS.
The following listings will be provided: study participants who did not meet study eligibility 
criteria, study participant disposition, study discontinuation, study participant analysis sets, study 
participants excluded from at least one analysis set, visit dates, and study participant number.
5.2
Protocol deviations
Important protocol deviations defined in the protocol-specific document, and additionally 
identified at the data evaluation meetings, will be listed. In addition, the number and percentage 
of study participants with at least one important protocol deviation will be summarized overall 
and by category of important protocol deviation for the SS-iv and the SS. The number and 
percentage of study participants with no important protocol deviations will also be summarized.
6
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS
6.1
Demographics and other Baseline characteristics
Demographic variables will be presented for the SS-iv and the SS. The variables to be considered 
are:
x
Age at entry into EP0060 
x
Categorized age:
o
EudraCT age categories: >=1 month to < 2 years, >=2 to <12 years and >=12 to
<17 years 
o
Age cohort categories: >=1 month to < 2 years, >=2 to <4 years, >=4 to <8 years, 
>=8 to <12 years and >=12 to <17 year
x
Gender
x
Study participant group (OLL, RxL, and IIL)
x
Target infusion duration (15-30 minutes and 30-60 minutes)
x
Subgroup: (OLL/15 – 30 minutes, OLL/30 – 60 minutes, RxL/15 – 30 minutes, RxL/30 –
60 minutes, IIL/15 – 30 minutes, IIL/30 – 60 minutes)
x
Weight (kg)
o
Categorized weight: 0 to <30kg, 30 to <50kg, >=50kg
x
Height (cm)
x
BMI (kg/m2) (as defined in Section 3.2.7 )
x
Racial group (American Indian/Alaskan Native, Asian, Black, Native Hawaiian or Other 
Pacific Islander, White, and Other/Mixed)
REDACTED COPY
hara
har
SS
SS-iviv
This document cannot
60 m
0 m
W
be
bgrou
bgro
min
mi
used
nfusi
nfusi
up
up
to 
ipa
pa
support 
ea
ant
ant
any
gorie
gori
ars an
rs an
marketing 
s: >=1 
>=1 
ies
ies
authorization
and
and
application 
ion
on
NE CH
E CH
cterist
teris
d th
and
SS
SS. . 
ns w
ns w
any 
mb
m
e sum
e sum
Th
T
extensions 
um
additio
dditio
mber 
ber 
or
mbe
mbe
variations 
y
, stud
stu
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 22 of 66
x
Ethnicity (Hispanic or Latino or Not Hispanic or Latino)
x
Country
o
US
o
Germany
o
Hungary
o
Italy
o
Poland
o
Thailand
o
Ukraine
x
Vagus nerve stimulation (VNS) use (Active VNS, No VNS, and VNS not active)
Listings of demographics, VNS at screening and childbearing potential will be provided.
6.2
Medical history 
Medical history for RxL and IIL will be obtained from the Screening Visit Medical History 
eCRF module in EP0060. Medical History for OLL study participants will come from their 
medical history from their respective previous study.
The number and percentage of study participants with a medical history condition (except 
epilepsy), including both resolved and ongoing conditions, will be summarized by MedDRA 
primary system organ class (SOC) and preferred term (PT) for the SS-iv. Previous and ongoing 
medical history glossary and previous and ongoing medical history conditions listings (except 
epilepsy) will be provided. 
6.3
Potential Drug-Induced Liver Injury (PDILI)
Where applicable, potential drug induced liver injury will be captured as described in
Section 12.2.4 and DILI information will be listed (see Section 8.3).
6.4
History of epilepsy
6.4.1
History of seizure types
The number and percentage of study participants experiencing partial-onset seizures (type I), 
simple partial (type IA), complex partial (type IB), partial, secondary generalized (type IC), 
generalized  (type II), absence (IIA), myoclonic (IIB), clonic (IIC), tonic (IID), tonic-clonic 
(IIE), and atonic (IIF) seizures during 4 weeks prior to the screening visit for EP0060 will be
summarized for the SS-iv based on the International League Against Epilepsy (ILAE) Seizure 
Classification Historical Seizure Count eCRF module.
A study participant will be classified as having a history of partial-onset seizures (I) if the study 
participant has a history of simple partial (IA), complex partial (IB), or partial evolving to
secondary generalized (IC) seizures. A study participant will be classified as having a history of 
generalized seizures (II) if the study participant has a history of primary generalized with an 
unknown subtype (II), absence (IIA), myoclonic (IIB), clonic (IIC), tonic (IID), tonic-clonic 
(IIE), or atonic (IIF) seizures. A study participant may also be classified as having a history of 
unclassified epileptic seizures (III).
REDACTED 
ntnts w
s 
oing co
ing co
referre
referr
 and o
 and 
COPY 
stud
stu
dy
dy.
wit
wi
This document 
a
A s
cannot
nd at
d at
marize
arize
ssifi
ssifi
be
d  (ty
d  (ty
toto
used
per
per
(type
(type
yp
to 
rce
rce
support 
f epile
f epil
ry of s
y of 
any 
ini
matio
matio
marketing 
uced L
ced L
induc
ndu
authorization 
ith a m
h a m
onditi
nditi
red ter
ed ter
ngoin
ngoin
application 
reening
eenin
partici
artic
and
al wi
w
any
NS 
NS
will b
will
extensions 
S no
no
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 23 of 66
6.4.2
History of seizure characteristics
History of withdrawal seizures, history of status epilepticus, age at first diagnosis (as defined in 
Section 3.2.5), time since first epileptic seizure (as defined in Section 3.2.6), and time since last 
status epilepticus (as defined in Section 3.2.6) will be summarized and listed where available.
For direct enrollers, this information will be collected in the History of Epileptic Seizures eCRF 
for EP0060. For OLL study participants this information will come from their previous study.
6.4.3
Historical seizure counts
The Historical Seizure Count eCRF module records the number of seizures per pre-selected 
ILAE seizure code experienced by the study participant during the 4 weeks prior to the 
Screening Visit. These data will be provided in a study participant data listing. For OLL study 
participants this information will come from their previous study.
6.5
Prior and concomitant medications
Prior medications include any medications that started prior to the date of first dose of LCM 
study drug. Concomitant medications are medications taken at least one day in common with 
study drug LCM in EP0060. Medications may be both prior and concomitant.
For OLL study participants only concomitant medication which started during the EP0060 study 
will be recorded in the EP0060 study. Information of medication which started before EP0060 
study start will come from the respective OLL study. Prior AEDs will be defined by a manual 
medical review of all unique combinations of ATC codes and indications reported in the 
database to identify prior medications taken to treat epilepsy.
Medications will be listed as follows: prior and concomitant non-AEDs, glossary of non-AEDs 
with verbatim term coded into ATC levels 1 and 2, prior and concomitant AEDs, and glossary of 
AEDs with verbatim term coded into ATC level 4.
Handling of prior and concomitant medications missing data is described in the Section 4.2.2.
6.5.1
Concomitant Non-AEDs
Non-AEDs taken at least one day in common with LCM study drug in EP0060 will be 
considered as concomitant medications. Medications will be summarized by ATC Code level 1
and 2 for the SS-iv. Study participants reporting multiple medications within an ATC class are 
counted once per medication and class. 
6.5.2
Concomitant AEDs
Concomitant AEDs are defined as AEDs taken concomitantly for at least one day in common 
with LCM study drug in EP0060. AEDs are reported on the Concomitant Medications (AEDs 
only) eCRF page. Concomitant AEDs will be summarized by Level 4 ATC code and generic 
medication name. If a medication identified as an AED does not code to a level 4 ATC code, the 
highest level of coding will be displayed along with the generic medication name. Summaries of 
AEDs will be presented separately from other concomitant medications for the SS-iv population.
6.6
VNS setting and ketogenic diet
Two separate listings for Vagus Nerve Stimulation Status at Screening and since last visit will be 
provided.
REDACTED 
AT
AT
to tre
to tre
rior an
rior an
evels 
evels 
o AT
AT
COPY 
me
m
dy.
dy. Pr
P
TC c
C c
This document
medi
edi
hig
high
A
cannot
CM s
y) eCR
eCR
dica
ica
be
ant A
ant A
used 
Con
Con
to
medi
medi
support
ne d
e d
nt med
nt me
tudy p
udy p
ca
any 
on-
day
day
marketing 
1 
TC lev
TC le
medica
medic
AE
A
authorization 
rior
codes 
odes 
eat epi
at epi
nd con
d con
 and
and
application 
conco
onc
ich star
ich sta
cation
catio
or AE
r A
and
o
one d
one d
com
o
any 
f firs
f firs
extensions 
he
OLL
OLL
or 
ed
e
variations 
d
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 24 of 66
Ketogenic diets data reported on Special Diets eCRF will be presented in a study participant
listing.
6.7
Medical procedures
Concomitant medical procedures per study participant will be listed.
In addition, a listing of procedure history for study participants who had any procedures or 
surgeries prior to study entry will be provided.
For RxL and IIL study participants, procedure history will be obtained from the Procedure 
History eCRF. For OLL study participants, procedures with stop dates prior to the date of first 
dose of iv LCM in EP0060, procedure history will be obtained from the respective OLL 
Concomitant Procedure eCRF.
7
MEASUREMENTS OF TREATMENT COMPLIANCE
Information reported on the eCRF Drug Accountability (iv formulation) will be listed. The data 
from the eCRF Drug Accountability (Oral solution) will also be listed. No summaries of these 
results are planned.
LCM dosing compliance will be evaluated through the review of important protocol deviations.
8
SAFETY ANALYSES
All analyses for extent of exposure and safety are performed for the SS-iv.  
Inferential statistical tests are not planned for the safety variables.
8.1
Extent of exposure
The duration of iv LCM exposure, as defined in Section 3.2.4, will be summarized as a 
continuous parameter (in days). The number of LCM infusions received will be summarized 
categorically. The exposure table will be presented by age cohort, all study participants and by 
subgroup. Handling of study medication missing data is described in Section 4.2.4.
The following listings will be provided: LCM dosing history, oral LCM administration, study 
medication administration and exposure to study medication. 
8.2
Adverse events
All adverse events occurring during EP0060 (ie, after signing of the ICF) must be reported. The 
treatment-emergent adverse events (TEAEs) are defined as those events that started on or after 
the date (and time) of first infusion of study medication and within 30 days following the date of 
last study medication, or adverse events whose intensity worsened on or after the date (and time)
of first infusion of study medication and within 30 days following the last study medication 
infusion date. For OLL study participants where the adverse event started prior to EP0060 
enrollment information will come from the respective OLL study.
Only RxL and IIL study participants who do not continue LCM treatment in SP848 will have a
Telephone Contact 2 visit (Section 2.3) 30 days after the last dose follow-up.
Data handling rules for management of missing or partial start or stop dates for adverse events 
should follow those defined in the Section 4.2.3.
AE Summaries
REDACTED
r the s
r the 
s defin
s defin
nu
nu
COPY 
e perfo
e perf
This document
enrol
nrol
O
cannot 
y m
infus
nfus
usion
sion
llll
be 
d ti
me
medid
used
s o
s 
rgent 
gent 
time
ime
to
occu
occ
support
and 
and 
e even
e eve
any 
provi
prov
ex
marketing 
ned
ed
mber o
mber 
ill be p
l be 
ication
catio
authorization
orm
rm
afety 
afety 
d in
d in
application 
of imp
of imp
med
med
and 
No
No
any
will
will b
o su
o s
extensions 
OLL
LL
or
of fi
of f
variations 
i
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 25 of 66
The following summaries will be produced:
x
Incidence of TEAEs – Overview 
x
Incidence of TEAEs  
x
Incidence of TEAEs – Study participant Numbers
x
Incidence of serious TEAEs 
x
Incidence of non-serious TEAEs
x
Incidence of serious TEAEs by relationship to LCM
x
Incidence of non-serious TEAEs by relationship to LCM
x
Incidence of other significant TEAEs (refer to Section 12.1 for a list of MedDRA 
preferred terms which define other significant TEAEs)
x
Incidence of TEAEs related to Potentially Drug Induced Liver Injury (PDILI) (refer to 
Appendix 12.4 for a list of MedDRA preferred terms which define TEAEs related to 
PDILI)
x
Incidence of TEAEs for iv Treatment Period and Post-iv Treatment Period 
x
Incidence of serious TEAEs for iv Treatment Period and Post-iv Treatment Period
x
Incidence of drug-related TEAEs
x
Incidence of TEAEs by Maximum Intensity  
x
Incidence of non-serious TEAEs occurring in at least 5% of study participants
x
Incidence of non-serious TEAEs occurring in at least 5% of study participants by 
relationship to LCM
x
Incidence of TEAEs leading to Study Discontinuation
x
Incidence of fatal TEAEs by relationship to LCM
x
Incidence of TEAEs leading to permanent discontinuation of LCM
x
Incidence of TEAEs Leading to permanent discontinuation of LCM - Study participant
Numbers 
Overview of the Incidence of AEs will include all study participants with at least one TEAE, 
serious TEAEs, non-serious TEAEs, study participant discontinuations due to TEAEs, 
permanent withdrawal of study medication due to TEAEs, drug-related TEAEs, drug-related 
serious TEAEs, severe TEAEs, all deaths (AEs leading to death), and TEAEs leading to death.
AEs will be summarized by MedDRA SOC and MedDRA PT. The tables will be presented by 
age cohort, all study participants and by subgroup. The number and percentage of study 
participants experiencing each event at least once will be summarized. All summaries will be 
sorted alphabetically by SOC and by frequency of events within PTs, starting with the most 
frequent event overall. 
AE Listings
Inten
Inten
Es occ
Es oc
AE
AE
COPY 
nt Per
nt Per
This document 
AEs 
AEs
ag
ag
cannot 
TEA
EA
anent w
nent 
ous T
ous T
be 
f thth
AEs
AEs
used 
s 
he
he I
to
f TE
f TE
support 
EAE
EA
EAEs le
AEs l
EA
EA
any 
din
din
AEs b
AEs
marketing 
Es occu
s occu
ng to
ng t
authorization 
nsity 
ity 
currin
urrin
application 
t-iv Tr
iv T
od an
od an
and 
Inju
nj
define
defin
any 
ury 
ury
extensions 
f Med
Med
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 26 of 66
All AEs reported during the study will be provided in a study participant data listing. 
The following AE listings will be provided:
x
Glossary table for all TEAEs, where the terms included on the table should match those 
presented in other AE displays 
x
All AEs 
x
All serious AEs 
x
All AEs leading to study discontinuation
x
Listing of all deaths 
x
Other significant TEAEs
x
All AEs related to PDILI
x
All AEs which worsened during the study
x
All AEs which occurred under oral LCM   
Should it occur, any uncoded AEs should be designated as “UNCODED” at all MedDRA levels, 
and such AEs should be included in summary tables and study participant data listings based on 
this classification (eg, SOC and PT set to UNCODED).
8.3
Clinical laboratory evaluations
Laboratory values are collected at screening and /or baseline visit (if baseline visit is a different 
day than screening visit) and at the Final Visit. Continuous laboratory variables (hematology and 
clinical chemistry) summary statistics of actual values and change from Baseline will be 
presented by age cohort, for all study participants overall and by subgroup at each study visit.
Shifts from baseline to end of treatment based on the normal range (ie, low, normal, high, and 
missing) for each hematology and clinical chemistry lab parameter will be presented. 
The number and percentage of study participants with laboratory treatment-emergent marked 
abnormalities (TEMA) (hematology and clinical chemistry) as defined in Section 12.2 are to be 
summarized by laboratory parameter. Laboratory TEMA are those that are observed during the 
iv treatment period at scheduled or unscheduled visits and were not observed at any visit during 
the Baseline period. A study participant number table will be presented for study participants
with laboratory assessments meeting the TEMA criteria. 
The following listings will be provided: a separate study participant data listing for TEMA (all
laboratory assessments for study participants with TEMA are to be included in the listing), all 
laboratory results of clinical chemistry and hematology and serum and urine pregnancy 
laboratory tests.
Study participants who meet one or more of the criteria for potential drug-induced liver injury 
(PDILI) at any timepoint (from both scheduled and unscheduled visits) will be listed (see 
Section 12.2.3). The listing will display only visits for which at least one of the criteria in
Section 12.2.3 was fulfilled for a given study participant, and will display all results obtained at 
that visit for the specified variables. Potential Hy’s law cases will be flagged. If applicable, a 
summary of study participants who met the criteria for PDILI will be presented separately from 
REDACTED 
ns
ns
g and 
g and
l Visit
l Visi
s of ac
s of ac
y pa
y pa
COPY 
nd
n
ED)
ED).
This document
labor
abor
St
St
cannot
w
tory a
ory a
orator
rator
ra
be
wi
wing 
ng 
used
iod. 
od. 
ry ass
y ass
to
at s
at s
A
support
o
hemato
emat
tory pa
ory p
sche
sch
any 
f f stud
stud
marketing 
ctu
articip
rticip
ment b
ment b
d clini
clin
authorization 
d /or b
/or b
it. . Con
Con
ual v
ual 
application 
NCOD
NCOD
udy par
dy pa
and any extensions or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 27 of 66
all relevant data collected. Results from unscheduled visits and local laboratory should be 
included, if applicable.
All potential drug-induced liver injury (PDILI) events require immediate action, testing, and 
monitoring (see Section 12.2.4). The measurements and additional information required for the 
assessment of PDILI events when there is a reasonable possibility that they may have been 
caused by the IMP are included but not limited to those listed in (laboratory measurements) and 
(Appendix 12.4) (additional information).
Additional PDILI information will also be listed. If specific PDILI information collected 
separately is matching to the entries in the standard eCRF pages collected for all study 
participants, the specific PDILI information will be added to the corresponding listing for the 
standard eCRF information. For information collected on top (eg, family history of PDILI,
lifestyle) a new listing will be generated.
The number of study participants meeting the criteria for Hy’s Law will be summarized. The 
criteria of Hy’s Law are as follows:  
• (ALT or AST ≥ 3×ULN) and total bilirubin ≥ 2×ULN 
In order to meet the above criteria, a study participant must experience the elevation in total 
bilirubin and ALT or AST at the same visit. For example, a study participant who experiences a 
>=2 x ULN elevation of total bilirubin at one visit and a 3 x ULN elevation in ALT (or AST) at a 
subsequent visit has not fulfilled the Hy’s Law criteria. A study participant with ALT and AST 
values missing or a study participant with total bilirubin value missing has not fulfilled the Hy’s 
Law criteria.
8.4
Vital signs, physical findings, and other observations related to safety
8.4.1
Vital signs
Vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], and pulse rate) will be 
collected according to the protocol schedule of study assessments.
Observed values of SBP, DBP, and pulse rate will be summarized for each visit and time point.
Change from Baseline for SBP, DBP, and pulse rate will be summarized for all post-Baseline 
visits and time points. Tables will be provided by age cohort and subgroup. Actual values and 
change from Baseline for SBP, DBP and pulse rate will be plotted for a line graph by visit, time 
point, and age cohort.
Markedly abnormal (MA) vital sign values are defined as those MA post-baseline values which 
occur on or after the first EP0060 iv LCM administration through to the end of the study.
The number and percentage of study participants with MA values at each post-Baseline visit will 
be presented. Percentages will be relative to the number of study participants with a value at each
visit. Summary of MA vital signs study participant numbers will be provided. All post-baseline 
vital signs measurements (scheduled and unscheduled) will be assessed to determine MA
criteria.
The abnormal vital sign criteria are defined as follows:
REDACTED
al bil
al bi
fin
fin
COPY 
plp
and a 
and a
riteria
iteri
i
This document
The n
he 
be p
be p
v
cannot
ly ab
y ab
on or
on or
nu
nu
be 
ge 
abn
abn
sed
aselin
selin
e coh
coh
to 
nts
nts.
support 
roto
P, DBP
 DBP
e for S
for S
Ta
T
any
ure 
ure
tocol
tocol
marketing 
ndings
dings
e [S
e [
authorization 
a. A
a. A
irubin 
rubin
application 
perien
erien
study 
study
3 x UL
 x U
t
and any
sum
su
extensions
ng for
ng fo
of PD
of PD
m
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 28 of 66
Table 8‒1: Vital signs abnormality criteria
Parameter
Age Range
Abnormality Criteria
Pulse Rate 
(beats/minute)
<6m
<100
>180
6m - <3y
<90
>150
3y - <12y
<60
>130
12y - <17y
<50
>120
≥17y
<50 and a decrease from Baseline of ≥15
>120 and an increase from Baseline of ≥15
Systolic Blood 
Pressure (mmHg)
<6m
<60
>100
6m - <3y
<70
>120
3y - <12y
<80
>140
12y - <17y
<90
>160
≥17y
≤ 90 and a decrease from Baseline of ≥20
≥ 180 and an increase from Baseline of ≥20
Diastolic Blood 
Pressure (mmHg)
<6m
<40
>65
6m - <3y
<45
>75
3y - <12y
<50
>80
12y - <17y
<50
>105
≥17y
<50 and a decrease from Baseline of ≥15
>105 and an increase from Baseline of ≥ 15
Respiratory Rate 
(breaths/minute)
<6m
<25
>55
6m - <3y
<20
>45
3y - <12y
<15
>35
≥12y
<10
>25
Temperature
>1m
>101 0F (38.3 0C)
Body Weight
1m - <17y
<3% or !97% of the normal body weight growth 
curve ranges based on gender and the age of study 
participant on date of weight assessmenta
REDACTED 
90 a
90 a
≥ 180
≥ 180
<4
<4
CT
AC
RE
COPY 
and
and
CO
This document 
m
cannot be used 
te
ute)
te)
to 
to support 
y y
≥17
≥1
po
u
any 
- <17
<17
ny marketing
<
ng
y
rk
authorization 
d a de
a de
0 and 
and 
on
40
>65
>65
ori
a
application 
n
lic
and any 
a
extensions 
≥15
15
ne of ≥
e of ≥
on
xt
or variations 
io
tioioio
v
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 29 of 66
Table 8‒1: Vital signs abnormality criteria
Parameter
Age Range
Abnormality Criteria
≥17y
≥ 10% change from Baseline (an increase or a 
decrease)a
Abbreviations: m = month, y = year. A month is defined as 30 days; a year is defined as 
365.25 days. 
aSource: http://www.cdc.gov/growthcharts/
A study participant data listing of all vital signs values for all study participants will be 
presented. The listing will contain a column indicating the MA criteria if a study participant had 
abnormal vital sign value. A separate study participant data listing for MA values (all vital signs 
assessments for study participants with MA values are to be included in the listing) will be 
provided.
8.4.2
Electrocardiograms (ECGs)
Standard 12-lead ECGs will be performed throughout the study according to the protocol 
schedule of assessments.
Observed the values of the ECG will be summarized for each visit. Change from Baseline in 
ECG results will be summarized for all post-Baseline visits and time points. The table will be 
presented by age cohort and subgroup. Actual values and change from Baseline will be plotted 
by visit, time point, and age cohort.
The number and percentage of study participants with normal, abnormal not clinically significant 
and abnormal clinically significant findings, as assessed by the investigator, will be summarized 
for all visits. Percentages will be relative to the number of study participants with an ECG 
assessment at each visit. Study participants are counted at most once at each visit based on the 
worst observed outcome across all abnormalities reported at that visit.
Summaries of shifts from Baseline to post-Baseline visits will also be provided based on the 
categories normal, abnormal, not clinically significant, and abnormal, clinically significant.
The number and percentage of study participants with treatment-emergent ECG abnormalities 
will be presented for each post-Baseline visit. Abnormalities reported at an unscheduled visit will 
be summarized under the scheduled visit preceding the unscheduled visit (if the abnormality was 
not present already at the preceding scheduled visit). Treatment-emergent is defined as meeting 
the criteria at any post-Baseline visit during the iv Treatment Period (including unscheduled 
visits) and not meeting the same criteria during Baseline. Abnormality criteria to be used in the 
determination of ECG abnormalities are defined as follows, where increase and decrease are 
relative to Baseline values:
Table 8‒2: ECG abnormality criteria
Parameter
Age
Abnormality Criteria
QT interval (ms)
1m-<12y
>500
REDACTED 
ase
ase
ual
ual val
val
partic
parti
ind
ind
COPY 
zed fo
ed f
elin
elin
This document 
eter
te
relat
relat
cannot
eria a
ria a
s) and
) and
erm
rm
be
t alre
t alre
t
used
d for
d for
d und
d und
to
ercen
rce
r e
support
Base
Base
ormal, 
rmal,
enta
nt
any
s all a
all 
lin
l
marketing 
cipip
ding
ings, a
ative to
tive 
rticipa
rticip
ab
authorization 
r e
e visi
e visi
lues a
ues a
pant
pant
application 
dy acco
y acc
each
ach
and any
he lis
e li
extensions 
ill be
l be
dy part
y part
alues
lues
t
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 30 of 66
Table 8‒2: ECG abnormality criteria
Parameter
Age
Abnormality Criteria
>12y
>500 or ≥60ms increase from Baseline
QTc(F) (ms)
<6m
>490, or >15% increase from Baseline
6m-<3y
>440, or >15% increase from Baseline
3y-<12y
>440, or >15% increase from Baseline
>12y- <17y
>440, or >15% increase from Baseline
≥17y
>500 or ≥60ms increase from Baseline
QTc(B) (ms)
<6m
>490, or >15% increase from Baseline
6m-<3y
>450, or >15% increase from Baseline
3y-<12y
>450, or >15% increase from Baseline
>12y- <17y
>450, or >15% increase from Baseline
≥17y
>500 or ≥60ms increase from Baseline
PR interval (ms)
<6m
>150, or >25% increase from Baseline
6m-<3y
>170, or >25% increase from Baseline
3y-<12y
>180, or >25% increase from Baseline
>12y - <17y
>200, or >25% increase from Baseline
≥17y
Treatment-emergent value >200, >220, >250
QRS interval (ms)
<6m
>90, or >25% increase from Baseline
6m-<3y
>90, or >25% increase from Baseline
3y-<12y
>100, or >25% increase from Baseline
>12y - <17y
>110, or >25% increase from Baseline
≥17y
Treatment-emergent value >100, >120, >140
Heart rate (bpm)
<6m
<100, >180
6m-<3y
<90, >150
3y-<12y
<60, >130
>12y
<50, >120
Abbreviations: bpm=beats per minute; m = months; ms=milliseconds; QTc=corrected QT 
interval; y=years. A month is defined as 30 days; a year is defined as 365.25 days.
A listing of ECG data will be provided for all study participants with other significant TEAEs in 
the Cardiac and ECG Related Terms category defined in Appendix 12.1. A study participant data 
listing of all ECG parameter values for all study participants will also be presented. 
REDACTED 
180, or
80, o
D
>20
>20
CT
DA
ED
R
COPY
25% 
25%
or >25
2
COPY
C
This document
Abb
Abb
inin
t cannot 
nn
c
be 
be used 
m)
se
to 
to support 
<1
<
>12y
12
pp rt
≥
upp
su
any 
y
12y
12y
y marketing 
Trea
Trea
>
ting
et
ark
authorization
5% in
5% in
r >25
25
ri
tio
00, or
0, or
ori
au
application
from
rom
ease fro
ase f
on
ncreas
ncrea
ica
ap
and
m Ba
Ba
om
nd any
elin
eli
asel
ase
ny extensions 
ne
sio
ine
ine
xte
or 
o variations 
io
tioioio
va
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 31 of 66
A study participant data listing will be provided that identifies study participants with a clinically 
significant finding after the first dose of iv LCM for each type of ECG abnormality. All ECG 
parameter values will be listed for study participants meeting any abnormality criteria.
8.4.3
Complete physical examination 
A complete physical examination will be performed at Screening Visit and the Final Visit 
according to the protocol schedule of study assessments.
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. 
Clinically significant physical examination findings will be reported as AEs.
A listing of clinically significant physical examination abnormalities from the complete physical 
examination will be provided.
8.4.4
Complete neurological examination
A complete neurological examination will be performed at the Screening Visit according to the 
protocol schedule of study assessments. The complete neurological examination will include 
selected assessment of general neurological status (level of consciousness, mental status, 
speech), cranial nerves, reflexes, motor system (general motor status, muscle strength, muscle 
tone), coordination/cerebellar function, and sensation. 
Clinically significant neurological findings will be reported as AEs.
A listing of neurological examination abnormalities from the complete neurological examination 
will be provided.
8.4.5
Assessment of suicidality
Suicidality will be assessed by trained study personnel using the Columbia Suicide Severity 
Rating Scale (C-SSRS). This will be completed according to the protocol schedule of study 
assessments.
For study participants ≥6 years of age, this scale will be used for screening as well as to assess 
suicidal ideation and behavior that may occur during the study. All study participants who are ≥6 
years of age will complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will 
complete the “Since Last Visit” version at subsequent visits. If a study participant becomes 6 
years of age during the study, the “Already Enrolled” version of the C-SSRS should be used at 
the first visit at which the study participant is 6 years of age and use the “Since Last Visit” 
version at subsequent visits. 
The C-SSRS is not validated for study participants <6 years of age and will not be used for this 
population, but signs and symptoms of depression will be assessed at each visit. 
Study participant data listings of the data for the C-SSRS will be provided. No summaries of 
these results are planned.
9
PHARMACOKINETICS AND PHARMACODYNAMICS
9.1
Pharmacokinetics
All study PK outcomes will be summarized for the PK-PPS.
 b
rmalit
rmalit
dality
dality
COPY 
n. 
n. 
be re
e re
This document 
p
Stud
Stud
tht
cannot 
-SSR
SSR
ulati
ulati
be
subs
subs
used
ring t
ng t
at wh
t wh
to
e La
e L
th
support
ears
ars
havior t
avior
plete th
plete t
ast
any 
s of 
s o
marketing 
d study
d stud
be com
e co
authorization
eporte
porte
ies
es frfr
application
al ex
l ex
nscious
sciou
tor stat
or sta
and
ning 
ning 
exa
xa
any 
V
extensions 
omple
omple
or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 32 of 66
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the protocol schedule of study assessments (on Visit 2 and if iv LCM treatment is 
continued after Day 1 also on Visit 3, pre-dose sample is taken between -59 min to -3 min in 
relation to iv LCM infusion and +1h to 4 hours after the end of the iv LCM infusion). Additional 
blood samples for the PK analysis can be taken at the discretion of the investigator, especially in 
the event of a relevant treatment-emergent AE. Blood samples with missing sampling time will 
be excluded from the analysis.
9.1.1
Pharmacokinetics Analysis
Descriptive summaries (n, geometric mean, geometric 95% confidence interval, geometric CV, 
mean, SD, median, minimum, and maximum) for the LCM and SPM 12809 plasma 
concentrations will be presented for pre-infusion and post-infusion time points on each infusion 
day where LCM and SPM 12809 plasma are collected. Summary statistics are only calculated if 
at least 2/3 of data are above the lower limit of quantification (LOQ). Values <LOQ will be set to 
LOQ/2 for the determination of all summary statistics. Data will be presented by age cohort and 
by weight group (0 to <30kg, 30 to <50kg, >=50kg).
A listing of plasma sample collection times and plasma concentrations of LCM and SPM 12809 
will be provided.
9.2
Pharmacodynamics
This section is not applicable for this study.
10
EFFICACY ANALYSES
This section is not applicable for this study.
REDACTED 
udy.
udy.
COPY 
This document cannot be used to support any marketing authorization application
ations
ation
and any 
es 
es 
ented 
nted b
extensions 
et
n each
n each
e only 
only
 <L
<L
or
ric C
ric 
variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 33 of 66
11
REFERENCES
This section is not applicable for this study.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 34 of 66
12
APPENDICES
12.1
List of Other significant AEs of VIMPAT
MedDRA Preferred Term
CARDIAC AND ECG RELATED TERMS
Atrioventricular block third degree
Atrioventricular block second degree
Bradyarrhythmia*
Bradycardia*
Cardiac pacemaker insertion
Atrial fibrillation
Atrial flutter
Sinus bradycardia*
Ventricular tachycardia
Ventricular fibrillation
Heart Rate decreased*
Sick sinus syndrome
Atrial conduction time prolongation
Atrioventricular dissociation
Conduction disorder
Cardiac fibrillation
Cardiac flutter
Sinus arrest
Torsade de pointes
Ventricular asystole
REDACTED 
ED
AC
R
COPY 
OP
This document 
Si
Si
t
m
cannot 
fifi
ardiac
rdiac
no be 
ibril
ibril
used 
isord
sord
u
to 
ss
to support
prolon
rolon
ociat
ociat
pp
any 
an marketing 
ing
ma
authorization 
at
th
application 
at
ap
and 
an
any 
ny extensions 
ns
te
or variations 
ioioioio
va
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 35 of 66
MedDRA Preferred Term
Ventricular flutter
Ventricular tachyarrhythmia
Implantable defibrillator insertion
SUICIDALITY RELATED TERMS
Completed suicide
Depression suicidal
Suicidal behaviour
Suicidal ideation
Suicide attempt
Intentional self-injury
Self injurious behaviour
Self-injurious ideation
Intentional overdose
Multiple drug overdose intentional
Poisoning deliberate
ADDITIONAL TERMS
Loss of consciousness
Syncope
Appetite disorder
Decreased appetite
Diet refusal
Hypophagia
Food aversion
REDACTED 
CT
ED
COPY 
Y
CO
This document
Dec
Dec
me
m
cannot 
etite d
tite d
t
cr
an
be 
b
used 
usn
sn
se
to 
nes
nes
support 
RMS
MS
or
s
any y marketing 
nalal
ke
authorization 
on
ori
a
application 
on
pli
and 
d any extensions 
si
ex
or 
o variations 
io
ria
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 36 of 66
MedDRA Preferred Term
Abnormal behaviour
*All cases with reported reduced heart rate will be reviewed and only cases with marked 
bradycardia (marked reduction in heart rate) with HR <45 bpm will be listed as ‘Other 
Significant AEs’.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 37 of 66
12.2
Marked abnormality criteria for laboratory data 
12.2.1
Hematology
PARAMETER
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
Hematocrit
<2y
%
≤27
>45
%
≤27
>45
2y -
<17y
≤29
>47
≤29
>47
≥17y
≤85% of LLN
≥115% of ULN
≤85% of LLN
≥115% of ULN
Hemoglobin
<2y
g/dL
≤9.0
>15.0
g/L
≤90
>150
2y -
<17y
≤9.5
>16.0
≤95
>160
≥17y
≤85% of LLN
≥115% of ULN
≤85% of LLN
≥115% of ULN
WBC/Leukocyte
s
All
109/L
≤3.0
≥16.0
G/L
≤3.0
≥16.0
Lymphocytes 
Absolute
<2y
109/L
<1.0
>9.8
G/L
<1.0
>9.8
2y -
<6y
<0.7
>6.9
<0.7
>6.9
≥6y
<0.6
>5.0
<0.6
>5.0
Basophils
>1m
%
≥5.0
%
≥5.0
Basophils 
Absolute
>1m
109/L
≥0.4
G/L
≥0.4
REDACTED
≤9
≤9
TE
COPY 
0
9 5
9 5
CO
This document 
m
cannot be used 
d to 
t
support 
rt
2y
or any 
0
marketing 
9/L
/L
ark
authorization 
5
>16.0
16.0
n
ut
ut
uth
aut
application 
on
tio
and any y extensions 
29
29
>4
>4
ns
e
or variations 
io
at
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 38 of 66
PARAMETER
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
Eosinophils
>1m
%
≥10
%
≥10
Eosinophils 
Absolute
>1m
109/L
≥1.0
G/L
≥1.0
Monocytes
>1m
%
≥20.0
%
≥20.0
Monocytes 
Absolute
>1m
109/L
≥2.0
G/L
≥2.0
Neutrophils 
Absolute
>1m
109/L
<1.5
G/L
<1.5
Platelets
>1m
109/L
≤100
≥600
G/L
≤100
≥600
RBC/ 
Erythrocytes
<2y
1012/L
<3.0
T/L
<3.0
≥2y
<3.5
<3.5
Abbreviations:  m =month, RBC=red blood cells, WBC=white blood cells, y = year. A month 
is defined as 30 days; a year is defined as 365.25 days.
12.2.2
Chemistry
PARAMETE
R
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
AST (SGOT)
All
U/L
≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULN
U/L
≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULN
ALT (SGPT)
All
U/L
≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULN
U/L
≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULN
REDACTED 
<
TE
CT
d
RE
COPY 
<3.0
3.0
OP
This document 
m
cannot
SGO
GO
be 
OT
OT
be used 
R
E
se
to
G
RAN
RAN
support 
y
GE 
E 
pp
any marketing 
d blood
blood
fined as
ned a
g authorization 
<3
<
hor
aut
a
application 
G
n 
tio
a
and 
L
any y y extensions 
≥2.0
≥2.0
io
e
or 
or variations 
oio
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 39 of 66
PARAMETE
R
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
Alkaline 
Phosphatase
<4y
U/L
≥690
U/L
≥690
4y -
<10y
≥834
≥834
10y -
<17y
≥1761
≥1761
≥17y
≥3.0 x ULN
≥3.0 x ULN
GGT
<6m
U/L
≥522
U/L
≥522
6m -
<1y
≥279
≥279
1y -
<13y
≥66
≥66
13y -
<17y
≥126
≥126
≥17y
≥3.0 x ULN
≥3.0 x ULN
Total Bilirubin
>1m
mg/dL
≥2.0
umol/L
≥34.208
Total Protein
2m-<1y
g/dL
<3.0
>11.9
g/L
<30
>119
1y -
<17y
<4.3
>12.0
<43
>120
≥17y
<4.3
>13.0
<43
>130
Albumin
<1y
g/dL
<1.6
>7.2
g/L
<16
>72
≥1y -
<17y
<2.4
>8.4
<24
>84
REDACTED 
≥
ED
CT
COPY 
Y
This document 
Alb
Alb
t
m
cannot 
c
be used
<
se
to 
1y y -
support 
g
po
sup
any 
g/dL
g/dL
y marketing 
g
dL
dL
ke
authorization 
126
26
at
a
application 
ati
pli
and any y
ny extensions 
≥3
≥3
en
e
or 
or variations 
oio
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 40 of 66
PARAMETE
R
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
≥17y
<2.6
<26
BUN
<1y
mg/dL
≥24
mmol/L
≥8.568
1y -
<17y
≥36
≥12.852
≥17y
≥40
≥14.28
Urea
<1y
mg/dL
>42
mmol/L
>7.014
≥1y
>60
>10.02
Creatinine
1y -
<10y
mg/dL
>1.2
umol/L
>106.8
10y -
<16y
>1.8
>159.12
≥16y
≥2.0
≥176.8
Creatinine 
Clearance*
All
mL/min
<50
mL/s
<0.835
Bicarbonate
>1m -
<17y
mEq/L
<15
>38
mmol/L
<15
>38
≥17y
<18
>38
<18
>38
Calcium
<1y
mg/dL
<6.9
>12.2
mmol/L
<1.725
>3.05
1y -
<17y
<7.4
>11.7
<1.85
>2.925
≥17y
≤7.6
≥11.0
≤1.9
≥2.75
Chloride
>1m
mEq/L
≤90
mmol/L
≤90
REDACTED 
1
CT
CT
CT
CT
RE
COPY 
.8.8
OP
This document 
m
cannot be used 
se
se
se
se
se
to support 
po
7y
pp
any
mEq/L
Eq/
marketing 
g
L
ma
authorization 
≥2.0
2.0
or
a
application 
u
on
ati
ap
and any 
L
y extensions 
≥14.2
14.2
sio
ex
e
or variations 
oio
va
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 41 of 66
PARAMETE
R
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
≥112
≥112
Phosphorous
<1y
mg/dL
<1.8
>8.2
mmol/L
<0.5814
>2.6486
1y -
<17y
<1.8
>7.4
<0.5814
>2.3902
≥17y
≤2.0
≥6.0
≤0.646
≥1.938
Potassium
<1y
mEq/L
≤3.0
≥6.5
mmol/L
≤3.0
≥6.5
≥1y
≤3.0
≥6.0
≤3.0
≥6.0
Sodium
>1m
mEq/L
<127
>151
mmol/L
<127
>151
Glucose
>1m -
<17y
mg/dL
<50
≥180
mmol/L
<2.775
≥9.99
≥17y
<50
≥200
<2.775
≥11.1
Total 
Cholesterol
≥1y
mg/dL
>250
mmol/L
>6.475
LDL 
(calculated)
1y -
<17y
mg/dL
>140
mmol/L
>3.626
≥17y
>200
>5.18
HDL
≤2y
mg/dL
<10
mmol/L
<0.259
>2y
<20
<0.518
REDACTED
≥6.0
6.
CT
CT
CT
CT
CT
COPY 
.0.0
PY
This document 
m
cannot 
alculat
lcula
be 
be used
≥1
≥
se
to 
to support 
po
any marketing 
g
L
ket
authorization 
0
<12
<12
or
a
application 
mm
mm
ati
pp
and 
a
any y extensions 
814
814
>2.39
>2.39
ex
e
or 
o variations 
oio
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 42 of 66
PARAMETE
R
AGE 
RANG
E
UNIT 
(conventional
)
ABNORMALIT
Y CRITERIA 
(conventional)
UNIT
(standard
)
ABNORMALIT
Y CRITERIA 
(standard)
Triglycerides
<1y
mg/dL
>750
mmol/L
>8.475
≥1y
>300
>3.39
Uric Acid
<1y
mg/dL
>7.7
umol/L
>457.996
1y -
<13y
>6.5
>386.62
13y -
<17y
>8.6
>511.528
≥17y
>9.5
>565.06
Thyroxine 
(T4)
<1y
ug/dL
≤4.3
≥18.4
nmol/L
≤55.3453
≥236.8264
≥1y
≤3.8
≥13.5
≤48.9098
≥173.7585
Globulin
<1y
g/dL
<1.0
>4.5
g/L
<10
>45
≥1y
<1.2
>5.3
<12
>53
Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea 
nitrogen; dL = deciliter; GGT: gamma-glutamyltransferase; HDL = high density lipoprotein; LDL = 
low density lipoprotein; L = liter; m = month (a month is defined as 30 days); mg = milligram; mmol = 
millimoles; μg = microgram; U = unit; ULN = upper limit of normal; y = years (a year is defined as 
365.25 days).
*Schwartz equation (patients <12 y): Cr Cl ml/min = [Height (cm) * 0.55] / serum creatinine; Cockroft 
equation (patients >12 y): Male: Cr Cl ml/min = [(140-age) x body weight (kg)] / (72 x serum 
creatinine); Female: Cr Cl ml/min = [(140-age) x body weight (kg)] / (72 x serum creatinine)] x 0.85.
REDACTED 
≤3
D
CT
ED
COPY 
8.4
8.4
C
This document
equ
equ
cre
cr
cannot
days
days
chwart
hwar
uati
uat
be
; μg 
; μg
s)s)
used
ecilit
ili
poprot
opro
=
to 
= a
iter
iter
supp
alani
alan
pport 
po
pp
any marketing 
g authorization 
8
≥13
13
tio
a
application 
ati
at
at
at
at
and any y extensions 
86.62
6.62
ns
ex
e
or variations 
oio
va
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 43 of 66
12.2.3
Required Investigations and follow up for PDILI
Abbreviations: ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; 
AST=aspartate aminotransferase; HCP=healthcare practitioner; IMP=investigational medicinal 
product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; 
hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
b If the study participant also has ≥2xULN ALP, the possibility of an indication of biliary obstruction 
should be discussed with the Medical Monitor.
c The local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist.
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible 
physician. Determination of stabilization is at the discretion of the investigator in consultation with the 
hepatologist (as applicable) and UCB responsible physician, as needed.
REDAC
atase; 
atase; 
ACTED COPY 
This document
phy
phy
hep
he
cannot
ntero
tero
Unless 
nless
ysic
ysi
be
ent of
ent o
olo
olo
used 
d
epatolo
patol
f p
f
to
d wit
wit
support 
nclu
cl
antnt also
als
h
any
igue
igue
ude e
ude 
marketing 
ALT
ALT
=healthc
health
=potenti
oten
e n
e
auth
T
thorization application and any extensions or 
ions 
variatio
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 44 of 66
12.2.4
PDILI laboratory measurements
Virology-related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, 
obtain heterophil antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and 
quantitative)
Hematology
Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
WBC differential count
Urinalysis
Toxicology screen
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % 
direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing 
transaminase elevation
ALT
AST
ALP
GGT
Albumin
Additional
Prothrombin time/INRa
Serum pregnancy test
PK sample
REDACTED 
TE
ntnt
DA
R
COPY 
PY
C
This document 
m
cannot be used to support 
If to
If t
d
t
pp
any 
mylase
mylas
y
a
marketing 
rential
entia
ng
ology s
logy 
rk
m
authorization 
ion
riz
ut
application
ntib
tib
ca
pp
and
and 
nd 
bod
bod
nd any 
ve
ve
qua
qu
ny extensions 
vailab
ailab
ns
e)e)
xte
or variations 
io
at
v
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 45 of 66
Abbreviations: ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate 
aminotransferase; CPK=creatine phosphokinase; GGT=gamma-glutamyltransferase; HBcAb-
IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis B surface antigen; 
IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate dehydrogenase; 
PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RBC=red blood cell; 
RNA=ribonucleic acid; ULN=upper limit of normal; WBC=white blood cell.
a Measured only for study participants with ALT >8xULN, elevations in total bilirubin, and 
symptoms of hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, 
vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include 
eosinophilia (>5%), rash, and fever (without clear alternative cause).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations 
e
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 46 of 66
12.3
Additional PDILI information
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal 
remedies, vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
x
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other 
“fatty liver disease”)
x
Adverse reactions to drugs
x
Allergies
x
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1
antitrypsin deficiency)
x
Recent travel
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, 
jaundice, fever, or rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary 
function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; 
PDILI=potential drug-induced liver injury
REDACTED
or te
or te
ion or
ion or
CT
R
COPY 
AST
AS
oms of
ms o
end
end
PY
This document cannot be used 
l dr
dr
to
T
drug
rug
supp
=alan
=alan
pport 
logy re
ogy r
rt
pp
any 
epato
epato
y marketing 
ing
biopsy
biop
rk
authorization
f hep
hep
dernes
erne
r hypo
hypo
ho
application 
atic dis
atic d
and/or 
and/or
epat
pat
pp
and any
me, a
me, 
extensions or 
he
variations 
o
her 
er 
oio
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 47 of 66
12.4
List of MedDRA Preferred Term for PDILI
MedDRA Preferred Term for PDILI
Cholestasis
Cholestatic liver injury
Cholestatic pruritus
Drug-induced liver injury
Hepatitis cholestatic
Hyperbilirubinaemia
Icterus index increased
Jaundice
Jaundice cholestatic
Jaundice hepatocellular
Mixed liver injury
Ocular icterus
Acute hepatic failure
Asterixis
Cholestatic liver injury
Coma hepatic
Cryptogenic cirrhosis
Drug-induced liver injury
Hepatic cirrhosis
Hepatic encephalopathy
Hepatic failure
Hepatic infiltration eosinophilic
REDACTED 
TE
DA
COPY 
O
This documen
H
ent 
He
He
en
m
cannot
induc
nduc
epati
pati
nn
be
be 
be used 
cirrh
cirrh
d to support 
y
t
up
any 
a
marketing 
eti
m
authorization 
n
iz
au
application 
n
ic
a
and 
a
any 
an extensions 
io
xt
or r variations 
io
ati
v
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 48 of 66
Hepatic necrosis
Hepatic steatosis
Hepatitis fulminant
Hepatobiliary disease
Hepatocellular foamy cell syndrome
Hepatocellular injury
Hepatotoxicity
Liver disorder
Liver injury
Mixed liver injury
Non-alcoholic steatohepatitis
Subacute hepatic failure
Allergic hepatitis
Chronic hepatitis
Hepatitis
Hepatitis acute
Hepatitis cholestatic
Hepatitis chronic active
Hepatitis chronic persistent
Hepatitis fulminant
Hepatitis toxic
Non-alcoholic steatohepatitis
Blood bilirubin abnormal
Blood bilirubin increased
REDACTED 
CT
ED
COPY 
Y
CO
This document
Hep
Hep
me
m
cannot 
atitis f
titis 
t
pa
an
be
chro
hro
b
used 
ic a
c a
oni
oni
se
to 
acti
acti
support 
or
s
any y marketing 
ke
authorization 
on
ori
a
application 
on
pli
and 
d any extensions 
si
ex
or 
o variations 
io
ria
thereof. 


UCB
21 June 2019
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 49 of 66
Hyperbilirubinaemia
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 50 of 66
13
AMENDMENTS TO THE STATISTICAL ANALYSIS PLAN
13.1
AMENDMENT 1
Rationale for the amendment
The primary purpose of this SAP amendment is to include subjects with the age of <4 years to
>=1 month in the second age cohort according to protocol amendment 3. In addition, non-
content related issues which were detected during the DMC-SAP review were updated.
Modifications and changes
Global changes
The following changes have been made throughout the SAP:
Text has been modified to lower the age of subject enrollment to ≥1 month of age.
x
Approximately 100 subjects will be included in EP0060.
x
Age stratification has been included within Cohort 2. Every attempt will be made to enroll 
20 subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 
month to <2 years of age.
x
Number of subjects in the DMC process in Cohort 2 has been revised.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a
duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available
safety and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC
will make recommendations as follows:
x
EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a
target infusion duration of 15 minutes but no longer than 30 minutes only in subjects
who would directly benefit from an increased infusion rate, in the opinion of the
Investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion,
in the opinion of the Investigator, cannot receive the faster infusion. These subjects
should receive an infusion of 30 minutes but no longer than 60 minutes.
x
OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target
infusion duration of 30 minutes but no longer than 60 minutes.
x
OR Cohort 2 should be stopped.
x
The following changes were made to PDILI laboratory measurements:
Hematocrit, hemoglobin, platelet count, RBC count, WBC count, and WBC differential
REDACTED
in Co
in C
than 6
than 6
ubject
ubjec
C
COPY
rt 2 
t 2
month 
onth
This document cannot
hou
hou
OR
O
be 
e 
uld
uld
used
tor. 
or.
opin
opin
to 
r Su
Su
support
ration 
ation
rectly 
ectly
any
ly 30 
y 30
marketing 
cts i
s i
Cohort 
Cohort
s follo
foll
authorization
 to <
to <
ohort 2
ohort 2
60 mi
60 mi
in C
in C
application
of ag
f ag
as been
s bee
<8
<8
and
mpt w
pt w
ge
ge
any 
il
extensions 
f age.
age.
or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 51 of 66
count have replaced eosinophil count as hematology measurements.
x
The SS-iv will be the primary analysis set for the analysis of safety data and PK-PPS will
include all subjects in the SS-iv having provided at least 1 measurable postdose plasma
sample (with recorded sampling time) on at least 1 study day with documented LCM intake
times.
x
Clarifications made to the definitions of prior and concomitant medication.
x
Vital signs and ECG abnormality criteria added for age <4 years of age.
x
General updates: “e.g.”/”i.e.” to “eg,”/”ie,”, dates without non-break space, spelling 
mistakes, wording and upper/lower case corrections.
Specific changes
Change #1
Title page
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥4 TO <17 YEARS
OF AGE) WITH EPILEPSY
Has been changed to:
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥1 MONTH TO 
<17 YEARS OF AGE) WITH EPILEPSY
Change #2
Section 1 Introduction
This SAP is based upon the following documents: (Final Protocol: 16 Dec 2014, Protocol 
Amendment 1: 21 Jul 2015, Protocol Amendment 2: 30 Nov 2016).   
Has been changed to:
This SAP is based upon the following documents: (Final Protocol: 16Dec2014, Protocol 
Amendment 1: 21Jul2015, Protocol Amendment 2: 30Nov2016, Protocol Amendment 3: 
30Apr2018).
Change #3
Section 2.1.1  Primary Objective
The primary objective of the study is to evaluate the safety and tolerability of intravenous (iv) 
Lacosamide (LCM) infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy.
REDACTED 
STUD
STU
U
COPY 
VE
AMID
AMID
This document
0Ap
0Ap
cannot
AP is
AP is
endme
ndme
Apr
pr
be
chan
han
used
21 Ju
1 Ju
ng
ng
to
upo
upo
support 
n t
any marketing 
DY
D
US LA
S LA
LEPSY
EPS
authorization
DE I
E I
Y T
Y T
application 
IGAT
GAT
IN
IN
and any extensions 
elling
lling
or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 52 of 66
Has been changed to:
Section 2.1.1  Primary Objective
The primary objective of the study is to evaluate the safety and tolerability of intravenous (iv) 
Lacosamide (LCM) infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy.
Change #4
Section 2.2.3 Pharmacokinetic variables
The PK variables will include plasma concentration of LCM and its main metabolite, SPM 
12809.
Has been changed to:
Section 2.2.3 Other pharmacokinetic variables
The other PK variables will include plasma concentration of LCM and its main metabolite, SPM 
12809.
Change #5
Section 2.3 Study design and conduct
This is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥4 to <17 years of age with epilepsy. The study will include 
approximately 75 subjects.
After completion of the first 20 subjects in Cohort 1, the Data Monitoring Committee (DMC) 
will review the safety and tolerability data from these subjects.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows:
x
EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x
OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes,
x
OR Cohort 2 should be stopped,
REDACTED 
study 
study 
o <17 
o <17
ects
ects
COPY 
This document
I
cannot 
ion
o
ectly 
ctly 
nn
who w
who 
nv
be 
R a
n du
n du
used
s as
as
appr
ppr
to 
a fro
a fr
s f
s f
support
henev
enev
he first 
e first
rom 
om
any
≥
2, iv 
2, iv
ver
marketing 
s in Co
in Co
y data 
y data
≥4 to
≥4 to
authorization 
to ev
to ev
years
years
application and
nd its
d its
any 
m
extensions
e, SPM
SP
or 
M
variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 53 of 66
x
AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to 
<4 years of age).  
The design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. 
Has been changed to:
Section 2.3 Study design and conduct
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥1 month to <17 years of age with epilepsy. Based on a 
local protocol amendment only patients between ≥ 1 month to <16 years of age will be 
enrolled in Ukraine. The study will include approximately 100 subjects.
The Data Monitoring Committee (DMC) will review the safety and tolerability data from the 
first 20 subjects completed in Cohort 1.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but not longer than 60 minutes whenever possible. 
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows:
x
EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but not longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
Investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes,
x
OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but not longer than 60 minutes,
x
OR Cohort 2 should be stopped.
The design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Change #6
Section 2.4
Determination of sample size
Approximately 75 subjects will be enrolled, which includes up to 2 cohorts of at least 40 subjects 
for Cohort 1and at least 20 subjects for Cohort 2. No formal sample size calculation has been 
performed. The sample size was deemed clinically appropriate for the evaluation of safety, 
tolerability, and PK of iv LCM administration in pediatric subjects with epilepsy.
The following cohorts are planned:
REDACTED 
ubjects
ubject
ot lon
ot lon
infusi
infusi
m a
m a 1
COPY
he
h
ased 
ased 
This document
Appr
Appr
for
for
cannot 
e #6
ion 2
on 2
be used
abilit
bilit
to
ult i
ult 
tyty
support 
butut
d be sto
be st
in a
in
any
iona
iona
t not
no
marketing
15 to 
15 to
ster inf
ster in
60 min
0 min
al s
l
authorization 
s will 
will 
nger th
ger th
on rat
on rat
3
application 
uld
e. . 
MC wil
MC w
on this
n thi
and
ge w
e w
d be
d be
any 
will
wil
extensions
will b
will 
ity da
ty da
or
on
on
variations 
of iv
of iv
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 54 of 66
•
Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from ≥12 
to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
•
Cohort 2: at least 20 subjects from ≥4 to <8 years of age
Has been changed to:
Approximately 100 subjects will be enrolled, which includes up to 2 cohorts of at least 40 
subjects for Cohort 1 and approximately 44 subjects for Cohort 2. No formal sample size 
calculation has been performed. The sample size was deemed clinically appropriate for the 
evaluation of safety, tolerability, and PK of iv LCM administration in pediatric subjects with 
epilepsy.
The following cohorts are planned:
x
Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from ≥12 
to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x
Cohort 2: approximately 44 subjects from ≥1 month to <8 years of age; every attempt will 
be made to enroll 20 subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, 
and 12 subjects ≥1 month to <2 years of age
Change #7
Section 3.1
General presentation of summaries and analyses
All summaries, unless otherwise stated, will be presented overall for all subjects and by the age 
cohorts (≥4 to <8 years and ≥8 to <17). Selected tables will be provided in addition by the
subject groups (OLL and RxL, and IIL) and target infusion duration (15-30 minutes, and 30-60
minutes).
Has been changed to:
All summaries, unless otherwise stated, will be presented overall for all subjects and by age 
cohorts (≥ 1 month to <8 years and ≥8 to <17). Selected tables will be provided in addition by 
subject groups (OLL and RxL, combined, and IIL) and target infusion duration (15-30 minutes, 
and 30-60 minutes).
Change #8
Section 3.2.2 Analysis periods
iv Treatment Period 
Treatment days are as follows:
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
End-of-Study/Final Visit (1 day) 
The iv Treatment Period is defined as the period of time from the iv LCM first dose date and 
time to the iv LCM last dose date and time, inclusive. The end date of the iv Treatment Period 
aries
aries
will be 
ll be 
. Selec
. Sele
IIL) a
IIL) a
COPY 
s a
This document
Trea
Trea
(1
(1
cannot 
.2
eatme
eatm
an
t
be 
2.2
2.2
used to support
years
ear
d RxL
d RxL
any
se sta
se st
rs an
rs a
marketing
and ta
nd t
t
authorization 
and an
nd an
e prese
prese
ected t
cted t
tar
tar
application 
ect
and
of a
of a
ts ≥
ts ≥
any 
age
extensions 
0 subj
0 subj
or
wit
wi
variations 
ithth
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 55 of 66
will be either the last assessment date in Visit 3 for completers, or the date of the Early 
Termination Visit (ETV) for subjects who discontinued during the iv Treatment Period. If a 
subject does not have a Visit 3/ETV, then either the date of the last scheduled or unscheduled 
visit during the iv Treatment Period or the date of last known dose of iv LCM during the iv 
Treatment Period, whichever is later, will define the end date of the iv Treatment Period.
Post-iv Treatment Period
This is defined as the period of time after the end date of the iv Treatment Period to the last 
contact with the subject.
End-of-Study/Telephone Contact 1 (1 to 3 days).
Has been changed to:
iv Treatment Period 
Treatment days are as follows:
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
The iv Treatment Period is defined as the period of time from the iv LCM first dose date and 
time to the iv LCM last dose date and time, inclusive. 
Post-iv Treatment Period
This is defined as the period of time after the end date and time of the iv Treatment Period to the 
last contact with the subject.
Listings will also include “Unscheduled Visit” as applicable.
Change #9
Section 3.2.3 Study visit labeling
Visits will be labeled in table summaries (according to the schedule outlined in Section 5.2 of the
protocol) as follows:
x
“Visit X (Descriptor)” for scheduled visits during the Screening/Baseline Period
x
“Visit X, Day X” for scheduled visits during the Treatment Period
x
“Final Visit, Day X”
x
“Telephone Contact, Day X”
x
“Transition Visit, Day X”
Has been changed to:
Visits will be labeled in table summaries (according to the schedule outlined in Section 5.2 of the 
protocol) as follows:
x
“Visit X (Descriptor)” for scheduled visits during the Screening/Baseline Period
x
“Visit X” for scheduled visits during the iv Treatment Period
REDACTED 
he end
e end
duled 
duled
COPY 
e.e.
This document
H
cannot 
l 
Telep
Telep
“T
“T
be 
Visit
Visi
used 
cr
Day X
Day X
to
ripto
ipto
support
able su
able s
)
any 
eling
eling
marketing
 Vi
Vi
authorization 
d date
date
Visit
isit
application
oxima
oxima
m the i
m the 
and any extensions or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 56 of 66
x
“Final Visit”
x
“Telephone Contact 1”
x
“Telephone Contact 2”
x
“Transition Visit”
Change #10
Section 3.5 
Analysis sets
3.5.1 Safety Set iv
The Safety Set iv (SS-iv) will include subjects who received at least 1 dose of iv LCM. The SS-
iv will be the primary analysis set for the analysis of safety data.
3.5.2 Safety Set 
The Safety Set (SS) will include subjects who received at least 1 dose of LCM (oral or iv). 
Selected safety summaries will be presented for the SS. If the SS and the SS-iv consist of the 
same number of subjects, tables will only be presented for the SS-iv.
3.5.3 Pharmacokinetic-Per Protocol Set 
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS having 
provided at least 1 measurable post-dose plasma sample (with recorded sampling time) on at 
least 1 study day with documented LCM intake times.
Has been changed to:
3.5.1   Safety Set
The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study drug
LCM (oral and/or iv). Selected safety summaries will be presented for the SS. If the SS and the 
SS-iv consist of the same number of subjects, tables will only be presented for the SS-iv.
3.5.2   Safety Set iv
The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of EP0060 
study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety data.
3.5.3
Pharmacokinetic-Per Protocol Set 
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS-iv having
provided at least 1 measurable post-dose plasma sample (with recorded sampling time) on at 
least 1 study day with documented iv LCM intake times and without important protocol 
deviations impacting the interpretability of the PK analysis.
Change #11
Section 3.6
Treatment assignment and treatment groups
This is an open-label study with a single treatment arm. Subjects are summarized based on the 
age-based cohorts defined as:
S)
sma s
sma s
intake
ntake
COPY 
 will
will
This document
devi
evi
cannot 
m
ded at 
ed at 
st 1 stu
t 1 st
at
be 
macok
maco
used 
M
arma
rma
to
S
M. T
M. T
support 
-iv) w
iv) w
h
any 
saf
sa
mber o
mber o
marketing 
ubjects 
bject
afety
fety
authorization
l inclu
l inclu
ample
ample
e times
e time
application
os
S and 
S and 
e SS
e SS-ivi
and 
se of 
e of
any extensions 
iv LC
v LC
or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 57 of 66
•
≥8 to <17 years (Age Cohort 1)
•
≥4 to <8 years (Age Cohort 2)
Has been changed to:
This is an open-label study with a single treatment arm. Subjects are summarized based on the 
age-based cohorts defined as:
•
≥8 to <17 years (Age Cohort 1)
•
≥1 month to <8 years (Age Cohort 2)
Change #12
Section 3.9
Changes to protocol-defined analyses
In the protocol the pharmacokinetic analyses were planned to be presented by age cohort and 
infusion duration, and the IIL and OLL and RxL groups. After careful consideration, it is more 
meaningful to have the analyses presented separately by age cohort and body weight group. 
In the protocol, all safety analyses were planned to be presented by age cohort and infusion 
duration, cohorts overall, and all subjects overall and within cohort and infusion duration, by the 
Ill, OLL and RxL groups of subjects. After careful consideration, it is more meaningful to have 
all safety tables by age cohort and only specific safety tables presented by target infusion 
duration and subject group.
Has been changed to:
There are no changes to analyses specified in the protocol.
Change #13
Section 4.3
Interim analyses and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 10 subjects in Cohort 2. 
No formal stopping rule will be applied. The DMC may give a recommendation to stop the study 
after reviewing the safety data as described below. A recommendation for stopping should be 
based on the collective experience of the DMC members. After meeting to review data from each 
cohort, the DMC will provide a recommendation in writing regarding whether to continue or to 
stop the study. UCB will consider this recommendation when deciding the actions to take 
following each DMC meeting.  UCB will and ensure the study investigators are informed of the 
sponsor’s decision on how to continue as described below.
The DMC members will be defined in the DMC charter. 
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
REDACTED 
specifi
specif
COPY 
wit
w
consi
consi
safety
afety
This document
follo
ollo
spo
spo
cannot
thth
, the D
the D
p the s
the s
ow
be 
ing
he co
he co
sed
ping 
ping 
g th
g th
to
s in 
in 
support
is is p
s is p
fter co
ter co
n Co
Co
any
es and
es an
marketing 
fied
authorization
id
y tabl
y tabl
d in
d in
application
rt an
t a
ed by a
d by 
n coho
coh
deratio
erati
and
ul con
con
and
nd
any 
ed by 
d by
ns
extensions or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 58 of 66
LCM should be infused over a duration of 30 minutes but not longer than 60 minutes whenever 
possible.
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows:
•
EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration as follows:
-
15 minutes but not longer than 30 minutes only in subjects who would directly benefit from 
an increased infusion rate, in the opinion of the Investigator; OR, 
-
30 minutes but not longer than 60 minutes in subjects who would not directly benefit from an 
increased infusion rate, in the opinion of the Investigator 
•
OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but not longer than 60 minutes,
•
OR the study should be stopped, 
•
AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but not 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make
recommendations as follows: 
•
EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration as follows:
-
15 minutes but not longer than 30 minutes only in subjects who would directly benefit from 
an increased infusion rate, in the opinion of the Investigator; OR,  
-
30 minutes but not longer than 60 minutes in subjects who would not directly benefit from an 
increased infusion rate, in the opinion of the Investigator
•
OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
•
OR Cohort 2 should be stopped,. 
•
AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1 month to <4 
years of age).
Has been changed to:
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 20 subjects in Cohort 2. 
No formal stopping rule will be applied. The DMC may give a recommendation to stop the study 
after reviewing the safety data as described below. A recommendation for stopping should be 
REDACTED 
Cohor
Cohor
Cohor
Coho
ion
io
COPY
ge w
ge w
e infus
e infu
This document 
Has 
Has
N
cannot 
ND w
ND w
rs of 
s of 
be
hort 
hort
used 
mate
ate
minu
minu
2
to
ely 
ely
support 
onger t
nger 
e, in th
e, in th
any
an 
an
the op
he op
marketing 
nal sub
nal sub
n 30 
n 30
authorization 
use
ort 2, t
rt 2, t
rt 2. B
t 2. B
application 
ll be en
be e
ed ov
d ov
and any
with 
with
extensions 
y bene
bene
h a
h a
or
it f
it 
variations 
from
from
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 59 of 66
based on the collective experience of the DMC members. After meeting to review data from each 
cohort, the DMC will provide a recommendation in writing regarding whether to continue or to 
stop the study. UCB will consider this recommendation and ensure the study investigators are 
informed of the sponsor’s decision on how to continue as described below.
The DMC members will be defined in the DMC charter. 
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but not longer than 60 minutes whenever 
possible.
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows:
x
EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with target 
infusion durations as follows:
-
15 minutes but not longer than 30 minutes only in subjects who would directly benefit 
from an increased infusion rate, in the opinion of the Investigator; OR, 
-
30 minutes but not longer than 60 minutes in subjects who would not directly benefit 
from an increased infusion rate, in the opinion of the Investigator 
x
OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but not longer than 60 minutes,
x
OR study should be stopped, 
x
AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x
EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with target 
infusion durations as follows:
-
15 minutes but not longer than 30 minutes only in subjects who would directly benefit 
from an increased infusion rate, in the opinion of the Investigator; OR,  
-
30 minutes but not longer than 60 minutes in subjects who would not directly benefit 
from an increased infusion rate, in the opinion of the Investigator
x
OR approximately 30 additional subjects will be enrolled in Cohort 2 with target infusion 
duration of 30 minutes but not longer than 60 minutes, 
x
OR Cohort 2 should be stopped. 
REDACTED 
the 
the
cts wil
cts wil
er than
er than
COPY 
nioio
utes
utes in
e op
op
This document cannot 
on
o
-
be 
R ap
n du
n du
used
s as
as
appr
ppr
to
a fro
a fr
s f
s f
support
er tha
r tha
he first 
e first
rom 
om
any 
s
20
20 sub
su
an
marketing 
nitiated
tiate
subje
subj
authorization 
n su
n su
n
pinion 
inion
ll be e
l be e
n 60 m
n 60 m
application 
subject
ubjec
ca
of the In
f the 
subje
ubj
and
Coh
Coh
any 
hor
extensions 
wh
safety
afety
ke rec
ke rec
or
hene
hen
variations 
f age
age
, iv
, iv
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 60 of 66
Change #14
Section 5.1 Subject disposition
A summary of disposition of analysis sets will be provided for all subjects screened and the SS-
iv:
The following listings will be provided: study eligibility criteria text, subjects who did not meet 
study eligibility criteria, subject disposition, study discontinuation, subject analysis sets, subjects 
excluded from at least one analysis set, and visit dates.
Has been changed to:
A summary of disposition of analysis sets will be provided for all subjects screened:
The following listings will be provided: subjects who did not meet study eligibility criteria, 
subject disposition, study discontinuation, subject analysis sets, subjects excluded from at least 
one analysis set, visit dates, and subject number.
Change #15
Section 6.1 Demographics and other Baseline characteristics
Demographic variables will be presented for the SS-iv and the SS. The variables to be considered 
are:
•
Age at entry into EP0060 (as defined in Section 3.1.6) – continuous and categorized as 
•
For EudraCT age categories are >=4 to <12 years and >=12 to <=17 years and the age cohort 
categories are >=4 to <8 years, >=8 to <12 years and >=12 to <17 years.
Has been changed to:
Section 6.1 Demographics and other Baseline characteristics
Demographic variables will be presented for the SS-iv and the SS. The variables to be considered 
are:
•
Age at entry into EP0060 
•
Categorized age:
o
EudraCT age categories: >=1 month to < 2 years, >=2 to <12 years and >=12 to
<17 years 
o
Age cohort categories: >=1 month to < 2 years, >=2 to <4 years, >=4 to <8 years, >=8 
to <12 years and >=12 to <17 year
Change #16
Section 6.2 Medical history
REDACTED
he S
he S
ed in S
ed in S
>=4 
>=4 
COPY 
racteri
racter
SS
SS
This document cannot 
Eud
Eud
<
be
rized
rize
used 
try int
y int
to support
cs and
s and
es will
s wi
any marketing
to <1
to <
=8 to <
=8 to <
authorization 
ris
iv an
v an
Sectio
ectio
1
application 
stics
tics
and any
igib
igi
exclu
exclu
extensions 
eened:
ened:
ibil
ibil
or variations 
eet 
eet 
ubject
ubject
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 61 of 66
Medical history for RxL and IIL will be obtained from the Screening Visit Medical History 
eCRF module in EP0060. Medical History for OLL subjects is the sum of their medical history 
from their respective previous study and if applicable data from the subject's Medical History 
update form in EP0060.
Has been changed to:
Medical history for RxL and IIL will be obtained from the Screening Visit Medical History 
eCRF module in EP0060. Medical History for OLL subjects will come from their medical 
history from their respective previous.
Change #17
Section 6.4.2 History of seizure characteristics
History of epileptic seizures, history of status epilepticus, age at diagnosis (as defined in 
Section 3.2.5), time since first epileptic seizure (as defined in Section 3.2.6 ), and time since last 
status epilepticus (as defined in Section 3.2.6) will be summarized and listed where available. 
For direct enrollers, this information will be collected in the History of Epileptic Seizures eCRF 
for EP0060. For OLL subjects this information will come from their previous study.
Has been changed to:
History of withdrawal seizures, history of status epilepticus, age at first diagnosis (as defined in 
Section 3.2.5), time since first epileptic seizure (as defined in Section 3.2.6), and time since last 
status epilepticus (as defined in Section 3.2.6) will be summarized and listed where available. 
For direct enrollers, this information will be collected in the History of Epileptic Seizures eCRF 
for EP0060. For OLL subjects this information will come from their previous study.
Change #18
Section 6.5 
Prior and concomitant medications
Added: 
Prior medications include any medications that started prior to the date of first dose of LCM 
study drug.  Concomitant medications are medications taken at least one day in common with 
study drug LCM in EP0060. Medications may be both prior and concomitant.
Change #19
Section 6.5.1     Concomitant Non-AEDs
Non-AEDs taken at any time during the Treatment Period will be considered as concomitant 
medications. Medications will be summarized by ATC Code level 1 and 2 for the SS-iv. Subjects 
reporting multiple medications within an ATC class are counted once per medication and class.
Section 6.5.2
Concomitant AEDs
AEDs are reported on the Concomitant Medications (AEDs only) eCRF as concomitant 
medications. Concomitant AEDs will be summarized by Level 4 ATC code and generic 
REDACTED
us 
ure (as
ure (a
2.6
2.6) w
) w
will be 
will be
nform
nform
COPY 
 epil
epil
This document 
ec
No
No
cannot 
ge #
ge #1
tion
ion
be used 
com
om
CM in 
M in 
to
ncl
mita
mit
support 
lude a
ude 
any 
omita
omita
marketing 
matio
matio
authorization 
leptic
eptic
s defin
s defin
will b
will b
colle
colle
on
on
application
an
tory o
tory o
om thei
om the
and
3.2.
.2
nd li
nd li
any
s (as 
s (as
6 )
extensions or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 62 of 66
medication name. If a medication identified as an AED does not code to a level 4 ATC code, the 
highest level of coding will be displayed along with the generic medication name. Summaries of 
AEDs will be presented separately from other concomitant medications for the SS-iv population.
Has been changed to:
Section 6.5.1     Concomitant Non-AEDs
Non-AEDs taken at least one day in common with LCM study drug in EP0060 will be 
considered as concomitant medications. Medications will be summarized by ATC Code level 1 
and 2 for the SS-iv. Subjects reporting multiple medications within an ATC class are counted 
once per medication and class. 
Section 6.5.2     Concomitant AEDs
Concomitant AEDs are defined as AEDs taken concomitantly for at least one day in 
common with LCM study drug in EP0060. AEDs are reported on the Concomitant 
Medications (AEDs only) eCRF page. Concomitant AEDs will be summarized by Level 4 ATC 
code and generic medication name. If a medication identified as an AED does not code to a level 
4 ATC code, the highest level of coding will be displayed along with the generic medication 
name. Summaries of AEDs will be presented separately from other concomitant medications for 
the SS-iv population.
Change #20
Section 8.2 Adverse events
AE Summaries
x
Incidence of AEs – Overview 
Has been changed to:
x
Incidence of TEAEs – Overview 
Added:
x
Incidence of TEAEs related to Potentially Drug Induced Liver Injury (PDILI) (refer to 
Appendix 12.4 for a list of MedDRA preferred terms which define TEAEs related to 
PDILI)
AE Listings
Added:
x
All AEs related to PDILI
Change #21
Section 8.3 Clinical laboratory evaluations
Added:
REDACTED COPY 
This document
x
cannot
ngs
ngs
ot
ed:
ed:
be 
s
used
ix 12
x 12
)
to
f TE
f TE
support 
EA
EA
any
Over
Ove
marketing authorization application
with t
with 
other c
ther 
and
mm
AED d
ED 
thth
any
onco
onc
marize
arize
extensions 
t one 
one 
com
om
or
unte
unt
variations 
vel 1
el 1
ted
ted
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 63 of 66
The number of subjects meeting the criteria for Hy’s Law should also be summarized. The 
criteria of Hy’s Law are as follows:  
• (ALT or AST ≥ 3×ULN) and total bilirubin ≥ 2×ULN 
In order to meet the above criteria, a subject must experience the elevation in total bilirubin and 
ALT or AST at the same visit. For example, a subject who experiences a >=2 x ULN elevation 
of total bilirubin at one visit and a 3 x ULN elevation in ALT (or AST) at a subsequent visit has 
not fulfilled the Hy’s Law criteria. A subject with ALT and AST values missing or a subject with 
total bilirubin value missing has not fulfilled the Hy’s Law criteria.
Change #22
Section 8.4.5   Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). This will be completed according to the protocol schedule of study 
assessments.
For subjects ≥6 years of age, this scale will be used for screening as well as to assess suicidal 
ideation and behavior that may occur during the study. All subjects who are ≥6 years of age will 
complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will complete the 
“Since Last Visit” version at subsequent visits. If a subject becomes 6 years of age during the 
study, the “Already Enrolled” version of the C-SSRS should be used at the first visit at which the 
subject is 6 years of age and use the “Since Last Visit” version at subsequent visits. 
The C SSRS is not validated and will not be used for subjects <6 years of age. For those subjects, 
signs and symptoms of depression will be assessed at each visit. 
Subject data listings of the data for the C-SSRS will be provided. No summaries of these results 
are planned.
Has been changed to:
Suicidality will be assessed by trained study personnel using the Columbia Suicide Severity 
Rating Scale (C-SSRS). This will be completed according to the protocol schedule of study 
assessments.
For subjects ≥6 years of age, this scale will be used for screening as well as to assess suicidal 
ideation and behavior that may occur during the study. All subjects who are ≥6 years of age will 
complete the “Baseline/Screening” version of the C-SSRS at Visit 1 and will complete the 
“Since Last Visit” version at subsequent visits. If a subject becomes 6 years of age during the 
study, the “Already Enrolled” version of the C-SSRS should be used at the first visit at which the 
subject is 6 years of age and use the “Since Last Visit” version at subsequent visits. 
The C-SSRS is not validated for subjects <6 years of age and will not be used for this 
population, but signs and symptoms of depression will be assessed at each visit. 
Subject data listings of the data for the C-SSRS will be provided. No summaries of these results 
are planned.
REDACTED
C-SS
SS
e Last 
e Last 
not be 
ot be
will be
will be
COPY
. A
SSR
SSR
f a sub
f a sub
SR
SR
This document
ubje
ubje
Th
Th
cannot
Last 
Last 
dy, the
y, the
ect
ec
be
b
he “B
he “
used
year
year
behav
ehav
to support
ed by 
d by 
S). Thi
. Th
any marketing 
e ass
ass
he C
e C-S
authorization
bject
bject
RS sho
S sho
Visit
Visit
used 
used
se
se
application 
ng as w
ng as
subject
ubjec
S at V
S at V
t b
t b
and
col s
ol s
any
(Col
(Co
sch
sc
extensions or variations 
s 
with
with
thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 64 of 66
Change #23
Section 9.1 Pharmacokinetics
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the protocol schedule of study assessments (on Visit 2 and 3, pre-dose between -
59min to -3min in relation to iv LCM infusion and +1h to 4 hours after the end of the iv LCM 
infusion). Additional blood samples for PK analysis can be taken at the discretion of the 
investigator, especially in the event of a relevant treatment-emergent AE.
Has been changed to:
Blood samples for the determination of LCM and SPM 12809 concentrations will be collected 
according to the protocol schedule of study assessments (on Visit 2 and if iv LCM treatment is 
continued after Day 1 also on Visit 3, pre-dose sample is taken between -59 min to -3 min in 
relation to iv LCM infusion and +1h to 4 hours after the end of the iv LCM infusion). Additional 
blood samples for the PK analysis can be taken at the discretion of the investigator, especially in 
the event of a relevant treatment-emergent AE. Blood samples with missing sampling time 
will be excluded from the analysis.
Change #24
Table 8‒1: Vital signs abnormality criteria
Criteria for age <4 years of age were added.
Table 8‒2: ECG abnormality criteria
Criteria for age <4 years of age were added.
Appendices 12.1 List of Other significant AEs of VIMPAT
List of Other significant AEs of VIMPAT has been updated
Appendices 12.2.4 PDILI laboratory measurements
List of hematology PDILI laboratory measurements has been updated.
List of chemistry PDILI laboratory measurements has been updated.
Appendices 12.4 List of MedDRA Preferred Term for PDILI
List of MedDRA Preferred Term for PDILI was added.
REDACTED
added
adde
age
age we
we
COPY 
This document cannot be 
of
used
Lis
Lis
f Me
Me
to 
stst
support 
gy PDI
y PD
try PD
try P
any 
orator
orato
marketing 
ere 
re 
icant A
cant A
AEs of 
Es of
authorization 
d.d.
ad
ad
application and
miss
mis
any
vestig
vesti
sin
i
extensions
e coll
coll
M trea
tre
min 
min 
nfus
nfus
or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 65 of 66
13.2
AMENDMENT 2
Change #1
Section 3.2.5 Age and Age at first diagnosis
Age will be given in years and will be derived applying the rules for missing data imputation 
(see Section 4.2.1 and the SDTM derivation definition). The age at first diagnosis will be given 
in years and will be derived applying all rules for missing data imputation (see Section 4.2.1) 
with the following formula: 
(Date of first diagnosis of epilepsy – Date of birth) / 365.25
Has been changed to:
Age will be given in years and will be derived applying the rules for missing data imputation 
(see Section 4.2.1 and the SDTM derivation definition). The age at first diagnosis will be given 
in years and will be derived applying all rules for missing data imputation (see Section 4.2.1) 
with the following formulas:
Missing or partial epilepsy diagnosis date will be derived applying all rules for missing data 
imputation (see Section 4.2.1) and age at first diagnosis will use the following formulas,
where applicable.
The following formula will be applied where birthdate is a complete date: 
(Date of first diagnosis of epilepsy – Date of birth) / 365.25
The following formula will be applied where birthdate is a partial date:
(Enrollment age in years) – [(Informed consent date – Epilepsy diagnosis date) / 365.25], if
the value is negative then age at diagnosis will be set to zero.
Change #2
Change the word “subject” to “study participant” throughout the document. 
Change the word “subject” to “patient” in part of section 2.3, study design and conduct.
REDACTED
birth
birth
where 
here 
med c
med c
iagn
iagn
COPY 
rthda
thd
h) /
h) /
This document cannot be used to support 
to o 
ect” to 
ct” to
any 
“stu
“st
marketing
nosis w
nosis w
authorization 
ate
/ 365.
365
birth
birth
onsen
nsen
application
lying
yin
l use th
use 
e is a
is a
and 
ng
any
n (see
n (se
extensions 
ata im
ata im
nosis
nosis
or variations thereof. 


UCB
02 July 2018
Statistical Analysis Plan
Lacosamide
EP0060
Confidential
Page 66 of 66
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures below indicate that the final version of 
the SAP or amended SAP is released for execution.
COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.